{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 67,
   "id": "37d78881",
   "metadata": {},
   "outputs": [],
   "source": [
    "# %load calculate_disruption_index\n",
    "import pandas as pd\n",
    "import numpy as np\n",
    "def calculate_disruption_index(focal_paper, citing_papers, references, full_data):\n",
    "    NF = 0\n",
    "    NB = 0\n",
    "    NR = 0\n",
    "\n",
    "    for citing_paper in citing_papers:\n",
    "        citing_references = full_data[full_data['Citing_Paper_Title'] == citing_paper]['Citing_Paper_References'].values\n",
    "        if len(citing_references) == 0:\n",
    "            continue\n",
    "\n",
    "        citing_references = citing_references[0]\n",
    "        if not isinstance(citing_references, str):\n",
    "            citing_references = \"\"\n",
    "\n",
    "        citing_references_list = citing_references.split(';')\n",
    "\n",
    "        # Debugging information for citing paper and references\n",
    "        print(f\"DEBUG - Citing Paper: {citing_paper}, References: {citing_references_list}\")\n",
    "\n",
    "        cites_focal_only = focal_paper in citing_references_list and not any(ref in citing_references_list for ref in references)\n",
    "        cites_both = focal_paper in citing_references_list and any(ref in citing_references_list for ref in references)\n",
    "        cites_refs_only = focal_paper not in citing_references_list and any(ref in citing_references_list for ref in references)\n",
    "\n",
    "        if cites_focal_only:\n",
    "            NF += 1\n",
    "        if cites_both:\n",
    "            NB += 1\n",
    "        if cites_refs_only:\n",
    "            NR += 1\n",
    "\n",
    "    try:\n",
    "        disruption_index = (NF - NB) / (NF + NB + NR)\n",
    "    except ZeroDivisionError:\n",
    "        disruption_index = 0\n",
    "\n",
    "    print(f\"DEBUG - focal: {focal_paper}, NF: {NF}, NB: {NB}, NR: {NR}, D: {disruption_index}\")\n",
    "    return disruption_index"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "id": "9bb2501c",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Index(['Paper_Title', 'Paper_Authors', 'Journal', 'Year', 'Citing_Paper_Title',\n",
      "       'Citing_Paper_References'],\n",
      "      dtype='object')\n"
     ]
    }
   ],
   "source": [
    "# Load your CSV file with a different encoding\n",
    "data = pd.read_csv('../final.csv', encoding='ISO-8859-1', low_memory=False)\n",
    "\n",
    "# Print column names to verify\n",
    "print(data.columns)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 69,
   "id": "2d6b0495",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Paper_Title</th>\n",
       "      <th>Paper_Authors</th>\n",
       "      <th>Journal</th>\n",
       "      <th>Year</th>\n",
       "      <th>Citing_Paper_Title</th>\n",
       "      <th>Citing_Paper_References</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Progress in vaccine development for infectious...</td>\n",
       "      <td>['Jennifer Cable', 'Barney S Graham', 'Richard...</td>\n",
       "      <td>Annals of the New York Academy of Sciences</td>\n",
       "      <td>2023</td>\n",
       "      <td>Oral tolerance to systemic vaccination remains...</td>\n",
       "      <td>['Cram J.A., Fiore-Gartland A.J., Srinivasan S...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Progress in vaccine development for infectious...</td>\n",
       "      <td>['Jennifer Cable', 'Barney S Graham', 'Richard...</td>\n",
       "      <td>Annals of the New York Academy of Sciences</td>\n",
       "      <td>2023</td>\n",
       "      <td>Extracellular microvesicles: biologic properti...</td>\n",
       "      <td>['Adnani L, Spinelli C, Tawil N, Rak J (2022) ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Modified uridines are the key to a successful ...</td>\n",
       "      <td>['Katalin KarikÃ³']</td>\n",
       "      <td>Nature reviews. Immunology</td>\n",
       "      <td>2021</td>\n",
       "      <td>Stabilized 5' Cap Analogue for Optochemical Ac...</td>\n",
       "      <td>['Curreri A.; Sankholkar D.; Mitragotri S.; Zh...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Modified uridines are the key to a successful ...</td>\n",
       "      <td>['Katalin KarikÃ³']</td>\n",
       "      <td>Nature reviews. Immunology</td>\n",
       "      <td>2021</td>\n",
       "      <td>Transfection of hypoxia-inducible factor-1Î± m...</td>\n",
       "      <td>['Sen CK, Gordillo GM, Roy S, Kirsner R, Lambe...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Modified uridines are the key to a successful ...</td>\n",
       "      <td>['Katalin KarikÃ³']</td>\n",
       "      <td>Nature reviews. Immunology</td>\n",
       "      <td>2021</td>\n",
       "      <td>Race with virus evolution: The development and...</td>\n",
       "      <td>['Wolff J.A., Malone R.W., Williams P., Chong ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6317</th>\n",
       "      <td>A noninflammatory mRNA vaccine for treatment o...</td>\n",
       "      <td>['Christina Krienke', 'Laura Kolb', 'Elif Dike...</td>\n",
       "      <td>Science (New York, N.Y.)</td>\n",
       "      <td>2021</td>\n",
       "      <td>&lt;i&gt;In vitro&lt;/i&gt; and &lt;i&gt;ex vivo&lt;/i&gt; functional ...</td>\n",
       "      <td>['Todd J.A., Acha-Orbea H., Bell J.I., Chao N....</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6318</th>\n",
       "      <td>A noninflammatory mRNA vaccine for treatment o...</td>\n",
       "      <td>['Christina Krienke', 'Laura Kolb', 'Elif Dike...</td>\n",
       "      <td>Science (New York, N.Y.)</td>\n",
       "      <td>2021</td>\n",
       "      <td>Human Vaccines &amp; Immunotherapeutics: news.</td>\n",
       "      <td>['Rappazzo CG, Tse LV, Kaku CI, Wrapp D, Sakha...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6319</th>\n",
       "      <td>A noninflammatory mRNA vaccine for treatment o...</td>\n",
       "      <td>['Christina Krienke', 'Laura Kolb', 'Elif Dike...</td>\n",
       "      <td>Science (New York, N.Y.)</td>\n",
       "      <td>2021</td>\n",
       "      <td>SARS-CoV-2 vaccines in patients with SLE.</td>\n",
       "      <td>['Johns Hopkins University coronavirus resourc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6320</th>\n",
       "      <td>A noninflammatory mRNA vaccine for treatment o...</td>\n",
       "      <td>['Christina Krienke', 'Laura Kolb', 'Elif Dike...</td>\n",
       "      <td>Science (New York, N.Y.)</td>\n",
       "      <td>2021</td>\n",
       "      <td>Non-Genetically Encoded Epitopes Are Relevant ...</td>\n",
       "      <td>['Atkinson M.A. The Pathogenesis and Natural H...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6321</th>\n",
       "      <td>A noninflammatory mRNA vaccine for treatment o...</td>\n",
       "      <td>['Christina Krienke', 'Laura Kolb', 'Elif Dike...</td>\n",
       "      <td>Science (New York, N.Y.)</td>\n",
       "      <td>2021</td>\n",
       "      <td>Suppressing autoimmunity with mRNA vaccines.</td>\n",
       "      <td>['Krienke, C. et al. A noninflammatory mRNA va...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>6322 rows × 6 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                            Paper_Title  \\\n",
       "0     Progress in vaccine development for infectious...   \n",
       "1     Progress in vaccine development for infectious...   \n",
       "2     Modified uridines are the key to a successful ...   \n",
       "3     Modified uridines are the key to a successful ...   \n",
       "4     Modified uridines are the key to a successful ...   \n",
       "...                                                 ...   \n",
       "6317  A noninflammatory mRNA vaccine for treatment o...   \n",
       "6318  A noninflammatory mRNA vaccine for treatment o...   \n",
       "6319  A noninflammatory mRNA vaccine for treatment o...   \n",
       "6320  A noninflammatory mRNA vaccine for treatment o...   \n",
       "6321  A noninflammatory mRNA vaccine for treatment o...   \n",
       "\n",
       "                                          Paper_Authors  \\\n",
       "0     ['Jennifer Cable', 'Barney S Graham', 'Richard...   \n",
       "1     ['Jennifer Cable', 'Barney S Graham', 'Richard...   \n",
       "2                                   ['Katalin KarikÃ³']   \n",
       "3                                   ['Katalin KarikÃ³']   \n",
       "4                                   ['Katalin KarikÃ³']   \n",
       "...                                                 ...   \n",
       "6317  ['Christina Krienke', 'Laura Kolb', 'Elif Dike...   \n",
       "6318  ['Christina Krienke', 'Laura Kolb', 'Elif Dike...   \n",
       "6319  ['Christina Krienke', 'Laura Kolb', 'Elif Dike...   \n",
       "6320  ['Christina Krienke', 'Laura Kolb', 'Elif Dike...   \n",
       "6321  ['Christina Krienke', 'Laura Kolb', 'Elif Dike...   \n",
       "\n",
       "                                         Journal  Year  \\\n",
       "0     Annals of the New York Academy of Sciences  2023   \n",
       "1     Annals of the New York Academy of Sciences  2023   \n",
       "2                     Nature reviews. Immunology  2021   \n",
       "3                     Nature reviews. Immunology  2021   \n",
       "4                     Nature reviews. Immunology  2021   \n",
       "...                                          ...   ...   \n",
       "6317                    Science (New York, N.Y.)  2021   \n",
       "6318                    Science (New York, N.Y.)  2021   \n",
       "6319                    Science (New York, N.Y.)  2021   \n",
       "6320                    Science (New York, N.Y.)  2021   \n",
       "6321                    Science (New York, N.Y.)  2021   \n",
       "\n",
       "                                     Citing_Paper_Title  \\\n",
       "0     Oral tolerance to systemic vaccination remains...   \n",
       "1     Extracellular microvesicles: biologic properti...   \n",
       "2     Stabilized 5' Cap Analogue for Optochemical Ac...   \n",
       "3     Transfection of hypoxia-inducible factor-1Î± m...   \n",
       "4     Race with virus evolution: The development and...   \n",
       "...                                                 ...   \n",
       "6317  <i>In vitro</i> and <i>ex vivo</i> functional ...   \n",
       "6318         Human Vaccines & Immunotherapeutics: news.   \n",
       "6319          SARS-CoV-2 vaccines in patients with SLE.   \n",
       "6320  Non-Genetically Encoded Epitopes Are Relevant ...   \n",
       "6321       Suppressing autoimmunity with mRNA vaccines.   \n",
       "\n",
       "                                Citing_Paper_References  \n",
       "0     ['Cram J.A., Fiore-Gartland A.J., Srinivasan S...  \n",
       "1     ['Adnani L, Spinelli C, Tawil N, Rak J (2022) ...  \n",
       "2     ['Curreri A.; Sankholkar D.; Mitragotri S.; Zh...  \n",
       "3     ['Sen CK, Gordillo GM, Roy S, Kirsner R, Lambe...  \n",
       "4     ['Wolff J.A., Malone R.W., Williams P., Chong ...  \n",
       "...                                                 ...  \n",
       "6317  ['Todd J.A., Acha-Orbea H., Bell J.I., Chao N....  \n",
       "6318  ['Rappazzo CG, Tse LV, Kaku CI, Wrapp D, Sakha...  \n",
       "6319  ['Johns Hopkins University coronavirus resourc...  \n",
       "6320  ['Atkinson M.A. The Pathogenesis and Natural H...  \n",
       "6321  ['Krienke, C. et al. A noninflammatory mRNA va...  \n",
       "\n",
       "[6322 rows x 6 columns]"
      ]
     },
     "execution_count": 69,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "id": "31727a5a",
   "metadata": {},
   "outputs": [],
   "source": [
    "# eval(data[:3]['Paper_Authors'][0])\n",
    "\n",
    "data['Paper_Authors'] = data['Paper_Authors'].apply(eval)\n",
    "data['Paper_Authors'] = data['Paper_Authors'].apply(lambda auth:' '.join(auth))\n",
    "\n",
    "data['Citing_Paper_References'] = data['Citing_Paper_References'].apply(eval)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "id": "537ba174",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Paper_Title                object\n",
       "Paper_Authors              object\n",
       "Journal                    object\n",
       "Year                        int64\n",
       "Citing_Paper_Title         object\n",
       "Citing_Paper_References    object\n",
       "dtype: object"
      ]
     },
     "execution_count": 71,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data.dtypes"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 72,
   "id": "12e98261",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Katalin KarikÃ³'"
      ]
     },
     "execution_count": 72,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data[:3]['Paper_Authors'][2]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "id": "bb3a8e81",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Adjust these lines based on the actual column names\n",
    "focal_column = 'Paper_Title'\n",
    "citing_column = 'Citing_Paper_Title'\n",
    "references_column = 'Citing_Paper_References'\n",
    "authors_column = 'Paper_Authors'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 74,
   "id": "25c2c415",
   "metadata": {},
   "outputs": [],
   "source": [
    "# data[data[authors_column].isin.contains('Katalin', na=False)]\n",
    "\n",
    "# data[authors_column].apply(lambda auth: True if )"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 75,
   "id": "c2eeb5c5",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Number of Katalin Karikó's papers: 5937\n",
      "                                         Paper_Title  \\\n",
      "0  Progress in vaccine development for infectious...   \n",
      "1  Progress in vaccine development for infectious...   \n",
      "2  Modified uridines are the key to a successful ...   \n",
      "3  Modified uridines are the key to a successful ...   \n",
      "4  Modified uridines are the key to a successful ...   \n",
      "\n",
      "                                       Paper_Authors  \n",
      "0  Jennifer Cable Barney S Graham Richard A Koup ...  \n",
      "1  Jennifer Cable Barney S Graham Richard A Koup ...  \n",
      "2                                    Katalin KarikÃ³  \n",
      "3                                    Katalin KarikÃ³  \n",
      "4                                    Katalin KarikÃ³  \n"
     ]
    }
   ],
   "source": [
    "# Filter for Katalin Karikó's papers\n",
    "kariko_papers = data[data[authors_column].str.contains('Katalin', na=False)]\n",
    "\n",
    "# Print the number of papers and some sample data to verify\n",
    "print(f\"Number of Katalin Karikó's papers: {kariko_papers.shape[0]}\")\n",
    "print(kariko_papers[[focal_column, authors_column]].head())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 66,
   "id": "411a994e",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DEBUG - Focal Paper: Progress in vaccine development for infectious diseases-a Keystone Symposia report., References: Abdel-Gadir A., Stephen-Victor E., Gerber G.K., Noval Rivas M., Wang S., Harb H., Wang L., Li N., Crestani E., Spielman S., et al. Microbiota therapy acts via a regulatory T cell MyD88/RORgammat pathway to suppress food allergy. Nat. Med. 2019;25:1164â1174.\n",
      "DEBUG - Citing Paper: Oral tolerance to systemic vaccination remains intact without RORÎ³t expression in regulatory TÂ cells., References: ['']\n",
      "DEBUG - Citing Paper: Extracellular microvesicles: biologic properties, biogenesis, and applications in leukemia., References: ['']\n",
      "DEBUG - focal: Progress in vaccine development for infectious diseases-a Keystone Symposia report., NF: 0, NB: 0, NR: 0, D: 0\n",
      "DEBUG - Focal Paper: Modified uridines are the key to a successful message., References: Adams D., Gonzalez-Duarte A., OâRiordan W.D., Yang C.C., Ueda M., Kristen A.V., et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11â21.\n",
      "DEBUG - Citing Paper: Stabilized 5' Cap Analogue for Optochemical Activation of mRNA Translation., References: ['']\n",
      "DEBUG - Citing Paper: Transfection of hypoxia-inducible factor-1Î± mRNA upregulates the expression of genes encoding angiogenic growth factors., References: ['']\n",
      "DEBUG - Citing Paper: Race with virus evolution: The development and application of mRNA vaccines against SARS-CoV-2., References: ['']\n",
      "DEBUG - focal: Modified uridines are the key to a successful message., NF: 0, NB: 0, NR: 0, D: 0\n",
      "DEBUG - Focal Paper: A systematic dissection of determinants and consequences of snoRNA-guided pseudouridylation of human mRNA., References: A. F. Lovejoy, D. P. Riordan, P. O. Brown, Transcriptome-wide mapping of pseudouridines: pseudouridine synthases modify specific mRNAs in S. cerevisiae. PLOS ONE 9, e110799 (2014).\n",
      "DEBUG - Citing Paper: How snoRNAs can contribute to cancer at multiple levels., References: ['']\n",
      "DEBUG - Citing Paper: RNA modification in cardiovascular disease: implications for therapeutic interventions., References: ['']\n",
      "DEBUG - Citing Paper: Control of protein synthesis through mRNA pseudouridylation by dyskerin., References: ['']\n",
      "DEBUG - Citing Paper: Small RNA modifications: regulatory molecules and potential applications., References: ['']\n",
      "DEBUG - Citing Paper: Emerging Personalized Opportunities for Enhancing Translational Readthrough in Rare Genetic Diseases and Beyond., References: ['']\n",
      "DEBUG - Citing Paper: The importance of pseudouridylation: human disorders related to the fifth nucleoside., References: ['']\n",
      "DEBUG - focal: A systematic dissection of determinants and consequences of snoRNA-guided pseudouridylation of human mRNA., NF: 0, NB: 0, NR: 0, D: 0\n",
      "DEBUG - Focal Paper: ASL mRNA-LNP Therapeutic for the Treatment of Argininosuccinic Aciduria Enables Survival Benefit in a Mouse Model., References: Acewicz A, Stepien T, Felczak P, Tarka S, Wierzba-Bobrowicz T. Incidence and morphology of secondary TDP-43 proteinopathies: Part 1. Folia Neuropathol. 2022;60:267â276. doi: 10.5114/fn.2022.120314.\n",
      "DEBUG - Citing Paper: Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity., References: ['']\n",
      "DEBUG - Citing Paper: Nuclear-import receptors as gatekeepers of pathological phase transitions in ALS/FTD., References: ['']\n",
      "DEBUG - focal: ASL mRNA-LNP Therapeutic for the Treatment of Argininosuccinic Aciduria Enables Survival Benefit in a Mouse Model., NF: 0, NB: 0, NR: 0, D: 0\n",
      "DEBUG - Focal Paper: Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors., References:  [(accessed on 10 March 2023)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT02442297.\n",
      "DEBUG - Citing Paper: Circular mRNA-based TCR-T offers a safe and effective therapeutic strategy for treatment of cytomegalovirus infection., References: ['']\n",
      "DEBUG - Citing Paper: Insight into the Progress in CAR-T Cell Therapy and Combination with Other Therapies for Glioblastoma., References: ['']\n",
      "DEBUG - Citing Paper: OpenPBTA: The Open Pediatric Brain Tumor Atlas., References: ['']\n",
      "DEBUG - Citing Paper: CAR T-Cell Therapy in Children with Solid Tumors., References: ['']\n",
      "DEBUG - Citing Paper: Association between GPC2 polymorphisms and neuroblastoma risk in Chinese children., References: ['']\n",
      "DEBUG - Citing Paper: Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor (CAR) T Cell Infusions in Mice., References: ['']\n",
      "DEBUG - Citing Paper: CAR-T Therapies in Solid Tumors: Opportunities and Challenges., References: ['']\n",
      "DEBUG - Citing Paper: Advances in the Treatment of Pediatric Brain Tumors., References: ['']\n",
      "DEBUG - focal: Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors., NF: 0, NB: 0, NR: 0, D: 0\n",
      "DEBUG - Focal Paper: What does the success of mRNA vaccines tell us about the future of biological therapeutics?, References: A Study of MRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults â¥50 Years of AgeâFull Text ViewâClinicalTrials.Gov.  [(accessed on 11 November 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT05330975.\n",
      "DEBUG - Citing Paper: mRNA-Based Vaccines and Therapeutics for COVID-19 and Future Pandemics., References: ['']\n",
      "DEBUG - Citing Paper: Editorial: Antimicrobial peptides and mRNA therapy: Clinical, Veterinary, and plant pathology perspectives with special attention to combatting MDR pathogens., References: ['']\n",
      "DEBUG - Citing Paper: Harnessing Rift Valley fever virus NSs gene for cancer gene therapy., References: ['']\n",
      "DEBUG - Citing Paper: Targeting Cross-Presentation as a Route to Improve the Efficiency of Peptide-Based Cancer Vaccines., References: ['']\n",
      "DEBUG - focal: What does the success of mRNA vaccines tell us about the future of biological therapeutics?, NF: 0, NB: 0, NR: 0, D: 0\n",
      "DEBUG - Focal Paper: Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses., References: \n",
      "As an oncologist I am seeing People With Stable Cancer Rapidly Progress After Being Forced to Have a Booster â The Daily Sceptic . Available at: https://dailysceptic.org/2022/11/26/as-an-oncologist-i-am-seeing-people-with-stable-cancer-rapidly-progress-after-being-forced-to-have-a-booster/.\n",
      "DEBUG - Citing Paper: Rare COVID-19 vaccine side effects got lost in the shuffle. Primary cutaneous lymphomas following COVID-19 vaccination: a systematic review., References: ['']\n",
      "DEBUG - Citing Paper: Applications and Potentials of a Silk Fibroin Nanoparticle Delivery System in Animal Husbandry., References: ['']\n",
      "DEBUG - Citing Paper: Nanoparticles and Antiviral Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Vaccine induction of CD4-mimicking HIV-1 broadly neutralizing antibody precursors in macaques., References: ['']\n",
      "DEBUG - Citing Paper: Generation of antigen-specific memory CD4 T cells by heterologous immunization enhances the magnitude of the germinal center response upon influenza infection., References: ['']\n",
      "DEBUG - Citing Paper: Vaccine adjuvants: mechanisms and platforms., References: ['']\n",
      "DEBUG - Citing Paper: Knife's edge: Balancing immunogenicity and reactogenicity in mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: mRNA, the beginning of a new influenza vaccine game., References: ['']\n",
      "DEBUG - Citing Paper: Characteristics and Roles of T Follicular Helper Cells in SARS-CoV-2 Vaccine Response., References: ['']\n",
      "DEBUG - Citing Paper: Innate and Adaptive Immune Parameters following mRNA Vaccination in Mice., References: ['']\n",
      "DEBUG - Citing Paper: Hypopituitarism with secondary adrenocortical insufficiency and arginine vasopressin deficiency due to hypophysitis after COVID-19 vaccination: a case report., References: ['']\n",
      "DEBUG - Citing Paper: Inhalable hybrid nanovaccines with virus-biomimetic structure boost protective immune responses against SARS-CoV-2 variants., References: ['']\n",
      "DEBUG - Citing Paper: Vaccine Strategies to Elicit Mucosal Immunity., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity., References: ['']\n",
      "DEBUG - Citing Paper: The Effect of Cholesterol Content on the Adjuvant Activity of Nucleic-Acid-Free Lipid Nanoparticles., References: ['']\n",
      "DEBUG - Citing Paper: The mRNA-LNP vaccines - the good, the bad and the ugly?, References: ['']\n",
      "DEBUG - Citing Paper: Exploring synergies between B- and T-cell vaccine approaches to optimize immune responses against HIV-workshop report., References: ['']\n",
      "DEBUG - Citing Paper: Nanotechnology's frontier in combatting infectious and inflammatory diseases: prevention and treatment., References: ['']\n",
      "DEBUG - Citing Paper: Transmission-Blocking Vaccines against Schistosomiasis Japonica., References: ['']\n",
      "DEBUG - Citing Paper: Strategies to reduce the risks of mRNA drug and vaccine toxicity., References: ['']\n",
      "DEBUG - Citing Paper: Herpes zoster mRNA vaccine induces superior vaccine immunity over licensed vaccine in mice and rhesus macaques., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccine Nanoplatforms and Innate Immunity., References: ['']\n",
      "DEBUG - Citing Paper: Assessment of Human SARS CoV-2-Specific T-Cell Responses Elicited In Vitro by New Computationally Designed mRNA Immunogens (COVARNA)., References: ['']\n",
      "DEBUG - Citing Paper: Nanoparticle-based DNA vaccine protects against SARS-CoV-2 variants in female preclinical models., References: ['']\n",
      "DEBUG - Citing Paper: Systematic development of ionizable lipid nanoparticles for placental mRNA delivery using a design of experiments approach., References: ['']\n",
      "DEBUG - Citing Paper: Breaking the mold with RNA-a \"RNAissance\" of life science., References: ['']\n",
      "DEBUG - Citing Paper: Cancer vaccines in the clinic., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 vaccination and risk of infectious diseases in hospitalized older patients., References: ['']\n",
      "DEBUG - Citing Paper: Unraveling the surface marker signature of cell-derived vesicles via proteome analysis and nanoparticle flow cytometry., References: ['']\n",
      "DEBUG - Citing Paper: Innate IRE1Î±-XBP1 activation by viral single-stranded RNA and its influence on lung cytokine production during SARS-CoV-2 pneumonia., References: ['']\n",
      "DEBUG - Citing Paper: Straight to the point: targeted mRNA-delivery to immune cells for improved vaccine design., References: ['']\n",
      "DEBUG - Citing Paper: Hepatitis C virus modified sE2<sub>F442NYT</sub> as an antigen in candidate vaccine facilitates human immune cell activation., References: ['']\n",
      "DEBUG - Citing Paper: Screening for lipid nanoparticles that modulate the immune activity of helper T cells towards enhanced antitumour activity., References: ['']\n",
      "DEBUG - Citing Paper: Heterologous booster with a novel formulation containing glycosylated trimeric S protein is effective against Omicron., References: ['']\n",
      "DEBUG - Citing Paper: Delineation of DNA and mRNA COVID-19 vaccine-induced immune responses in preclinical animal models., References: ['']\n",
      "DEBUG - Citing Paper: Intranasal Liposomal Formulation of Spike Protein Adjuvanted with CpG Protects and Boosts Heterologous Immunity of hACE2 Transgenic Mice to SARS-CoV-2 Infection., References: ['']\n",
      "DEBUG - Citing Paper: B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity., References: ['']\n",
      "DEBUG - Citing Paper: IL6 suppresses vaccine responses in neonates by enhancing IL2 activity on T follicular helper cells., References: ['']\n",
      "DEBUG - Citing Paper: The Expression Kinetics and Immunogenicity of Lipid Nanoparticles Delivering Plasmid DNA and mRNA in Mice., References: ['']\n",
      "DEBUG - Citing Paper: The advances of adjuvants in mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Reducing cell intrinsic immunity to mRNA vaccine alters adaptive immune responses in mice., References: ['']\n",
      "DEBUG - Citing Paper: Dendritic Cell-Mimicking Nanoparticles Promote mRNA Delivery to Lymphoid Organs., References: ['']\n",
      "DEBUG - Citing Paper: Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability., References: ['']\n",
      "DEBUG - Citing Paper: An Ionizable Lipid Material with a Vitamin E Scaffold as an mRNA Vaccine Platform for Efficient Cytotoxic T Cell Responses., References: ['']\n",
      "DEBUG - Citing Paper: Lipid carriers for mRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Targeted modulation of immune cells and tissues using engineered biomaterials., References: ['']\n",
      "DEBUG - Citing Paper: Comprehensive Evaluation of Lipid Nanoparticles and Polyplex Nanomicelles for Muscle-Targeted mRNA Delivery., References: ['']\n",
      "DEBUG - Citing Paper: Tolerogenic Lipid Nanoparticles for Delivering Self-Antigen mRNA for the Treatment of Experimental Autoimmune Encephalomyelitis., References: ['']\n",
      "DEBUG - Citing Paper: Broad-spectrum vaccine via combined immunization routes triggers potent immunity to SARS-CoV-2 and its variants., References: ['']\n",
      "DEBUG - Citing Paper: Enhancing the immunogenicity of lipid-nanoparticle mRNA vaccines by adjuvanting the ionizable lipid and the mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Vaccines' New Era-RNA Vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Just Keep Rolling?-An Encompassing Review towards Accelerated Vaccine Product Life Cycles., References: ['']\n",
      "DEBUG - Citing Paper: From Bench to Bedside: Implications of Lipid Nanoparticle Carrier Reactogenicity for Advancing Nucleic Acid Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Gastrointestinal Delivery of an mRNA Vaccine Using Immunostimulatory Polymeric Nanoparticles., References: ['']\n",
      "DEBUG - Citing Paper: Targeting cancer with mRNA-lipid nanoparticles: key considerations and future prospects., References: ['']\n",
      "DEBUG - Citing Paper: Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Development of an mRNA-lipid nanoparticle vaccine against Lyme disease., References: ['']\n",
      "DEBUG - Citing Paper: PepFect14 mediates the delivery of mRNA into human primary keratinocytes and <i>in vivo</i>., References: ['']\n",
      "DEBUG - Citing Paper: Nanoparticle-Based Adjuvants and Delivery Systems for Modern Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Baseline Gut Microbiome Signatures Correlate with Immunogenicity of SARS-CoV-2 mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Delivery and Expression of mRNA in the Secondary Lymphoid Organs Drive Immune Responses to Lipid Nanoparticle-mRNA Vaccines after Intramuscular Injection., References: ['']\n",
      "DEBUG - Citing Paper: Expanding the Reach of Monoclonal Antibodies: A Review of Synthetic Nucleic Acid Delivery in Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: New-onset and relapsed Graves' disease following COVID-19 vaccination: aÂ comprehensive review of reported cases., References: ['']\n",
      "DEBUG - Citing Paper: Comb-structured mRNA vaccine tethered with short double-stranded RNA adjuvants maximizes cellular immunity for cancer treatment., References: ['']\n",
      "DEBUG - Citing Paper: The impact of nucleoside base modification in mRNA vaccine is influenced by the chemistry of its lipid nanoparticle delivery system., References: ['']\n",
      "DEBUG - Citing Paper: Enhancement of bone regeneration by coadministration of angiogenic and osteogenic factors using messenger RNA., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-based cancer therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Two Modes of Th1 Polarization Induced by Dendritic-Cell-Priming Adjuvant in Vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Graves' Disease after mRNA COVID-19 Vaccination, with the Presence of Autoimmune Antibodies Even One Year Later., References: ['']\n",
      "DEBUG - Citing Paper: Adjuvants for COVID-19 Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19, Myocarditis and Pericarditis., References: ['']\n",
      "DEBUG - Citing Paper: Cationic crosslinked carbon dots-adjuvanted intranasal vaccine induces protective immunity against Omicron-included SARS-CoV-2 variants., References: ['']\n",
      "DEBUG - Citing Paper: Cytokinopathy with aberrant cytotoxic lymphocytes and profibrotic myeloid response in SARS-CoV-2 mRNA vaccine-associated myocarditis., References: ['']\n",
      "DEBUG - Citing Paper: The tumor therapeutic potential of long non-coding RNA delivery and targeting., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Development of an mRNA vaccine against a panel of heterologous H1N1 seasonal influenza viruses using a consensus hemagglutinin sequence., References: ['']\n",
      "DEBUG - Citing Paper: Engineering cytokine therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: mRNA melanoma vaccine revolution spurred by the COVID-19 pandemic., References: ['']\n",
      "DEBUG - Citing Paper: Lynch syndrome cancer vaccines: A roadmap for the development of precision immunoprevention strategies., References: ['']\n",
      "DEBUG - Citing Paper: Research Advances on the Stability of mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Biomimetic Nanotechnology for SARS-CoV-2 Treatment., References: ['']\n",
      "DEBUG - Citing Paper: Recent Advances in the Lipid Nanoparticle-Mediated Delivery of mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Biomaterials for intranasal and inhaled vaccine delivery., References: ['']\n",
      "DEBUG - Citing Paper: DLin-MC3-Containing mRNA Lipid Nanoparticles Induce an Antibody Th2-Biased Immune Response Polarization in a Delivery Route-Dependent Manner in Mice., References: ['']\n",
      "DEBUG - Citing Paper: Encapsulation: A Strategy to Deliver Therapeutics and Bioactive Compounds?, References: ['']\n",
      "DEBUG - Citing Paper: Breast tumors interfere with endothelial TRAIL at the premetastatic niche to promote cancer cell seeding., References: ['']\n",
      "DEBUG - Citing Paper: Hepatitis C virus E1 and modified E2 delivered from an mRNA vaccine induces protective immunity., References: ['']\n",
      "DEBUG - Citing Paper: Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain., References: ['']\n",
      "DEBUG - Citing Paper: A-910823, a squalene-based emulsion adjuvant, induces T follicular helper cells and humoral immune responses <i>via</i> Î±-tocopherol component., References: ['']\n",
      "DEBUG - Citing Paper: A single-dose F1-based mRNA-LNP vaccine provides protection against the lethal plague bacterium., References: ['']\n",
      "DEBUG - Citing Paper: Impaired antibody response to inactivated COVID-19 vaccines in hospitalized patients with type 2 diabetes., References: ['']\n",
      "DEBUG - Citing Paper: Toxicological Assessments of a Pandemic COVID-19 Vaccine-Demonstrating the Suitability of a Platform Approach for mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Opposite Effects of mRNA-Based and Adenovirus-Vectored SARS-CoV-2 Vaccines on Regulatory T Cells: A Pilot Study., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticles (LNP) induce activation and maturation of antigen presenting cells in young and aged individuals., References: ['']\n",
      "DEBUG - Citing Paper: Advanced delivery systems for peptide antibiotics., References: ['']\n",
      "DEBUG - Citing Paper: A Comprehensive Review of mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Immunization of Mice with Virus-Like Vesicles of Kaposi Sarcoma-Associated Herpesvirus Reveals a Role for Antibodies Targeting ORF4 in Activating Complement-Mediated Neutralization., References: ['']\n",
      "DEBUG - Citing Paper: Review: Current trends, challenges, and success stories in adjuvant research., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines against SARS-CoV-2 induce comparably low long-term IgG Fc galactosylation and sialylation levels but increasing long-term IgG4 responses compared to an adenovirus-based vaccine., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 vaccines and a perspective on Africa., References: ['']\n",
      "DEBUG - Citing Paper: Biomaterials-Mediated Engineering of the Immune System., References: ['']\n",
      "DEBUG - Citing Paper: Cutaneous Manifestations of SARS-CoV-2, Cutaneous Adverse Reactions to Vaccines Anti-SARS-CoV-2 and Clinical/Dermoscopical Findings: Where We Are and Where We Will Go., References: ['']\n",
      "DEBUG - Citing Paper: A novel heterologous receptor-binding domain dodecamer universal mRNA vaccine against SARS-CoV-2 variants., References: ['']\n",
      "DEBUG - Citing Paper: Efficacy and risk of mRNA vaccination in patients with autoimmune inflammatory rheumatic diseases., References: ['']\n",
      "DEBUG - Citing Paper: The mRNA vaccine BNT162b2 demonstrates impaired T<sub>H</sub>1 immunogenicity in human elders <i>in vitro</i> and aged mice <i>in vivo</i>., References: ['']\n",
      "DEBUG - Citing Paper: Exploring <i>in vitro</i> expression and immune potency in mice using mRNA encoding the <i>Plasmodium falciparum</i> malaria antigen, CelTOS., References: ['']\n",
      "DEBUG - Citing Paper: Formulation, inflammation, and RNA sensing impact the immunogenicity of self-amplifying RNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: A Possibility of Vasospastic Angina after mRNA COVID-19 Vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticles Delivering Constitutively Active STING mRNA to Stimulate Antitumor Immunity., References: ['']\n",
      "DEBUG - Citing Paper: DNA and mRNA Vaccines for Chronic Viral Infections and Cancer: Rationale, Mechanisms, and Progress., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-LNP expressing PfCSP and Pfs25 vaccine candidates targeting infection and transmission of Plasmodium falciparum., References: ['']\n",
      "DEBUG - Citing Paper: cGAMP-adjuvanted multivalent influenza mRNA vaccines induce broadly protective immunity through cutaneous vaccination in mice., References: ['']\n",
      "DEBUG - Citing Paper: The landscape of mRNA nanomedicine., References: ['']\n",
      "DEBUG - Citing Paper: Innate immune mechanisms of mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination., References: ['']\n",
      "DEBUG - Citing Paper: The lymphatic system and COVID-19 vaccines., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 mRNA-based vaccines in the Aicardi GoutiÃ¨res Syndrome., References: ['']\n",
      "DEBUG - Citing Paper: Trends and patterns in cancer nanotechnology research: A survey of NCI's caNanoLab and nanotechnology characterization laboratory., References: ['']\n",
      "DEBUG - Citing Paper: Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 and Myocarditis: Review of Clinical Presentations, Pathogenesis and Management., References: ['']\n",
      "DEBUG - Citing Paper: Design and lyophilization of lipid nanoparticles for mRNA vaccine and its robust immune response in mice and nonhuman primates., References: ['']\n",
      "DEBUG - Citing Paper: Potential of mRNA vaccines to become versatile cancer vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Pre-exposure to mRNA-LNP inhibits adaptive immune responses and alters innate immune fitness in an inheritable fashion., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 mRNA vaccine BNT162b2 induces autoantibodies against type I interferons in a healthy woman., References: ['']\n",
      "DEBUG - Citing Paper: Immunogenicity of SARS-CoV-2 vaccines in patients with cancer., References: ['']\n",
      "DEBUG - Citing Paper: Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies., References: ['']\n",
      "DEBUG - Citing Paper: Safety and Prophylactic Efficacy of Liposome-Based Vaccine against the Drug-Resistant <i>Acinetobacter baumannii</i> in Mice., References: ['']\n",
      "DEBUG - Citing Paper: \"Don't Look Up\" Your Science-Herd Immunity or Herd Mentality?, References: ['']\n",
      "DEBUG - Citing Paper: Advances in COVID-19 Vaccines and New Coronavirus Variants., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-LNP vaccines tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cells., References: ['']\n",
      "DEBUG - Citing Paper: Targeting T<sub>FH</sub> cells in human diseases and vaccination: rationale and practice., References: ['']\n",
      "DEBUG - Citing Paper: The role of lipid components in lipid nanoparticles for vaccines and gene therapy., References: ['']\n",
      "DEBUG - Citing Paper: Evaluation of the diagnostic features and clinical course of COVID-19 vaccine-associated subacute thyroiditis., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccine boosting enhances antibody responses against SARS-CoV-2 Omicron variant in individuals with antibody deficiency syndromes., References: ['']\n",
      "DEBUG - Citing Paper: Messenger ribonucleic acid vaccines against infectious diseases: current concepts and future prospects., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticle delivery of unmodified mRNAs encoding multiple monoclonal antibodies targeting poxviruses in rabbits., References: ['']\n",
      "DEBUG - Citing Paper: Correlates of protection against SARS-CoV-2 infection and COVID-19 disease., References: ['']\n",
      "DEBUG - Citing Paper: Instructing durable humoral immunity for COVID-19 and other vaccinable diseases., References: ['']\n",
      "DEBUG - Citing Paper: Ionizable Lipid Nanoparticles Enhanced the Synergistic Adjuvant Effect of CpG ODNs and QS21 in a Varicella Zoster Virus Glycoprotein E Subunit Vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Modified E2 Glycoprotein of Hepatitis C Virus Enhances Proinflammatory Cytokines and Protective Immune Response., References: ['']\n",
      "DEBUG - Citing Paper: Lipid-based regulators of immunity., References: ['']\n",
      "DEBUG - Citing Paper: A Precision Adjuvant Approach to Enhance Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines Optimized for Immunologically Distinct Vulnerable Populations., References: ['']\n",
      "DEBUG - Citing Paper: Circular RNA vaccines against SARS-CoV-2 and emerging variants., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 Vaccine: Between Myth and Truth., References: ['']\n",
      "DEBUG - Citing Paper: A flexible, thermostable nanostructured lipid carrier platform for RNA vaccine delivery., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice., References: ['']\n",
      "DEBUG - Citing Paper: Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Increased Interleukin 18-Dependent Immune Responses Are Associated With Myopericarditis After COVID-19 mRNA Vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Relapsed and newly diagnosed Graves' disease due to immunization against COVID-19: A case series and review of the literature., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccine Development for Emerging Animal and Zoonotic Diseases., References: ['']\n",
      "DEBUG - Citing Paper: The Potential of Nanomedicine to Unlock the Limitless Applications of mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 mRNA vaccines: Platforms and current developments., References: ['']\n",
      "DEBUG - Citing Paper: Generation of High Quality Memory B Cells., References: ['']\n",
      "DEBUG - Citing Paper: Nanotechnologies in Delivery of DNA and mRNA Vaccines to the Nasal and Pulmonary Mucosa., References: ['']\n",
      "DEBUG - Citing Paper: Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities., References: ['']\n",
      "DEBUG - Citing Paper: Fatballs foster fabulous follicles., References: ['']\n",
      "DEBUG - focal: Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses., NF: 0, NB: 0, NR: 0, D: 0\n",
      "DEBUG - Focal Paper: Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice., References: \n",
      "ClinicalTrials.gov . C.g., a phase 2 study of BNT113 in participants with human papillomavirus 16 positive (HPV16+) head and neck squamous cell carcinoma (HNSCC) (NCT04534205). Available at: https://clinicaltrials.gov/ct2/show/NCT04534205.\n",
      "DEBUG - Citing Paper: Cancer mRNA vaccines: clinical advances and future opportunities., References: ['']\n",
      "DEBUG - Citing Paper: Pseudouridine and <i>N</i>1-methylpseudouridine as potent nucleotide analogues for RNA therapy and vaccine development., References: ['']\n",
      "DEBUG - Citing Paper: Immunogenicity and effectiveness of an mRNA therapeutic vaccine for HPV-related malignancies., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity., References: ['']\n",
      "DEBUG - Citing Paper: The quest for nanoparticle-powered vaccines in cancer immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Recent progress in mRNA cancer vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Cancer vaccines: from an immunology perspective., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines and their delivery strategies: A journey from infectious diseases to cancer., References: ['']\n",
      "DEBUG - Citing Paper: Full eradication of pre-clinical human papillomaÂ virus-induced tumors by a lentiviral vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Advances in saRNA Vaccine Research against Emerging/Re-Emerging Viruses., References: ['']\n",
      "DEBUG - Citing Paper: HPV16 E6/E7 -based mRNA vaccine is therapeutic in mice bearing aggressive HPV-positive lesions., References: ['']\n",
      "DEBUG - Citing Paper: The antiviral effects of a MEK1/2 inhibitor promote tumor regression in a preclinical model of human papillomavirus infection-induced tumorigenesis., References: ['']\n",
      "DEBUG - Citing Paper: Bioengineered Bovine Papillomavirus L1 Protein Virus-like Particle (VLP) Vaccines for Enhanced Induction of CD8 T Cell Responses through Cross-Priming., References: ['']\n",
      "DEBUG - Citing Paper: Transcription Factor ATF3 Participates in DeltaNp63-Mediated Proliferation of Corneal Epithelial Cells., References: ['']\n",
      "DEBUG - focal: Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice., NF: 0, NB: 0, NR: 0, D: 0\n",
      "DEBUG - Focal Paper: Ribozyme Assays to Quantify the Capping Efficiency of In Vitro-Transcribed mRNA., References: 837. Improving the Specificity of RNAi-Based Therapeutics for Huntingtonâs Disease. Mol Ther. 2011;19:S320.\n",
      "DEBUG - Citing Paper: Future Prospects, Approaches, and the Government's Role in the Development of a Hepatitis C Virus Vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Design and generation of mRNAs encoding conserved regions of SARS-CoV-2 ORF1ab for T cell-mediated immune activation., References: ['']\n",
      "DEBUG - Citing Paper: Selective Characterization of mRNA 5' End-Capping by DNA Probe-Directed Enrichment with Site-Specific Endoribonucleases., References: ['']\n",
      "DEBUG - Citing Paper: Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability., References: ['']\n",
      "DEBUG - Citing Paper: Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Biochemical characterization of mRNA capping enzyme from Faustovirus., References: ['']\n",
      "DEBUG - Citing Paper: The use of RNA-based treatments in the field of cancer immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Cap analogs with a hydrophobic photocleavable tag enable facile purification of fully capped mRNA with various cap structures., References: ['']\n",
      "DEBUG - Citing Paper: mRNA in the Context of Protein Replacement Therapy., References: ['']\n",
      "DEBUG - Citing Paper: Nurturing Deep Tech to Solve Social Problems: Learning from COVID-19 mRNA Vaccine Development., References: ['']\n",
      "DEBUG - Citing Paper: Low Resource Integrated Platform for Production and Analysis of Capped mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Challenges and emerging trends in liquid chromatography-based analyses of mRNA pharmaceuticals., References: ['']\n",
      "DEBUG - Citing Paper: N2 modified dinucleotide cap analogs as a potent tool for mRNA engineering., References: ['']\n",
      "DEBUG - Citing Paper: RNase H-based analysis of synthetic mRNA 5' cap incorporation., References: ['']\n",
      "DEBUG - focal: Ribozyme Assays to Quantify the Capping Efficiency of In Vitro-Transcribed mRNA., NF: 0, NB: 0, NR: 0, D: 0\n",
      "DEBUG - Focal Paper: Publisher Correction: COVID-19 vaccine BNT162b1 elicits human antibody and T<sub>H</sub>1 T cell responses., References: \n",
      "\n",
      " https://bestpractice.bmj.com/topics/enâgb/3000201/prevention\n",
      "DEBUG - Citing Paper: High-dimensional multi-pass flow cytometry via spectrally encoded cellular barcoding., References: ['']\n",
      "DEBUG - Citing Paper: Secure reversal of immune evasion from refractory NSCLC and highly contagious CoV-2 mutants by using 3D-engineered multifunctional biologics., References: ['']\n",
      "DEBUG - Citing Paper: Coronavirus Disease 2019 Vaccine-Induced Flare-Up of Severe Bronchial Asthma Previously Controlled With Dupilumab: A Case Report., References: ['']\n",
      "DEBUG - Citing Paper: Impact of age and comorbidities on SARS-CoV-2 vaccine-induced T cell immunity., References: ['']\n",
      "DEBUG - Citing Paper: Unravelling the role of individual components in pBAE/polynucleotide polyplexes in the synthesis of tailored carriers for specific applications: on the road to rational formulations., References: ['']\n",
      "DEBUG - Citing Paper: In-depth analysis of T cell immunity and antibody responses in heterologous prime-boost-boost vaccine regimens against SARS-CoV-2 and Omicron variant., References: ['']\n",
      "DEBUG - Citing Paper: The Relation between Immunological Features and the Positive SARS-CoV-2 Nucleic Acid in Patients with Nonsevere COVIDâ19., References: ['']\n",
      "DEBUG - Citing Paper: Immediate Hypersensitivity Reactions Induced by COVID-19 Vaccines: Current Trends, Potential Mechanisms and Prevention Strategies., References: ['']\n",
      "DEBUG - Citing Paper: Vaccines for COVID-19: A Systematic Review of Immunogenicity, Current Development, and Future Prospects., References: ['']\n",
      "DEBUG - Citing Paper: Specific antibody response of 14 patients with common variable immunodeficiency to 3 BNT162b2 messenger RNA coronavirus disease 2019 vaccinations., References: ['']\n",
      "DEBUG - Citing Paper: Advances in COVID-19 mRNA vaccine development., References: ['']\n",
      "DEBUG - Citing Paper: Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy., References: ['']\n",
      "DEBUG - Citing Paper: Study of humoral and cellular immunity in vaccinated with mRNA-1273., References: ['']\n",
      "DEBUG - Citing Paper: Lichen planus flare following COVID-19 vaccination: A case report., References: ['']\n",
      "DEBUG - Citing Paper: Nano-carriers of COVID-19 vaccines: the main pillars of efficacy., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 vaccination in solid-organ transplant recipients: What the clinician needs to know., References: ['']\n",
      "DEBUG - Citing Paper: Immunomodulatory Nanomedicine for the Treatment of Atherosclerosis., References: ['']\n",
      "DEBUG - focal: Publisher Correction: COVID-19 vaccine BNT162b1 elicits human antibody and T<sub>H</sub>1 T cell responses., NF: 0, NB: 0, NR: 0, D: 0\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DEBUG - Focal Paper: Nucleoside-modified VEGFC mRNA induces organ-specific lymphatic growth and reverses experimental lymphedema., References: \n",
      "Badger C., Seers K., Preston N., Mortimer P. (2004). Antibiotics/Anti-inflammatories for Reducing Acute Inflammatory Episodes in Lymphoedema of the Limbs. Cochrane database Syst. Rev.\n",
      "10.1002/14651858.cd003143.pub2\n",
      "Available at: https://libguides.jcu.edu.au/ama10th/articles/cochrane-review\n",
      "\n",
      "\n",
      "DEBUG - Citing Paper: Characterization of Atherosclerotic Mice Reveals a Sex-Dependent Susceptibility to Plaque Calcification but No Major Changes in the Lymphatics in the Arterial Wall., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity., References: ['']\n",
      "DEBUG - Citing Paper: Topical tissue nanotransfection of <i>Prox1</i> is effective in the prophylactic management of lymphedema., References: ['']\n",
      "DEBUG - Citing Paper: Strategies to reduce the risks of mRNA drug and vaccine toxicity., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines in disease prevention and treatment., References: ['']\n",
      "DEBUG - Citing Paper: Recombinant VEGF-C (Cys156Ser) improves mesenteric lymphatic drainage and gut immune surveillance in experimental cirrhosis., References: ['']\n",
      "DEBUG - Citing Paper: The use of RNA-based treatments in the field of cancer immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: The Future of Lymphedema: Potential Therapeutic Targets for Treatment., References: ['']\n",
      "DEBUG - Citing Paper: Intestinal Lymphatic Dysfunction in Kidney Disease., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticles for Nucleic Acid Delivery to Endothelial Cells., References: ['']\n",
      "DEBUG - Citing Paper: Single and combined impacts of irradiation and surgery on lymphatic vasculature and fibrosis associated to secondary lymphedema., References: ['']\n",
      "DEBUG - Citing Paper: Pharmacological Treatment of Secondary Lymphedema., References: ['']\n",
      "DEBUG - Citing Paper: CAR T cells produced in vivo to treat cardiac injury., References: ['']\n",
      "DEBUG - focal: Nucleoside-modified VEGFC mRNA induces organ-specific lymphatic growth and reverses experimental lymphedema., NF: 0, NB: 0, NR: 0, D: 0\n",
      "DEBUG - Focal Paper: InÂ vitro-Transcribed mRNA Therapeutics: Out of the Shadows and Into the Spotlight., References: \n",
      "Centers for Disease Control and Prevention. SARS-CoV-2 variant classifications and definitions. Atlanta (GA): Centers for Disease Control and Prevention; 2021. https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html [accessed 2021 Sep 23]\n",
      "DEBUG - Citing Paper: Non-coding RNAs and neuroinflammation: implications for neurological disorders., References: ['']\n",
      "DEBUG - Citing Paper: Harnessing eukaryotic retroelement proteins for transgene insertion into human safe-harbor loci., References: ['']\n",
      "DEBUG - Citing Paper: Gene Therapy of Extracellular Vesicles in Cardiovascular and Metabolic Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Streamlined and on-demand preparation of mRNA products on a universal integrated platform., References: ['']\n",
      "DEBUG - Citing Paper: Combined therapy with pioglitazone and FGF21 mRNA synergistically ameliorates metabolic disorders in NAFLD rats., References: ['']\n",
      "DEBUG - Citing Paper: Modified Bacteriophage for Tumor Detection and Targeted Therapy., References: ['']\n",
      "DEBUG - Citing Paper: Gene Therapy and Cardiovascular Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Utilization and Potential of RNA-Based Therapies in Cardiovascular Disease., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-based modalities for infectious disease management., References: ['']\n",
      "DEBUG - Citing Paper: Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects., References: ['']\n",
      "DEBUG - Citing Paper: Modified mRNA-Based Vaccines Against Coronavirus Disease 2019., References: ['']\n",
      "DEBUG - Citing Paper: Leishmaniac Quest for Developing a Novel Vaccine Platform. Is a Roadmap for Its Advances Provided by the Mad Dash to Produce Vaccines for COVID-19?, References: ['']\n",
      "DEBUG - Citing Paper: Recent Advances in RNA Therapy and Its Carriers to Treat the Single-Gene Neurological Disorders., References: ['']\n",
      "DEBUG - Citing Paper: Empowering patients from within: Emerging nanomedicines for in vivo immune cell reprogramming., References: ['']\n",
      "DEBUG - Citing Paper: Heterogeneous Longitudinal Antibody Responses to Covid-19 mRNA Vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Concentration of Na<sup>+</sup>-taurocholate-cotransporting polypeptide expressed after in vitro-transcribed mRNA transfection determines susceptibility of hepatoma cells for hepatitis B virus., References: ['']\n",
      "DEBUG - Citing Paper: Biopharmaceutics 4.0, Advanced Pre-Clinical Development of mRNA-Encoded Monoclonal Antibodies to Immunosuppressed Murine Models., References: ['']\n",
      "DEBUG - Citing Paper: Application of Modified mRNA in Somatic Reprogramming to Pluripotency and Directed Conversion of Cell Fate., References: ['']\n",
      "DEBUG - Citing Paper: From Recoding to Peptides for MHC Class I Immune Display: Enriching Viral Expression, Virus Vulnerability and Virus Evasion., References: ['']\n",
      "DEBUG - Citing Paper: Editorial: mRNA Vaccines and Future Epidemic, Pandemic, and Endemic Zoonotic Virus Infections., References: ['']\n",
      "DEBUG - Citing Paper: The Limitless Future of RNA Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Encapsulation state of messenger RNA inside lipid nanoparticles., References: ['']\n",
      "DEBUG - Citing Paper: Self-assembled miRNA-switch nanoparticles target denuded regions and prevent restenosis., References: ['']\n",
      "DEBUG - Citing Paper: Phosphodiester modifications in mRNA poly(A) tail prevent deadenylation without compromising protein expression., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Transfection-Induced Activation of Primary Human Monocytes and Macrophages: Dependence on Carrier System and Nucleotide Modification., References: ['']\n",
      "DEBUG - focal: InÂ vitro-Transcribed mRNA Therapeutics: Out of the Shadows and Into the Spotlight., NF: 0, NB: 0, NR: 0, D: 0\n",
      "DEBUG - Focal Paper: Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine., References: \n",
      "Arcturus Announces self-amplifying COVID-19 mRNA vaccine candidate ARCT-154 meets primary efficacy endpoint in phase 3 study . Arcturus Therapeutics, Inc. Available at: https://ir.arcturusrx.com/news-releases/news-release-details/arcturus-announces-self-amplifying-covid-19-mrna-vaccine (Accessed July 13, 2022).\n",
      "DEBUG - Citing Paper: Overcoming thermostability challenges in mRNA-lipid nanoparticle systems with piperidine-based ionizable lipids., References: ['']\n",
      "DEBUG - Citing Paper: Long-term stability and immunogenicity of lipid nanoparticle COVID-19 mRNA vaccine is affected by particle size., References: ['']\n",
      "DEBUG - Citing Paper: Preparation and Optimization of MiR-375 Nano-Vector Using Two Novel Chitosan-Coated Nano-Structured Lipid Carriers as Gene Therapy for Hepatocellular Carcinoma., References: ['']\n",
      "DEBUG - Citing Paper: Identification of film-based formulations that move mRNA lipid nanoparticles out of the freezer., References: ['']\n",
      "DEBUG - Citing Paper: Silicon Ether Ionizable Lipids Enable Potent mRNA Lipid Nanoparticles with Rapid Tissue Clearance., References: ['']\n",
      "DEBUG - Citing Paper: Hybrid Lipid Nanocapsules: A Robust Platform for mRNA Delivery., References: ['']\n",
      "DEBUG - Citing Paper: Recent Progress in Nucleic Acid Pulmonary Delivery toward Overcoming Physiological Barriers and Improving Transfection Efficiency., References: ['']\n",
      "DEBUG - Citing Paper: Recent advances in nanoparticulate RNA delivery systems., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity., References: ['']\n",
      "DEBUG - Citing Paper: Durable cross-protective neutralizing antibody responses elicited by lipid nanoparticle-formulated SARS-CoV-2 mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticle-Based Delivery System-A Competing Place for mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Chemistry and Art of Developing Lipid Nanoparticles for Biologics Delivery: Focus on Development and Scale-Up., References: ['']\n",
      "DEBUG - Citing Paper: Engineered EVs with pathogen proteins: promising vaccine alternatives to LNP-mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Breaking the mold with RNA-a \"RNAissance\" of life science., References: ['']\n",
      "DEBUG - Citing Paper: Circular RNA vaccines with long-term lymph node-targeting delivery stability after lyophilization induce potent and persistent immune responses., References: ['']\n",
      "DEBUG - Citing Paper: Enabling mRNA Therapeutics: Current Landscape and Challenges in Manufacturing., References: ['']\n",
      "DEBUG - Citing Paper: The Nobel Prize awarded to pioneers of mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability., References: ['']\n",
      "DEBUG - Citing Paper: A single immunization with core-shell structured lipopolyplex mRNA vaccine against rabies induces potent humoral immunity in mice and dogs., References: ['']\n",
      "DEBUG - Citing Paper: Lyophilization process optimization and molecular dynamics simulation of mRNA-LNPs for SARS-CoV-2 vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Recent Developments in Vaccine Design: From Live Vaccines to Recombinant Toxin Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Microfluidics for nano-drug delivery systems: From fundamentals to industrialization., References: ['']\n",
      "DEBUG - Citing Paper: Novel PEGylated cholephytosomes for targeting fisetin to breast cancer: in vitro appraisal and in vivo antitumoral studies., References: ['']\n",
      "DEBUG - Citing Paper: Targeting cancer with mRNA-lipid nanoparticles: key considerations and future prospects., References: ['']\n",
      "DEBUG - Citing Paper: Recent Advances in Messenger Ribonucleic Acid (mRNA) Vaccines and Their Delivery Systems: A Review., References: ['']\n",
      "DEBUG - Citing Paper: Practical Considerations for Next-Generation Adjuvant Development and Translation., References: ['']\n",
      "DEBUG - Citing Paper: Development of an Alcohol Dilution-Lyophilization Method for the Preparation of mRNA-LNPs with Improved Storage Stability., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-based cancer therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Development of Nanopackaging for Storage and Transport of Loaded Lipid Nanoparticles., References: ['']\n",
      "DEBUG - Citing Paper: Which strain of the avian coronavirus vaccine will become the prevalent one in China next?, References: ['']\n",
      "DEBUG - Citing Paper: Revolutionizing viral disease vaccination: the promising clinical advancements of non-replicating mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Research Advances on the Stability of mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Continuous freeze-drying of messenger RNA lipid nanoparticles enables storage at higher temperatures., References: ['']\n",
      "DEBUG - Citing Paper: Nanobiotechnology-Enabled mRNA Stabilization., References: ['']\n",
      "DEBUG - Citing Paper: Gene-encoded nanoparticle vaccine platforms for in vivo assembly of multimeric antigen to promote adaptive immunity., References: ['']\n",
      "DEBUG - Citing Paper: Advanced delivery systems for peptide antibiotics., References: ['']\n",
      "DEBUG - Citing Paper: Freeze Drying of Polymer Nanoparticles and Liposomes Exploiting Different Saccharide-Based Approaches., References: ['']\n",
      "DEBUG - Citing Paper: A Comprehensive Review of mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: mRNA in the Context of Protein Replacement Therapy., References: ['']\n",
      "DEBUG - Citing Paper: Exosomes based advancements for application in medical aesthetics., References: ['']\n",
      "DEBUG - Citing Paper: Nurturing Deep Tech to Solve Social Problems: Learning from COVID-19 mRNA Vaccine Development., References: ['']\n",
      "DEBUG - Citing Paper: Optimization of storage conditions for lipid nanoparticle-formulated self-replicating RNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Advancing mRNA technologies for therapies and vaccines: An African context., References: ['']\n",
      "DEBUG - Citing Paper: The Storage and In-Use Stability of mRNA Vaccines and Therapeutics: Not A Cold Case., References: ['']\n",
      "DEBUG - Citing Paper: A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model., References: ['']\n",
      "DEBUG - Citing Paper: Freeze-drying for the preservation of immunoengineering products., References: ['']\n",
      "DEBUG - Citing Paper: Design Strategies for and Stability of mRNA-Lipid Nanoparticle COVID-19 Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Design and lyophilization of lipid nanoparticles for mRNA vaccine and its robust immune response in mice and nonhuman primates., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines in the prevention and treatment of diseases., References: ['']\n",
      "DEBUG - Citing Paper: Emerging trends of research on mRNA vaccines: A co-citation analysis., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-based modalities for infectious disease management., References: ['']\n",
      "DEBUG - Citing Paper: Overcoming the challenge of long-term storage of mRNA-lipid nanoparticle vaccines., References: ['']\n",
      "DEBUG - focal: Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine., NF: 0, NB: 0, NR: 0, D: 0\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DEBUG - Focal Paper: Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models., References: \n",
      "BioNTech[homepage on the Internet]. mRNA-based BNT111 FixVac melanoma trial in Nature [cited 2022 Jan]. Available from: https://investors.biontech.de/news-releases/news-release-details/biontech-publishes-data-mrna-based-bnt111-fixvac-melanoma-trial/.\n",
      "DEBUG - Citing Paper: Efficient signal sequence of mRNA vaccines enhances the antigen expression to expand the immune protection against viral infection., References: ['']\n",
      "DEBUG - Citing Paper: Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities., References: ['']\n",
      "DEBUG - Citing Paper: Combination therapy with oncolytic virus and T cells or mRNA vaccine amplifies antitumor effects., References: ['']\n",
      "DEBUG - Citing Paper: Noncovalently particle-anchored cytokines with prolonged tumor retention safely elicit potent antitumor immunity., References: ['']\n",
      "DEBUG - Citing Paper: Nucleic acid-based drugs for patients with solid tumours., References: ['']\n",
      "DEBUG - Citing Paper: Type III interferon inhibits bladder cancer progression by reprogramming macrophage-mediated phagocytosis and orchestrating effective immune responses., References: ['']\n",
      "DEBUG - Citing Paper: Universal STING mimic boosts antitumour immunity via preferential activation of tumour control signalling pathways., References: ['']\n",
      "DEBUG - Citing Paper: Lipid-Encapsulated mRNAs Encoding Complex Fusion Proteins Potentiate Antitumor Immune Responses., References: ['']\n",
      "DEBUG - Citing Paper: Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target., References: ['']\n",
      "DEBUG - Citing Paper: Oncometabolite 2-hydroxyglutarate regulates anti-tumor immunity., References: ['']\n",
      "DEBUG - Citing Paper: Harnessing natural killer cell effector function against cancer., References: ['']\n",
      "DEBUG - Citing Paper: Inhalable extracellular vesicle delivery of IL-12 mRNA to treat lung cancer and promote systemic immunity., References: ['']\n",
      "DEBUG - Citing Paper: Strategies for non-viral vectors targeting organs beyond the liver., References: ['']\n",
      "DEBUG - Citing Paper: An extracellular humanized IFNAR immunocompetent mouse model for analyses of human interferon alpha and subtypes., References: ['']\n",
      "DEBUG - Citing Paper: Local application of engineered insulin-like growth factor I mRNA demonstrates regenerative therapeutic potential <i>inÂ vivo</i>., References: ['']\n",
      "DEBUG - Citing Paper: Current State of Human Gene Therapy: Approved Products and Vectors., References: ['']\n",
      "DEBUG - Citing Paper: Reducing cell intrinsic immunity to mRNA vaccine alters adaptive immune responses in mice., References: ['']\n",
      "DEBUG - Citing Paper: Targeted modulation of immune cells and tissues using engineered biomaterials., References: ['']\n",
      "DEBUG - Citing Paper: Circular RNA vaccine in disease prevention and treatment., References: ['']\n",
      "DEBUG - Citing Paper: Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-Î² antagonists., References: ['']\n",
      "DEBUG - Citing Paper: Intratumoral injection of IL-12-encoding mRNA targeted to CSFR1 and PD-L1 exerts potent anti-tumor effects without substantial systemic exposure., References: ['']\n",
      "DEBUG - Citing Paper: Strategies to therapeutically modulate cytokine action., References: ['']\n",
      "DEBUG - Citing Paper: mRNA lipid nanoparticle-mediated pyroptosis sensitizes immunologically cold tumors to checkpoint immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Restoring tumor immunogenicity with dendritic cell reprogramming., References: ['']\n",
      "DEBUG - Citing Paper: Emerging Progress of RNA-Based Antitumor Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-based cancer therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Amplifying gene expression with RNA-targeted therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Engineering cytokine therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Revolutionizing viral disease vaccination: the promising clinical advancements of non-replicating mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Worth a Pound of Cure? Emerging Strategies and Challenges in Cancer Immunoprevention., References: ['']\n",
      "DEBUG - Citing Paper: Combination of immune checkpoint blockade and targeted gene regulation of angiogenesis for facilitating antitumor immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Synthetic enforcement of STING signaling in cancer cells appropriates the immune microenvironment for checkpoint inhibitor therapy., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-Based Therapeutics in Cancer Treatment., References: ['']\n",
      "DEBUG - Citing Paper: Biomaterials-Mediated Engineering of the Immune System., References: ['']\n",
      "DEBUG - Citing Paper: Cytokine conjugation to enhance T cell therapy., References: ['']\n",
      "DEBUG - Citing Paper: Nanoformulations targeting immune cells for cancer therapy: mRNA therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: In situ Preparation of a Phospholipid Gel Co-Loaded with Methotrexate and Dexamethasone for Synergistic Rheumatoid Arthritis Treatment., References: ['']\n",
      "DEBUG - Citing Paper: A (Controlled) Spill of IL2 for Localized Treatment of Mesothelioma., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines in the prevention and treatment of diseases., References: ['']\n",
      "DEBUG - Citing Paper: Friend or foe: RIG- I like receptors and diseases., References: ['']\n",
      "DEBUG - Citing Paper: Cancer vaccines: Building a bridge over troubled waters., References: ['']\n",
      "DEBUG - Citing Paper: Targeting Cytokine Signals to Enhance Î³Î´T Cell-Based Cancer Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: An armed oncolytic virus enhances the efficacy of tumor-infiltrating lymphocyte therapy by converting tumors to artificial antigen-presenting cells in situ., References: ['']\n",
      "DEBUG - Citing Paper: Intratumorally anchored cytokine therapy., References: ['']\n",
      "DEBUG - Citing Paper: RNA in Cancer Immunotherapy: Unlocking the Potential of the Immune System., References: ['']\n",
      "DEBUG - Citing Paper: Delivery Systems of Plasmid DNA and Messenger RNA for Advanced Therapies., References: ['']\n",
      "DEBUG - Citing Paper: mRNA cancer vaccines: Advances, trends and challenges., References: ['']\n",
      "DEBUG - Citing Paper: Messenger RNA vaccines for cancer immunotherapy: progress promotes promise., References: ['']\n",
      "DEBUG - Citing Paper: RNA-mediated immunotherapy regulating tumor immune microenvironment: next wave of cancer therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Co-Delivery of mRNA and pDNA Using Thermally Stabilized Coacervate-Based Core-Shell Nanosystems., References: ['']\n",
      "DEBUG - Citing Paper: Capitalizing on the messenger: Intra-tumoral delivery of RNA with a systemic effect., References: ['']\n",
      "DEBUG - focal: Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models., NF: 0, NB: 0, NR: 0, D: 0\n",
      "DEBUG - Focal Paper: The Emerging Role of InÂ Vitro-Transcribed mRNA in Adoptive T Cell Immunotherapy., References: \n",
      "Autoimmune Registry, Inc . Available at: https://www.autoimmuneregistry.org.\n",
      "DEBUG - Citing Paper: Advances in nano-immunotherapy for hematological malignancies., References: ['']\n",
      "DEBUG - Citing Paper: Engineered Adoptive T-Cell Therapies for Breast Cancer: Current Progress, Challenges, and Potential., References: ['']\n",
      "DEBUG - Citing Paper: Advancing CART therapy for acute myeloid leukemia: recent breakthroughs and strategies for future development., References: ['']\n",
      "DEBUG - Citing Paper: Recruiting In Vitro Transcribed mRNA against Cancer Immunotherapy: A Contemporary Appraisal of the Current Landscape., References: ['']\n",
      "DEBUG - Citing Paper: CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn., References: ['']\n",
      "DEBUG - Citing Paper: Enabling mRNA Therapeutics: Current Landscape and Challenges in Manufacturing., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticle-based mRNA delivery systems for cancer immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Immunotargeting of Cancer Stem Cells., References: ['']\n",
      "DEBUG - Citing Paper: Immune subtype identification and multi-layer perceptron classifier construction for breast cancer., References: ['']\n",
      "DEBUG - Citing Paper: Current strategies employed in the manipulation of gene expression for clinical purposes., References: ['']\n",
      "DEBUG - Citing Paper: Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors., References: ['']\n",
      "DEBUG - Citing Paper: Epigenetic regulation and T-cell responses in endometriosis - something other than autoimmunity., References: ['']\n",
      "DEBUG - Citing Paper: Fingolimod-Conjugated Charge-Altering Releasable Transporters Efficiently and Specifically Deliver mRNA to Lymphocytes In Vivo and In Vitro., References: ['']\n",
      "DEBUG - Citing Paper: RNA in Cancer Immunotherapy: Unlocking the Potential of the Immune System., References: ['']\n",
      "DEBUG - Citing Paper: Hydroxycholesterol substitution in ionizable lipid nanoparticles for mRNA delivery to T cells., References: ['']\n",
      "DEBUG - Citing Paper: Advanced Biomaterials for Cell-Specific Modulation and Restore of Cancer Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Chimeric antigen receptor T-cell therapy in acute myeloid leukemia., References: ['']\n",
      "DEBUG - Citing Paper: NK cell upraise in the dark world of cancer stem cells., References: ['']\n",
      "DEBUG - Citing Paper: NKG7 Is a T-cell-Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: T Cell Engaging Immunotherapies, Highlighting Chimeric Antigen Receptor (CAR) T Cell Therapy., References: ['']\n",
      "DEBUG - Citing Paper: Orthogonal Design of Experiments for Optimization of Lipid Nanoparticles for mRNA Engineering of CAR T Cells., References: ['']\n",
      "DEBUG - Citing Paper: CARTing Away Cardiac Fibrosis., References: ['']\n",
      "DEBUG - Citing Paper: NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma., References: ['']\n",
      "DEBUG - Citing Paper: Intracellular Delivery of mRNA in Adherent and Suspension Cells by Vapor Nanobubble Photoporation., References: ['']\n",
      "DEBUG - Citing Paper: Highly efficient CD4+ TÂ cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs., References: ['']\n",
      "DEBUG - Citing Paper: mRNA in cancer immunotherapy: beyond a source of antigen., References: ['']\n",
      "DEBUG - Citing Paper: In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo., References: ['']\n",
      "DEBUG - Citing Paper: Advances in Lipid Nanoparticles for mRNA-Based Cancer Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug Delivery., References: ['']\n",
      "DEBUG - Citing Paper: Advances in Development of mRNA-Based Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Impact of mRNA chemistry and manufacturing process on innate immune activation., References: ['']\n",
      "DEBUG - Citing Paper: Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma., References: ['']\n",
      "DEBUG - Citing Paper: Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives., References: ['']\n",
      "DEBUG - Citing Paper: Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering., References: ['']\n",
      "DEBUG - Citing Paper: Targeting cancers through TCR-peptide/MHC interactions., References: ['']\n",
      "DEBUG - Citing Paper: Overcoming Challenges in Process Development of Cellular Therapies., References: ['']\n",
      "DEBUG - Citing Paper: Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy., References: ['']\n",
      "DEBUG - focal: The Emerging Role of InÂ Vitro-Transcribed mRNA in Adoptive T Cell Immunotherapy., NF: 0, NB: 0, NR: 0, D: 0\n",
      "DEBUG - Focal Paper: Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques., References: \n",
      "ClinicalTrials.gov\n",
      ". NIH U.S. National Library of Medicine, https://clinicaltrials.gov/ct2/results?term=vaccine&cond=Covid19&age_v=&gndr=&type=&rslt=&phase=2&Search=Apply (accessed: October 2020).\n",
      "DEBUG - Citing Paper: Potent cancer therapy by liposome microstructure tailoring with active-to-passive targeting and shell-to-core thermosensitive features., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity., References: ['']\n",
      "DEBUG - Citing Paper: Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadth., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticle-Based Delivery System-A Competing Place for mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Screening for lipid nanoparticles that modulate the immune activity of helper T cells towards enhanced antitumour activity., References: ['']\n",
      "DEBUG - Citing Paper: Recent Advances in Messenger Ribonucleic Acid (mRNA) Vaccines and Their Delivery Systems: A Review., References: ['']\n",
      "DEBUG - Citing Paper: Applications of advances in mRNA-based platforms as therapeutics and diagnostics in reproductive technologies., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV., References: ['']\n",
      "DEBUG - Citing Paper: DLin-MC3-Containing mRNA Lipid Nanoparticles Induce an Antibody Th2-Biased Immune Response Polarization in a Delivery Route-Dependent Manner in Mice., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccines against SARS-CoV-2: Advantages and Caveats., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccine Mitigates SARS-CoV-2 Infections and COVID-19., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-based vaccine technology for HIV., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines: Past, present, future., References: ['']\n",
      "DEBUG - Citing Paper: Synthesis of point-modified mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Nanoparticles in clinical trials of COVID-19: An update., References: ['']\n",
      "DEBUG - Citing Paper: The legacy of mRNA engineering: A lineup of pioneers for the Nobel Prize., References: ['']\n",
      "DEBUG - Citing Paper: Nucleic Acid Vaccine Platform for DENGUE and ZIKA Flaviviruses., References: ['']\n",
      "DEBUG - Citing Paper: Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects., References: ['']\n",
      "DEBUG - Citing Paper: Functional and Highly Cross-Linkable HIV-1 Envelope Glycoproteins Enriched in a Pretriggered Conformation., References: ['']\n",
      "DEBUG - Citing Paper: Modification of Lipid-Based Nanoparticles: An Efficient Delivery System for Nucleic Acid-Based Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Advances in COVID-19 mRNA vaccine development., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Vaccine-Induced, High-Magnitude HIV Env-Specific Antibodies with Fc-Mediated Effector Functions Are Insufficient to Protect Infant Rhesus Macaques against Oral SHIV Infection., References: ['']\n",
      "DEBUG - Citing Paper: A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses., References: ['']\n",
      "DEBUG - Citing Paper: Pneumococcal Vaccines: Past Findings, Present Work, and Future Strategies., References: ['']\n",
      "DEBUG - Citing Paper: Nucleoside-Modified mRNA Vaccines Protect IFNAR<sup>-/-</sup> Mice against Crimean-Congo Hemorrhagic Fever Virus Infection., References: ['']\n",
      "DEBUG - Citing Paper: Advances in mRNA and other vaccines against MERS-CoV., References: ['']\n",
      "DEBUG - Citing Paper: Strategies for eliciting multiple lineages of broadly neutralizing antibodies to HIV by vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticles for Organ-Specific mRNA Therapeutic Delivery., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines for infectious diseases: principles, delivery and clinical translation., References: ['']\n",
      "DEBUG - Citing Paper: Development and Delivery Systems of mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: HIV and Messenger RNA (mRNA) Vaccine., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccination compared to infection elicits an IgG-predominant response with greater SARS-CoV-2 specificity and similar decrease in variant spike recognition., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates., References: ['']\n",
      "DEBUG - Citing Paper: In the Era of mRNA Vaccines, Is There Any Hope for HIV Functional Cure?, References: ['']\n",
      "DEBUG - Citing Paper: A Dengue Virus Serotype 1 mRNA-LNP Vaccine Elicits Protective Immune Responses., References: ['']\n",
      "DEBUG - Citing Paper: Advanced Nanobiomedical Approaches to Combat Coronavirus Disease of 2019., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccines against Flaviviruses., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-Based Vaccines and Mode of Action., References: ['']\n",
      "DEBUG - Citing Paper: HIV mRNA Vaccines-Progress and Future Paths., References: ['']\n",
      "DEBUG - Citing Paper: BNT162b vaccines protect rhesus macaques from SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: Promising Extracellular Vesicle-Based Vaccines against Viruses, Including SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: Self-amplifying RNA vaccines for infectious diseases., References: ['']\n",
      "DEBUG - Citing Paper: Modified mRNA-LNP Vaccines Confer Protection against Experimental DENV-2 Infection in Mice., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticle technology for therapeutic gene regulation in the liver., References: ['']\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DEBUG - Citing Paper: Messenger RNA-Based Vaccines Against Infectious Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection., References: ['']\n",
      "DEBUG - Citing Paper: Strategies for inducing effective neutralizing antibody responses against HIV-1., References: ['']\n",
      "DEBUG - focal: Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques., NF: 0, NB: 0, NR: 0, D: 0\n",
      "DEBUG - Focal Paper: Erratum: Elimination of large tumors in mice by mRNA-encoded bispecific antibodies., References: Adjei A. A. Blocking Oncogenic Ras Signaling for Cancer Therapy. J. Natl. Cancer Inst. 2001, 93, 1062â1074. 10.1093/jnci/93.14.1062.\n",
      "DEBUG - Citing Paper: Lipid-mRNA Nanoparticle Designed to Enhance Intracellular Delivery Mediated by Shock Waves., References: ['']\n",
      "DEBUG - Citing Paper: Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells., References: ['']\n",
      "DEBUG - focal: Erratum: Elimination of large tumors in mice by mRNA-encoded bispecific antibodies., NF: 0, NB: 0, NR: 0, D: 0\n",
      "DEBUG - Focal Paper: Oxidative damage of SP-D abolishes control of eosinophil extracellular DNA trap formation., References: ARCHER GT, HIRSCH JG (1963) Motion picture studies on degranulation of horse eosinophils during phagocytosis. J Exp Med 118:287â294\n",
      "DEBUG - Citing Paper: Eosinophil extracellular traps in asthma: implications for pathogenesis and therapy., References: ['']\n",
      "DEBUG - Citing Paper: Impact of Air Pollution on Asthma: A Scoping Review., References: ['']\n",
      "DEBUG - Citing Paper: Single-Walled vs. Multi-Walled Carbon Nanotubes: Influence of Physico-Chemical Properties on Toxicogenomics Responses in Mouse Lungs., References: ['']\n",
      "DEBUG - Citing Paper: Regulation of macrophage activation by S-Nitrosothiols following ozone-induced lung injury., References: ['']\n",
      "DEBUG - Citing Paper: A Novel Nonhuman Primate Model of Nonatopic Asthma., References: ['']\n",
      "DEBUG - Citing Paper: SP-D and CC-16 Pneumoproteins' Kinetics and Their Predictive Role During SARS-CoV-2 Infection., References: ['']\n",
      "DEBUG - Citing Paper: Lower Oligomeric Form of Surfactant Protein D in Murine Acute Lung Injury Induces M1 Subtype Macrophages Through Calreticulin/p38 MAPK Signaling Pathway., References: ['']\n",
      "DEBUG - Citing Paper: The Immune System Throws Its Traps: Cells and Their Extracellular Traps in Disease and Protection., References: ['']\n",
      "DEBUG - Citing Paper: Ozone-Based Eye Drops Activity on Ocular Epithelial Cells and Potential Pathogens Infecting the Front of the Eye., References: ['']\n",
      "DEBUG - Citing Paper: Eosinophils as Major Player in Type 2 Inflammation: Autoimmunity and Beyond., References: ['']\n",
      "DEBUG - Citing Paper: Ozone-Induced Oxidative Stress, Neutrophilic Airway Inflammation, and Glucocorticoid Resistance in Asthma., References: ['']\n",
      "DEBUG - Citing Paper: The Release Kinetics of Eosinophil Peroxidase and Mitochondrial DNA Is Different in Association with Eosinophil Extracellular Trap Formation., References: ['']\n",
      "DEBUG - Citing Paper: SP-A and SP-D: Dual Functioning Immune Molecules With Antiviral and Immunomodulatory Properties., References: ['']\n",
      "DEBUG - Citing Paper: Pulmonary Surfactants: a New Therapeutic Target in Asthma., References: ['']\n",
      "DEBUG - Citing Paper: In vivo evidence for extracellular DNA trap formation., References: ['']\n",
      "DEBUG - Citing Paper: Eosinophil responses during COVID-19 infections and coronavirus vaccination., References: ['']\n",
      "DEBUG - Citing Paper: The Cellular Functions of Eosinophils: Collegium Internationale Allergologicum (CIA) Update 2020., References: ['']\n",
      "DEBUG - Citing Paper: Eosinophil cytolysis on Immunoglobulin G is associated with microtubule formation and suppression of rho-associated protein kinase signalling., References: ['']\n",
      "DEBUG - Citing Paper: Ozone-induced enhancement of airway hyperreactivity in rhesus macaques: Effects of antioxidant treatment., References: ['']\n",
      "DEBUG - Citing Paper: Acute Respiratory Barrier Disruption by Ozone Exposure in Mice., References: ['']\n",
      "DEBUG - Citing Paper: Ozone Inhalation Attenuated the Effects of Budesonide on <i>Aspergillus fumigatus</i>-Induced Airway Inflammation and Hyperreactivity in Mice., References: ['']\n",
      "DEBUG - Citing Paper: [Eosinophilic granulocytes-Physiology and pathophysiology]., References: ['']\n",
      "DEBUG - focal: Oxidative damage of SP-D abolishes control of eosinophil extracellular DNA trap formation., NF: 0, NB: 0, NR: 0, D: 0\n",
      "DEBUG - Focal Paper: Purification of mRNA Encoding Chimeric Antigen Receptor Is Critical for Generation of a Robust T-Cell Response., References: \n",
      "Carroll J. Exclusive: Carl Juneâs Tmunity encounters a lethal roadblock as 2 patient deaths derail lead trial, raise red flag forcing rethink of CAR-T for solid tumors, 2021. Endpoints News [Internet]. Available: https://bit.ly/3wPYWm0\n",
      "\n",
      "DEBUG - Citing Paper: Profile of Katalin KarikÃ³ and Drew Weissman: 2023 Nobel laureates in Physiology or Medicine., References: ['']\n",
      "DEBUG - Citing Paper: mRNA as a medicine in nephrology: the future is now., References: ['']\n",
      "DEBUG - Citing Paper: RNA-Based Therapeutic Technology., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications., References: ['']\n",
      "DEBUG - Citing Paper: Recent Advances and Innovations in the Preparation and Purification of In Vitro-Transcribed-mRNA-Based Molecules., References: ['']\n",
      "DEBUG - Citing Paper: Anti-CD117 CAR TÂ cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticle-based mRNA delivery systems for cancer immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Expanding the Reach of Monoclonal Antibodies: A Review of Synthetic Nucleic Acid Delivery in Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: In Situ Programming of CAR-T Cells: A Pressing Need in Modern Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Enhancing the effectiveness of Î³Î´ TÂ cells by mRNA transfection of chimeric antigen receptors or bispecific TÂ cell engagers., References: ['']\n",
      "DEBUG - Citing Paper: Education and Empowering Special Forces to Eradicate Secret Defectors: Immune System-Based Treatment Approaches for Mature T- and NK-Cell Malignancies., References: ['']\n",
      "DEBUG - Citing Paper: BiTE-Secreting CAR-Î³Î´T as a Dual Targeting Strategy for the Treatment of Solid Tumors., References: ['']\n",
      "DEBUG - Citing Paper: Advanced delivery systems for peptide antibiotics., References: ['']\n",
      "DEBUG - Citing Paper: Harnessing the Potential of Chimeric Antigen Receptor T-Cell Therapy for the Treatment of T-Cell Malignancies: A Dare or Double Dare?, References: ['']\n",
      "DEBUG - Citing Paper: Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19., References: ['']\n",
      "DEBUG - Citing Paper: Nanoformulations targeting immune cells for cancer therapy: mRNA therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: RNA sensor response in HeLa cells for transfected mRNAs prepared <i>in vitro</i> by SP6 and HiT7 RNA polymerases: A comparative study., References: ['']\n",
      "DEBUG - Citing Paper: Current strategies employed in the manipulation of gene expression for clinical purposes., References: ['']\n",
      "DEBUG - Citing Paper: Innate immune mechanisms of mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors., References: ['']\n",
      "DEBUG - Citing Paper: Double-stranded RNA reduction by chaotropic agents during <i>inÂ vitro</i> transcription of messenger RNA., References: ['']\n",
      "DEBUG - Citing Paper: Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL., References: ['']\n",
      "DEBUG - Citing Paper: The Pivotal Role of Chemical Modifications in mRNA Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Potentialities and Challenges of mRNA Vaccine in Cancer Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?, References: ['']\n",
      "DEBUG - Citing Paper: mRNA-based therapeutics: powerful and versatile tools to combat diseases., References: ['']\n",
      "DEBUG - Citing Paper: An mRNA vaccine to prevent genital herpes., References: ['']\n",
      "DEBUG - Citing Paper: Microfluidic transfection of mRNA into human primary lymphocytes and hematopoietic stem and progenitor cells using ultra-fast physical deformations., References: ['']\n",
      "DEBUG - Citing Paper: Orthogonal Design of Experiments for Optimization of Lipid Nanoparticles for mRNA Engineering of CAR T Cells., References: ['']\n",
      "DEBUG - Citing Paper: CAR-T cellÂ therapy in T-cell malignancies: Is success a low-hanging fruit?, References: ['']\n",
      "DEBUG - Citing Paper: Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across., References: ['']\n",
      "DEBUG - Citing Paper: Intracellular Delivery of mRNA in Adherent and Suspension Cells by Vapor Nanobubble Photoporation., References: ['']\n",
      "DEBUG - Citing Paper: Highly efficient CD4+ TÂ cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs., References: ['']\n",
      "DEBUG - Citing Paper: Effects of Chemotherapy Agents on Circulating Leukocyte Populations: Potential Implications for the Success of CAR-T Cell Therapies., References: ['']\n",
      "DEBUG - Citing Paper: mRNA therapeutics in cancer immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: mRNA in cancer immunotherapy: beyond a source of antigen., References: ['']\n",
      "DEBUG - Citing Paper: Neo-Antigen mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update., References: ['']\n",
      "DEBUG - Citing Paper: Overhauling CAR T Cells to Improve Efficacy, Safety and Cost., References: ['']\n",
      "DEBUG - Citing Paper: Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia., References: ['']\n",
      "DEBUG - Citing Paper: Impact of mRNA chemistry and manufacturing process on innate immune activation., References: ['']\n",
      "DEBUG - Citing Paper: Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma., References: ['']\n",
      "DEBUG - Citing Paper: Emerging Approaches for Regulation and Control of CAR T Cells: A Mini Review., References: ['']\n",
      "DEBUG - Citing Paper: Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering., References: ['']\n",
      "DEBUG - Citing Paper: Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies., References: ['']\n",
      "DEBUG - Citing Paper: Establishing Preferred Product Characterization for the Evaluation of RNA Vaccine Antigens., References: ['']\n",
      "DEBUG - Citing Paper: Overcoming Challenges in Process Development of Cellular Therapies., References: ['']\n",
      "DEBUG - Citing Paper: A Facile Method for the Removal of dsRNA Contaminant from InÂ Vitro-Transcribed mRNA., References: ['']\n",
      "DEBUG - Citing Paper: The Emerging Role of InÂ Vitro-Transcribed mRNA in Adoptive T Cell Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases., References: ['']\n",
      "DEBUG - focal: Purification of mRNA Encoding Chimeric Antigen Receptor Is Critical for Generation of a Robust T-Cell Response., NF: 0, NB: 0, NR: 0, D: 0\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DEBUG - Focal Paper: Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies., References: \n",
      "CDC . Key Facts About Seasonal Flu Vaccine (2023). Centers for Disease Control and Prevention. Available online at: https://t.cdc.gov/2S4F (Accessed December 13, 2023).\n",
      "DEBUG - Citing Paper: Very Broadly Effective Hemagglutinin-Directed Influenza Vaccines with Anti-Herpetic Activity., References: ['']\n",
      "DEBUG - Citing Paper: Harnessing T-Cells for Enhanced Vaccine Development against Viral Infections., References: ['']\n",
      "DEBUG - Citing Paper: Development of a nucleoside-modified mRNA vaccine against clade 2.3.4.4b H5 highly pathogenic avian influenza virus., References: ['']\n",
      "DEBUG - Citing Paper: Evaluation of the immunogenicity of an mRNA vectored Nipah virus vaccine candidate in pigs., References: ['']\n",
      "DEBUG - Citing Paper: Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response., References: ['']\n",
      "DEBUG - Citing Paper: A review on Gaucher disease: therapeutic potential of Î²-glucocerebrosidase-targeted mRNA/saRNA approach., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines encoding computationally optimized hemagglutinin elicit protective antibodies against future antigenically drifted H1N1 and H3N2 influenza viruses isolated between 2018-2020., References: ['']\n",
      "DEBUG - Citing Paper: Recent Advances, Approaches and Challenges in the Development of Universal Influenza Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Polymeric nanoparticle-based mRNA vaccine is protective against influenza virus infection in ferrets., References: ['']\n",
      "DEBUG - Citing Paper: Profile of Katalin KarikÃ³ and Drew Weissman: 2023 Nobel laureates in Physiology or Medicine., References: ['']\n",
      "DEBUG - Citing Paper: Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadth., References: ['']\n",
      "DEBUG - Citing Paper: Recent trends in the delivery of RNA drugs: Beyond the liver, more than vaccine., References: ['']\n",
      "DEBUG - Citing Paper: A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax., References: ['']\n",
      "DEBUG - Citing Paper: N<sup>1</sup>-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting., References: ['']\n",
      "DEBUG - Citing Paper: Low-sugar universal mRNA vaccine against coronavirus variants with deletion of glycosites in the S2 or stem of SARS-CoV-2 spike messenger RNA (mRNA)., References: ['']\n",
      "DEBUG - Citing Paper: In Vitro Transcribed RNA-Based Platform Vaccines: Past, Present, and Future., References: ['']\n",
      "DEBUG - Citing Paper: An RNA-Scaffold Protein Subunit Vaccine for Nasal Immunization., References: ['']\n",
      "DEBUG - Citing Paper: Reducing cell intrinsic immunity to mRNA vaccine alters adaptive immune responses in mice., References: ['']\n",
      "DEBUG - Citing Paper: An mRNA-based broad-spectrum vaccine candidate confers cross-protection against heterosubtypic influenza A viruses., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-Based Nanomedicine: A New Strategy for Treating Infectious Diseases and Beyond., References: ['']\n",
      "DEBUG - Citing Paper: Multiple Vaccines and Strategies for Pandemic Preparedness of Avian Influenza Virus., References: ['']\n",
      "DEBUG - Citing Paper: Development of an mRNA-lipid nanoparticle vaccine against Lyme disease., References: ['']\n",
      "DEBUG - Citing Paper: Photobiomodulation reduces neuropathic pain after spinal cord injury by downregulating CXCL10 expression., References: ['']\n",
      "DEBUG - Citing Paper: Potential cross-species transmission of highly pathogenic avian influenza H5 subtype (HPAI H5) viruses to humans calls for the development of H5-specific and universal influenza vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticles (LNP) induce activation and maturation of antigen presenting cells in young and aged individuals., References: ['']\n",
      "DEBUG - Citing Paper: On the Evolutionary Trajectory of SARS-CoV-2: Host Immunity as a Driver of Adaptation in RNA Viruses., References: ['']\n",
      "DEBUG - Citing Paper: The mRNA Vaccine Technology Era and the Future Control of Parasitic Infections., References: ['']\n",
      "DEBUG - Citing Paper: Third-Generation Vaccines: Features of Nucleic Acid Vaccines and Strategies to Improve Their Efficiency., References: ['']\n",
      "DEBUG - Citing Paper: Agent-based model of the impact of higher influenza vaccine efficacy on seasonal influenza burden., References: ['']\n",
      "DEBUG - Citing Paper: Nucleoside-Modified mRNA-Based Influenza Vaccines Circumvent Problems Associated with H3N2 Vaccine Strain Egg Adaptation., References: ['']\n",
      "DEBUG - Citing Paper: Lipid-Based Delivery Systems in Development of Genetic and Subunit Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes., References: ['']\n",
      "DEBUG - Citing Paper: cGAMP-adjuvanted multivalent influenza mRNA vaccines induce broadly protective immunity through cutaneous vaccination in mice., References: ['']\n",
      "DEBUG - Citing Paper: Self-Amplifying RNA Approach for Protein Replacement Therapy., References: ['']\n",
      "DEBUG - Citing Paper: The Coming of Age of Nucleic Acid Vaccines during COVID-19., References: ['']\n",
      "DEBUG - Citing Paper: mRNA nanomedicine: Design and recent applications., References: ['']\n",
      "DEBUG - Citing Paper: Design Strategies for and Stability of mRNA-Lipid Nanoparticle COVID-19 Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Pre-exposure to mRNA-LNP inhibits adaptive immune responses and alters innate immune fitness in an inheritable fashion., References: ['']\n",
      "DEBUG - Citing Paper: Progress towards the Development of a Universal Influenza Vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Polymer formulated self-amplifying RNA vaccine is partially protective against influenza virus infection in ferrets., References: ['']\n",
      "DEBUG - Citing Paper: Clinical Development of mRNA Vaccines: Challenges and Opportunities., References: ['']\n",
      "DEBUG - Citing Paper: Rational development of a combined mRNA vaccine against COVID-19 and influenza., References: ['']\n",
      "DEBUG - Citing Paper: A Single Dose of Anti-HBsAg Antibody-Encoding mRNA-LNPs Suppressed HBsAg Expression: a Potential Cure of Chronic Hepatitis B Virus Infection., References: ['']\n",
      "DEBUG - Citing Paper: Effects of Different Lengths of a Nucleic Acid Binding Region and Bound Nucleic Acids on the Phase Behavior and Purification Process of HBcAg Virus-Like Particles., References: ['']\n",
      "DEBUG - Citing Paper: Message in a bottle: mRNA vaccination for influenza., References: ['']\n",
      "DEBUG - Citing Paper: Prediction of lipid nanoparticles for mRNA vaccines by the machine learning algorithm., References: ['']\n",
      "DEBUG - Citing Paper: Engineered Nanoparticulate Vaccines to Combat Recurring and Pandemic Influenza Threats., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: mRNA as a Therapeutics: Understanding mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Transient production of receptor-binding domain of SARS-CoV-2 in Nicotiana benthamiana plants induces specific antibodies in immunized mice., References: ['']\n",
      "DEBUG - Citing Paper: Modified mRNA-Based Vaccines Against Coronavirus Disease 2019., References: ['']\n",
      "DEBUG - Citing Paper: mRNA cancer vaccines: Advances, trends and challenges., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice., References: ['']\n",
      "DEBUG - Citing Paper: Role of drug delivery technologies in the success of COVID-19 vaccines: a perspective., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccine Development for Emerging Animal and Zoonotic Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals., References: ['']\n",
      "DEBUG - Citing Paper: Langerhans cells and cDC1s play redundant roles in mRNA-LNP induced protective anti-influenza and anti-SARS-CoV-2 immune responses., References: ['']\n",
      "DEBUG - Citing Paper: Subtype H3N2 Influenza A Viruses: An Unmet Challenge in the Western Pacific., References: ['']\n",
      "DEBUG - Citing Paper: Regulation of Antiviral Immune Response by <i>N</i> <sup>6</sup>-Methyladenosine of mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Chimeric Fusion (F) and Attachment (G) Glycoprotein Antigen Delivery by mRNA as a Candidate Nipah Vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccines to Protect Against Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses., References: ['']\n",
      "DEBUG - Citing Paper: The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory., References: ['']\n",
      "DEBUG - Citing Paper: Nucleoside-Modified mRNA Vaccines Protect IFNAR<sup>-/-</sup> Mice against Crimean-Congo Hemorrhagic Fever Virus Infection., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticle chemistry determines how nucleoside base modifications alter mRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: Bioengineering Strategies for Developing Vaccines against Respiratory Viral Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Enabling online determination of the size-dependent RNA content of lipid nanoparticle-based RNA formulations., References: ['']\n",
      "DEBUG - Citing Paper: An Update on mRNA-Based Viral Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Influenza Viruses: Innate Immunity and mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Antigen modifications improve nucleoside-modified mRNA-based influenza virus vaccines in mice., References: ['']\n",
      "DEBUG - Citing Paper: Conserved Sequence Analysis of Influenza A Virus HA Segment and Its Application in Rapid Typing., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines for infectious diseases: principles, delivery and clinical translation., References: ['']\n",
      "DEBUG - Citing Paper: Ability of nucleoside-modified mRNA to encode HIV-1 envelope trimer nanoparticles., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticles for mRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: Development and Delivery Systems of mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Langerhans cells and cDC1s play redundant roles in mRNA-LNP induced protective anti-influenza and anti-SARS-CoV-2 responses., References: ['']\n",
      "DEBUG - Citing Paper: Animal Models Utilized for the Development of Influenza Virus Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Nano-Microparticle Platforms in Developing Next-Generation Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: The Status and Prospects of Epstein-Barr Virus Prophylactic Vaccine Development., References: ['']\n",
      "DEBUG - Citing Paper: From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases., References: ['']\n",
      "DEBUG - Citing Paper: Construction and Immunogenicity of Modified mRNA-Vaccine Variants Encoding Influenza Virus Antigens., References: ['']\n",
      "DEBUG - Citing Paper: Lipid-nanoparticle-encapsulated mRNA vaccines induce protective memory CD8 TÂ cells against a lethal viral infection., References: ['']\n",
      "DEBUG - Citing Paper: Influenza vaccines: Past, present, and future., References: ['']\n",
      "DEBUG - Citing Paper: Functionalized lipid nanoparticles for subcutaneous administration of mRNA to achieve systemic exposures of a therapeutic protein., References: ['']\n",
      "DEBUG - Citing Paper: Advances in vaccine delivery systems against viral infectious diseases., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccines against Flaviviruses., References: ['']\n",
      "DEBUG - Citing Paper: Adenoviral Vectors as Vaccines for Emerging Avian Influenza Viruses., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-Based Vaccines and Mode of Action., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: An Update on Self-Amplifying mRNA Vaccine Development., References: ['']\n",
      "DEBUG - Citing Paper: Next-Generation Vaccines: Nanoparticle-Mediated DNA and mRNA Delivery., References: ['']\n",
      "DEBUG - Citing Paper: The Next Generation of Influenza Vaccines: Towards a Universal Solution., References: ['']\n",
      "DEBUG - Citing Paper: Promising Adjuvants and Platforms for Influenza Vaccine Development., References: ['']\n",
      "DEBUG - Citing Paper: N<sup>6</sup>-Methyladenosine Regulates Host Responses to Viral Infection., References: ['']\n",
      "DEBUG - Citing Paper: Influenza Vaccines toward Universality through Nanoplatforms and Given by Microneedle Patches., References: ['']\n",
      "DEBUG - Citing Paper: Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in mice., References: ['']\n",
      "DEBUG - Citing Paper: Viral Emerging Diseases: Challenges in Developing Vaccination Strategies., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccine Era-Mechanisms, Drug Platform and Clinical Prospection., References: ['']\n",
      "DEBUG - Citing Paper: Modified mRNA-LNP Vaccines Confer Protection against Experimental DENV-2 Infection in Mice., References: ['']\n",
      "DEBUG - Citing Paper: A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19: Progress in diagnostics, therapy and vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticle technology for therapeutic gene regulation in the liver., References: ['']\n",
      "DEBUG - Citing Paper: Anti-PfGARP activates programmed cell death of parasites and reduces severe malaria., References: ['']\n",
      "DEBUG - Citing Paper: A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice., References: ['']\n",
      "DEBUG - Citing Paper: The Transcription Factor T-bet Resolves Memory B Cell Subsets with Distinct Tissue Distributions and Antibody Specificities in Mice and Humans., References: ['']\n",
      "DEBUG - Citing Paper: Messenger RNA-Based Vaccines Against Infectious Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Vaccines to prevent genital herpes., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccines Encoding the HA Protein of Influenza A H1N1 Virus Delivered by Cationic Lipid Nanoparticles Induce Protective Immune Responses in Mice., References: ['']\n",
      "DEBUG - Citing Paper: Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection., References: ['']\n",
      "DEBUG - Citing Paper: Next-generation influenza vaccines: opportunities and challenges., References: ['']\n",
      "DEBUG - Citing Paper: Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization., References: ['']\n",
      "DEBUG - Citing Paper: Influenza Vaccines Delivered in Early Childhood Could Turn Antigenic Sin into Antigenic Blessings., References: ['']\n",
      "DEBUG - Citing Paper: Nucleoside-modified mRNA vaccination partially overcomes maternal antibody inhibition of de novo immune responses in mice., References: ['']\n",
      "DEBUG - Citing Paper: Novel vaccine technologies for the 21st century., References: ['']\n",
      "DEBUG - Citing Paper: Development of Universal Influenza Vaccines Targeting Conserved Viral Proteins., References: ['']\n",
      "DEBUG - Citing Paper: The Quest for a Truly Universal Influenza Vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Enlisting the mRNA Vaccine Platform to Combat Parasitic Infections., References: ['']\n",
      "DEBUG - Citing Paper: Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes., References: ['']\n",
      "DEBUG - Citing Paper: Messenger RNA translation enhancement by immune evasion proteins: a comparative study between EKB (vaccinia virus) and NS1 (influenza A virus)., References: ['']\n",
      "DEBUG - Citing Paper: Innovative Mucosal Vaccine Formulations Against Influenza A Virus Infections., References: ['']\n",
      "DEBUG - Citing Paper: Regulation of Viral Infection by the RNA Modification <i>N6</i>-Methyladenosine., References: ['']\n",
      "DEBUG - Citing Paper: The Skin You Are In: Design-of-Experiments Optimization of Lipid Nanoparticle Self-Amplifying RNA Formulations in Human Skin Explants., References: ['']\n",
      "DEBUG - Citing Paper: Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques., References: ['']\n",
      "DEBUG - Citing Paper: Advances in mRNA Vaccines for Infectious Diseases., References: ['']\n",
      "DEBUG - Citing Paper: mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Inhibiting neuraminidase can make the difference., References: ['']\n",
      "DEBUG - Citing Paper: Advances in Influenza Virus Research: A Personal Perspective., References: ['']\n",
      "DEBUG - focal: Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies., NF: 0, NB: 0, NR: 0, D: 0\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DEBUG - Focal Paper: Elimination of large tumors in mice by mRNA-encoded bispecific antibodies., References: \n",
      "172 countries & multiple candidate vaccines engaged in COVID-19 Vaccine Global Access Facility â CEPI . Available at: https://cepi.net/news_cepi/172-countries-multiple-candidate-vaccines-engaged-in-covid-19-vaccine-global-access-facility/ (Accessed September 1, 2020).\n",
      "DEBUG - Citing Paper: Antitumor activity of Z15-0-2, a bispecific nanobody targeting PD-1 and CTLA-4., References: ['']\n",
      "DEBUG - Citing Paper: The present and future of bispecific antibodies for cancer therapy., References: ['']\n",
      "DEBUG - Citing Paper: Profile of Katalin KarikÃ³ and Drew Weissman: 2023 Nobel laureates in Physiology or Medicine., References: ['']\n",
      "DEBUG - Citing Paper: N<sup>1</sup>-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting., References: ['']\n",
      "DEBUG - Citing Paper: Emerging Strategies for Immunotherapy of Solid Tumors Using Lipid-Based Nanoparticles., References: ['']\n",
      "DEBUG - Citing Paper: An mRNA vaccine against rabies provides strong and durable protection in mice., References: ['']\n",
      "DEBUG - Citing Paper: Induction of long-term tolerance to a specific antigen using anti-CD3 lipid nanoparticles following gene therapy., References: ['']\n",
      "DEBUG - Citing Paper: The advances of adjuvants in mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications., References: ['']\n",
      "DEBUG - Citing Paper: Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Recent Advances and Innovations in the Preparation and Purification of In Vitro-Transcribed-mRNA-Based Molecules., References: ['']\n",
      "DEBUG - Citing Paper: Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-Î² antagonists., References: ['']\n",
      "DEBUG - Citing Paper: Vasculature organotropism in drug delivery., References: ['']\n",
      "DEBUG - Citing Paper: Stability Criterion for the Assembly of Core-Shell Lipid-Polymer-Nucleic Acid Nanoparticles., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticle-based mRNA delivery systems for cancer immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Expanding the Reach of Monoclonal Antibodies: A Review of Synthetic Nucleic Acid Delivery in Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Transitional Insight into the RNA-Based Oligonucleotides in Cancer Treatment., References: ['']\n",
      "DEBUG - Citing Paper: The Screening of Broadly Neutralizing Antibodies Targeting the SARS-CoV-2 Spike Protein by mRNA Immunization in Mice., References: ['']\n",
      "DEBUG - Citing Paper: Cap analogs with a hydrophobic photocleavable tag enable facile purification of fully capped mRNA with various cap structures., References: ['']\n",
      "DEBUG - Citing Paper: Engineering Bifunctional Calcium Alendronate Gene-Delivery Nanoneedle for Synergistic Chemo/Immuno-Therapy Against HER2 Positive Ovarian Cancer., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-Based Therapeutics in Cancer Treatment., References: ['']\n",
      "DEBUG - Citing Paper: Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs., References: ['']\n",
      "DEBUG - Citing Paper: Empowering gene delivery with protein engineering platforms., References: ['']\n",
      "DEBUG - Citing Paper: Antibody specificity against highly conserved membrane protein Claudin 6 driven by single atomic contact point., References: ['']\n",
      "DEBUG - Citing Paper: Nanoformulations targeting immune cells for cancer therapy: mRNA therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticle Delivery System for mRNA Encoding B7H3-redirected Bispecific Antibody Displays Potent Antitumor Effects on Malignant Tumors., References: ['']\n",
      "DEBUG - Citing Paper: Advancing mRNA technologies for therapies and vaccines: An African context., References: ['']\n",
      "DEBUG - Citing Paper: Applications and challenges of biomaterial mediated mRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: Application of mRNA Technology in Cancer Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: The Pivotal Role of Chemical Modifications in mRNA Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Therapeutic Potential of Intrabodies for Cancer Immunotherapy: Current Status and Future Directions., References: ['']\n",
      "DEBUG - Citing Paper: A Single Dose of Anti-HBsAg Antibody-Encoding mRNA-LNPs Suppressed HBsAg Expression: a Potential Cure of Chronic Hepatitis B Virus Infection., References: ['']\n",
      "DEBUG - Citing Paper: Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question., References: ['']\n",
      "DEBUG - Citing Paper: Potentialities and Challenges of mRNA Vaccine in Cancer Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Blocking phospholamban with VHH intrabodies enhances contractility and relaxation in heart failure., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-based therapeutics: powerful and versatile tools to combat diseases., References: ['']\n",
      "DEBUG - Citing Paper: RNA in Cancer Immunotherapy: Unlocking the Potential of the Immune System., References: ['']\n",
      "DEBUG - Citing Paper: The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: The Potential of Nanomedicine to Unlock the Limitless Applications of mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Intravenous Delivery of RNA Encoding Anti-PD-1 Human Monoclonal Antibody for Treating Intestinal Cancer., References: ['']\n",
      "DEBUG - Citing Paper: Intracranial delivery of synthetic mRNA to suppress glioblastoma., References: ['']\n",
      "DEBUG - Citing Paper: Engineered mRNA-expressed bispecific antibody prevent intestinal cancer via lipid nanoparticle delivery., References: ['']\n",
      "DEBUG - Citing Paper: A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus., References: ['']\n",
      "DEBUG - Citing Paper: Engineered mRNA and the Rise of Next-Generation Antibodies., References: ['']\n",
      "DEBUG - Citing Paper: Intranasal delivery of replicating mRNA encoding neutralizing antibody against SARS-CoV-2 infection in mice., References: ['']\n",
      "DEBUG - Citing Paper: Muscle Regeneration and RNA: New Perspectives for Ancient Molecules., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines for infectious diseases: principles, delivery and clinical translation., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticles for mRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Non-Immunotherapy Application of LNP-mRNA: Maximizing Efficacy and Safety., References: ['']\n",
      "DEBUG - Citing Paper: Stoichiometry of multi-specific immune checkpoint RNA Abs for TÂ cell activation and tumor inhibition using ultra-stable RNA nanoparticles., References: ['']\n",
      "DEBUG - Citing Paper: mRNA therapeutics in cancer immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Recent Advances in the Molecular Design and Applications of Multispecific Biotherapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Immunotherapy perspectives in the new era of B-cell editing., References: ['']\n",
      "DEBUG - Citing Paper: Clinical and immunological effects of mRNA vaccines in malignant diseases., References: ['']\n",
      "DEBUG - Citing Paper: mRNA in cancer immunotherapy: beyond a source of antigen., References: ['']\n",
      "DEBUG - Citing Paper: Exquisitely Specific anti-KRAS Biodegraders Inform on the Cellular Prevalence of Nucleotide-Loaded States., References: ['']\n",
      "DEBUG - Citing Paper: Neural stem cells secreting bispecific T cell engager to induce selective antiglioma activity., References: ['']\n",
      "DEBUG - Citing Paper: A paradigm shift in cancer nanomedicine: from traditional tumor targeting to leveraging the immune system., References: ['']\n",
      "DEBUG - Citing Paper: Advancements in mRNA Encoded Antibodies for Passive Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Nanomaterial Delivery Systems for mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: An Inside Job: Applications of Intracellular Single Domain Antibodies., References: ['']\n",
      "DEBUG - Citing Paper: Combining T-cell-specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors., References: ['']\n",
      "DEBUG - Citing Paper: Advances in Lipid Nanoparticles for mRNA-Based Cancer Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Hybridization Networks of mRNA and Branched RNA Hybrids., References: ['']\n",
      "DEBUG - Citing Paper: Emerging Concepts and Technologies in Vaccine Development., References: ['']\n",
      "DEBUG - Citing Paper: Dual mRNA therapy restores metabolic function in long-term studies in mice with propionic acidemia., References: ['']\n",
      "DEBUG - Citing Paper: Nano-Enhanced Cancer Immunotherapy: Immunology Encounters Nanotechnology., References: ['']\n",
      "DEBUG - Citing Paper: Engineering Immune Cells for <i>in vivo</i> Secretion of Tumor-Specific T Cell-Redirecting Bispecific Antibodies., References: ['']\n",
      "DEBUG - Citing Paper: The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies., References: ['']\n",
      "DEBUG - Citing Paper: Rapid Assembly and Screening of Multivalent Immune Cell-Redirecting Therapies for Leukemia., References: ['']\n",
      "DEBUG - Citing Paper: Intramuscular Delivery of Replicon RNA Encoding ZIKV-117 Human Monoclonal Antibody Protects against Zika Virus Infection., References: ['']\n",
      "DEBUG - Citing Paper: Advances in Development of mRNA-Based Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Formulation and Delivery Technologies for mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Encoding a Bispecific Single Domain Antibody Construct Protects against Influenza A Virus Infection in Mice., References: ['']\n",
      "DEBUG - Citing Paper: In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies., References: ['']\n",
      "DEBUG - Citing Paper: Polylactide-Based Reactive Micelles as a Robust Platform for mRNA Delivery., References: ['']\n",
      "DEBUG - Citing Paper: Bispecific antibodies in cancer immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Human and translational immunology in the third millennium: progress, challenges and opportunities., References: ['']\n",
      "DEBUG - Citing Paper: A Trans-amplifying RNA Vaccine Strategy for Induction of Potent Protective Immunity., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Delivery for Therapeutic Anti-HER2 Antibody Expression InÂ Vivo., References: ['']\n",
      "DEBUG - Citing Paper: Healing with RNA., References: ['']\n",
      "DEBUG - Citing Paper: DNA-encoded bispecific T cell engagers and antibodies present long-term antitumor activity., References: ['']\n",
      "DEBUG - Citing Paper: mRNA: A Novel Avenue to Antibody Therapy?, References: ['']\n",
      "DEBUG - Citing Paper: Improved Efficacy in a Fabry Disease Model Using a Systemic mRNA Liver Depot System as Compared to Enzyme Replacement Therapy., References: ['']\n",
      "DEBUG - Citing Paper: Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery., References: ['']\n",
      "DEBUG - Citing Paper: The Emerging Role of InÂ Vitro-Transcribed mRNA in Adoptive T Cell Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: How mRNA therapeutics are entering the monoclonal antibody field., References: ['']\n",
      "DEBUG - Citing Paper: A non-functional neoepitope specific CD8<sup>+</sup> T-cell response induced by tumor derived antigen exposure <i>in vivo</i>., References: ['']\n",
      "DEBUG - Citing Paper: The genetic shortcut to antibody drugs., References: ['']\n",
      "DEBUG - Citing Paper: Induction of immunosuppressive functions and NF-ÎºB by FLIP in monocytes., References: ['']\n",
      "DEBUG - Citing Paper: Synthetic RNA-based logic computation in mammalian cells., References: ['']\n",
      "DEBUG - Citing Paper: Bispecific antibodies: Potential immunotherapies for HIV treatment., References: ['']\n",
      "DEBUG - Citing Paper: PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake., References: ['']\n",
      "DEBUG - Citing Paper: mRNA as novel technology for passive immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Cancer Vaccine Immunotherapy with RNA-Loaded Liposomes., References: ['']\n",
      "DEBUG - Citing Paper: Optimization of a Degradable Polymer-Lipid Nanoparticle for Potent Systemic Delivery of mRNA to the Lung Endothelium and Immune Cells., References: ['']\n",
      "DEBUG - Citing Paper: CIMT 2018: Pushing frontiers in cancer immunotherapy - Report on the 16<sup>th</sup> Annual Meeting of the Association for Cancer Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Purification of mRNA Encoding Chimeric Antigen Receptor Is Critical for Generation of a Robust T-Cell Response., References: ['']\n",
      "DEBUG - Citing Paper: Ionizable Amino-Polyesters Synthesized via Ring Opening Polymerization of Tertiary Amino-Alcohols for Tissue Selective mRNA Delivery., References: ['']\n",
      "DEBUG - Citing Paper: Bispecific light T-cell engagers for gene-based immunotherapy of epidermal growth factor receptor (EGFR)-positive malignancies., References: ['']\n",
      "DEBUG - Citing Paper: De Novo Synthesis of Elastin by Exogenous Delivery of Synthetic Modified mRNA into Skin and Elastin-Deficient Cells., References: ['']\n",
      "DEBUG - Citing Paper: Intradermal Delivery of Synthetic mRNA Using Hollow Microneedles for Efficient and Rapid Production of Exogenous Proteins in Skin., References: ['']\n",
      "DEBUG - Citing Paper: Multiâlayered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/Î²âcatenin signaling activation (Review)., References: ['']\n",
      "DEBUG - Citing Paper: Incorporation of Synthetic mRNA in Injectable Chitosan-Alginate Hybrid Hydrogels for Local and Sustained Expression of Exogenous Proteins in Cells., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines - a new era in vaccinology., References: ['']\n",
      "DEBUG - Citing Paper: In Situ Liver Expression of HBsAg/CD3-Bispecific Antibodies for HBV Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Erratum: Elimination of large tumors in mice by mRNA-encoded bispecific antibodies., References: ['']\n",
      "DEBUG - Citing Paper: VHH-Based Bispecific Antibodies Targeting Cytokine Production., References: ['']\n",
      "DEBUG - Citing Paper: Cancer: mRNA-encoded bispecific antibodies eliminate tumours., References: ['']\n",
      "DEBUG - focal: Elimination of large tumors in mice by mRNA-encoded bispecific antibodies., NF: 0, NB: 0, NR: 0, D: 0\n",
      "DEBUG - Focal Paper: Identification of Cyclobutane Pyrimidine Dimer-Responsive Genes Using UVB-Irradiated Human Keratinocytes Transfected with In Vitro-Synthesized Photolyase mRNA., References: Abd Ghafar N., Jalil N.A.A., Kamarudin T.A. Wound healing of the corneal epithelium: A review. Asian Biomed. 2021;15:199â212. doi: 10.2478/abm-2021-0026.\n",
      "DEBUG - Citing Paper: Short-Term UVB Irradiation Leads to Persistent DNA Damage in Limbal Epithelial Stem Cells, Partially Reversed by DNA Repairing Enzymes., References: ['']\n",
      "DEBUG - Citing Paper: UV Protection in the Cornea: Failure and Rescue., References: ['']\n",
      "DEBUG - Citing Paper: Expression of p15 in a spectrum of spitzoid melanocytic neoplasms., References: ['']\n",
      "DEBUG - Citing Paper: KIND1 Loss Sensitizes Keratinocytes to UV-Induced Inflammatory Response and DNA Damage., References: ['']\n",
      "DEBUG - focal: Identification of Cyclobutane Pyrimidine Dimer-Responsive Genes Using UVB-Irradiated Human Keratinocytes Transfected with In Vitro-Synthesized Photolyase mRNA., NF: 0, NB: 0, NR: 0, D: 0\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DEBUG - Focal Paper: A Facile Method for the Removal of dsRNA Contaminant from InÂ Vitro-Transcribed mRNA., References: \n",
      "\n",
      " https://assets.thermofisher.com/TFSâAssets/LSG/manuals/65011_65012_Dynabeads_MyOne_Carboxylic_Acid_PI.pdf\n",
      "DEBUG - Citing Paper: Development of a nucleoside-modified mRNA vaccine against clade 2.3.4.4b H5 highly pathogenic avian influenza virus., References: ['']\n",
      "DEBUG - Citing Paper: Evaluation of the immunogenicity of an mRNA vectored Nipah virus vaccine candidate in pigs., References: ['']\n",
      "DEBUG - Citing Paper: Potential Application of Modified mRNA in Cardiac Regeneration., References: ['']\n",
      "DEBUG - Citing Paper: High-throughput iSpinach fluorescent aptamer-based real-time monitoring of in vitro transcription., References: ['']\n",
      "DEBUG - Citing Paper: Physiologically based modeling of LNP-mediated delivery of mRNA in the vascular system., References: ['']\n",
      "DEBUG - Citing Paper: IL7 increases targeted lipid nanoparticle-mediated mRNA expression in T cells in vitro and in vivo by enhancing T cell protein translation., References: ['']\n",
      "DEBUG - Citing Paper: Antibody-independent protection against heterologous SARS-CoV-2 challenge conferred by prior infection or vaccination., References: ['']\n",
      "DEBUG - Citing Paper: ACE mRNA (Additional Chimeric Element incorporated IVT mRNA) for Enhancing Protein Expression by Modulating Immunogenicity., References: ['']\n",
      "DEBUG - Citing Paper: Determination of linearized pDNA template in mRNA production process using HPLC., References: ['']\n",
      "DEBUG - Citing Paper: SMART-lipid nanoparticles enabled mRNA vaccine elicits cross-reactive humoral responses against the omicron sub-variants., References: ['']\n",
      "DEBUG - Citing Paper: Urea supplementation improves mRNA in vitro transcription by decreasing both shorter and longer RNA byproducts., References: ['']\n",
      "DEBUG - Citing Paper: In situ combinatorial synthesis of degradable branched lipidoids for systemic delivery of mRNA therapeutics and gene editors., References: ['']\n",
      "DEBUG - Citing Paper: The Effect of Cholesterol Content on the Adjuvant Activity of Nucleic-Acid-Free Lipid Nanoparticles., References: ['']\n",
      "DEBUG - Citing Paper: Profile of Katalin KarikÃ³ and Drew Weissman: 2023 Nobel laureates in Physiology or Medicine., References: ['']\n",
      "DEBUG - Citing Paper: Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadth., References: ['']\n",
      "DEBUG - Citing Paper: Comprehensive Impurity Profiling of mRNA: Evaluating Current Technologies and Advanced Analytical Techniques., References: ['']\n",
      "DEBUG - Citing Paper: Assessing the impact of mRNA vaccination in chronic inflammatory murine model., References: ['']\n",
      "DEBUG - Citing Paper: Strategies to reduce the risks of mRNA drug and vaccine toxicity., References: ['']\n",
      "DEBUG - Citing Paper: Neoantigen vaccine nanoformulations based on Chemically synthesized minimal mRNA (CmRNA): small molecules, big impact., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccination of rabbits alters the fecundity, but not the attachment, of adult Ixodes scapularis., References: ['']\n",
      "DEBUG - Citing Paper: Path towards mRNA delivery for cancer immunotherapy from bench to bedside., References: ['']\n",
      "DEBUG - Citing Paper: Formation of dsRNA by-products during <i>in vitro</i> transcription can be reduced by using low steady-state levels of UTP., References: ['']\n",
      "DEBUG - Citing Paper: mRNA and Adenoviral Vector Vaccine Platforms Utilized in COVID-19 Vaccines: Technologies, Ecosystem, and Future Directions., References: ['']\n",
      "DEBUG - Citing Paper: A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax., References: ['']\n",
      "DEBUG - Citing Paper: mRNA as a medicine in nephrology: the future is now., References: ['']\n",
      "DEBUG - Citing Paper: VEGFA mRNA-LNP promotes biliary epithelial cell-to-hepatocyte conversion in acute and chronic liver diseases and reverses steatosis and fibrosis., References: ['']\n",
      "DEBUG - Citing Paper: Enhancing anti-viral neutralization response to immunization with HIV-1 envelope glycoprotein immunogens., References: ['']\n",
      "DEBUG - Citing Paper: In Vitro Transcribed RNA-Based Platform Vaccines: Past, Present, and Future., References: ['']\n",
      "DEBUG - Citing Paper: RNA-Based Therapeutic Technology., References: ['']\n",
      "DEBUG - Citing Paper: Enabling mRNA Therapeutics: Current Landscape and Challenges in Manufacturing., References: ['']\n",
      "DEBUG - Citing Paper: Reducing cell intrinsic immunity to mRNA vaccine alters adaptive immune responses in mice., References: ['']\n",
      "DEBUG - Citing Paper: The Dual Role of the Innate Immune System in the Effectiveness of mRNA Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Cryptic MHC-E epitope from influenza elicits a potent cytolytic T cell response., References: ['']\n",
      "DEBUG - Citing Paper: Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability., References: ['']\n",
      "DEBUG - Citing Paper: Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Application of Lung-Targeted Lipid Nanoparticle-delivered mRNA of soluble PD-L1 via SORT Technology in Acute Respiratory Distress Syndrome., References: ['']\n",
      "DEBUG - Citing Paper: Sending a Message: Use of mRNA Vaccines to Target the Tumor Immune Microenvironment., References: ['']\n",
      "DEBUG - Citing Paper: Recent Advances and Innovations in the Preparation and Purification of In Vitro-Transcribed-mRNA-Based Molecules., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccine quality analysis using RNA sequencing., References: ['']\n",
      "DEBUG - Citing Paper: A nasal vaccine with inactivated whole-virion elicits protective mucosal immunity against SARS-CoV-2 in mice., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-Based Nanomedicine: A New Strategy for Treating Infectious Diseases and Beyond., References: ['']\n",
      "DEBUG - Citing Paper: Polysarcosine-Functionalized mRNA Lipid Nanoparticles Tailored for Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Targeting cancer with mRNA-lipid nanoparticles: key considerations and future prospects., References: ['']\n",
      "DEBUG - Citing Paper: Mesoporous Silica Particle as an RNA Adsorbent for Facile Purification of In Vitro-Transcribed RNA., References: ['']\n",
      "DEBUG - Citing Paper: Recent Advances in Messenger Ribonucleic Acid (mRNA) Vaccines and Their Delivery Systems: A Review., References: ['']\n",
      "DEBUG - Citing Paper: Development of an mRNA-lipid nanoparticle vaccine against Lyme disease., References: ['']\n",
      "DEBUG - Citing Paper: CMC Strategies and Advanced Technologies for Vaccine Development to Boost Acceleration and Pandemic Preparedness., References: ['']\n",
      "DEBUG - Citing Paper: Development of an Alcohol Dilution-Lyophilization Method for the Preparation of mRNA-LNPs with Improved Storage Stability., References: ['']\n",
      "DEBUG - Citing Paper: In vivo hematopoietic stem cell modification by mRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: Expanding the Reach of Monoclonal Antibodies: A Review of Synthetic Nucleic Acid Delivery in Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: The use of RNA-based treatments in the field of cancer immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Specific mRNA lipid nanoparticles and acquired resistance to ticks., References: ['']\n",
      "DEBUG - Citing Paper: A localizing nanocarrier formulation enables multi-target immune responses to multivalent replicating RNA with limited systemic inflammation., References: ['']\n",
      "DEBUG - Citing Paper: Screening Libraries to Discover Molecular Design Principles for the Targeted Delivery of mRNA with One-Component Ionizable Amphiphilic Janus Dendrimers Derived from Plant Phenolic Acids., References: ['']\n",
      "DEBUG - Citing Paper: ASL mRNA-LNP Therapeutic for the Treatment of Argininosuccinic Aciduria Enables Survival Benefit in a Mouse Model., References: ['']\n",
      "DEBUG - Citing Paper: A mosquito AgTRIO mRNA vaccine contributes to immunity against malaria., References: ['']\n",
      "DEBUG - Citing Paper: Analyzing immune responses to varied mRNA and protein vaccine sequences., References: ['']\n",
      "DEBUG - Citing Paper: A tool for optimizing messenger RNA sequence., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccine Platform: mRNA Production and Delivery., References: ['']\n",
      "DEBUG - Citing Paper: Lateral flow immunoassay for rapid and sensitive detection of dsRNA contaminants in <i>inÂ vitro</i>-transcribed mRNA products., References: ['']\n",
      "DEBUG - Citing Paper: Cap analogs with a hydrophobic photocleavable tag enable facile purification of fully capped mRNA with various cap structures., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV., References: ['']\n",
      "DEBUG - Citing Paper: Immunogenicity and protective efficacy of SARS-CoV-2 mRNA vaccine encoding secreted non-stabilized spike in female mice., References: ['']\n",
      "DEBUG - Citing Paper: mRNA melanoma vaccine revolution spurred by the COVID-19 pandemic., References: ['']\n",
      "DEBUG - Citing Paper: Revolutionizing viral disease vaccination: the promising clinical advancements of non-replicating mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Breast tumors interfere with endothelial TRAIL at the premetastatic niche to promote cancer cell seeding., References: ['']\n",
      "DEBUG - Citing Paper: Restoration of Motor Function through Delayed Intraspinal Delivery of Human IL-10-Encoding Nucleoside-Modified mRNA after Spinal Cord Injury., References: ['']\n",
      "DEBUG - Citing Paper: Identification of Five Tumor Antigens for Development and Two Immune Subtypes for Personalized Medicine of mRNA Vaccines in Papillary Renal Cell Carcinoma., References: ['']\n",
      "DEBUG - Citing Paper: Advanced delivery systems for peptide antibiotics., References: ['']\n",
      "DEBUG - Citing Paper: Immunity to Seasonal Coronavirus Spike Proteins Does Not Protect from SARS-CoV-2 Challenge in a Mouse Model but Has No Detrimental Effect on Protection Mediated by COVID-19 mRNA Vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Ionizable lipid nanoparticles deliver mRNA to pancreatic Î² cells via macrophage-mediated gene transfer., References: ['']\n",
      "DEBUG - Citing Paper: Self-Amplifying RNA Vaccine Candidates: Alternative Platforms for mRNA Vaccine Development., References: ['']\n",
      "DEBUG - Citing Paper: Advances of mRNA vaccine in tumor: a maze of opportunities and challenges., References: ['']\n",
      "DEBUG - Citing Paper: Molecular fate-mapping of serum antibody responses to repeat immunization., References: ['']\n",
      "DEBUG - Citing Paper: Exploring <i>in vitro</i> expression and immune potency in mice using mRNA encoding the <i>Plasmodium falciparum</i> malaria antigen, CelTOS., References: ['']\n",
      "DEBUG - Citing Paper: Separation of long-stranded RNAs by RP-HPLC using an octadecyl-based column with super-wide pores., References: ['']\n",
      "DEBUG - Citing Paper: Manganese-coordinated mRNA vaccines with enhanced mRNA expression and immunogenicity induce robust immune responses against SARS-CoV-2 variants., References: ['']\n",
      "DEBUG - Citing Paper: Recent Advances in Lipid Nanoparticles for Delivery of mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Nurturing Deep Tech to Solve Social Problems: Learning from COVID-19 mRNA Vaccine Development., References: ['']\n",
      "DEBUG - Citing Paper: A universal influenza mRNA vaccine candidate boosts T cell responses and reduces zoonotic influenza virus disease in ferrets., References: ['']\n",
      "DEBUG - Citing Paper: Lessons learned from COVID-19 pandemic: Vaccine platform is a key player., References: ['']\n",
      "DEBUG - Citing Paper: Nanoformulations targeting immune cells for cancer therapy: mRNA therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-LNP expressing PfCSP and Pfs25 vaccine candidates targeting infection and transmission of Plasmodium falciparum., References: ['']\n",
      "DEBUG - Citing Paper: RNA sensor response in HeLa cells for transfected mRNAs prepared <i>in vitro</i> by SP6 and HiT7 RNA polymerases: A comparative study., References: ['']\n",
      "DEBUG - Citing Paper: An engineered T7 RNA polymerase that produces mRNA free of immunostimulatory byproducts., References: ['']\n",
      "DEBUG - Citing Paper: The landscape of mRNA nanomedicine., References: ['']\n",
      "DEBUG - Citing Paper: Advancing mRNA technologies for therapies and vaccines: An African context., References: ['']\n",
      "DEBUG - Citing Paper: The Storage and In-Use Stability of mRNA Vaccines and Therapeutics: Not A Cold Case., References: ['']\n",
      "DEBUG - Citing Paper: Innate immune mechanisms of mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 mRNA-based vaccines in the Aicardi GoutiÃ¨res Syndrome., References: ['']\n",
      "DEBUG - Citing Paper: Unlocking the promise of mRNA therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses., References: ['']\n",
      "DEBUG - Citing Paper: Cytidine-containing tails robustly enhance and prolong protein production of synthetic mRNA in cell and <i>inÂ vivo</i>., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model., References: ['']\n",
      "DEBUG - Citing Paper: Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines: A novel weapon to control infectious diseases., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations., References: ['']\n",
      "DEBUG - Citing Paper: Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models., References: ['']\n",
      "DEBUG - Citing Paper: Double-stranded RNA reduction by chaotropic agents during <i>inÂ vitro</i> transcription of messenger RNA., References: ['']\n",
      "DEBUG - Citing Paper: Advances in mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-Loaded Lipid Nanoparticles Targeting Dendritic Cells for Cancer Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses., References: ['']\n",
      "DEBUG - Citing Paper: N<sup>1</sup>-methyl-pseudouridine is incorporated with higher fidelity than pseudouridine in synthetic RNAs., References: ['']\n",
      "DEBUG - Citing Paper: Ozone Eliminates SARS-CoV-2 from Difficult-to-Clean Office Supplies and Clinical Equipment., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: A protocol to construct RNA-protein devices for photochemical translational regulation of synthetic mRNAs in mammalian cells., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-based therapeutics: powerful and versatile tools to combat diseases., References: ['']\n",
      "DEBUG - Citing Paper: RNA in Cancer Immunotherapy: Unlocking the Potential of the Immune System., References: ['']\n",
      "DEBUG - Citing Paper: The clinical progress of mRNA vaccines and immunotherapies., References: ['']\n",
      "DEBUG - Citing Paper: mRNA- and Adenovirus-Based Vaccines against SARS-CoV-2 in HIV-Positive People., References: ['']\n",
      "DEBUG - Citing Paper: Therapeutic Vaccines Targeting Neoantigens to Induce T-Cell Immunity against Cancers., References: ['']\n",
      "DEBUG - Citing Paper: A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through TÂ cell-mediated immunity., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines: the most recent clinical applications of synthetic mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Myocarditis following COVID-19 vaccination: incidence, mechanisms, and clinical considerations., References: ['']\n",
      "DEBUG - Citing Paper: mRNA cancer vaccines: Advances, trends and challenges., References: ['']\n",
      "DEBUG - Citing Paper: IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice., References: ['']\n",
      "DEBUG - Citing Paper: Messenger RNA vaccines for cancer immunotherapy: progress promotes promise., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 mRNA vaccines: Platforms and current developments., References: ['']\n",
      "DEBUG - Citing Paper: Chemical modification of uridine modulates mRNA-mediated proinflammatory and antiviral response in primary human macrophages., References: ['']\n",
      "DEBUG - Citing Paper: Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Breadth of SARS-CoV-2 Neutralization and Protection Induced by a Nanoparticle Vaccine., References: ['']\n",
      "DEBUG - Citing Paper: CAR T cells produced in vivo to treat cardiac injury., References: ['']\n",
      "DEBUG - Citing Paper: Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities., References: ['']\n",
      "DEBUG - Citing Paper: Added to pre-existing inflammation, mRNA-lipid nanoparticles induce inflammation exacerbation (IE)., References: ['']\n",
      "DEBUG - Citing Paper: Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials., References: ['']\n",
      "DEBUG - Citing Paper: Tick immunity using mRNA, DNA and protein-based Salp14 delivery strategies., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses., References: ['']\n",
      "DEBUG - Citing Paper: Co-Delivery of mRNA and pDNA Using Thermally Stabilized Coacervate-Based Core-Shell Nanosystems., References: ['']\n",
      "DEBUG - Citing Paper: Nucleoside-Modified mRNA Vaccines Protect IFNAR<sup>-/-</sup> Mice against Crimean-Congo Hemorrhagic Fever Virus Infection., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticle chemistry determines how nucleoside base modifications alter mRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: Amniotic fluid stabilized lipid nanoparticles for in utero intra-amniotic mRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: Development of a 3D-printed single-use separation chamber for use in mRNA-based vaccine production with magnetic microparticles., References: ['']\n",
      "DEBUG - Citing Paper: Immunogenicity of <i>In Vitro</i>-Transcribed RNA., References: ['']\n",
      "DEBUG - Citing Paper: Pharma 4.0 Continuous mRNA Drug Products Manufacturing., References: ['']\n",
      "DEBUG - Citing Paper: Antigen modifications improve nucleoside-modified mRNA-based influenza virus vaccines in mice., References: ['']\n",
      "DEBUG - Citing Paper: Ability of nucleoside-modified mRNA to encode HIV-1 envelope trimer nanoparticles., References: ['']\n",
      "DEBUG - Citing Paper: Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration., References: ['']\n",
      "DEBUG - Citing Paper: Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across., References: ['']\n",
      "DEBUG - Citing Paper: From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases., References: ['']\n",
      "DEBUG - Citing Paper: Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice., References: ['']\n",
      "DEBUG - Citing Paper: Highly efficient CD4+ TÂ cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs., References: ['']\n",
      "DEBUG - Citing Paper: Non-Immunotherapy Application of LNP-mRNA: Maximizing Efficacy and Safety., References: ['']\n",
      "DEBUG - Citing Paper: In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels., References: ['']\n",
      "DEBUG - Citing Paper: Lipid-nanoparticle-encapsulated mRNA vaccines induce protective memory CD8 TÂ cells against a lethal viral infection., References: ['']\n",
      "DEBUG - Citing Paper: Self-amplifying mRNA-Based Vaccine Technology and Its Mode of Action., References: ['']\n",
      "DEBUG - Citing Paper: mRNA therapeutics in cancer immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Considerations for bioanalytical characterization and batch release of COVID-19 vaccines., References: ['']\n",
      "DEBUG - Citing Paper: The dawn of mRNA vaccines: The COVID-19 case., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines manufacturing: Challenges and bottlenecks., References: ['']\n",
      "DEBUG - Citing Paper: Clinical and immunological effects of mRNA vaccines in malignant diseases., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccines against Flaviviruses., References: ['']\n",
      "DEBUG - Citing Paper: mRNA in cancer immunotherapy: beyond a source of antigen., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccine for cancer immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-Based Vaccines and Mode of Action., References: ['']\n",
      "DEBUG - Citing Paper: An Update on Self-Amplifying mRNA Vaccine Development., References: ['']\n",
      "DEBUG - Citing Paper: Corticosteroids and cellulose purification improve, respectively, the inÂ vivo translation and vaccination efficacy of sa-mRNAs., References: ['']\n",
      "DEBUG - Citing Paper: Nanomaterial Delivery Systems for mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Nanoparticles as Adjuvants and Nanodelivery Systems for mRNA-Based Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Neo-Antigen mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 Vaccine Development: An Overview and Perspectives., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccine Era-Mechanisms, Drug Platform and Clinical Prospection., References: ['']\n",
      "DEBUG - Citing Paper: A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice., References: ['']\n",
      "DEBUG - Citing Paper: A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice., References: ['']\n",
      "DEBUG - Citing Paper: The Transcription Factor T-bet Resolves Memory B Cell Subsets with Distinct Tissue Distributions and Antibody Specificities in Mice and Humans., References: ['']\n",
      "DEBUG - Citing Paper: Messenger RNA-Based Vaccines Against Infectious Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Opportunities and Challenges in the Delivery of mRNA-based Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Synthesis of low immunogenicity RNA with high-temperature in vitro transcription., References: ['']\n",
      "DEBUG - Citing Paper: Enlisting the mRNA Vaccine Platform to Combat Parasitic Infections., References: ['']\n",
      "DEBUG - Citing Paper: Efficient inhibition of RNA self-primed extension by addition of competing 3'-capture DNA-improved RNA synthesis by T7 RNA polymerase., References: ['']\n",
      "DEBUG - focal: A Facile Method for the Removal of dsRNA Contaminant from InÂ Vitro-Transcribed mRNA., NF: 0, NB: 0, NR: 0, D: 0\n",
      "DEBUG - Focal Paper: Transfection of pseudouridine-modified mRNA encoding CPD-photolyase leads to repair of DNA damage in human keratinocytes: a new approach with future therapeutic potential., References: Abbasi J. COVID-19 and mRNA Vaccines-First Large Test for a New Approach. JAMA. 2020;324:1125â1127. doi: 10.1001/jama.2020.16866.\n",
      "DEBUG - Citing Paper: Preparation of CPD Photolyase Nanoliposomes Derived from Antarctic Microalgae and Their Effect on UVB-Induced Skin Damage in Mice., References: ['']\n",
      "DEBUG - Citing Paper: UV Protection in the Cornea: Failure and Rescue., References: ['']\n",
      "DEBUG - Citing Paper: UV Radiation in DNA Damage and Repair Involving DNA-Photolyases and Cryptochromes., References: ['']\n",
      "DEBUG - Citing Paper: An Update on mRNA-Based Viral Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: A Nobel-Winning Scientist: Aziz Sancar and the Impact of his Work on the Molecular Pathology of Neoplastic Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Inhibitors of Nucleotide Excision Repair Decrease UVB-Induced Mutagenesis-An In Vitro Study., References: ['']\n",
      "DEBUG - Citing Paper: PARP1 Inhibition Augments UVB-Mediated Mitochondrial Changes-Implications for UV-Induced DNA Repair and Photocarcinogenesis., References: ['']\n",
      "DEBUG - Citing Paper: Silymarin: Friend or Foe of UV Exposed Keratinocytes?, References: ['']\n",
      "DEBUG - Citing Paper: A highly efficient and cost-effective recombinant production of a bacterial photolyase from the Antarctic isolate Hymenobacter sp. UV11., References: ['']\n",
      "DEBUG - Citing Paper: Optimizing Cardiac Delivery of Modified mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Pseudouridine in the Anticodon of Escherichia coli tRNATyr(QÎ¨A) Is Catalyzed by the Dual Specificity Enzyme RluF., References: ['']\n",
      "DEBUG - Citing Paper: Viral and Synthetic RNA Vector Technologies and Applications., References: ['']\n",
      "DEBUG - Citing Paper: Identification of Cyclobutane Pyrimidine Dimer-Responsive Genes Using UVB-Irradiated Human Keratinocytes Transfected with In Vitro-Synthesized Photolyase mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Pseudouridine: still mysterious, but never a fake (uridine)!, References: ['']\n",
      "DEBUG - focal: Transfection of pseudouridine-modified mRNA encoding CPD-photolyase leads to repair of DNA damage in human keratinocytes: a new approach with future therapeutic potential., NF: 0, NB: 0, NR: 0, D: 0\n",
      "DEBUG - Focal Paper: mRNA: Fulfilling the Promise of Gene Therapy., References: \n",
      "Arcturus Announces self-amplifying COVID-19 mRNA vaccine candidate ARCT-154 meets primary efficacy endpoint in phase 3 study . Arcturus Therapeutics, Inc. Available at: https://ir.arcturusrx.com/news-releases/news-release-details/arcturus-announces-self-amplifying-covid-19-mrna-vaccine (Accessed July 13, 2022).\n",
      "DEBUG - Citing Paper: Recent progress in mRNA cancer vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Enabling mRNA Therapeutics: Current Landscape and Challenges in Manufacturing., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines in disease prevention and treatment., References: ['']\n",
      "DEBUG - Citing Paper: In vivo hematopoietic stem cell modification by mRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: Mutations in the non-structural protein coding region regulate gene expression from replicon RNAs derived from Venezuelan equine encephalitis virus., References: ['']\n",
      "DEBUG - Citing Paper: Lynch syndrome cancer vaccines: A roadmap for the development of precision immunoprevention strategies., References: ['']\n",
      "DEBUG - Citing Paper: Research Advances on the Stability of mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-From COVID-19 Treatment to Cancer Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Advancing mRNA technologies for therapies and vaccines: An African context., References: ['']\n",
      "DEBUG - Citing Paper: Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine., References: ['']\n",
      "DEBUG - Citing Paper: The legacy of mRNA engineering: A lineup of pioneers for the Nobel Prize., References: ['']\n",
      "DEBUG - Citing Paper: Nanomedicine for the Delivery of RNA in Cancer., References: ['']\n",
      "DEBUG - Citing Paper: Hantavirus Induced Kidney Disease., References: ['']\n",
      "DEBUG - Citing Paper: Potential Immune Biomarker Candidates and Immune Subtypes of Lung Adenocarcinoma for Developing mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Virus-Mimic mRNA Vaccine for Cancer Treatment., References: ['']\n",
      "DEBUG - Citing Paper: Facile Synthesis of N-Doped Graphene Quantum Dots as Novel Transfection Agents for mRNA and pDNA., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticle-mRNA Formulations for Therapeutic Applications., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients., References: ['']\n",
      "DEBUG - Citing Paper: An Update on mRNA-Based Viral Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Pharma 4.0 Continuous mRNA Drug Products Manufacturing., References: ['']\n",
      "DEBUG - Citing Paper: Cationic Liposomes as Vectors for Nucleic Acid and Hydrophobic Drug Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across., References: ['']\n",
      "DEBUG - Citing Paper: Lipids and Lipid Derivatives for RNA Delivery., References: ['']\n",
      "DEBUG - Citing Paper: Editorial: mRNA Vaccines and Future Epidemic, Pandemic, and Endemic Zoonotic Virus Infections., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccine: a potential therapeutic strategy., References: ['']\n",
      "DEBUG - Citing Paper: RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges., References: ['']\n",
      "DEBUG - Citing Paper: Regulatory Considerations on the Development of mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Combinatorial Library of Cyclic Benzylidene Acetal-Containing pH-Responsive Lipidoid Nanoparticles for Intracellular mRNA Delivery., References: ['']\n",
      "DEBUG - Citing Paper: Optimization of 5' Untranslated Region of Modified mRNA for Use in Cardiac or Hepatic Ischemic Injury., References: ['']\n",
      "DEBUG - Citing Paper: Vaccines to prevent genital herpes., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Transfection-Induced Activation of Primary Human Monocytes and Macrophages: Dependence on Carrier System and Nucleotide Modification., References: ['']\n",
      "DEBUG - Citing Paper: Selective targeting of nanomedicine to inflamed cerebral vasculature to enhance the blood-brain barrier., References: ['']\n",
      "DEBUG - Citing Paper: Nanoparticles versus Dendritic Cells as Vehicles to Deliver mRNA Encoding Multiple Epitopes for Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening., References: ['']\n",
      "DEBUG - Citing Paper: Practical Synthesis of Cap-4 RNA., References: ['']\n",
      "DEBUG - Citing Paper: Intranodal administration of mRNA encoding nucleoprotein provides cross-strain immunity against influenza in mice., References: ['']\n",
      "DEBUG - Citing Paper: mRNA transfection by a Xentry-protamine cell-penetrating peptide is enhanced by TLR antagonist E6446., References: ['']\n",
      "DEBUG - Citing Paper: Synthetic mRNA capping., References: ['']\n",
      "DEBUG - Citing Paper: Intradermal Delivery of Synthetic mRNA Using Hollow Microneedles for Efficient and Rapid Production of Exogenous Proteins in Skin., References: ['']\n",
      "DEBUG - Citing Paper: Tapping the RNA world for therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Messenger RNA Delivery for Tissue Engineering and Regenerative Medicine Applications., References: ['']\n",
      "DEBUG - Citing Paper: Modified mRNAs in the Cardiovascular System: A New Platform for Gene Therapy., References: ['']\n",
      "DEBUG - Citing Paper: Retroviral vectors and transposons for stable gene therapy: advances, current challenges and perspectives., References: ['']\n",
      "DEBUG - Citing Paper: Efficacy and immunogenicity of unmodified and pseudouridine-modified mRNA delivered systemically with lipid nanoparticles inÂ vivo., References: ['']\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DEBUG - Citing Paper: The notorious R.N.A. in the spotlight - drug or target for the treatment of disease., References: ['']\n",
      "DEBUG - Citing Paper: Poly(glycoamidoamine) Brushes Formulated Nanomaterials for Systemic siRNA and mRNA Delivery in Vivo., References: ['']\n",
      "DEBUG - focal: mRNA: Fulfilling the Promise of Gene Therapy., NF: 0, NB: 0, NR: 0, D: 0\n",
      "DEBUG - Focal Paper: Autologous blood injection to model spontaneous intracerebral hemorrhage in mice., References: Abdel-Rahman R.F., Alqasoumi S.I., Ogaly H.A., Abd-Elsalam R.M., El-Banna H.A., Soliman G.A. Propolis ameliorates cerebral injury in focal cerebral ischemia/reperfusion (I/R) rat model via upregulation of TGF-Î²1. Saudi Pharmaceutical Journal. 2020;28(1):116â126. doi: 10.1016/j.jsps.2019.11.013.\n",
      "DEBUG - Citing Paper: Role of N-formyl peptide receptor 2 in germinal matrix hemorrhage: an intrinsic review of a hematoma resolving pathway., References: ['']\n",
      "DEBUG - Citing Paper: Berberine mitigates intracerebral hemorrhage-induced neuroinflammation in a gut microbiota-dependent manner in mice., References: ['']\n",
      "DEBUG - Citing Paper: Effects of prolactin on movement disorders and APOE, GFAP, and PRL receptor gene expression following intracerebral hemorrhage in rats., References: ['']\n",
      "DEBUG - Citing Paper: Neuroprotective efficacy of 4-Hydroxyisoleucine in experimentally induced intracerebral hemorrhage., References: ['']\n",
      "DEBUG - Citing Paper: 17Î²-Estradiol Attenuates Intracerebral Hemorrhage-Induced Blood-Brain Barrier Injury and Oxidative Stress Through SRC3-Mediated PI3K/Akt Signaling Pathway in a Mouse Model., References: ['']\n",
      "DEBUG - Citing Paper: Effect of Recombinant Insulin-like Growth Factor-2 Injected into the Hippocampus on Memory Impairment Following Hippocampal Intracerebral Hemorrhage in Rats., References: ['']\n",
      "DEBUG - Citing Paper: Inhibition of P2X4R attenuates white matter injury in mice after intracerebral hemorrhage by regulating microglial phenotypes., References: ['']\n",
      "DEBUG - Citing Paper: Pharmacological Activation of RXR-Î± Promotes Hematoma Absorption via a PPAR-Î³-dependent Pathway After Intracerebral Hemorrhage., References: ['']\n",
      "DEBUG - Citing Paper: Local Experimental Intracerebral Hemorrhage in Rats., References: ['']\n",
      "DEBUG - Citing Paper: Germinal Matrix-Intraventricular Hemorrhage of the Preterm Newborn and Preclinical Models: Inflammatory Considerations., References: ['']\n",
      "DEBUG - Citing Paper: Erythrocyte efferocytosis modulates macrophages towards recovery after intracerebral hemorrhage., References: ['']\n",
      "DEBUG - Citing Paper: TGF-Î²1 modulates microglial phenotype and promotes recovery after intracerebral hemorrhage., References: ['']\n",
      "DEBUG - Citing Paper: Intrastriatal injection of autologous blood or clostridial collagenase as murine models of intracerebral hemorrhage., References: ['']\n",
      "DEBUG - Citing Paper: Î±4 integrin is a regulator of leukocyte recruitment after experimental intracerebral hemorrhage., References: ['']\n",
      "DEBUG - Citing Paper: Mouse intracerebral hemorrhage models produce different degrees of initial and delayed damage, axonal sprouting, and recovery., References: ['']\n",
      "DEBUG - Citing Paper: CCR2+ Ly6C(hi) inflammatory monocyte recruitment exacerbates acute disability following intracerebral hemorrhage., References: ['']\n",
      "DEBUG - Citing Paper: Transplantation of neural stem cells that overexpress SOD1 enhances amelioration of intracerebral hemorrhage in mice., References: ['']\n",
      "DEBUG - Citing Paper: Gr1+ Macrophages and Dendritic Cells Dominate the Inflammatory Infiltrate 12 Hours After Experimental Intracerebral Hemorrhage., References: ['']\n",
      "DEBUG - focal: Autologous blood injection to model spontaneous intracerebral hemorrhage in mice., NF: 0, NB: 0, NR: 0, D: 0\n",
      "DEBUG - Focal Paper: Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge., References: \n",
      "Arcturus Announces self-amplifying COVID-19 mRNA vaccine candidate ARCT-154 meets primary efficacy endpoint in phase 3 study . Arcturus Therapeutics, Inc. Available at: https://ir.arcturusrx.com/news-releases/news-release-details/arcturus-announces-self-amplifying-covid-19-mrna-vaccine (Accessed July 13, 2022).\n",
      "DEBUG - Citing Paper: Long-term stability and immunogenicity of lipid nanoparticle COVID-19 mRNA vaccine is affected by particle size., References: ['']\n",
      "DEBUG - Citing Paper: Self-assembly of peptide nanocapsules by a solvent concentration gradient., References: ['']\n",
      "DEBUG - Citing Paper: Comprehensive evaluation of T7 promoter for enhanced yield and quality in mRNA production., References: ['']\n",
      "DEBUG - Citing Paper: Does the SARS-CoV-2 mRNA vaccine and its serum IgG levels affect fertility treatments and obstetric outcomes? An observational cohort study., References: ['']\n",
      "DEBUG - Citing Paper: vNARs as Neutralizing Intracellular Therapeutic Agents: Glioblastoma as a Target., References: ['']\n",
      "DEBUG - Citing Paper: The clinical impact of mRNA therapeutics in the treatment of cancers, infections, genetic disorders, and autoimmune diseases., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticle structure and delivery route during pregnancy dictate mRNA potency, immunogenicity, and maternal and fetal outcomes., References: ['']\n",
      "DEBUG - Citing Paper: An overview on mRNA-based vaccines to prevent monkeypox infection., References: ['']\n",
      "DEBUG - Citing Paper: Identification of Messenger RNA Signatures in Age-Dependent Renal Impairment., References: ['']\n",
      "DEBUG - Citing Paper: Clinical Analysis and Applications of mRNA Vaccines in Infectious Diseases and Cancer Treatment., References: ['']\n",
      "DEBUG - Citing Paper: Induction of long-term tolerance to a specific antigen using anti-CD3 lipid nanoparticles following gene therapy., References: ['']\n",
      "DEBUG - Citing Paper: Regulatory circular RNAs in viral diseases: applications in diagnosis and therapy., References: ['']\n",
      "DEBUG - Citing Paper: Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications., References: ['']\n",
      "DEBUG - Citing Paper: Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Recent Advancement in mRNA Vaccine Development and Applications., References: ['']\n",
      "DEBUG - Citing Paper: Expanding the Reach of Monoclonal Antibodies: A Review of Synthetic Nucleic Acid Delivery in Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: The Screening of Broadly Neutralizing Antibodies Targeting the SARS-CoV-2 Spike Protein by mRNA Immunization in Mice., References: ['']\n",
      "DEBUG - Citing Paper: RNA Therapeutics: A Healthcare Paradigm Shift., References: ['']\n",
      "DEBUG - Citing Paper: Messenger RNA rescues medium-chain acyl-CoA dehydrogenase deficiency in fibroblasts from patients and a murine model., References: ['']\n",
      "DEBUG - Citing Paper: Revolutionizing viral disease vaccination: the promising clinical advancements of non-replicating mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticle-encapsulated mRNA therapy corrects serum total bilirubin level in Crigler-Najjar syndrome mouse model., References: ['']\n",
      "DEBUG - Citing Paper: Advanced delivery systems for peptide antibiotics., References: ['']\n",
      "DEBUG - Citing Paper: Leading Edge: Intratumor Delivery of Monoclonal Antibodies for the Treatment of Solid Tumors., References: ['']\n",
      "DEBUG - Citing Paper: Cholesterol-Amino-Phosphate (CAP) Derived Lipid Nanoparticles for Delivery of Self-Amplifying RNA and Restoration of Spermatogenesis in Infertile Mice., References: ['']\n",
      "DEBUG - Citing Paper: Modulating the expression of tumor suppressor genes using activating oligonucleotide technologies as a therapeutic approach in cancer., References: ['']\n",
      "DEBUG - Citing Paper: Synthetic mRNA rescues very long-chain acyl-CoA dehydrogenase deficiency in patient fibroblasts and a murine model., References: ['']\n",
      "DEBUG - Citing Paper: Intranasal delivery of replicating mRNA encoding hACE2-targeting antibody against SARS-CoV-2 Omicron infection in the hamster., References: ['']\n",
      "DEBUG - Citing Paper: Nanovaccines against Viral Infectious Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Empowering gene delivery with protein engineering platforms., References: ['']\n",
      "DEBUG - Citing Paper: Lipid-Based Delivery Systems in Development of Genetic and Subunit Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-based vaccine technology for HIV., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticle Delivery System for mRNA Encoding B7H3-redirected Bispecific Antibody Displays Potent Antitumor Effects on Malignant Tumors., References: ['']\n",
      "DEBUG - Citing Paper: The landscape of mRNA nanomedicine., References: ['']\n",
      "DEBUG - Citing Paper: Advancing mRNA technologies for therapies and vaccines: An African context., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticles: A Novel Gene Delivery Technique for Clinical Application., References: ['']\n",
      "DEBUG - Citing Paper: Clinically relevant dosing and pharmacokinetics of DNA-encoded antibody therapeutics in a sheep model., References: ['']\n",
      "DEBUG - Citing Paper: mRNA nanomedicine: Design and recent applications., References: ['']\n",
      "DEBUG - Citing Paper: Applications and challenges of biomaterial mediated mRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: Synthesis of point-modified mRNA., References: ['']\n",
      "DEBUG - Citing Paper: The Delivery of mRNA Vaccines for Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Recent Progress in the Discovery and Development of Monoclonal Antibodies against Viral Infections., References: ['']\n",
      "DEBUG - Citing Paper: Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticle delivery of unmodified mRNAs encoding multiple monoclonal antibodies targeting poxviruses in rabbits., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-based therapeutics: powerful and versatile tools to combat diseases., References: ['']\n",
      "DEBUG - Citing Paper: Recent advances in lipid nanoparticles for delivery of nucleic acid, mRNA, and gene editing-based therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Messenger RNA vaccines for cancer immunotherapy: progress promotes promise., References: ['']\n",
      "DEBUG - Citing Paper: The Potential of Nanomedicine to Unlock the Limitless Applications of mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Phase-separating peptides for direct cytosolic delivery and redox-activated release of macromolecular therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Intravenous Delivery of RNA Encoding Anti-PD-1 Human Monoclonal Antibody for Treating Intestinal Cancer., References: ['']\n",
      "DEBUG - Citing Paper: Intracranial delivery of synthetic mRNA to suppress glioblastoma., References: ['']\n",
      "DEBUG - Citing Paper: Regulation of Antiviral Immune Response by <i>N</i> <sup>6</sup>-Methyladenosine of mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities., References: ['']\n",
      "DEBUG - Citing Paper: Added to pre-existing inflammation, mRNA-lipid nanoparticles induce inflammation exacerbation (IE)., References: ['']\n",
      "DEBUG - Citing Paper: The Development of mRNA Vaccines for Infectious Diseases: Recent Updates., References: ['']\n",
      "DEBUG - Citing Paper: Engineered mRNA-expressed bispecific antibody prevent intestinal cancer via lipid nanoparticle delivery., References: ['']\n",
      "DEBUG - Citing Paper: A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus., References: ['']\n",
      "DEBUG - Citing Paper: In Vivo Electroporation of Plasmid DNA: A Promising Strategy for Rapid, Inexpensive, and Flexible Delivery of Anti-Viral Monoclonal Antibodies., References: ['']\n",
      "DEBUG - Citing Paper: Targeting the Inside of Cells with Biologicals: Chemicals as a Delivery Strategy., References: ['']\n",
      "DEBUG - Citing Paper: Intranasal delivery of replicating mRNA encoding neutralizing antibody against SARS-CoV-2 infection in mice., References: ['']\n",
      "DEBUG - Citing Paper: Vaccines against COVID-19: Priority to mRNA-Based Formulations., References: ['']\n",
      "DEBUG - Citing Paper: Immunogenicity of <i>In Vitro</i>-Transcribed RNA., References: ['']\n",
      "DEBUG - Citing Paper: Reappraisal of PRRS Immune Control Strategies: The Way Forward., References: ['']\n",
      "DEBUG - Citing Paper: Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines for infectious diseases: principles, delivery and clinical translation., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticles for mRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: Strategies to deliver RNA by nanoparticles for therapeutic potential., References: ['']\n",
      "DEBUG - Citing Paper: Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: Lipids and Lipid Derivatives for RNA Delivery., References: ['']\n",
      "DEBUG - Citing Paper: Nucleoside-modified VEGFC mRNA induces organ-specific lymphatic growth and reverses experimental lymphedema., References: ['']\n",
      "DEBUG - Citing Paper: Humanized Mice for Infectious and Neurodegenerative disorders., References: ['']\n",
      "DEBUG - Citing Paper: Non-Immunotherapy Application of LNP-mRNA: Maximizing Efficacy and Safety., References: ['']\n",
      "DEBUG - Citing Paper: An integrated self-powered 3D printed sample concentrator for highly sensitive molecular detection of HIV in whole blood at the point of care., References: ['']\n",
      "DEBUG - Citing Paper: Lipid-nanoparticle-encapsulated mRNA vaccines induce protective memory CD8 TÂ cells against a lethal viral infection., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Delivery of a Bispecific Single-Domain Antibody to Polarize Tumor-Associated Macrophages and Synergize Immunotherapy against Liver Malignancies., References: ['']\n",
      "DEBUG - Citing Paper: Designing biomaterials for the delivery of RNA therapeutics to stimulate bone healing., References: ['']\n",
      "DEBUG - Citing Paper: Humanized Mice for the Evaluation of Novel HIV-1 Therapies., References: ['']\n",
      "DEBUG - Citing Paper: In the Era of mRNA Vaccines, Is There Any Hope for HIV Functional Cure?, References: ['']\n",
      "DEBUG - Citing Paper: What it will take to vaccinate the world against COVID-19., References: ['']\n",
      "DEBUG - Citing Paper: Immunotherapy perspectives in the new era of B-cell editing., References: ['']\n",
      "DEBUG - Citing Paper: Advances in vaccine delivery systems against viral infectious diseases., References: ['']\n",
      "DEBUG - Citing Paper: The significance of bioengineered nanoplatforms against SARS-CoV-2: From detection to genome editing., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccine: a potential therapeutic strategy., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-Based Vaccines and Mode of Action., References: ['']\n",
      "DEBUG - Citing Paper: Advancements in mRNA Encoded Antibodies for Passive Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: HIV mRNA Vaccines-Progress and Future Paths., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Murine liver repair via transient activation of regenerative pathways in hepatocytes using lipid nanoparticle-complexed nucleoside-modified mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Nanomaterial Delivery Systems for mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Development of nanoparticle-delivery systems for antiviral agents: A review., References: ['']\n",
      "DEBUG - Citing Paper: Self-assembled mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Platforms Exploited for SARS-CoV-2 Vaccine Development., References: ['']\n",
      "DEBUG - Citing Paper: An Inside Job: Applications of Intracellular Single Domain Antibodies., References: ['']\n",
      "DEBUG - Citing Paper: Quantum leap of monoclonal antibody (mAb) discovery and development in the COVID-19 era., References: ['']\n",
      "DEBUG - Citing Paper: Advances in Lipid Nanoparticles for mRNA-Based Cancer Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Self-amplifying RNA vaccines for infectious diseases., References: ['']\n",
      "DEBUG - Citing Paper: Nanotheranostics against COVID-19: From multivalent to immune-targeted materials., References: ['']\n",
      "DEBUG - Citing Paper: Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo., References: ['']\n",
      "DEBUG - Citing Paper: Intramuscular Delivery of Replicon RNA Encoding ZIKV-117 Human Monoclonal Antibody Protects against Zika Virus Infection., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticle technology for therapeutic gene regulation in the liver., References: ['']\n",
      "DEBUG - Citing Paper: In vivo expressed biologics for infectious disease prophylaxis: rapid delivery of DNA-based antiviral antibodies., References: ['']\n",
      "DEBUG - Citing Paper: Active immunoprophylaxis with a synthetic DNA-encoded monoclonal anti-respiratory syncytial virus scFv-Fc fusion protein confers protection against infection and durable activity., References: ['']\n",
      "DEBUG - Citing Paper: Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19., References: ['']\n",
      "DEBUG - Citing Paper: Formulation and Delivery Technologies for mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Encoding a Bispecific Single Domain Antibody Construct Protects against Influenza A Virus Infection in Mice., References: ['']\n",
      "DEBUG - Citing Paper: Messenger RNA-Based Vaccines Against Infectious Diseases., References: ['']\n",
      "DEBUG - Citing Paper: RNA-based scaffolds for bone regeneration: application and mechanisms of mRNA, miRNA and siRNA., References: ['']\n",
      "DEBUG - Citing Paper: In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies., References: ['']\n",
      "DEBUG - Citing Paper: Antibody-based therapeutic interventions: possible strategy to counter chikungunya viral infection., References: ['']\n",
      "DEBUG - Citing Paper: Innovations in HIV-1 Vaccine Design., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticles Potentiate CpG-Oligodeoxynucleotide-Based Vaccine for Influenza Virus., References: ['']\n",
      "DEBUG - Citing Paper: Polylactide-Based Reactive Micelles as a Robust Platform for mRNA Delivery., References: ['']\n",
      "DEBUG - Citing Paper: Synthesis of low immunogenicity RNA with high-temperature in vitro transcription., References: ['']\n",
      "DEBUG - Citing Paper: In-Vivo Gene Therapy with Foamy Virus Vectors., References: ['']\n",
      "DEBUG - Citing Paper: In vivo delivery of synthetic DNA-encoded antibodies induces broad HIV-1-neutralizing activity., References: ['']\n",
      "DEBUG - Citing Paper: Smart cancer nanomedicine., References: ['']\n",
      "DEBUG - Citing Paper: Expression Kinetics and Innate Immune Response after Electroporation and LNP-Mediated Delivery of a Self-Amplifying mRNA in the Skin., References: ['']\n",
      "DEBUG - Citing Paper: Biosimilar Gene Therapy: Investigational Assessment of Secukinumab Gene Therapy., References: ['']\n",
      "DEBUG - Citing Paper: Long-term efficacy and safety of mRNA therapy in two murine models of methylmalonic acidemia., References: ['']\n",
      "DEBUG - Citing Paper: Correction of bleeding in experimental severe hemophilia A by systemic delivery of factor VIII-encoding mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Regulation of Viral Infection by the RNA Modification <i>N6</i>-Methyladenosine., References: ['']\n",
      "DEBUG - Citing Paper: Current and Future PrEP Medications and Modalities: On-demand, Injectables, and Topicals., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Delivery for Therapeutic Anti-HER2 Antibody Expression InÂ Vivo., References: ['']\n",
      "DEBUG - Citing Paper: A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection., References: ['']\n",
      "DEBUG - Citing Paper: Advances in mRNA Vaccines for Infectious Diseases., References: ['']\n",
      "DEBUG - Citing Paper: mRNA: A Novel Avenue to Antibody Therapy?, References: ['']\n",
      "DEBUG - Citing Paper: Improved Efficacy in a Fabry Disease Model Using a Systemic mRNA Liver Depot System as Compared to Enzyme Replacement Therapy., References: ['']\n",
      "DEBUG - Citing Paper: Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery., References: ['']\n",
      "DEBUG - Citing Paper: How mRNA therapeutics are entering the monoclonal antibody field., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticles silence tumor necrosis factor Î± to improve wound healing in diabetic mice., References: ['']\n",
      "DEBUG - Citing Paper: Delivery of mRNA Therapeutics for the Treatment of Hepatic Diseases., References: ['']\n",
      "DEBUG - Citing Paper: The genetic shortcut to antibody drugs., References: ['']\n",
      "DEBUG - Citing Paper: Exploitation of Synthetic mRNA To Drive Immune Effector Cell Recruitment and Functional Reprogramming In Vivo., References: ['']\n",
      "DEBUG - Citing Paper: Chemically modified hCFTR mRNAs recuperate lung function in a mouse model of cystic fibrosis., References: ['']\n",
      "DEBUG - Citing Paper: Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes., References: ['']\n",
      "DEBUG - Citing Paper: HIV Entry and Its Inhibition by Bifunctional Antiviral Proteins., References: ['']\n",
      "DEBUG - Citing Paper: PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake., References: ['']\n",
      "DEBUG - Citing Paper: mRNA as novel technology for passive immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: New Vaccine Technologies to Combat Outbreak Situations., References: ['']\n",
      "DEBUG - Citing Paper: Engineered mRNA-expressed antibodies prevent respiratory syncytial virus infection., References: ['']\n",
      "DEBUG - Citing Paper: Optimization of a Degradable Polymer-Lipid Nanoparticle for Potent Systemic Delivery of mRNA to the Lung Endothelium and Immune Cells., References: ['']\n",
      "DEBUG - Citing Paper: Metabolically stabilized double-stranded mRNA polyplexes., References: ['']\n",
      "DEBUG - Citing Paper: Customizable Lipid Nanoparticle Materials for the Delivery of siRNAs and mRNAs., References: ['']\n",
      "DEBUG - Citing Paper: A Nanostructured Lipid Carrier for Delivery of a Replicating Viral RNA Provides Single, Low-Dose Protection against Zika., References: ['']\n",
      "DEBUG - Citing Paper: M<sup>3</sup>RNA Drives Targeted Gene Delivery in Acute Myocardial Infarction., References: ['']\n",
      "DEBUG - Citing Paper: Ionizable Amino-Polyesters Synthesized via Ring Opening Polymerization of Tertiary Amino-Alcohols for Tissue Selective mRNA Delivery., References: ['']\n",
      "DEBUG - Citing Paper: Intradermal Delivery of Synthetic mRNA Using Hollow Microneedles for Efficient and Rapid Production of Exogenous Proteins in Skin., References: ['']\n",
      "DEBUG - Citing Paper: mRNA treatment produces sustained expression of enzymatically active human ADAMTS13 in mice., References: ['']\n",
      "DEBUG - Citing Paper: Nanoscale platforms for messenger RNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: HIV Vaccination: A Roadmap among Advancements and Concerns., References: ['']\n",
      "DEBUG - Citing Paper: An origin of the immunogenicity of in vitro transcribed RNA., References: ['']\n",
      "DEBUG - Citing Paper: Targeted mRNA Therapy for Ornithine Transcarbamylase Deficiency., References: ['']\n",
      "DEBUG - Citing Paper: Passive immunotherapy of viral infections: 'super-antibodies' enter the fray., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines - a new era in vaccinology., References: ['']\n",
      "DEBUG - Citing Paper: Modified mRNA-Based Vaccines Elicit Robust Immune Responses and Protect Guinea Pigs From Ebola Virus Disease., References: ['']\n",
      "DEBUG - Citing Paper: Brief introduction of current technologies in isolation of broadly neutralizing HIV-1 antibodies., References: ['']\n",
      "DEBUG - Citing Paper: Cationic Nanoliposomes Meet mRNA: Efficient Delivery of Modified mRNA Using Hemocompatible and Stable Vectors for Therapeutic Applications., References: ['']\n",
      "DEBUG - Citing Paper: mRNA mediates passive vaccination against infectious agents, toxins, and tumors., References: ['']\n",
      "DEBUG - Citing Paper: Advances in the delivery of RNA therapeutics: from concept to clinical reality., References: ['']\n",
      "DEBUG - Citing Paper: State of play and clinical prospects of antibody gene transfer., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticle Systems for Enabling Gene Therapies., References: ['']\n",
      "DEBUG - focal: Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge., NF: 0, NB: 0, NR: 0, D: 0\n",
      "DEBUG - Focal Paper: Toll-like receptor 4 contributes to poor outcome after intracerebral hemorrhage., References: \n",
      "Paolicelli R, Sierra A, Stevens B, Tremblay M-E, Aguzzi A, Ajami B, et al. . Defining microglial states and nomenclature: A roadmap to 2030 . Available at: https://ssrn.com/abstract=4065080.\n",
      "DEBUG - Citing Paper: The Role of Glial Cells in Neurobiology and Prion Neuropathology., References: ['']\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DEBUG - Citing Paper: The dynamic changes of peripheral blood cell counts predict the clinical outcomes of aneurysmal subarachnoid hemorrhage., References: ['']\n",
      "DEBUG - Citing Paper: Targeting brain-peripheral immune responses for secondary brain injury after ischemic and hemorrhagic stroke., References: ['']\n",
      "DEBUG - Citing Paper: Development of a 3D Brain Model to Study Sex-Specific Neuroinflammation After Hemorrhagic Stroke., References: ['']\n",
      "DEBUG - Citing Paper: Intracerebral hemorrhage-induced brain injury in mice: The role of peroxiredoxin 2-Toll-like receptor 4 inflammatory axis., References: ['']\n",
      "DEBUG - Citing Paper: Exosomes derived from human umbilical cord mesenchymal stem cells decrease neuroinflammation and facilitate the restoration of nerve function in rats suffering from intracerebral hemorrhage., References: ['']\n",
      "DEBUG - Citing Paper: Brain FADE syndrome: the final common pathway of chronic inflammation in neurological disease., References: ['']\n",
      "DEBUG - Citing Paper: Therapeutic strategies for intracerebral hemorrhage., References: ['']\n",
      "DEBUG - Citing Paper: MicroRNAs modulate neuroinflammation after intracerebral hemorrhage: Prospects for new therapy., References: ['']\n",
      "DEBUG - Citing Paper: Neuroinflammation of microglia polarization in intracerebral hemorrhage and its potential targets for intervention., References: ['']\n",
      "DEBUG - Citing Paper: miR-30e-5p attenuates neuronal deficit and inflammation of rats with intracerebral hemorrhage by regulating TLR4., References: ['']\n",
      "DEBUG - Citing Paper: Microglia Phenotypes in Aging and Neurodegenerative Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Heme Oxygenase-1 may Mediate Early Inflammatory Response of Intracerebral Hemorrhage through Toll-like Receptor 4 Signaling Pathway., References: ['']\n",
      "DEBUG - Citing Paper: Cerebral Hemorrhage: Pathophysiology, Treatment, and Future Directions., References: ['']\n",
      "DEBUG - Citing Paper: Pathogenetic Mechanisms of Hypertension-Brain-Induced Complications: Focus on Molecular Mediators., References: ['']\n",
      "DEBUG - Citing Paper: Sepsis-Exacerbated Brain Dysfunction After Intracerebral Hemorrhage., References: ['']\n",
      "DEBUG - Citing Paper: Neuroprotective Effects of Hesperetin in Regulating Microglia Polarization after Ischemic Stroke by Inhibiting TLR4/NF-<i>Îº</i>B Pathway., References: ['']\n",
      "DEBUG - Citing Paper: Application of Programmable Tetrahedral Framework Nucleic Acid-Based Nanomaterials in Neurological Disorders: Progress and Prospects., References: ['']\n",
      "DEBUG - Citing Paper: Microglia Phenotype and Intracerebral Hemorrhage: A Balance of Yin and Yang., References: ['']\n",
      "DEBUG - Citing Paper: Bone mesenchymal stem cell-derived extracellular vesicles deliver microRNA-23b to alleviate spinal cord injury by targeting toll-like receptor TLR4 and inhibiting NF-ÎºB pathway activation., References: ['']\n",
      "DEBUG - Citing Paper: Time Course of Peripheral Leukocytosis and Clinical Outcomes After Aneurysmal Subarachnoid Hemorrhage., References: ['']\n",
      "DEBUG - Citing Paper: Critical Role of Hemopexin Mediated Cytoprotection in the Pathophysiology of Sickle Cell Disease., References: ['']\n",
      "DEBUG - Citing Paper: Toll-Like Receptor Signaling Pathways: Novel Therapeutic Targets for Cerebrovascular Disorders., References: ['']\n",
      "DEBUG - Citing Paper: When the Blood Hits Your Brain: The Neurotoxicity of Extravasated Blood., References: ['']\n",
      "DEBUG - Citing Paper: Microglia: A Double-Edged Sword in Intracerebral Hemorrhage From Basic Mechanisms to Clinical Research., References: ['']\n",
      "DEBUG - Citing Paper: Effect of hemopexin treatment on outcome after intracerebral hemorrhage in mice., References: ['']\n",
      "DEBUG - Citing Paper: NOD1/RIP2 signalling enhances the microglia-driven inflammatory response and undergoes crosstalk with inflammatory cytokines to exacerbate brain damage following intracerebral haemorrhage in mice., References: ['']\n",
      "DEBUG - Citing Paper: Brain injury and repair after intracerebral hemorrhage: The role of microglia and brain-infiltrating macrophages., References: ['']\n",
      "DEBUG - Citing Paper: Molecular Correlates of Hemorrhage and Edema Volumes Following Human Intracerebral Hemorrhage Implicate Inflammation, Autophagy, mRNA Splicing, and T Cell Receptor Signaling., References: ['']\n",
      "DEBUG - Citing Paper: Role of DAMPs and of Leukocytes Infiltration in Ischemic Stroke: Insights from Animal Models and Translation to the Human Disease., References: ['']\n",
      "DEBUG - Citing Paper: Interaction of Microglia and Astrocytes in the Neurovascular Unit., References: ['']\n",
      "DEBUG - Citing Paper: Pro-inflammatory Actions of Heme and Other Hemoglobin-Derived DAMPs., References: ['']\n",
      "DEBUG - Citing Paper: Inflammation in acquired hydrocephalus: pathogenic mechanisms and therapeutic targets., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like Receptor 4 Signaling in Neurons Enhances Calcium-Permeable Î±-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid Receptor Currents and Drives Post-Traumatic Epileptogenesis., References: ['']\n",
      "DEBUG - Citing Paper: Neuroinflammation after Intracerebral Hemorrhage and Potential Therapeutic Targets., References: ['']\n",
      "DEBUG - Citing Paper: Pathophysiological Mechanisms and Potential Therapeutic Targets in Intracerebral Hemorrhage., References: ['']\n",
      "DEBUG - Citing Paper: Inhibition of activator protein 1 attenuates neuroinflammation and brain injury after experimental intracerebral hemorrhage., References: ['']\n",
      "DEBUG - Citing Paper: miR-140-5p Attenuates Neuroinflammation and Brain Injury in Rats Following Intracerebral Hemorrhage by Targeting TLR4., References: ['']\n",
      "DEBUG - Citing Paper: Emerging therapeutic targets associated with the immune system in patients with intracerebral haemorrhage (ICH): From mechanisms to translation., References: ['']\n",
      "DEBUG - Citing Paper: Intracerebral hemorrhage induces monocyte-related gene expression within six hours: Global transcriptional profiling in swine ICH., References: ['']\n",
      "DEBUG - Citing Paper: Resistin-Inhibited Neural Stem Cell-Derived Astrocyte Differentiation Contributes to Permeability Destruction of the Blood-Brain Barrier., References: ['']\n",
      "DEBUG - Citing Paper: Mechanisms and Therapeutic Targets of Depression After Intracerebral Hemorrhage., References: ['']\n",
      "DEBUG - Citing Paper: Sheng-Di-Da-Huang Decoction Inhibited Inflammation Expressed in Microglia after Intracerebral Hemorrhage in Rats., References: ['']\n",
      "DEBUG - Citing Paper: The Dual Role of Hepcidin in Brain Iron Load and Inflammation., References: ['']\n",
      "DEBUG - Citing Paper: Theaflavin alleviates inflammatory response and brain injury induced by cerebral hemorrhage via inhibiting the nuclear transcription factor kappa Î²-related pathway in rats., References: ['']\n",
      "DEBUG - Citing Paper: The intracerebral hemorrhage blood transcriptome in humans differs from the ischemic stroke and vascular risk factor control blood transcriptomes., References: ['']\n",
      "DEBUG - Citing Paper: Hepcidin, an emerging and important player in brain iron homeostasis., References: ['']\n",
      "DEBUG - Citing Paper: Erythrocyte efferocytosis modulates macrophages towards recovery after intracerebral hemorrhage., References: ['']\n",
      "DEBUG - Citing Paper: Preclinical Studies and Translational Applications of Intracerebral Hemorrhage., References: ['']\n",
      "DEBUG - Citing Paper: Modulators of microglial activation and polarization after intracerebral haemorrhage., References: ['']\n",
      "DEBUG - Citing Paper: A20 Ameliorates Intracerebral Hemorrhage-Induced Inflammatory Injury by Regulating TRAF6 Polyubiquitination., References: ['']\n",
      "DEBUG - Citing Paper: TGF-Î²1 modulates microglial phenotype and promotes recovery after intracerebral hemorrhage., References: ['']\n",
      "DEBUG - Citing Paper: High Morphologic Plasticity of Microglia/Macrophages Following Experimental Intracerebral Hemorrhage in Rats., References: ['']\n",
      "DEBUG - Citing Paper: Stages of the Inflammatory Response in Pathology and Tissue Repair after Intracerebral Hemorrhage., References: ['']\n",
      "DEBUG - Citing Paper: Blood lipid levels, statin therapy and the risk of intracerebral hemorrhage., References: ['']\n",
      "DEBUG - Citing Paper: Microglial Polarization and Inflammatory Mediators After Intracerebral Hemorrhage., References: ['']\n",
      "DEBUG - Citing Paper: Ischemia, Immunosuppression and Infection--Tackling the Predicaments of Post-Stroke Complications., References: ['']\n",
      "DEBUG - Citing Paper: Autophagy Promotes Microglia Activation Through Beclin-1-Atg5 Pathway in Intracerebral Hemorrhage., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like Receptors in the Vascular System: Sensing the Dangers Within., References: ['']\n",
      "DEBUG - Citing Paper: The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Confers Acute Neuroprotection After Intracerebral Hemorrhage in Mice., References: ['']\n",
      "DEBUG - Citing Paper: Rethinking the roles of inflammation in the intracerebral hemorrhage., References: ['']\n",
      "DEBUG - Citing Paper: Targeting secondary injury in intracerebral haemorrhage--perihaematomal oedema., References: ['']\n",
      "DEBUG - Citing Paper: Neuroinflammation after intracerebral hemorrhage., References: ['']\n",
      "DEBUG - Citing Paper: CX3CR1 signaling on monocytes is dispensable after intracerebral hemorrhage., References: ['']\n",
      "DEBUG - Citing Paper: Vascular disruption and blood-brain barrier dysfunction in intracerebral hemorrhage., References: ['']\n",
      "DEBUG - Citing Paper: Association between plasma levels of hyaluronic acid and functional outcome in acute stroke patients., References: ['']\n",
      "DEBUG - Citing Paper: Heme on innate immunity and inflammation., References: ['']\n",
      "DEBUG - Citing Paper: Intracerebral hemorrhage in mouse models: therapeutic interventions and functional recovery., References: ['']\n",
      "DEBUG - Citing Paper: CD36-mediated hematoma absorption following intracerebral hemorrhage: negative regulation by TLR4 signaling., References: ['']\n",
      "DEBUG - Citing Paper: CCR2+ Ly6C(hi) inflammatory monocyte recruitment exacerbates acute disability following intracerebral hemorrhage., References: ['']\n",
      "DEBUG - Citing Paper: New avenues for treatment of intracranial hemorrhage., References: ['']\n",
      "DEBUG - Citing Paper: Chronic intermittent hypoxia exerts CNS region-specific effects on rat microglial inflammatory and TLR4 gene expression., References: ['']\n",
      "DEBUG - Citing Paper: Microglial responses after ischemic stroke and intracerebral hemorrhage., References: ['']\n",
      "DEBUG - Citing Paper: Progress in translational research on intracerebral hemorrhage: is there an end in sight?, References: ['']\n",
      "DEBUG - Citing Paper: Peripheral monocyte count is associated with case fatality after intracerebral hemorrhage., References: ['']\n",
      "DEBUG - Citing Paper: Different TLR4 expression and microglia/macrophage activation induced by hemorrhage in the rat spinal cord after compressive injury., References: ['']\n",
      "DEBUG - Citing Paper: Differential effects of aging and sex on stroke induced inflammation across the lifespan., References: ['']\n",
      "DEBUG - Citing Paper: Dysregulated expression of T cell immunoglobulin and mucin domain 3 is associated with the disease severity and the outcome of patients with spontaneous intracerebral hemorrhage., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor 4 signaling in intracerebral hemorrhage-induced inflammation and injury., References: ['']\n",
      "DEBUG - Citing Paper: Fingolimod reduces cerebral lymphocyte infiltration in experimental models of rodent intracerebral hemorrhage., References: ['']\n",
      "DEBUG - Citing Paper: Gr1+ Macrophages and Dendritic Cells Dominate the Inflammatory Infiltrate 12 Hours After Experimental Intracerebral Hemorrhage., References: ['']\n",
      "DEBUG - Citing Paper: Intracerebral haemorrhage: mechanisms of injury and therapeutic targets., References: ['']\n",
      "DEBUG - Citing Paper: The immunology of acute stroke., References: ['']\n",
      "DEBUG - Citing Paper: A critical appraisal of experimental intracerebral hemorrhage research., References: ['']\n",
      "DEBUG - focal: Toll-like receptor 4 contributes to poor outcome after intracerebral hemorrhage., NF: 0, NB: 0, NR: 0, D: 0\n",
      "DEBUG - Focal Paper: Cerebral preconditioning using cortical application of hypertonic salt solutions: upregulation of mRNAs encoding inhibitors of inflammation., References: Abdelmohsen K, Kuwano Y, Kim HH, Gorospe M. Posttranscriptional gene regulation by RNA-binding proteins during oxidative stress: implications for cellular senescence. Biol Chem. 2008;389:243â255.\n",
      "DEBUG - Citing Paper: Non-linear actions of physiological agents: Finite disarrangements elicit fitness benefits., References: ['']\n",
      "DEBUG - Citing Paper: Tristetraprolin expression and microRNA-mediated regulation during simian immunodeficiency virus infection of the central nervous system., References: ['']\n",
      "DEBUG - focal: Cerebral preconditioning using cortical application of hypertonic salt solutions: upregulation of mRNAs encoding inhibitors of inflammation., NF: 0, NB: 0, NR: 0, D: 0\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DEBUG - Focal Paper: Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase resistance to cleavage by RNase L., References: \n",
      "\n",
      "Tollervey, D.\n",
      ", \n",
      "Lehtonen, H.\n",
      ", \n",
      "CarmoâFonseca, M.\n",
      ", & \n",
      "Hurt, E. C.\n",
      " (1991). The small nucleolar RNP protein NOP1 (fibrillarin) is required for preârRNA processing in yeast. The EMBO Journal, 10(3), 573â583. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/1825809\n",
      "\n",
      "DEBUG - Citing Paper: Physiologically based modeling of LNP-mediated delivery of mRNA in the vascular system., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccine designs for optimal adjuvanticity and delivery., References: ['']\n",
      "DEBUG - Citing Paper: RNA editing enzymes: structure, biological functions and applications., References: ['']\n",
      "DEBUG - Citing Paper: Can the Revolution in mRNA-Based Vaccine Technologies Solve the Intractable Health Issues of Current Ruminant Production Systems?, References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccine Nanoplatforms and Innate Immunity., References: ['']\n",
      "DEBUG - Citing Paper: An oncolytic circular RNA therapy., References: ['']\n",
      "DEBUG - Citing Paper: A Comprehensive Review of Small Interfering RNAs (siRNAs): Mechanism, Therapeutic Targets, and Delivery Strategies for Cancer Therapy., References: ['']\n",
      "DEBUG - Citing Paper: Why U matters: detection and functions of pseudouridine modifications in mRNAs., References: ['']\n",
      "DEBUG - Citing Paper: Engineering a Novel Modular Adenoviral mRNA Delivery Platform Based on Tag/Catcher Bioconjugation., References: ['']\n",
      "DEBUG - Citing Paper: The regulation of antiviral innate immunity through non-m<sup>6</sup>A RNA modifications., References: ['']\n",
      "DEBUG - Citing Paper: Reducing cell intrinsic immunity to mRNA vaccine alters adaptive immune responses in mice., References: ['']\n",
      "DEBUG - Citing Paper: Engineering siRNA therapeutics: challenges and strategies., References: ['']\n",
      "DEBUG - Citing Paper: An in vitro-transcribed circular RNA targets the mitochondrial inner membrane cardiolipin to ablate EIF4G2<sup>+</sup>/PTBP1<sup>+</sup> pan-adenocarcinoma., References: ['']\n",
      "DEBUG - Citing Paper: Seasonal quadrivalent mRNA vaccine prevents and mitigates influenza infection., References: ['']\n",
      "DEBUG - Citing Paper: Application of Lung-Targeted Lipid Nanoparticle-delivered mRNA of soluble PD-L1 via SORT Technology in Acute Respiratory Distress Syndrome., References: ['']\n",
      "DEBUG - Citing Paper: Circular RNA vaccine in disease prevention and treatment., References: ['']\n",
      "DEBUG - Citing Paper: Improved tropoelastin synthesis in the skin by codon optimization and nucleotide modification of tropoelastin-encoding synthetic mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Control of protein synthesis through mRNA pseudouridylation by dyskerin., References: ['']\n",
      "DEBUG - Citing Paper: The impact of nucleoside base modification in mRNA vaccine is influenced by the chemistry of its lipid nanoparticle delivery system., References: ['']\n",
      "DEBUG - Citing Paper: Innate immune regulations and various siRNA modalities., References: ['']\n",
      "DEBUG - Citing Paper: Recent Advancements in Mosquito-Borne Flavivirus Vaccine Development., References: ['']\n",
      "DEBUG - Citing Paper: Promoter-independent synthesis of chemically modified RNA by human DNA polymerase Î¸ variants., References: ['']\n",
      "DEBUG - Citing Paper: Research Advances on the Stability of mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Role of Innate Interferon Responses at the Ocular Surface in Herpes Simplex Virus-1-Induced Herpetic Stromal Keratitis., References: ['']\n",
      "DEBUG - Citing Paper: Shaping the future from the small scale: dry powder inhalation of CRISPR-Cas9 lipid nanoparticles for the treatment of lung diseases., References: ['']\n",
      "DEBUG - Citing Paper: Nanobiotechnology-Enabled mRNA Stabilization., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccine Mitigates SARS-CoV-2 Infections and COVID-19., References: ['']\n",
      "DEBUG - Citing Paper: Semi-quantitative detection of pseudouridine modifications and type I/II hypermodifications in human mRNAs using direct long-read sequencing., References: ['']\n",
      "DEBUG - Citing Paper: Advances of mRNA vaccine in tumor: a maze of opportunities and challenges., References: ['']\n",
      "DEBUG - Citing Paper: Exploring <i>in vitro</i> expression and immune potency in mice using mRNA encoding the <i>Plasmodium falciparum</i> malaria antigen, CelTOS., References: ['']\n",
      "DEBUG - Citing Paper: Design, Synthesis, and Characterization of a Novel 2'-5'-Linked Amikacin-Binding Aptamer: An Experimental and MD Simulation Study., References: ['']\n",
      "DEBUG - Citing Paper: Scope and challenges of nanoparticle-based mRNA delivery in cancer treatment., References: ['']\n",
      "DEBUG - Citing Paper: The landscape of mRNA nanomedicine., References: ['']\n",
      "DEBUG - Citing Paper: Advancing mRNA technologies for therapies and vaccines: An African context., References: ['']\n",
      "DEBUG - Citing Paper: Innate immune mechanisms of mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Immunization with a Prefusion SARS-CoV-2 Spike Protein Vaccine (RBMRNA-176) Protects against Viral Challenge in Mice and Nonhuman Primates., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines: A novel weapon to control infectious diseases., References: ['']\n",
      "DEBUG - Citing Paper: Characteristics of the Cytotoxicity of <i>Taraxacum mongolicum</i> and <i>Taraxacum formosanum</i> in Human Breast Cancer Cells., References: ['']\n",
      "DEBUG - Citing Paper: Nucleic acid-protein condensates in innate immune signaling., References: ['']\n",
      "DEBUG - Citing Paper: The life and death of RNA across temperatures., References: ['']\n",
      "DEBUG - Citing Paper: Recent Advances in the Molecular Design and Delivery Technology of mRNA for Vaccination Against Infectious Diseases., References: ['']\n",
      "DEBUG - Citing Paper: The Pivotal Role of Chemical Modifications in mRNA Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: N<sup>1</sup>-methyl-pseudouridine is incorporated with higher fidelity than pseudouridine in synthetic RNAs., References: ['']\n",
      "DEBUG - Citing Paper: Efficient Induction of Antigen-Specific CD8<sup>+</sup> T-Cell Responses by Cationic Peptide-Based mRNA Nanoparticles., References: ['']\n",
      "DEBUG - Citing Paper: The legacy of mRNA engineering: A lineup of pioneers for the Nobel Prize., References: ['']\n",
      "DEBUG - Citing Paper: An imidazole modified lipid confers enhanced mRNA-LNP stability and strong immunization properties in mice and non-human primates., References: ['']\n",
      "DEBUG - Citing Paper: Role of main RNA modifications in cancer: N<sup>6</sup>-methyladenosine, 5-methylcytosine, and pseudouridine., References: ['']\n",
      "DEBUG - Citing Paper: mRNA- and Adenovirus-Based Vaccines against SARS-CoV-2 in HIV-Positive People., References: ['']\n",
      "DEBUG - Citing Paper: Advances in COVID-19 mRNA vaccine development., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 mRNA vaccines: Platforms and current developments., References: ['']\n",
      "DEBUG - Citing Paper: Cell-Penetrating Peptides: Emerging Tools for mRNA Delivery., References: ['']\n",
      "DEBUG - Citing Paper: Intracellular RNase activity dampens zinc finger nuclease-mediated gene editing in hematopoietic stem and progenitor cells., References: ['']\n",
      "DEBUG - Citing Paper: Membrane-dependent relief of translation elongationÂ arrest on pseudouridine- and N1-methyl-pseudouridine-modified mRNAs., References: ['']\n",
      "DEBUG - Citing Paper: The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticle chemistry determines how nucleoside base modifications alter mRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: CRISPR/Cas9 Delivery System Engineering for Genome Editing in Therapeutic Applications., References: ['']\n",
      "DEBUG - Citing Paper: Immunogenicity of <i>In Vitro</i>-Transcribed RNA., References: ['']\n",
      "DEBUG - Citing Paper: CRISPR-derived genome editing therapies: Progress from bench to bedside., References: ['']\n",
      "DEBUG - Citing Paper: Application of Modified mRNA in Somatic Reprogramming to Pluripotency and Directed Conversion of Cell Fate., References: ['']\n",
      "DEBUG - Citing Paper: Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across., References: ['']\n",
      "DEBUG - Citing Paper: Intracellular Routing and Recognition of Lipid-Based mRNA Nanoparticles., References: ['']\n",
      "DEBUG - Citing Paper: Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice., References: ['']\n",
      "DEBUG - Citing Paper: Synthetic modified messenger RNA for therapeutic applications., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines for COVID-19: what, why and how., References: ['']\n",
      "DEBUG - Citing Paper: Virus Eradication and Synthetic Biology: Changes with SARS-CoV-2?, References: ['']\n",
      "DEBUG - Citing Paper: mRNA-encoded, constitutively active STING<sup>V155M</sup> is a potent genetic adjuvant of antigen-specific CD8<sup>+</sup> TÂ cell response., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccines against Flaviviruses., References: ['']\n",
      "DEBUG - Citing Paper: mRNA in cancer immunotherapy: beyond a source of antigen., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-Based Vaccines and Mode of Action., References: ['']\n",
      "DEBUG - Citing Paper: HIV mRNA Vaccines-Progress and Future Paths., References: ['']\n",
      "DEBUG - Citing Paper: What We Do Know and Do Not Yet Know about COVID-19 Vaccines as of the Beginning of the Year 2021., References: ['']\n",
      "DEBUG - Citing Paper: Current State of the First COVID-19 Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: The epitranscriptome beyond m<sup>6</sup>A., References: ['']\n",
      "DEBUG - Citing Paper: Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in mice., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccine Era-Mechanisms, Drug Platform and Clinical Prospection., References: ['']\n",
      "DEBUG - Citing Paper: Designing a novel mRNA vaccine against SARS-CoV-2: An immunoinformatics approach., References: ['']\n",
      "DEBUG - Citing Paper: Controlling timing and location in vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Therapeutic siRNA: state of the art., References: ['']\n",
      "DEBUG - Citing Paper: m<sup>6</sup>A Modification Prevents Formation of Endogenous Double-Stranded RNAs and Deleterious Innate Immune Responses during Hematopoietic Development., References: ['']\n",
      "DEBUG - Citing Paper: Immunomodulation in Cystic Fibrosis: Why and How?, References: ['']\n",
      "DEBUG - Citing Paper: Photochemical Internalization for Intracellular Drug Delivery. From Basic Mechanisms to Clinical Research., References: ['']\n",
      "DEBUG - Citing Paper: Epitranscriptomic marks: Emerging modulators of RNA virus gene expression., References: ['']\n",
      "DEBUG - Citing Paper: In vitro evolution of enhanced RNA replicons for immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Biomedical applications of mRNA nanomedicine., References: ['']\n",
      "DEBUG - Citing Paper: RNA regulation of the antiviral protein 2'-5'-oligoadenylate synthetase., References: ['']\n",
      "DEBUG - Citing Paper: Recent Developments in mRNA-Based Protein Supplementation Therapy to Target Lung Diseases., References: ['']\n",
      "DEBUG - Citing Paper: mRNA: A Novel Avenue to Antibody Therapy?, References: ['']\n",
      "DEBUG - Citing Paper: mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases., References: ['']\n",
      "DEBUG - Citing Paper: How mRNA therapeutics are entering the monoclonal antibody field., References: ['']\n",
      "DEBUG - Citing Paper: Nucleotide Modification Alters MicroRNA-Dependent Silencing of MicroRNA Switches., References: ['']\n",
      "DEBUG - Citing Paper: Delivery of mRNA Therapeutics for the Treatment of Hepatic Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Exploitation of Synthetic mRNA To Drive Immune Effector Cell Recruitment and Functional Reprogramming In Vivo., References: ['']\n",
      "DEBUG - Citing Paper: Recent Advances in Zika Virus Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: mRNA as novel technology for passive immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Uridine Depletion and Chemical Modification Increase Cas9 mRNA Activity and Reduce Immunogenicity without HPLC Purification., References: ['']\n",
      "DEBUG - Citing Paper: Biocompatible, Purified <i>VEGF-A</i> mRNA Improves Cardiac Function after Intracardiac Injection 1 Week Post-myocardial Infarction in Swine., References: ['']\n",
      "DEBUG - Citing Paper: Purification of mRNA Encoding Chimeric Antigen Receptor Is Critical for Generation of a Robust T-Cell Response., References: ['']\n",
      "DEBUG - Citing Paper: Exploring Cytotoxic mRNAs as a Novel Class of Anti-cancer Biotherapeutics., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines - a new era in vaccinology., References: ['']\n",
      "DEBUG - Citing Paper: Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses., References: ['']\n",
      "DEBUG - Citing Paper: Efficient Targeting and Activation of Antigen-Presenting Cells InÂ Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques., References: ['']\n",
      "DEBUG - Citing Paper: Stimuli-Responsive Mesoporous Silica NPs as Non-viral Dual siRNA/Chemotherapy Carriers for Triple Negative Breast Cancer., References: ['']\n",
      "DEBUG - Citing Paper: Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses., References: ['']\n",
      "DEBUG - Citing Paper: Characterizing exogenous mRNA delivery, trafficking, cytoplasmic release and RNA-protein correlations at the level of single cells., References: ['']\n",
      "DEBUG - Citing Paper: N1-methyl-pseudouridine in mRNA enhances translation through eIF2Î±-dependent and independent mechanisms by increasing ribosome density., References: ['']\n",
      "DEBUG - Citing Paper: Modified mRNA Vaccines Protect against Zika Virus Infection., References: ['']\n",
      "DEBUG - Citing Paper: Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems., References: ['']\n",
      "DEBUG - Citing Paper: Modified mRNA as a therapeutic tool to induce cardiac regeneration in ischemic heart disease., References: ['']\n",
      "DEBUG - Citing Paper: Efficacy and immunogenicity of unmodified and pseudouridine-modified mRNA delivered systemically with lipid nanoparticles inÂ vivo., References: ['']\n",
      "DEBUG - Citing Paper: Type I Interferons Interfere with the Capacity of mRNA Lipoplex Vaccines to Elicit Cytolytic T Cell Responses., References: ['']\n",
      "DEBUG - Citing Paper: The Epitranscriptome and Innate Immunity., References: ['']\n",
      "DEBUG - Citing Paper: Efficient expression of stabilized mRNA PEG-peptide polyplexes in liver., References: ['']\n",
      "DEBUG - Citing Paper: Identification of Cyclobutane Pyrimidine Dimer-Responsive Genes Using UVB-Irradiated Human Keratinocytes Transfected with In Vitro-Synthesized Photolyase mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals., References: ['']\n",
      "DEBUG - Citing Paper: 2'-O-Methylation within Bacterial RNA Acts as Suppressor of TLR7/TLR8 Activation in Human Innate Immune Cells., References: ['']\n",
      "DEBUG - Citing Paper: Emerging roles for RNA degradation in viral replication and antiviral defense., References: ['']\n",
      "DEBUG - Citing Paper: Pseudouridine: still mysterious, but never a fake (uridine)!, References: ['']\n",
      "DEBUG - Citing Paper: Efficient delivery and functional expression of transfected modified mRNA in human embryonic stem cell-derived retinal pigmented epithelial cells., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-based therapeutics--developing a new class of drugs., References: ['']\n",
      "DEBUG - Citing Paper: Non-viral vectors for gene-based therapy., References: ['']\n",
      "DEBUG - Citing Paper: Can't RIDD off viruses., References: ['']\n",
      "DEBUG - Citing Paper: Association of dengue virus infection susceptibility with polymorphisms of 2'-5'-oligoadenylate synthetase genes: a case-control study., References: ['']\n",
      "DEBUG - Citing Paper: Transfection of pseudouridine-modified mRNA encoding CPD-photolyase leads to repair of DNA damage in human keratinocytes: a new approach with future therapeutic potential., References: ['']\n",
      "DEBUG - Citing Paper: Influenza A induced cellular signal transduction pathways., References: ['']\n",
      "DEBUG - Citing Paper: RNase-L deficiency exacerbates experimental colitis and colitis-associated cancer., References: ['']\n",
      "DEBUG - Citing Paper: Developing mRNA-vaccine technologies., References: ['']\n",
      "DEBUG - Citing Paper: The genomic signature of human rhinoviruses A, B and C., References: ['']\n",
      "DEBUG - Citing Paper: Multi-level regulation of cellular recognition of viral dsRNA., References: ['']\n",
      "DEBUG - Citing Paper: Mechanistic characterization of the 5'-triphosphate-dependent activation of PKR: lack of 5'-end nucleobase specificity, evidence for a distinct triphosphate binding site, and a critical role for the dsRBD., References: ['']\n",
      "DEBUG - Citing Paper: RNA mediated Toll-like receptor stimulation in health and disease., References: ['']\n",
      "DEBUG - Citing Paper: Expression, purification and characterization of the interferon-inducible, antiviral and tumour-suppressor protein, human RNase L., References: ['']\n",
      "DEBUG - Citing Paper: Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin., References: ['']\n",
      "DEBUG - Citing Paper: Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA., References: ['']\n",
      "DEBUG - focal: Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase resistance to cleavage by RNase L., NF: 0, NB: 0, NR: 0, D: 0\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DEBUG - Focal Paper: BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans., References: \n",
      "\n",
      "BIND Therapeutics Determines Pfizer's $40 Million Bid Is Highest and Best in 363 Auction for Substantially All of BIND's Assets\n",
      ". 2021. https://www.businesswire.com/news/home/20160726006576/en/BIND-Therapeutics-Determines-Pfizer%E2%80%99s-40-Million-Bid-Is-Highest-and-Best-in-363-Auction-for-Substantially-All-of-BIND%E2%80%99s-Assets\n",
      "\n",
      "DEBUG - Citing Paper: SARS-CoV-2 Neutralization Assays Used in Clinical Trials: A Narrative Review., References: ['']\n",
      "DEBUG - Citing Paper: FASTMAP-a flexible and scalable immunopeptidomics pipeline for HLA- and antigen-specific T-cell epitope mapping based on artificial antigen-presenting cells., References: ['']\n",
      "DEBUG - Citing Paper: Humoral responses to multiple SARS-CoV-2 variants after two doses of vaccine in kidney transplant patients., References: ['']\n",
      "DEBUG - Citing Paper: Innate Responses to the Former COVID-19 Vaccine Candidate CVnCoV and Their Relation to Reactogenicity and Adaptive Immunogenicity., References: ['']\n",
      "DEBUG - Citing Paper: Clonal structure and the specificity of vaccine-induced T cell response to SARS-CoV-2 Spike protein., References: ['']\n",
      "DEBUG - Citing Paper: Maternal mortality and COVID-19: A nationwide ecological analysis from Ecuador., References: ['']\n",
      "DEBUG - Citing Paper: Impact of the SARS-CoV-2 Spike Protein on the Innate Immune System: A Review., References: ['']\n",
      "DEBUG - Citing Paper: An Exploratory Bioinformatic Investigation of Cats' Susceptibility to Coronavirus-Deriving Epitopes., References: ['']\n",
      "DEBUG - Citing Paper: Expansion of memory VÎ´2 T cells following SARS-CoV-2 vaccination revealed by temporal single-cell transcriptomics., References: ['']\n",
      "DEBUG - Citing Paper: Inhalation of ACE2-expressing lung exosomes provides prophylactic protection against SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: The race for clinical trials on Omicron-based COVID-19 vaccine candidates: Updates from global databases., References: ['']\n",
      "DEBUG - Citing Paper: Comparable safety and non-inferior immunogenicity of the SARS-CoV-2 mRNA vaccine candidate PTX-COVID19-B and BNT162b2 in a phase 2 randomized, observer-blinded study., References: ['']\n",
      "DEBUG - Citing Paper: Global research on RNA vaccines for COVID-19 from 2019 to 2023: a bibliometric analysis., References: ['']\n",
      "DEBUG - Citing Paper: Humoral and cellular immune responses to COVID-19 mRNA vaccines in immunosuppressed liver transplant recipients., References: ['']\n",
      "DEBUG - Citing Paper: Safety and reactogenicity of the BNT162b2 COVID-19 vaccine: Development, post-marketing surveillance, and real-world data., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 Vaccines: Where Did We Stand at the End of 2023?, References: ['']\n",
      "DEBUG - Citing Paper: Ocular Complications after COVID-19 Vaccination: A Systematic Review., References: ['']\n",
      "DEBUG - Citing Paper: tANCHOR-cell-based assay for monitoring of SARS-CoV-2 neutralizing antibodies rapidly adaptive to various receptor-binding domains., References: ['']\n",
      "DEBUG - Citing Paper: BioNTech COVID-19 (BNT162b2) Vaccination and Varicella Zoster Reactivation: A Comprehensive Cross-sectional Study., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 vaccination may mitigate dysregulation of IL-1/IL-18 and gastrointestinal symptoms of the post-COVID-19 condition., References: ['']\n",
      "DEBUG - Citing Paper: Increased prevalence of erythema multiforme in patients with COVID-19 infection or vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Ad5-nCoV Vaccination Could Induce HLA-E Restricted CD8<sup>+</sup> T Cell Responses Specific for Epitopes on Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein., References: ['']\n",
      "DEBUG - Citing Paper: Differences in Responses of Immunosuppressed Kidney Transplant Patients to Moderna mRNA-1273 versus Pfizer-BioNTech., References: ['']\n",
      "DEBUG - Citing Paper: Mathematical Optimization Strategy for Effectiveness Profile Estimation in Two-Dose Vaccines and Its Use in Designing Improved Vaccination Strategies Focused on Pandemic Containment., References: ['']\n",
      "DEBUG - Citing Paper: Assessment of Human SARS CoV-2-Specific T-Cell Responses Elicited In Vitro by New Computationally Designed mRNA Immunogens (COVARNA)., References: ['']\n",
      "DEBUG - Citing Paper: Determination of the factors associated with antigen-specific CD4+ T-cell responses to BNT162b2 in patients with rheumatoid arthritis., References: ['']\n",
      "DEBUG - Citing Paper: Safety, immunogenicity, and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: a phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos)., References: ['']\n",
      "DEBUG - Citing Paper: A quest for universal anti-SARS-CoV-2 T cell assay: systematic review, meta-analysis, and experimental validation., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 vaccination and corneal allograft rejection- a review., References: ['']\n",
      "DEBUG - Citing Paper: Development of a Ready-to-Use-Type RNA Vaccine Carrier Based on an Intracellular Environment-Responsive Lipid-like Material with Immune-Activating Vitamin E Scaffolds., References: ['']\n",
      "DEBUG - Citing Paper: Monovalent SARS-COV-2 mRNA vaccine using optimal UTRs and LNPs is highly immunogenic and broadly protective against Omicron variants., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-based VP8* nanoparticle vaccines against rotavirus are highly immunogenic in rodents., References: ['']\n",
      "DEBUG - Citing Paper: The HLA-II immunopeptidome of SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: Safety and Immunogenicity of a Recombinant Two-Component SARS-CoV-2 Protein Vaccine: Randomized, Double-Blind, Placebo-Controlled PhaseÂ I and PhaseÂ II Studies., References: ['']\n",
      "DEBUG - Citing Paper: Screening for lipid nanoparticles that modulate the immune activity of helper T cells towards enhanced antitumour activity., References: ['']\n",
      "DEBUG - Citing Paper: A 12-month follow-up of the immune response to SARS-CoV-2 primary vaccination: evidence from a real-world study., References: ['']\n",
      "DEBUG - Citing Paper: Effectiveness of the BNT162b2 vaccine in preventing morbidity and mortality associated with COVID-19 in children aged 5 to 11 years: A systematic review and meta-analysis., References: ['']\n",
      "DEBUG - Citing Paper: Towards a comprehensive view of the herpes B virus., References: ['']\n",
      "DEBUG - Citing Paper: Immunogenicity and Protective Efficacy of Nucleic Acid-Based Vaccines Against COVID-19: A Systematic Review., References: ['']\n",
      "DEBUG - Citing Paper: Convalescent Adaptive Immunity Is Highly Heterogenous after SARS-CoV-2 Infection., References: ['']\n",
      "DEBUG - Citing Paper: The characterization of CD8<sup>+</sup> T-cell responses in COVID-19., References: ['']\n",
      "DEBUG - Citing Paper: Age- and sex-specific differences in immune responses to BNT162b2 COVID-19 and live-attenuated influenza vaccines in UK adolescents., References: ['']\n",
      "DEBUG - Citing Paper: A novel SARS-CoV-2 Beta RBD DNA vaccine directly targeted to antigen-presenting cells induces strong humoral and T cell responses., References: ['']\n",
      "DEBUG - Citing Paper: Editorial: Women in primary immunodeficiencies., References: ['']\n",
      "DEBUG - Citing Paper: Respiratory mucosal immune memory to SARS-CoV-2 after infection and vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Reducing cell intrinsic immunity to mRNA vaccine alters adaptive immune responses in mice., References: ['']\n",
      "DEBUG - Citing Paper: Chronic shoulder injury related to vaccine administration following coronavirus disease 2019 vaccination: a case report., References: ['']\n",
      "DEBUG - Citing Paper: Immune monitoring of SARS-CoV-2-specific T cell and B cell responses in patients with multiple sclerosis treated with ocrelizumab., References: ['']\n",
      "DEBUG - Citing Paper: Prior SARS-CoV-2 Infection Enhances Initial mRNA Vaccine Response with a Lower Impact on Long-Term Immunity., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 spike-specific T<sub>FH</sub> cells exhibit unique responses in infected and vaccinated individuals., References: ['']\n",
      "DEBUG - Citing Paper: Airway surveillance and lung viral control by memory T cells induced by COVID-19 mRNA vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Enhancing Anti-SARS-CoV-2 Neutralizing Immunity by Genetic Delivery of Enveloped Virus-like Particles Displaying SARS-CoV-2 Spikes., References: ['']\n",
      "DEBUG - Citing Paper: Recent Advances and Innovations in the Preparation and Purification of In Vitro-Transcribed-mRNA-Based Molecules., References: ['']\n",
      "DEBUG - Citing Paper: Humoral and Cellular Immune Response Elicited by the BNT162b2 COVID-19 Vaccine Booster in Elderly., References: ['']\n",
      "DEBUG - Citing Paper: Re-Emerging COVID-19: Controversy of Its Zoonotic Origin, Risks of Severity of Reinfection and Management., References: ['']\n",
      "DEBUG - Citing Paper: Multimodal single-cell datasets characterize antigen-specific CD8<sup>+</sup> T cells across SARS-CoV-2 vaccination and infection., References: ['']\n",
      "DEBUG - Citing Paper: Responses of patients with cancer to mRNA vaccines depend on the time interval between vaccination and last treatment., References: ['']\n",
      "DEBUG - Citing Paper: Multiantigen pan-sarbecovirus DNA vaccines generate protective T cell immune responses., References: ['']\n",
      "DEBUG - Citing Paper: Immunocytometric analysis of patients with thymic epithelial tumors revealed that COVID-19 vaccine booster strongly enhanced the immune response., References: ['']\n",
      "DEBUG - Citing Paper: Convalescent Adaptive Immunity is Highly Heterogenous after SARS-CoV-2 Infection., References: ['']\n",
      "DEBUG - Citing Paper: Dynamical modelling of viral infection and cooperative immune protection in COVID-19 patients., References: ['']\n",
      "DEBUG - Citing Paper: Immune Response to Initial and Booster SARS-CoV-2 mRNA Vaccination in Patients Treated with Siponimod-Final Analysis of a Nonrandomized Controlled Clinical Trial (AMA-VACC)., References: ['']\n",
      "DEBUG - Citing Paper: Differences in SARS-CoV-2 specific humoral and cellular immune responses after contralateral and ipsilateral COVID-19 vaccination., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccination boosts S-specific TÂ cell memory and promotes expansion of CD45RA<sub>int</sub> T<sub>EMRA</sub>-like CD8<sup>+</sup> TÂ cells in COVID-19 recovered individuals., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 infection risk is higher in vaccinated patients with inflammatory autoimmune diseases or liver transplantation treated with mycophenolate due to an impaired antiviral immune response: results of the extended follow up of the RIVALSA prospective cohort., References: ['']\n",
      "DEBUG - Citing Paper: NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Syndrome of Transient Headache and Neurological Deficits with Cerebrospinal Fluid Lymphocytosis (HaNDL): A Case Report - Is there an Association with the COVID-19 Vaccine?, References: ['']\n",
      "DEBUG - Citing Paper: Impact of vaccination on infection or death from COVID-19 in individuals with laboratory-confirmed cases: Case-control study., References: ['']\n",
      "DEBUG - Citing Paper: Cluster Analysis Identifies Distinct Patterns of T-Cell and Humoral Immune Responses Evolution Following a Third Dose of SARS-CoV-2 Vaccine in People Living with HIV., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 T Cell Immunity Responses following Natural Infection and Vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Receptor-Binding-Domain-Specific B Cell Responses Induced by mRNA Immunization against SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: The Cellular and Humoral Immune Response to SARS-CoV-2 Messenger RNA Vaccines Is Significantly Better in Liver Transplant Patients Compared with Kidney Transplant Patients., References: ['']\n",
      "DEBUG - Citing Paper: The Importance of Measuring SARS-CoV-2-Specific T-Cell Responses in an Ongoing Pandemic., References: ['']\n",
      "DEBUG - Citing Paper: Dissecting the Protective Effect of CD8<sup>+</sup> T Cells in Response to SARS-CoV-2 mRNA Vaccination and the Potential Link with Lymph Node CD8<sup>+</sup> T Cells., References: ['']\n",
      "DEBUG - Citing Paper: Nephrotic syndrome following COVID-19 vaccination: a systematic review., References: ['']\n",
      "DEBUG - Citing Paper: Association between SARS-CoV-2 Symptoms, Ct Values, and Serological Response in Vaccinated and Unvaccinated Healthcare Personnel., References: ['']\n",
      "DEBUG - Citing Paper: Structural definition of HLA class II-presented SARS-CoV-2 epitopes reveals a mechanism to escape pre-existing CD4<sup>+</sup> TÂ cell immunity., References: ['']\n",
      "DEBUG - Citing Paper: Humoral and cellular responses to repeated COVID-19 exposure in multiple sclerosis patients receiving B-cell depleting therapies: a single-center, one-year, prospective study., References: ['']\n",
      "DEBUG - Citing Paper: PLSCR1 is a cell-autonomous defence factor against SARS-CoV-2 infection., References: ['']\n",
      "DEBUG - Citing Paper: Additive effects of booster mRNA vaccination and SARS-CoV-2 Omicron infection on T cell immunity across immunocompromised states., References: ['']\n",
      "DEBUG - Citing Paper: Vaccine-breakthrough SARS-CoV-2 infections in people with multiple sclerosis and related conditions: An observational study by the New York COVID-19 Neuro-Immunology Consortium (NYCNIC-2)., References: ['']\n",
      "DEBUG - Citing Paper: Knife's edge: Balancing immunogenicity and reactogenicity in mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Multiregional Population-Based Cohort Study for Evaluation of the Association Between Herpes Zoster and mRNA Vaccinations for Severe Acute Respiratory Syndrome Coronavirus-2: The VENUS Study., References: ['']\n",
      "DEBUG - Citing Paper: Treatment mechanism of immune triad from the repurposing drug against COVID-19., References: ['']\n",
      "DEBUG - Citing Paper: Regulation and functions of non-m<sup>6</sup>A mRNA modifications., References: ['']\n",
      "DEBUG - Citing Paper: Evaluation of T and B cell immunophenotyping and antibody response post Covid-19 vaccination., References: ['']\n",
      "DEBUG - Citing Paper: A SARS-CoV-2 and influenza double hit vaccine based on RBD-conjugated inactivated influenza A virus., References: ['']\n",
      "DEBUG - Citing Paper: Live-attenuated pediatric parainfluenza vaccine expressing 6P-stabilized SARS-CoV-2 spike protein is protective against SARS-CoV-2 variants in hamsters., References: ['']\n",
      "DEBUG - Citing Paper: Age, Sex and BMI Relations with Anti-SARS-CoV-2-Spike IgG Antibodies after BNT162b2 COVID-19 Vaccine in Health Care Workers in Northern Greece., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 and the liver: clinical and immunological features in chronic liver disease., References: ['']\n",
      "DEBUG - Citing Paper: Potentiating the Cross-Reactive IFN-Î³ T Cell and Polyfunctional T Cell Responses by Heterologous GX-19N DNA Booster in Mice Primed with Either a COVID-19 mRNA Vaccine or Inactivated Vaccine., References: ['']\n",
      "DEBUG - Citing Paper: The Immune Response to SARS-CoV-2 Vaccine in a Cohort of Family Pediatricians from Southern Italy., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticles-Based Therapy in Liver Metastasis Management: From Tumor Cell-Directed Strategy to Liver Microenvironment-Directed Strategy., References: ['']\n",
      "DEBUG - Citing Paper: Epigenomic landscape exhibits interferon signaling suppression in the patient of myocarditis after BNT162b2 vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Robust and prototypical immune responses toward COVID-19 vaccine in First Nations peoples are impacted by comorbidities., References: ['']\n",
      "DEBUG - Citing Paper: Cytokine Response Following SARS-CoV-2 Antigen Stimulation in Patients with Predominantly Antibody Deficiencies., References: ['']\n",
      "DEBUG - Citing Paper: Is the Effect of the COVID-19 Vaccine on Heart Rate Variability Permanent?, References: ['']\n",
      "DEBUG - Citing Paper: Hybrid immunity expands the functional humoral footprint of both mRNA and vector-based SARS-CoV-2 vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Immunological fingerprint in coronavirus disease-19 convalescents with and without post-COVID syndrome., References: ['']\n",
      "DEBUG - Citing Paper: Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer., References: ['']\n",
      "DEBUG - Citing Paper: The T-cell-directed vaccine BNT162b4 encoding conserved non-spike antigens protects animals from severe SARS-CoV-2 infection., References: ['']\n",
      "DEBUG - Citing Paper: Timing and implications for immune response to vaccine in SARS-CoV-2 breakthrough infections., References: ['']\n",
      "DEBUG - Citing Paper: What has vaccination against COVID-19 in CKD patients taught us?, References: ['']\n",
      "DEBUG - Citing Paper: Humoral and T Cell Immune Responses against SARS-CoV-2 after Primary and Homologous or Heterologous Booster Vaccinations and Breakthrough Infection: A Longitudinal Cohort Study in Malaysia., References: ['']\n",
      "DEBUG - Citing Paper: Effectiveness, Immunogenicity and Harms of Additional SARS-CoV-2 Vaccine Doses in Kidney Transplant Recipients: A Systematic Review., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Towards T7 RNA polymerase (T7RNAP)-based expression system in yeast: challenges and opportunities., References: ['']\n",
      "DEBUG - Citing Paper: Development of SARS-CoV-2 Vaccine: Challenges and Prospects., References: ['']\n",
      "DEBUG - Citing Paper: Detection of humoral and cellular immune response to anti-SARS-CoV-2 BNT162b2 vaccine in breastfeeding women and naÃ¯ve and previously infected individuals., References: ['']\n",
      "DEBUG - Citing Paper: Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants., References: ['']\n",
      "DEBUG - Citing Paper: Comparable cellular and humoral immunity upon homologous and heterologous COVID-19 vaccination regimens in kidney transplant recipients., References: ['']\n",
      "DEBUG - Citing Paper: Exploring Determinants of COVID-19 Vaccine Acceptance, Uptake, and Hesitancy in the Pediatric Population: A Study of Parents and Caregivers in Saudi Arabia during the Initial Vaccination Phase., References: ['']\n",
      "DEBUG - Citing Paper: Single-epitope T cell-based vaccine protects against SARS-CoV-2 infection in a preclinical animal model., References: ['']\n",
      "DEBUG - Citing Paper: Third SARS-CoV-2 vaccination and breakthrough infections enhance humoral and cellular immunity against variants of concern., References: ['']\n",
      "DEBUG - Citing Paper: Robust SARS-CoV-2 TÂ cell responses with common TCRÎ±Î² motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells., References: ['']\n",
      "DEBUG - Citing Paper: Underlying medical conditions and anti-SARS-CoV-2 spike IgG antibody titers after two doses of BNT162b2 vaccination: A cross-sectional study., References: ['']\n",
      "DEBUG - Citing Paper: Spheromers reveal robust TÂ cell responses to the Pfizer/BioNTech vaccine and attenuated peripheral CD8<sup>+</sup> TÂ cell responses post SARS-CoV-2 infection., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccines against SARS-CoV-2: Advantages and Caveats., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 Neutralizing Antibodies in Mexican Population: A Five Vaccine Comparison., References: ['']\n",
      "DEBUG - Citing Paper: ZnO-Based Electrochemical Immunosensor to Assess Vaccine-Induced Antibody-Mediated Immunity against Wild-Type and Gamma SARS-CoV-2 Strains., References: ['']\n",
      "DEBUG - Citing Paper: A specific anti-COVID-19 BNT162b2 vaccine-induced early innate immune signature positively correlates with the humoral protective response in healthy and multiple sclerosis vaccine recipients., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 epitope-specific T cells: Immunity response feature, TCR repertoire characteristics and cross-reactivity., References: ['']\n",
      "DEBUG - Citing Paper: Immunomodulatory nanosystems: An emerging strategy to combat viral infections., References: ['']\n",
      "DEBUG - Citing Paper: Self-Organization of Iron Sulfide Nanoparticles into Complex Multicompartment Supraparticles., References: ['']\n",
      "DEBUG - Citing Paper: Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial., References: ['']\n",
      "DEBUG - Citing Paper: Cytotoxic T Cells Targeting Spike Glycoprotein Are Associated with Hybrid Immunity to SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: Immune response to BNT162b2 SARS-CoV-2 vaccine in patients living with HIV: The COVIH-DAPT study., References: ['']\n",
      "DEBUG - Citing Paper: Vector-based SARS-CoV-2 vaccination is associated with improved T-cell responses in hematological neoplasia., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 infection and COVID19 vaccination across eight immune-mediated inflammatory disorders: A prospective, real-life Belgian cohort study - the BELCOMID study., References: ['']\n",
      "DEBUG - Citing Paper: Covid-19: virology, variants, and vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Micro and nanotechnologies: The little formulations that could., References: ['']\n",
      "DEBUG - Citing Paper: Vaccine-induced neutralizing antibodies against SARS-CoV-2 Omicron variant isolated in Osaka, Japan., References: ['']\n",
      "DEBUG - Citing Paper: Performance of an interferon-Î³ release assay-based test for cell-mediated immunity to SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: DALK rejection following vaccination against SARS-CoV-2: 2 case reports., References: ['']\n",
      "DEBUG - Citing Paper: Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Long-Term Immunological Memory of SARS-CoV-2 Is Present in Patients with Primary Antibody Deficiencies for up to a Year after Vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Detailed characterization of SARS-CoV-2-specific T and B cells after infection or heterologous vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Incorporation of SARS-CoV-2 spike NTD to RBD protein vaccine improves immunity against viral variants., References: ['']\n",
      "DEBUG - Citing Paper: Humoral immune response to SARS-CoV-2 mRNA vaccines is associated with choice of vaccine and systemic adverse reactions., References: ['']\n",
      "DEBUG - Citing Paper: Prevalence of COVID-19 in Kidney Transplant Patients in Relation to Their Immune Status after Repeated Anti-SARS-CoV-2 Vaccination., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2-Specific T Cell Responses in Immunocompromised Individuals with Cancer, HIV or Solid Organ Transplants., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 Vaccination-Induced Immunogenicity in Heart Transplant Recipients., References: ['']\n",
      "DEBUG - Citing Paper: Boosting compromised SARS-CoV-2-specific immunity with mRNA vaccination in liver transplant recipients., References: ['']\n",
      "DEBUG - Citing Paper: From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era., References: ['']\n",
      "DEBUG - Citing Paper: Primary ChAdOx1 vaccination does not reactivate pre-existing, cross-reactive immunity., References: ['']\n",
      "DEBUG - Citing Paper: Defending against SARS-CoV-2: The T cell perspective., References: ['']\n",
      "DEBUG - Citing Paper: Role of T cells in severe COVID-19 disease,Â protection, and long term immunity., References: ['']\n",
      "DEBUG - Citing Paper: Multimodal characterization of antigen-specific CD8 <sup>+</sup> T cells across SARS-CoV-2 vaccination and infection., References: ['']\n",
      "DEBUG - Citing Paper: Assessing the Dynamics of COVID-19 Morbidity and Mortality in Response to Mass Vaccination: A Comparative Study Between Saudi Arabia and the United Kingdom., References: ['']\n",
      "DEBUG - Citing Paper: Hypereosinophilia after vaccination with the SARS-CoV-2 mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: IFN-Î³-Based ELISpot as a New Tool to Detect Human Infections with Borna Disease Virus 1 (BoDV-1): A Pilot Study., References: ['']\n",
      "DEBUG - Citing Paper: Corneal Adverse Events Associated with SARS-CoV-2/COVID-19 Vaccination: A Systematic Review., References: ['']\n",
      "DEBUG - Citing Paper: mRNA in the Context of Protein Replacement Therapy., References: ['']\n",
      "DEBUG - Citing Paper: Prevalent and immunodominant CD8 TÂ cell epitopes are conserved in SARS-CoV-2 variants., References: ['']\n",
      "DEBUG - Citing Paper: Intermediate Levels of Pre-Existing Protective Antibody Allow Priming of Protective T Cell Immunity against Influenza., References: ['']\n",
      "DEBUG - Citing Paper: Race with virus evolution: The development and application of mRNA vaccines against SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: Durability of Vaccine-Induced and Natural Immunity Against COVID-19: A Narrative Review., References: ['']\n",
      "DEBUG - Citing Paper: Functional studies of HLA and its role in SARS-CoV-2: Stimulating T cell response and vaccine development., References: ['']\n",
      "DEBUG - Citing Paper: Immune Response to SARS-CoV-2 mRNA Vaccines in an Open-Label Multicenter Study in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab., References: ['']\n",
      "DEBUG - Citing Paper: Higher Immunological Response after BNT162b2 Vaccination among COVID-19 Convalescents-The Data from the Study among Healthcare Workers in an Infectious Diseases Center., References: ['']\n",
      "DEBUG - Citing Paper: Antibody and T cell responses against wild-type and Omicron SARS-CoV-2 after third-dose BNT162b2 in adolescents., References: ['']\n",
      "DEBUG - Citing Paper: Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections., References: ['']\n",
      "DEBUG - Citing Paper: Humoral and T-cell mediated response after administration of mRNA vaccine BNT162b2 in frail populations., References: ['']\n",
      "DEBUG - Citing Paper: Humoral and cellular immune responses to Pfizer-BioNTech BNT162b2 SARS-CoV-2 vaccine in adolescents with liver transplantation: Single center experience., References: ['']\n",
      "DEBUG - Citing Paper: Low Resource Integrated Platform for Production and Analysis of Capped mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Durability of humoral and cell-mediated immune response after SARS-CoV-2 mRNA vaccine administration., References: ['']\n",
      "DEBUG - Citing Paper: Association of cellular immunity with severity of COVID-19 from the perspective of antigen-specific memory T cell responses and cross-reactivity., References: ['']\n",
      "DEBUG - Citing Paper: Longitudinal antibody titer, avidity, and neutralizing responses after SARS-CoV-2 infection., References: ['']\n",
      "DEBUG - Citing Paper: A review on structural, non-structural, and accessory proteins of SARS-CoV-2: Highlighting drug target sites., References: ['']\n",
      "DEBUG - Citing Paper: Corneal Complications after COVID-19 Vaccination: A Systemic Review., References: ['']\n",
      "DEBUG - Citing Paper: Evaluation of humoral and cellular response to four vaccines against COVID-19 in different age groups: A longitudinal study., References: ['']\n",
      "DEBUG - Citing Paper: Assessing the immune response to SARS-CoV-2 mRNA vaccines in siponimod-treated patients: a nonrandomized controlled clinical trial (AMA-VACC)., References: ['']\n",
      "DEBUG - Citing Paper: Adverse events following administration of COVID-19 vaccines in Saudi Arabia., References: ['']\n",
      "DEBUG - Citing Paper: Impact of vaccination on kinetics of neutralizing antibodies against SARS-CoV-2 by serum live neutralization test based on a prospective cohort., References: ['']\n",
      "DEBUG - Citing Paper: Nucleic Acid Vaccines against SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: Evaluation of the Efficacy of COVID-19 Booster Vaccinations in Healthcare Personnel., References: ['']\n",
      "DEBUG - Citing Paper: Healthcare Worker Study Cohort to Determine the Level and Durability of Cellular and Humoral Immune Responses after Two Doses of SARS-CoV-2 Vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Comparison of the duration of viral RNA shedding and anti-SARS-CoV-2 spike IgG and IgM antibody titers in COVID-19 patients who were vaccinated with inactivated vaccines or not: a retrospective study., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 mRNA-based vaccines in the Aicardi GoutiÃ¨res Syndrome., References: ['']\n",
      "DEBUG - Citing Paper: Evaluation of immunoprotection against coronavirus disease 2019: Novel variants, vaccine inoculation, and complications., References: ['']\n",
      "DEBUG - Citing Paper: Susceptibility to SARS-CoV-2 omicron following ChAdOx1 nCoV-19 and BNT162b2 versus CoronaVac vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Efficacy of three COVID-19 vaccine doses in lung transplant recipients: a multicentre cohort study., References: ['']\n",
      "DEBUG - Citing Paper: Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: Parallel detection of SARS-CoV-2 epitopes reveals dynamic immunodominance profiles of CD8<sup>+</sup> T memory cells in convalescent COVID-19 donors., References: ['']\n",
      "DEBUG - Citing Paper: Intradermal Testing With COVID-19 mRNA Vaccines Predicts Tolerance., References: ['']\n",
      "DEBUG - Citing Paper: OX40 agonist stimulation increases and sustains humoral and cell-mediated responses to SARS-CoV-2 protein and saRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: The bullwhip effect, T-cell telomeres, and SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 and cellular senescence., References: ['']\n",
      "DEBUG - Citing Paper: Evidence of premature lymphocyte aging in people with low anti-spike antibody levels after BNT162b2 vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Comparable antigen-specific T cell responses in vaccinees with diverse humoral immune responses after the primary and booster BBIBP-CorV vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Presumably Corneal Graft Rejection after COVID-19 Vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Vaccine-Induced T-Cell and Antibody Responses at 12 Months after Full Vaccination Differ with Respect to Omicron Recognition., References: ['']\n",
      "DEBUG - Citing Paper: Act Early and at the Right Location: SARS-CoV-2 T Cell Kinetics and Tissue Localization., References: ['']\n",
      "DEBUG - Citing Paper: T Cell and Antibody Response Following Double Dose of BNT162b2 mRNA Vaccine in SARS-CoV-2 NaÃ¯ve Heart Transplant Recipients., References: ['']\n",
      "DEBUG - Citing Paper: From Immunotoxins to Suicide Toxin Delivery Approaches: Is There a Clinical Opportunity?, References: ['']\n",
      "DEBUG - Citing Paper: Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial., References: ['']\n",
      "DEBUG - Citing Paper: Single-cell analysis of the adaptive immune response to SARS-CoV-2 infection and vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Viral vector and nucleic acid vaccines against COVID-19: A narrative review., References: ['']\n",
      "DEBUG - Citing Paper: Immune responses following 3rd and 4th doses of heterologous and homologous COVID-19 vaccines in kidney transplant recipients., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines: Past, present, future., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines expressing homo-prototype/Omicron and hetero-chimeric RBD-dimers against SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2: a 9Â months longitudinal study., References: ['']\n",
      "DEBUG - Citing Paper: Innate immune responses to three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Long-term memory CD8<sup>+</sup> T cells specific for SARS-CoV-2 in individuals who received the BNT162b2 mRNA vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Acute Ischemic Stroke in the Context of SARS-CoV-2 Vaccination: A Systematic Review., References: ['']\n",
      "DEBUG - Citing Paper: Advances in mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with breast and gynecological cancer on active anticancer therapy: Results of a prospective observational study., References: ['']\n",
      "DEBUG - Citing Paper: Heterologous immunization with adenovirus vectored and inactivated vaccines effectively protects against SARS-CoV-2 variants in mice and macaques., References: ['']\n",
      "DEBUG - Citing Paper: Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses., References: ['']\n",
      "DEBUG - Citing Paper: T cells in SARS-CoV-2 infection and vaccination., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2-specific TÂ cells in the changing landscape of the COVID-19 pandemic., References: ['']\n",
      "DEBUG - Citing Paper: Heterologous immunity induced by 1<sup>st</sup> generation COVID-19 vaccines and its role in developing a pan-coronavirus vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Epitope-Evaluator: An interactive web application to study predicted T-cell epitopes., References: ['']\n",
      "DEBUG - Citing Paper: Effectiveness of the BNT162b2 mRNA Vaccine Compared with Hybrid Immunity in Populations Prioritized and Non-Prioritized for COVID-19 Vaccination in 2021-2022: A Naturalistic Case-Control Study in Sweden., References: ['']\n",
      "DEBUG - Citing Paper: Comparative Characterization of Human Antibody Response Induced by BNT162b2 Vaccination vs. SARS-CoV-2 Wild-Type Infection., References: ['']\n",
      "DEBUG - Citing Paper: Immunogenicity of SARS-CoV-2 vaccines in patients with cancer., References: ['']\n",
      "DEBUG - Citing Paper: [SARS-CoV-2 antibody response to the second COVID-19 vaccination in neuromuscular disease patients under immune modulating treatment]., References: ['']\n",
      "DEBUG - Citing Paper: The current status of COVID-19 vaccines. A scoping review., References: ['']\n",
      "DEBUG - Citing Paper: Third dose of the BNT162b2 vaccine in cardiothoracic transplant recipients: predictive factors for humoral response., References: ['']\n",
      "DEBUG - Citing Paper: Infecting kidney organoids with a cDNA reporter clone of SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: Strong T-cell activation in response to COVID-19 vaccination in multiple sclerosis patients receiving B-cell depleting therapies., References: ['']\n",
      "DEBUG - Citing Paper: Characteristics and Clinical Ocular Manifestations in Patients with Acute Corneal Graft Rejection after Receiving the COVID-19 Vaccine: A Systematic Review., References: ['']\n",
      "DEBUG - Citing Paper: Effectiveness of SARS-CoV-2 Vaccines for Short- and Long-Term Immunity: A General Overview for the Pandemic Contrast., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 mRNA booster vaccine induces transient CD8+ T effector cell responses while conserving the memory pool for subsequent reactivation., References: ['']\n",
      "DEBUG - Citing Paper: Acceptance Rates of COVID-19 Vaccine Highlight the Need for Targeted Public Health Interventions., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 Outbreak and BNT162b2 mRNA Vaccination Coverage in a Correctional Facility during Circulation of the SARS-CoV-2 Omicron BA.1 Variant in Italy., References: ['']\n",
      "DEBUG - Citing Paper: Specific T-Cell Immune Response to SARS-CoV-2 Spike Protein over Time in NaÃ¯ve and SARS-CoV-2 Previously Infected Subjects Vaccinated with BTN162b2., References: ['']\n",
      "DEBUG - Citing Paper: Evaluation of Safety and Immunogenicity of BNT162B2 mRNA COVID-19 Vaccine in IBD Pediatric Population with Distinct Immune Suppressive Regimens., References: ['']\n",
      "DEBUG - Citing Paper: The Role of Cellular Immunity in the Protective Efficacy of the SARS-CoV-2 Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Neutralization Activity against SARS-CoV-2 Variants after Booster Vaccination in Populations without COVID-19: A Meta-Analysis., References: ['']\n",
      "DEBUG - Citing Paper: Neutralizing Antibodies to Human Cytomegalovirus Recombinant Proteins Reduce Infection in an Ex Vivo Model of Developing Human Placentas., References: ['']\n",
      "DEBUG - Citing Paper: Immunity after COVID-19 Recovery and Vaccination: Similarities and Differences., References: ['']\n",
      "DEBUG - Citing Paper: Short-Term Side Effects and SARS-CoV-2 Infection after COVID-19 Pfizer-BioNTech Vaccine in Children Aged 5-11 Years: An Italian Real-World Study., References: ['']\n",
      "DEBUG - Citing Paper: Cellular Immune Response to BNT162b2 mRNA COVID-19 Vaccine in a Large Cohort of Healthcare Workers in a Tertiary Care University Hospital., References: ['']\n",
      "DEBUG - Citing Paper: Efficient Induction of Antigen-Specific CD8<sup>+</sup> T-Cell Responses by Cationic Peptide-Based mRNA Nanoparticles., References: ['']\n",
      "DEBUG - Citing Paper: A predictive model to estimate fever after receipt of the second dose of Pfizer-BioNTech coronavirus disease 2019 vaccine: An observational cohort study., References: ['']\n",
      "DEBUG - Citing Paper: Neutralization assays for SARS-CoV-2: Implications for assessment of protective efficacy of COVID-19 vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Relatively rapid evolution rates of SARS-CoV-2 spike gene at the primary stage of massive vaccination., References: ['']\n",
      "DEBUG - Citing Paper: The generation of stem cell-like memory cells early after BNT162b2 vaccination is associated with durability of memory CD8<sup>+</sup> TÂ cell responses., References: ['']\n",
      "DEBUG - Citing Paper: Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273., References: ['']\n",
      "DEBUG - Citing Paper: The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection., References: ['']\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DEBUG - Citing Paper: Immune Responses Against SARS-CoV-2 WT and Delta Variant in Elderly BNT162b2 Vaccinees., References: ['']\n",
      "DEBUG - Citing Paper: [Not Available]., References: ['']\n",
      "DEBUG - Citing Paper: Preclinical study of formulated recombinant nucleocapsid protein, the receptor binding domain of the spike protein, and truncated spike (S1) protein as vaccine candidates against COVID-19 in animal models., References: ['']\n",
      "DEBUG - Citing Paper: Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial., References: ['']\n",
      "DEBUG - Citing Paper: Humoral and cellular immune memory to four COVID-19 vaccines., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2-specific TÂ cell memory with common TCRÎ±Î² motifs is established in unvaccinated children who seroconvert after infection., References: ['']\n",
      "DEBUG - Citing Paper: Perinatally Human Immunodeficiency Virus-Infected Adolescents and Young Adults Demonstrate Distinct BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Immunogenicity., References: ['']\n",
      "DEBUG - Citing Paper: Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Benefit-risk evaluation of COVID-19 vaccination in special population groups of interest., References: ['']\n",
      "DEBUG - Citing Paper: Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in NaÃ¯ve and Previously Infected Individuals: A 1-Year Observational Study in Healthcare Professionals., References: ['']\n",
      "DEBUG - Citing Paper: Materials-based vaccines for infectious diseases., References: ['']\n",
      "DEBUG - Citing Paper: The magnitude and timing of recalled immunity after breakthrough infection is shaped by SARS-CoV-2 variants., References: ['']\n",
      "DEBUG - Citing Paper: Safety and Efficacy of the COVID-19 Vaccine in Kidney Transplant Recipients., References: ['']\n",
      "DEBUG - Citing Paper: Acute kidney injury after COVID-19 vaccines: a real-world study., References: ['']\n",
      "DEBUG - Citing Paper: Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infection., References: ['']\n",
      "DEBUG - Citing Paper: Real-Word Effectiveness of Global COVID-19 Vaccines Against SARS-CoV-2 Variants: A Systematic Review and Meta-Analysis., References: ['']\n",
      "DEBUG - Citing Paper: Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes., References: ['']\n",
      "DEBUG - Citing Paper: New-Onset Acute Kidney Disease Post COVID-19 Vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Association of Current Active Illnesses and Severe Acute Kidney Injury after COVID-19 Vaccines: A Real-World Study., References: ['']\n",
      "DEBUG - Citing Paper: A Case Report of Herpes Zoster Ophthalmicus and Meningitis After COVID-19 Vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Vaccines for COVID-19: A Systematic Review of Immunogenicity, Current Development, and Future Prospects., References: ['']\n",
      "DEBUG - Citing Paper: Markers of Memory CD8 T Cells Depicting the Effect of the BNT162b2 mRNA COVID-19 Vaccine in Japan., References: ['']\n",
      "DEBUG - Citing Paper: Distinct immune cell dynamics correlate with the immunogenicity and reactogenicity of SARS-CoV-2 mRNA vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis., References: ['']\n",
      "DEBUG - Citing Paper: Favorable vaccine-induced SARS-CoV-2-specific T cell response profile in patients undergoing immune-modifying therapies., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 vaccine development: milestones, lessons and prospects., References: ['']\n",
      "DEBUG - Citing Paper: Count on us: TÂ cells in SARS-CoV-2 infection and vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 mRNA Vaccine in Patients With Lymphoid Malignancy or Anti-CD20 Antibody Therapy: A Systematic Review and Meta-Analysis., References: ['']\n",
      "DEBUG - Citing Paper: mRNA- and Adenovirus-Based Vaccines against SARS-CoV-2 in HIV-Positive People., References: ['']\n",
      "DEBUG - Citing Paper: Impact of Moderna mRNA-1273 Booster Vaccine on Fully Vaccinated High-Risk Chronic Dialysis Patients after Loss of Humoral Response., References: ['']\n",
      "DEBUG - Citing Paper: Hemophagocytic Lymphohistiocytosis Following BNT162b2 mRNA COVID-19 Vaccination., References: ['']\n",
      "DEBUG - Citing Paper: An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Effect of BTN162b2 and CoronaVac boosters on humoral and cellular immunity of individuals previously fully vaccinated with CoronaVac against SARS-CoV-2: A longitudinal study., References: ['']\n",
      "DEBUG - Citing Paper: Herpes zoster in the era of COVID 19: A prospective observational study to probe the association of herpes zoster with COVID 19 infection and vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates., References: ['']\n",
      "DEBUG - Citing Paper: Sex, Age, and Ethnic Background Shape Adaptive Immune Responses Induced by the SARS-CoV-2 mRNA Vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Development of antibody resistance in emerging mutant strains of SARS CoV-2: Impediment for COVID-19 vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Immunogenicity and Risk Factors Associated With Poor Humoral Immune Response of SARS-CoV-2 Vaccines in Recipients of Solid Organ Transplant: A Systematic Review and Meta-Analysis., References: ['']\n",
      "DEBUG - Citing Paper: Evaluation of Humoral and Cellular Responses in SARS-CoV-2 mRNA Vaccinated Immunocompromised Patients., References: ['']\n",
      "DEBUG - Citing Paper: A Meta-Analysis on the Safety and Immunogenicity of Covid-19 Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19?, References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8<sup>+</sup> T cells., References: ['']\n",
      "DEBUG - Citing Paper: Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases., References: ['']\n",
      "DEBUG - Citing Paper: The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Temporary antimetabolite treatment hold boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients., References: ['']\n",
      "DEBUG - Citing Paper: The effect of immunization with inactivated SARS-CoV-2 vaccine (CoronaVac) and/or SARS-CoV-2 infection on antibody levels, plasmablasts, long-lived-plasma-cells, and IFN-Î³ release by natural killer cells., References: ['']\n",
      "DEBUG - Citing Paper: Delivery of mRNA for regulating functions of immune cells., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 Vaccine: Between Myth and Truth., References: ['']\n",
      "DEBUG - Citing Paper: Adverse Reactions to Anti-SARS-CoV-2 Vaccine: A Prospective Cohort Study Based on an Active Surveillance System., References: ['']\n",
      "DEBUG - Citing Paper: The association between adverse reactions and immune response against SARS-CoV-2 spike protein after vaccination with BNT162b2 among healthcare workers in a single healthcare system: a prospective observational cohort study., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines for COVID-19 and diverse diseases., References: ['']\n",
      "DEBUG - Citing Paper: Oral erythema multiforme after Pfizer-BioNTech COVID-19 vaccination: a report of four cases., References: ['']\n",
      "DEBUG - Citing Paper: Nucleic Acid-Based COVID-19 Therapy Targeting Cytokine Storms: Strategies to Quell the Storm., References: ['']\n",
      "DEBUG - Citing Paper: Longitudinal Humoral and Cellular Immune Responses Following SARS-CoV-2 Vaccination in Patients with Myeloid and Lymphoid Neoplasms Compared to a Reference Cohort: Results of a Prospective Trial of the East German Study Group for Hematology and Oncology (OSHO)., References: ['']\n",
      "DEBUG - Citing Paper: Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine., References: ['']\n",
      "DEBUG - Citing Paper: A systematic review on mucocutaneous presentations after COVID-19 vaccination and expert recommendations about vaccination of important immune-mediated dermatologic disorders., References: ['']\n",
      "DEBUG - Citing Paper: Decline of Humoral and Cellular Immune Responses Against SARS-CoV-2 6 Months After Full BNT162b2 Vaccination in Hospital Healthcare Workers., References: ['']\n",
      "DEBUG - Citing Paper: Insights From Early Clinical Trials Assessing Response to mRNA SARS-CoV-2 Vaccination in Immunocompromised Patients., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 vaccine dose sparing: strategies to improve vaccine equity and pandemic preparedness., References: ['']\n",
      "DEBUG - Citing Paper: Novel T cell interferon gamma release assay (IGRA) using spike recombinant protein for COVID19 vaccine response and Nucleocapsid for SARS-Cov2 response., References: ['']\n",
      "DEBUG - Citing Paper: Messenger RNA vaccines for cancer immunotherapy: progress promotes promise., References: ['']\n",
      "DEBUG - Citing Paper: Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Is COVID vaccine effective in patients with myeloid malignancy?, References: ['']\n",
      "DEBUG - Citing Paper: Convergent CDR3 homology amongst Spike-specific antibody responses in convalescent COVID-19 subjects receiving the BNT162b2 vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Improved immunologic response to COVID-19 vaccine with prolonged dosing interval in haemodialysis patients., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 Immunization Orchestrates the Amplification of IFNÎ³-Producing T Cell and NK Cell Persistence., References: ['']\n",
      "DEBUG - Citing Paper: Immunity Against the Omicron Variant From Vaccination, Recovery, or Both., References: ['']\n",
      "DEBUG - Citing Paper: Immunogenicity and reactogenicity of homologous mRNA-based and vector-based SARS-CoV-2 vaccine regimens in patients receiving maintenance dialysis., References: ['']\n",
      "DEBUG - Citing Paper: Trajectory of SARS-CoV-2 anti-S IgG levels following transfusion and a third dose of BNT162b2 vaccine in a patient with massive postoperative bleeding: A case report., References: ['']\n",
      "DEBUG - Citing Paper: Modelling SARS-CoV-2 Binding Antibody Waning 8 Months after BNT162b2 Vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Peculiarities of the T Cell Immune Response in COVID-19., References: ['']\n",
      "DEBUG - Citing Paper: Cellular Immune Response after Vaccination in Patients with Cancer-Review on Past and Present Experiences., References: ['']\n",
      "DEBUG - Citing Paper: Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 variant B.1.1.7 caused HLA-A2<sup>+</sup> CD8<sup>+</sup> TÂ cell epitope mutations for impaired cellular immune response., References: ['']\n",
      "DEBUG - Citing Paper: A single dose of COVID-19 vaccine induces a strong T cell and B cell response in healthcare professionals recovered from SARS-CoV-2 infection., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 mRNA vaccines: Platforms and current developments., References: ['']\n",
      "DEBUG - Citing Paper: Pemphigus vulgaris after SARS-CoV-2 vaccination: A case with new-onset and two cases with severe aggravation., References: ['']\n",
      "DEBUG - Citing Paper: Zoster meningitis in an immunocompetent young patient post first dose of BNT162b2 mRNA COVID-19 vaccine, a case report., References: ['']\n",
      "DEBUG - Citing Paper: Coronavirus disease 2019 (COVID-19) vaccine platforms: how novel platforms can prepare us for future pandemics: a narrative review., References: ['']\n",
      "DEBUG - Citing Paper: A protease-activatable luminescent biosensor and reporter cell line for authentic SARS-CoV-2 infection., References: ['']\n",
      "DEBUG - Citing Paper: Psoriasis exacerbation after COVID-19 vaccination in high-risk group: How to manage it?, References: ['']\n",
      "DEBUG - Citing Paper: Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Common Variable Immunodeficiency Disorders as a Model for Assessing COVID-19 Vaccine Responses in Immunocompromised Patients., References: ['']\n",
      "DEBUG - Citing Paper: B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications., References: ['']\n",
      "DEBUG - Citing Paper: The T cell immune response against SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern., References: ['']\n",
      "DEBUG - Citing Paper: Immune response to three doses of mRNA SARS-CoV-2 vaccines in CD19-targeted chimeric antigen receptor TÂ cell immunotherapy recipients., References: ['']\n",
      "DEBUG - Citing Paper: Impact of prior infection status on antibody response to the BNT162b2 mRNA COVID-19 vaccine in healthcare workers at a COVID-19 referral hospital in Milan, Italy., References: ['']\n",
      "DEBUG - Citing Paper: Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals., References: ['']\n",
      "DEBUG - Citing Paper: Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients., References: ['']\n",
      "DEBUG - Citing Paper: Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Protocol for SARS-CoV-2 post-vaccine surveillance study in Australian adults and children with cancer: an observational study of safety and serological and immunological response to SARS-CoV-2 vaccination (SerOzNET)., References: ['']\n",
      "DEBUG - Citing Paper: Review of Ribosome Interactions with SARS-CoV-2 and COVID-19 mRNA Vaccine., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Therapeutic Modalities Design, Formulation and Manufacturing under Pharma 4.0 Principles., References: ['']\n",
      "DEBUG - Citing Paper: Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera., References: ['']\n",
      "DEBUG - Citing Paper: Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine-induced antibody and T cell immunity and function., References: ['']\n",
      "DEBUG - Citing Paper: Waning antibody levels after COVID-19 vaccination with mRNA Comirnaty and inactivated CoronaVac vaccines in blood donors, Hong Kong, April 2020 to October 2021., References: ['']\n",
      "DEBUG - Citing Paper: Structural assessment of HLA-A2-restricted SARS-CoV-2 spike epitopes recognized by public and private T-cell receptors., References: ['']\n",
      "DEBUG - Citing Paper: Elucidating T Cell and B Cell Responses to SARS-CoV-2 in Humans: Gaining Insights into Protective Immunity and Immunopathology., References: ['']\n",
      "DEBUG - Citing Paper: HLA-Aâ03:01 is associated with increased risk of fever, chills, and stronger side effects from Pfizer-BioNTech COVID-19 vaccination., References: ['']\n",
      "DEBUG - Citing Paper: T Cells Targeting SARS-CoV-2: By Infection, Vaccination, and Against Future Variants., References: ['']\n",
      "DEBUG - Citing Paper: COVID-specific T's may offset therapeutically endangered B's., References: ['']\n",
      "DEBUG - Citing Paper: Short-term effectiveness of COVID-19 vaccines in immunocompromised patients: A systematic literature review and meta-analysis., References: ['']\n",
      "DEBUG - Citing Paper: Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History., References: ['']\n",
      "DEBUG - Citing Paper: Axillary adenopathy after COVID-19 vaccine in patients undergoing breast ultrasound., References: ['']\n",
      "DEBUG - Citing Paper: Rituximab Impairs B Cell Response But Not T Cell Response to COVID-19 Vaccine in Autoimmune Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities., References: ['']\n",
      "DEBUG - Citing Paper: Membrane-dependent relief of translation elongationÂ arrest on pseudouridine- and N1-methyl-pseudouridine-modified mRNAs., References: ['']\n",
      "DEBUG - Citing Paper: Attenuated anti-SARS-CoV-2 antibody response to vaccination in patients with rheumatic diseases., References: ['']\n",
      "DEBUG - Citing Paper: Advances in the design and development of SARS-CoV-2 vaccines., References: ['']\n",
      "DEBUG - Citing Paper: A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults., References: ['']\n",
      "DEBUG - Citing Paper: QnAs with Katalin KarikÃ³., References: ['']\n",
      "DEBUG - Citing Paper: Long-Lasting Immunity Against SARS-CoV-2: Dream or Reality?, References: ['']\n",
      "DEBUG - Citing Paper: Anti-SARS-CoV-2 Spike Protein RBD Antibody Levels After Receiving a Second Dose of ChAdOx1 nCov-19 (AZD1222) Vaccine in Healthcare Workers: Lack of Association With Age, Sex, Obesity, and Adverse Reactions., References: ['']\n",
      "DEBUG - Citing Paper: Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2-experienced individuals., References: ['']\n",
      "DEBUG - Citing Paper: A 1-minute blood test detects decreased immune function and increased clinical risk in COVID-19 patients., References: ['']\n",
      "DEBUG - Citing Paper: Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization., References: ['']\n",
      "DEBUG - Citing Paper: What Happens to the Immune System after Vaccination or Recovery from COVID-19?, References: ['']\n",
      "DEBUG - Citing Paper: B Cell Response Induced by SARS-CoV-2 Infection Is Boosted by the BNT162b2 Vaccine in Primary Antibody Deficiencies., References: ['']\n",
      "DEBUG - Citing Paper: Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges., References: ['']\n",
      "DEBUG - Citing Paper: Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review., References: ['']\n",
      "DEBUG - Citing Paper: Immunogenicity of Anti-SARS-CoV-2 Vaccines in Common Variable Immunodeficiency., References: ['']\n",
      "DEBUG - Citing Paper: New-onset pediatric nephrotic syndrome following Pfizer-BioNTech SARS-CoV-2 vaccination: a case report and literature review., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network., References: ['']\n",
      "DEBUG - Citing Paper: Sustained Delivery of SARS-CoV-2 RBD Subunit Vaccine Using a High Affinity Injectable Hydrogel Scaffold., References: ['']\n",
      "DEBUG - Citing Paper: The way of SARS-CoV-2 vaccine development: success and challenges., References: ['']\n",
      "DEBUG - Citing Paper: Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection., References: ['']\n",
      "DEBUG - Citing Paper: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review., References: ['']\n",
      "DEBUG - Citing Paper: The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Robust Neutralizing Antibody Levels Detected after Either SARS-CoV-2 Vaccination or One Year after Infection., References: ['']\n",
      "DEBUG - Citing Paper: Reactogenicity Correlates Only Weakly with Humoral Immunogenicity after COVID-19 Vaccination with BNT162b2 mRNA (Comirnaty<sup>Â®</sup>)., References: ['']\n",
      "DEBUG - Citing Paper: Molecular Basis of a Dominant SARS-CoV-2 Spike-Derived Epitope Presented by HLA-A*02:01 Recognised by a Public TCR., References: ['']\n",
      "DEBUG - Citing Paper: Coronavirus disease 2019 (Covid-19) vaccination recommendations in special populations and patients with existing comorbidities., References: ['']\n",
      "DEBUG - Citing Paper: Humoral and Cellular Response Following Vaccination With the BNT162b2 mRNA COVID-19 Vaccine in Patients Affected by Primary Immunodeficiencies., References: ['']\n",
      "DEBUG - Citing Paper: The Successful Vaccination of an IVIgG Naive CVID Patient with an mRNA COVID-19 Vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans., References: ['']\n",
      "DEBUG - Citing Paper: Rapid measurement of SARS-CoV-2 spike T cells in whole blood from vaccinated and naturally infected individuals., References: ['']\n",
      "DEBUG - Citing Paper: Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients., References: ['']\n",
      "DEBUG - Citing Paper: ImmunosuppressiveTherapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients., References: ['']\n",
      "DEBUG - Citing Paper: State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses., References: ['']\n",
      "DEBUG - Citing Paper: Impact of multiple sclerosis disease-modifying therapies on SARS-CoV-2 vaccine-induced antibody and T cell immunity., References: ['']\n",
      "DEBUG - Citing Paper: Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection., References: ['']\n",
      "DEBUG - Citing Paper: A Peptide-Based Assay Discriminates Individual Antibody Response to the COVID-19 Pfizer/BioNTech mRNA Vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis., References: ['']\n",
      "DEBUG - Citing Paper: Degenerate CD8 Epitopes Mapping to Structurally Constrained Regions of the Spike Protein: A T Cell-Based Way-Out From the SARS-CoV-2 Variants Storm., References: ['']\n",
      "DEBUG - Citing Paper: Addressing the 'hypoxia paradox' in severe COVID-19: literature review and report of four cases treated with erythropoietin analogues., References: ['']\n",
      "DEBUG - Citing Paper: Evaluation of the QuantiFERON SARS-CoV-2 interferon-É£ release assay in mRNA-1273 vaccinated health care workers., References: ['']\n",
      "DEBUG - Citing Paper: Nucleic acid delivery and nanoparticle design for COVID vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months., References: ['']\n",
      "DEBUG - Citing Paper: Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells., References: ['']\n",
      "DEBUG - Citing Paper: Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 infection and disease outcomes in non-human primate models: advances and implications., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2-specific T cells in infection and vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Pseudouridines in RNAs: switching atoms means shifting paradigms., References: ['']\n",
      "DEBUG - Citing Paper: Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Using Adjuvants to Drive T Cell Responses for Next-Generation Infectious Disease Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Humoral and cellular immune responses in SARS-CoV-2 mRNA-vaccinated patients with cancer., References: ['']\n",
      "DEBUG - Citing Paper: Impact of Age and Sex on Antibody Response Following the Second Dose of COVID-19 BNT162b2 mRNA Vaccine in Greek Healthcare Workers., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 Pathogenesis: From Molecular Pathway to Vaccine Administration., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines for infectious diseases: principles, delivery and clinical translation., References: ['']\n",
      "DEBUG - Citing Paper: Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naÃ¯ve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients., References: ['']\n",
      "DEBUG - Citing Paper: Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection., References: ['']\n",
      "DEBUG - Citing Paper: Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy Trial., References: ['']\n",
      "DEBUG - Citing Paper: Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8 T cells., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 spike protein: pathogenesis, vaccines, and potential therapies., References: ['']\n",
      "DEBUG - Citing Paper: Structure-guided TÂ cell vaccine design for SARS-CoV-2 variants and sarbecoviruses., References: ['']\n",
      "DEBUG - Citing Paper: Immunogenicity and Protective Efficacy of a Highly Thermotolerant, Trimeric SARS-CoV-2 Receptor Binding Domain Derivative., References: ['']\n",
      "DEBUG - Citing Paper: [A case of acute interstitial nephritis following the Pfizer-BioNTech COVID-19 vaccine]., References: ['']\n",
      "DEBUG - Citing Paper: BNT162b2 mRNA SARS-CoV-2 Vaccine Elicits High Avidity and Neutralizing Antibodies in Healthcare Workers., References: ['']\n",
      "DEBUG - Citing Paper: A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and TÂ cell responses., References: ['']\n",
      "DEBUG - Citing Paper: Adenoviral Vector DNA- and SARS-CoV-2 mRNA-Based Covid-19 Vaccines: Possible Integration into the Human Genome - Are Adenoviral Genes Expressed in Vector-based Vaccines?, References: ['']\n",
      "DEBUG - Citing Paper: Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients., References: ['']\n",
      "DEBUG - Citing Paper: Early TÂ cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset., References: ['']\n",
      "DEBUG - Citing Paper: The dawn of mRNA vaccines: The COVID-19 case., References: ['']\n",
      "DEBUG - Citing Paper: Robust immune responses after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals., References: ['']\n",
      "DEBUG - Citing Paper: Self-assembled mRNA vaccines., References: ['']\n",
      "DEBUG - focal: BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans., NF: 0, NB: 0, NR: 0, D: 0\n",
      "DEBUG - Focal Paper: gp340 expressed on human genital epithelia binds HIV-1 envelope protein and facilitates viral transmission., References: \n",
      "Frappart L, FontaniÃ¨re B, Lucas E, Sankaranarayanan R. Histopathology of the uterine cervixâdigital atlas. Chapter 1\n",
      "An introduction to the anatomy of the uterine cervix. IARC Screening Group, WHO; \n",
      "2004; Available: http://screening.iarc.fr/atlashisto.php.\n",
      "DEBUG - Citing Paper: Targeting the BspC-vimentin interaction to develop anti-virulence therapies during Group B streptococcal meningitis., References: ['']\n",
      "DEBUG - Citing Paper: The Glycoprotein 340's Scavenger Receptor Cysteine-Rich Domain Promotes Adhesion of Staphylococcus aureus and Pseudomonas aeruginosa to Contact Lens Polymers., References: ['']\n",
      "DEBUG - Citing Paper: Structure-Function Characterization of Streptococcus intermedius Surface Antigen Pas., References: ['']\n",
      "DEBUG - Citing Paper: Structures of SALSA/DMBT1 SRCR domains reveal the conserved ligand-binding mechanism of the ancient SRCR fold., References: ['']\n",
      "DEBUG - Citing Paper: Transcriptomic Analysis of Streptococcus pyogenes Colonizing the Vaginal Mucosa Identifies <i>hupY</i>, an MtsR-Regulated Adhesin Involved in Heme Utilization., References: ['']\n",
      "DEBUG - Citing Paper: The Group B Streptococcal surface antigen I/II protein, BspC, interacts with host vimentin to promote adherence to brain endothelium and inflammation during the pathogenesis of meningitis., References: ['']\n",
      "DEBUG - Citing Paper: Surfactant Protein D Reverses the Gene Signature of Transepithelial HIV-1 Passage and Restricts the Viral Transfer Across the Vaginal Barrier., References: ['']\n",
      "DEBUG - Citing Paper: Increased expression of deleted in malignant brain tumors (DMBT1) gene in precancerous gastric lesions: Findings from human and animal studies., References: ['']\n",
      "DEBUG - Citing Paper: The scavenging capacity of DMBT1 is impaired by germline deletions., References: ['']\n",
      "DEBUG - Citing Paper: Visualization of X4- and R5-Tropic HIV-1 Viruses Expressing Fluorescent Proteins in Human Endometrial Cells: Application to Tropism Study., References: ['']\n",
      "DEBUG - Citing Paper: Structural and Functional Analysis of Cell Wall-anchored Polypeptide Adhesin BspA in Streptococcus agalactiae., References: ['']\n",
      "DEBUG - Citing Paper: Altered gene expression in the lower respiratory tract of Car6 (-/-) mice., References: ['']\n",
      "DEBUG - Citing Paper: SALSA: A Regulator of the Early Steps of Complement Activation on Mucosal Surfaces., References: ['']\n",
      "DEBUG - Citing Paper: The Salivary Scavenger and Agglutinin (SALSA) in Healthy and Complicated Pregnancy., References: ['']\n",
      "DEBUG - Citing Paper: Periluminal Distribution of HIV-Binding Target Cells and Gp340 in the Oral, Cervical and Sigmoid/Rectal Mucosae: A Mapping Study., References: ['']\n",
      "DEBUG - Citing Paper: Exosomes in human semen restrict HIV-1 transmission by vaginal cells and block intravaginal replication of LP-BM5 murine AIDS virus complex., References: ['']\n",
      "DEBUG - Citing Paper: Heparin-independent, PF4-dependent binding of HIT antibodies to platelets: implications for HIT pathogenesis., References: ['']\n",
      "DEBUG - Citing Paper: Mucosal immunity in the female genital tract, HIV/AIDS., References: ['']\n",
      "DEBUG - Citing Paper: Proteins, pathogens, and failure at the composite-tooth interface., References: ['']\n",
      "DEBUG - Citing Paper: The calcium-induced conformation and glycosylation of scavenger-rich cysteine repeat (SRCR) domains of glycoprotein 340 influence the high affinity interaction with antigen I/II homologs., References: ['']\n",
      "DEBUG - Citing Paper: Transcytosis of HIV-1 through vaginal epithelial cells is dependent on trafficking to the endocytic recycling pathway., References: ['']\n",
      "DEBUG - Citing Paper: Interactions between HIV-1 and mucosal cells in the female reproductive tract., References: ['']\n",
      "DEBUG - Citing Paper: The Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cells., References: ['']\n",
      "DEBUG - Citing Paper: First evidence of the interaction between deleted in malignant brain tumor 1 and galectin-3 in the mammalian oviduct., References: ['']\n",
      "DEBUG - Citing Paper: Identification of human immunodeficiency virus type 1 (HIV-1) gp120-binding sites on scavenger receptor cysteine rich 1 (SRCR1) domain of gp340., References: ['']\n",
      "DEBUG - Citing Paper: An electrochemiluminescence assay for gp340 (DMBT1)., References: ['']\n",
      "DEBUG - Citing Paper: Cloning, expression and purification of the SRCR domains of glycoprotein 340., References: ['']\n",
      "DEBUG - Citing Paper: Innate and adaptive anti-HIV immune responses in the female reproductive tract., References: ['']\n",
      "DEBUG - Citing Paper: The salivary scavenger and agglutinin binds MBL and regulates the lectin pathway of complement in solution and on surfaces., References: ['']\n",
      "DEBUG - Citing Paper: HIV gp120 binds to mannose receptor on vaginal epithelial cells and induces production of matrix metalloproteinases., References: ['']\n",
      "DEBUG - Citing Paper: Plausibility of HIV-1 Infection of Oral Mucosal Epithelial Cells., References: ['']\n",
      "DEBUG - Citing Paper: Antiviral activities in human saliva., References: ['']\n",
      "DEBUG - Citing Paper: Anti-HIV activity in cervical-vaginal secretions from HIV-positive and -negative women correlate with innate antimicrobial levels and IgG antibodies., References: ['']\n",
      "DEBUG - Citing Paper: Global transcriptional response to carbonic anhydrase IX deficiency in the mouse stomach., References: ['']\n",
      "DEBUG - Citing Paper: The mouth: a gateway or a trap for HIV?, References: ['']\n",
      "DEBUG - Citing Paper: Short communication: The dead cell: a potent escort for HIV type 1 transinfection., References: ['']\n",
      "DEBUG - Citing Paper: TSLP production by epithelial cells exposed to immunodeficiency virus triggers DC-mediated mucosal infection of CD4+ T cells., References: ['']\n",
      "DEBUG - Citing Paper: gp340 promotes transcytosis of human immunodeficiency virus type 1 in genital tract-derived cell lines and primary endocervical tissue., References: ['']\n",
      "DEBUG - Citing Paper: HIV infection of the genital mucosa in women., References: ['']\n",
      "DEBUG - Citing Paper: Excretion of human immunodeficiency virus type 1 through polarized epithelium by immunoglobulin A., References: ['']\n",
      "DEBUG - Citing Paper: HIV envelope binding by macrophage-expressed gp340 promotes HIV-1 infection., References: ['']\n",
      "DEBUG - Citing Paper: Setting the stage: host invasion by HIV., References: ['']\n",
      "DEBUG - Citing Paper: Effects of Muclin (Dmbt1) deficiency on the gastrointestinal system., References: ['']\n",
      "DEBUG - focal: gp340 expressed on human genital epithelia binds HIV-1 envelope protein and facilitates viral transmission., NF: 0, NB: 0, NR: 0, D: 0\n",
      "DEBUG - Focal Paper: Induction of tolerance to focal ischemia in rat brain: dissociation between cortical lesioning and spreading depression., References: 10Mies G, Iijima T, Hossman K-A. Correlation between peri-infarct DC shifts and ischaemic neuronal damage in rat. Neuroreport 1993; 4: 709â711.\n",
      "DEBUG - Citing Paper: Ketamine-induced prevention of SD-associated late infarct progression in experimental ischemia., References: ['']\n",
      "DEBUG - Citing Paper: The Critical Role of Spreading Depolarizations in Early Brain Injury: Consensus and Contention., References: ['']\n",
      "DEBUG - Citing Paper: Efficacy profile of noninvasive vagus nerve stimulation on cortical spreading depression susceptibility and the tissue response in a rat model., References: ['']\n",
      "DEBUG - Citing Paper: Non-linear actions of physiological agents: Finite disarrangements elicit fitness benefits., References: ['']\n",
      "DEBUG - Citing Paper: Exploitation of the spreading depolarization-induced cytotoxic edema for high-resolution, 3D mapping of its heterogeneous propagation paths., References: ['']\n",
      "DEBUG - Citing Paper: Cortical spreading depression-induced preconditioning in the brain., References: ['']\n",
      "DEBUG - Citing Paper: Optogenetic induction of cortical spreading depression in anesthetized and freely behaving mice., References: ['']\n",
      "DEBUG - Citing Paper: Preconditioning cortical lesions reduce the incidence of peri-infarct depolarizations during focal ischemia in the Spontaneously Hypertensive Rat: interaction with prior anesthesia and the impact of hyperglycemia., References: ['']\n",
      "DEBUG - Citing Paper: Cortical spreading depolarization stimulates gliogenesis in the rat entorhinal cortex., References: ['']\n",
      "DEBUG - Citing Paper: Muscle microdialysis to confirm sublethal ischemia in the induction of remote ischemic preconditioning., References: ['']\n",
      "DEBUG - Citing Paper: Is there a place for cerebral preconditioning in the clinic?, References: ['']\n",
      "DEBUG - Citing Paper: Ischemic tolerance as an active and intrinsic neuroprotective mechanism., References: ['']\n",
      "DEBUG - Citing Paper: Cerebral preconditioning using cortical application of hypertonic salt solutions: upregulation of mRNAs encoding inhibitors of inflammation., References: ['']\n",
      "DEBUG - focal: Induction of tolerance to focal ischemia in rat brain: dissociation between cortical lesioning and spreading depression., NF: 0, NB: 0, NR: 0, D: 0\n",
      "DEBUG - Focal Paper: Short interfering RNA-mediated inhibition of herpes simplex virus type 1 gene expression and function during infection of human keratinocytes., References: Aalto AP, Sarin LP, van Dijk AA, Saarma M, Poranen MM, et al. (2007) Large-scale production of dsRNA and siRNA pools for RNA interference utilizing bacteriophage f6 RNA-dependent RNA polymerase. RNA 13: 422â429.\n",
      "DEBUG - Citing Paper: A review on current status of antiviral siRNA., References: ['']\n",
      "DEBUG - Citing Paper: Adenovirus-mediated shRNA interference against HSV-1 replication in vitro., References: ['']\n",
      "DEBUG - Citing Paper: Decrease of murine cytomegalovirus-induced retinitis by intravenous delivery of immediate early protein-3-specific siRNA., References: ['']\n",
      "DEBUG - Citing Paper: RNA interference inhibits herpes simplex virus type 1 isolated from saliva samples and mucocutaneous lesions., References: ['']\n",
      "DEBUG - Citing Paper: Silencing herpes simplex virus type 1 capsid protein encoding genes by siRNA: a promising antiviral therapeutic approach., References: ['']\n",
      "DEBUG - Citing Paper: Targeting herpetic keratitis by gene therapy., References: ['']\n",
      "DEBUG - Citing Paper: Analysis of virion-incorporated host proteins required for herpes simplex virus type 1 infection through a RNA interference screen., References: ['']\n",
      "DEBUG - Citing Paper: Enzymatically produced pools of canonical and Dicer-substrate siRNA molecules display comparable gene silencing and antiviral activities against herpes simplex virus., References: ['']\n",
      "DEBUG - Citing Paper: Enhanced inhibition of Avian leukosis virus subgroup J replication by multi-target miRNAs., References: ['']\n",
      "DEBUG - Citing Paper: The effect of murine cytomegalovirus IE-3 specific shRNA is dependent on intragenic target site due to multiple transcription initiation sites., References: ['']\n",
      "DEBUG - Citing Paper: Small interfering RNA targeting for infected-cell polypeptide 4 inhibits herpes simplex virus type 1 replication in retinal pigment epithelial cells., References: ['']\n",
      "DEBUG - Citing Paper: Interleukin 29 enhances expression of Toll receptor 3 and mediates antiviral signals in human keratinocytes., References: ['']\n",
      "DEBUG - Citing Paper: Antiviral RNAi: translating science towards therapeutic success., References: ['']\n",
      "DEBUG - Citing Paper: Optimizing siRNA delivery to the genital mucosa., References: ['']\n",
      "DEBUG - Citing Paper: Effect of siRNAs on HSV-1 plaque formation and relative expression levels of RR mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Inhibition of herpes simplex virus type 1 by small interfering RNA., References: ['']\n",
      "DEBUG - Citing Paper: RNA interference for antiviral therapy., References: ['']\n",
      "DEBUG - Citing Paper: Inhibition of viruses by RNA interference., References: ['']\n",
      "DEBUG - Citing Paper: RNA interference: its use as antiviral therapy., References: ['']\n",
      "DEBUG - Citing Paper: New therapeutics targets in chronic viral cardiomyopathy., References: ['']\n",
      "DEBUG - Citing Paper: The human herpesvirus 6 G protein-coupled receptor homolog U51 positively regulates virus replication and enhances cell-cell fusion in vitro., References: ['']\n",
      "DEBUG - Citing Paper: Silencing viruses by RNA interference., References: ['']\n",
      "DEBUG - focal: Short interfering RNA-mediated inhibition of herpes simplex virus type 1 gene expression and function during infection of human keratinocytes., NF: 0, NB: 0, NR: 0, D: 0\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DEBUG - Focal Paper: Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: implication for therapeutic RNA development., References:  [(accessed on 11 March 2021)]; Available online:  https://www.pfizer.com/news/press-release/press-release-detail/real-world-evidence-confirms-high-effectiveness-pfizer.\n",
      "DEBUG - Citing Paper: Effective synthesis of circRNA via a thermostable T7 RNA polymerase variant as the catalyst., References: ['']\n",
      "DEBUG - Citing Paper: Reversible oxidative dimerization of 4-thiouridines in tRNA isolates., References: ['']\n",
      "DEBUG - Citing Paper: Profile of Katalin KarikÃ³ and Drew Weissman: 2023 Nobel laureates in Physiology or Medicine., References: ['']\n",
      "DEBUG - Citing Paper: Sending a Message: Use of mRNA Vaccines to Target the Tumor Immune Microenvironment., References: ['']\n",
      "DEBUG - Citing Paper: A Comprehensive Review of mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs., References: ['']\n",
      "DEBUG - Citing Paper: MicroRNA-dependent suppression of biological pacemaker activity induced by TBX18., References: ['']\n",
      "DEBUG - Citing Paper: Structural Elements of DNA and RNA Eukaryotic Expression Vectors for In Vitro and In Vivo Genome Editor Delivery., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticles Delivering Constitutively Active STING mRNA to Stimulate Antitumor Immunity., References: ['']\n",
      "DEBUG - Citing Paper: RNA sensor response in HeLa cells for transfected mRNAs prepared <i>in vitro</i> by SP6 and HiT7 RNA polymerases: A comparative study., References: ['']\n",
      "DEBUG - Citing Paper: Utilization and Potential of RNA-Based Therapies in Cardiovascular Disease., References: ['']\n",
      "DEBUG - Citing Paper: The legacy of mRNA engineering: A lineup of pioneers for the Nobel Prize., References: ['']\n",
      "DEBUG - Citing Paper: Blocking phospholamban with VHH intrabodies enhances contractility and relaxation in heart failure., References: ['']\n",
      "DEBUG - Citing Paper: What goes around comes around: Artificial circular RNAs bypass cellular antiviral responses., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Acute Mild Pancreatitis Following COVID-19 mRNA Vaccine in an Adolescent., References: ['']\n",
      "DEBUG - Citing Paper: BiTE secretion from in situ-programmed myeloid cells results in tumor-retained pharmacology., References: ['']\n",
      "DEBUG - Citing Paper: Hydrophobic Optimization of Functional Poly(TPAE-co-suberoyl chloride) for Extrahepatic mRNA Delivery following Intravenous Administration., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticle chemistry determines how nucleoside base modifications alter mRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: A New Generation of Vaccines in the Age of Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 Pathogenesis: From Molecular Pathway to Vaccine Administration., References: ['']\n",
      "DEBUG - Citing Paper: Genetic in situ engineering of myeloid regulatory cells controls inflammation in autoimmunity., References: ['']\n",
      "DEBUG - Citing Paper: Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Vaccines in Gastrointestinal Malignancies: From Prevention to Treatment., References: ['']\n",
      "DEBUG - Citing Paper: Highly efficient CD4+ TÂ cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs., References: ['']\n",
      "DEBUG - Citing Paper: Multifunctional Immunoadjuvants for Use in Minimalist Nucleic Acid Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: In Situ Programming of CAR T Cells., References: ['']\n",
      "DEBUG - Citing Paper: Self-assembled mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo., References: ['']\n",
      "DEBUG - Citing Paper: RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges., References: ['']\n",
      "DEBUG - Citing Paper: Rapid Delivery of Nanobodies/V<sub>H</sub>Hs into Living Cells via Expressing <i>InÂ Vitro</i>-Transcribed mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Expression Kinetics and Innate Immune Response after Electroporation and LNP-Mediated Delivery of a Self-Amplifying mRNA in the Skin., References: ['']\n",
      "DEBUG - Citing Paper: Generation of iPSCs by Nonintegrative RNA-Based Reprogramming Techniques: Benefits of Self-Replicating RNA versus Synthetic mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Efficient reduction of synthetic mRNA induced immune activation by simultaneous delivery of B18R encoding mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Turning the corner on therapeutic cancer vaccines., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-Based Genetic Reprogramming., References: ['']\n",
      "DEBUG - Citing Paper: RNA therapy: Are we using the right molecules?, References: ['']\n",
      "DEBUG - Citing Paper: Double methylation of tRNA-U54 to 2'-O-methylthymidine (Tm) synergistically decreases immune response by Toll-like receptor 7., References: ['']\n",
      "DEBUG - Citing Paper: Combinatorial programming of human neuronal progenitors using magnetically-guided stoichiometric mRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: Adjuvant-Loaded Spiky Gold Nanoparticles for Activation of Innate Immune Cells., References: ['']\n",
      "DEBUG - Citing Paper: Efficient Generation of Dopamine Neurons by Synthetic Transcription Factor mRNAs., References: ['']\n",
      "DEBUG - Citing Paper: Identification of an optimized 2'-<i>O</i>-methylated trinucleotide RNA motif inhibiting Toll-like receptors 7 and 8., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticle Systems for Enabling Gene Therapies., References: ['']\n",
      "DEBUG - Citing Paper: V-Maf Musculoaponeurotic Fibrosarcoma Oncogene Homolog A Synthetic Modified mRNA Drives Reprogramming of Human Pancreatic Duct-Derived Cells Into Insulin-Secreting Cells., References: ['']\n",
      "DEBUG - Citing Paper: Reprogramming of Pancreatic Exocrine Cells AR42J Into Insulin-producing Cells Using mRNAs for Pdx1, Ngn3, and MafA Transcription Factors., References: ['']\n",
      "DEBUG - Citing Paper: Bioengineering of noncoding RNAs for research agents and therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Nebulisation of IVT mRNA Complexes for Intrapulmonary Administration., References: ['']\n",
      "DEBUG - Citing Paper: 2'-O-Methylation within Bacterial RNA Acts as Suppressor of TLR7/TLR8 Activation in Human Innate Immune Cells., References: ['']\n",
      "DEBUG - Citing Paper: In vitro synthesis of modified mRNA for induction of protein expression in human cells., References: ['']\n",
      "DEBUG - Citing Paper: A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs., References: ['']\n",
      "DEBUG - Citing Paper: Optimized conditions for successful transfection of human endothelial cells with in vitro synthesized and modified mRNA for induction of protein expression., References: ['']\n",
      "DEBUG - Citing Paper: RNA-based tools for nuclear reprogramming and lineage-conversion: towards clinical applications., References: ['']\n",
      "DEBUG - Citing Paper: Reprogramming human fibroblasts to pluripotency using modified mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor 3: implications for proinflammatory microenvironment in human breast cancer., References: ['']\n",
      "DEBUG - Citing Paper: RNA mediated Toll-like receptor stimulation in health and disease., References: ['']\n",
      "DEBUG - Citing Paper: Identification of modifications in microbial, native tRNA that suppress immunostimulatory activity., References: ['']\n",
      "DEBUG - Citing Paper: Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Regulation of innate immunity through RNA structure and the protein kinase PKR., References: ['']\n",
      "DEBUG - Citing Paper: Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation., References: ['']\n",
      "DEBUG - Citing Paper: Double-stranded RNA analog poly(I:C) inhibits human immunodeficiency virus amplification in dendritic cells via type I interferon-mediated activation of APOBEC3G., References: ['']\n",
      "DEBUG - Citing Paper: A brilliant disguise for self RNA: 5'-end and internal modifications of primary transcripts suppress elements of innate immunity., References: ['']\n",
      "DEBUG - Citing Paper: Nucleoside modifications modulate activation of the protein kinase PKR in an RNA structure-specific manner., References: ['']\n",
      "DEBUG - focal: Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: implication for therapeutic RNA development., NF: 0, NB: 0, NR: 0, D: 0\n",
      "DEBUG - Focal Paper: Exogenous siRNA mediates sequence-independent gene suppression by signaling through toll-like receptor 3., References: AIDS. 2005 Jan 3;19(1):35-43\n",
      "DEBUG - Citing Paper: Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Efficient reduction of synthetic mRNA induced immune activation by simultaneous delivery of B18R encoding mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Nano-mediated delivery of double-stranded RNA for gene therapy of glioblastoma multiforme., References: ['']\n",
      "DEBUG - Citing Paper: Antitumor and Antimetastatic Effect of Small Immunostimulatory RNA against B16 Melanoma in Mice., References: ['']\n",
      "DEBUG - Citing Paper: Fusogenic-oligoarginine peptide-mediated silencing of the CIP2A oncogene suppresses oral cancer tumor growth in vivo., References: ['']\n",
      "DEBUG - Citing Paper: TLR3 Plays Significant Roles against HBV-Associated HCC., References: ['']\n",
      "DEBUG - Citing Paper: LINGO-1 promotes lysosomal degradation of amyloid-Î² protein precursor., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor 3 activation is required for normal skin barrier repair following UV damage., References: ['']\n",
      "DEBUG - Citing Paper: Immunotherapy of hepatocellular carcinoma with small double-stranded RNA., References: ['']\n",
      "DEBUG - Citing Paper: Therapeutic expression of hairpins targeting apolipoprotein B100 induces phenotypic and transcriptome changes in murine liver., References: ['']\n",
      "DEBUG - Citing Paper: Lentiviral vector-mediated RNA silencing in the central nervous system., References: ['']\n",
      "DEBUG - Citing Paper: Nucleic acids and endosomal pattern recognition: how to tell friend from foe?, References: ['']\n",
      "DEBUG - Citing Paper: Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering., References: ['']\n",
      "DEBUG - Citing Paper: In vivo screening of modified siRNAs for non-specific antiviral effect in a small fish model: number and localization in the strands are important., References: ['']\n",
      "DEBUG - Citing Paper: Possibilities for RNA interference in developing hepatitis C virus therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Delivery of RNAi mediators., References: ['']\n",
      "DEBUG - Citing Paper: The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR-ABL tyrosine kinase inhibitors., References: ['']\n",
      "DEBUG - Citing Paper: Age-related macular degeneration and the other double helix. The Cogan Lecture., References: ['']\n",
      "DEBUG - Citing Paper: X4 and R5 HIV-1 have distinct post-entry requirements for uracil DNA glycosylase during infection of primary cells., References: ['']\n",
      "DEBUG - Citing Paper: Minimizing off-target effects by using diced siRNAs for RNA interference., References: ['']\n",
      "DEBUG - Citing Paper: Gene silencing in the therapy of influenza and other respiratory diseases: Targeting to RNase P by use of External Guide Sequences (EGS)., References: ['']\n",
      "DEBUG - Citing Paper: Systemic delivery of DNA or siRNA mediated by linear polyethylenimine (L-PEI) does not induce an inflammatory response., References: ['']\n",
      "DEBUG - Citing Paper: Therapeutic potential of RNA interference against cellular targets of HIV infection., References: ['']\n",
      "DEBUG - Citing Paper: Controlling activation of the RNA-dependent protein kinase by siRNAs using site-specific chemical modification., References: ['']\n",
      "DEBUG - Citing Paper: Progress towards in vivo use of siRNAs., References: ['']\n",
      "DEBUG - Citing Paper: Human endometrial epithelial cells cyclically express Toll-like receptor 3 (TLR3) and exhibit TLR3-dependent responses to dsRNA., References: ['']\n",
      "DEBUG - Citing Paper: RNA interference: from gene silencing to gene-specific therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Silencing viruses by RNA interference., References: ['']\n",
      "DEBUG - focal: Exogenous siRNA mediates sequence-independent gene suppression by signaling through toll-like receptor 3., NF: 0, NB: 0, NR: 0, D: 0\n",
      "DEBUG - Focal Paper: Cutting edge: innate immune system discriminates between RNA containing bacterial versus eukaryotic structural features that prime for high-level IL-12 secretion by dendritic cells., References: \n",
      "American College of Rheumatology. COVIDâ19 vaccine clinical guidance summary for patients with rheumatic and musculoskeletal diseases. 2021. https://www.rheumatology.org/Portals/0/Files/COVIDâ19âVaccineâClinicalâGuidanceâRheumaticâDiseasesâSummary.pdf. Accessed on March 9, 2021.\n",
      "DEBUG - Citing Paper: Strategies to reduce the risks of mRNA drug and vaccine toxicity., References: ['']\n",
      "DEBUG - Citing Paper: The forerunners and successful partnerships behind the BioNTech mRNA vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Synthesis of point-modified mRNA., References: ['']\n",
      "DEBUG - Citing Paper: The legacy of mRNA engineering: A lineup of pioneers for the Nobel Prize., References: ['']\n",
      "DEBUG - Citing Paper: Oral mRNA Vaccines Against Infectious Diseases- A Bacterial Perspective [Invited]., References: ['']\n",
      "DEBUG - Citing Paper: From the Editor-in-Chief., References: ['']\n",
      "DEBUG - Citing Paper: The infinite possibilities of RNA therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across., References: ['']\n",
      "DEBUG - Citing Paper: Recommendations for COVID-19 vaccination in people with rheumatic disease: Developed by the Singapore Chapter of Rheumatologists., References: ['']\n",
      "DEBUG - Citing Paper: siRNA Therapeutics against Respiratory Viral Infections-What Have We Learned for Potential COVID-19 Therapies?, References: ['']\n",
      "DEBUG - Citing Paper: Bacterial RNA as a signal to eukaryotic cells as part of the infection process., References: ['']\n",
      "DEBUG - Citing Paper: 2'-<i>O</i>-methylation within prokaryotic and eukaryotic tRNA inhibits innate immune activation by endosomal Toll-like receptors but does not affect recognition of whole organisms., References: ['']\n",
      "DEBUG - Citing Paper: Crucial Role of Nucleic Acid Sensing via Endosomal Toll-Like Receptors for the Defense of <i>Streptococcus pyogenes in vitro</i> and <i>in vivo</i>., References: ['']\n",
      "DEBUG - Citing Paper: RNA Modifications Modulate Activation of Innate Toll-Like Receptors., References: ['']\n",
      "DEBUG - Citing Paper: <i>Mycobacterium tuberculosis</i>-induced IFN-Î² production requires cytosolic DNA and RNA sensing pathways., References: ['']\n",
      "DEBUG - Citing Paper: Identification of an optimized 2'-<i>O</i>-methylated trinucleotide RNA motif inhibiting Toll-like receptors 7 and 8., References: ['']\n",
      "DEBUG - Citing Paper: Cardiac RNA induces inflammatory responses in cardiomyocytes and immune cells via Toll-like receptor 7 signaling., References: ['']\n",
      "DEBUG - Citing Paper: mRNA: Fulfilling the Promise of Gene Therapy., References: ['']\n",
      "DEBUG - Citing Paper: 2'-O-Methylation within Bacterial RNA Acts as Suppressor of TLR7/TLR8 Activation in Human Innate Immune Cells., References: ['']\n",
      "DEBUG - Citing Paper: Phagosomal TLR signaling upon Borrelia burgdorferi infection., References: ['']\n",
      "DEBUG - Citing Paper: A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs., References: ['']\n",
      "DEBUG - Citing Paper: RIG-I detects mRNA of intracellular Salmonella enterica serovar Typhimurium during bacterial infection., References: ['']\n",
      "DEBUG - Citing Paper: TLR7 inhibition: A novel strategy for pancreatic cancer treatment?, References: ['']\n",
      "DEBUG - Citing Paper: Nucleic acids and endosomal pattern recognition: how to tell friend from foe?, References: ['']\n",
      "DEBUG - Citing Paper: Extracellular ATP and Toll-like receptor 2 agonists trigger in human monocytes an activation program that favors T helper 17., References: ['']\n",
      "DEBUG - Citing Paper: JAK kinases are required for the bacterial RNA and poly I:C induced tyrosine phosphorylation of PKR., References: ['']\n",
      "DEBUG - Citing Paper: Bacterial RNA induces myocyte cellular dysfunction through the activation of PKR., References: ['']\n",
      "DEBUG - Citing Paper: Bacterial RNA mediates activation of caspase-1 and IL-1Î² release independently of TLRs 3, 7, 9 and TRIF but is dependent on UNC93B., References: ['']\n",
      "DEBUG - Citing Paper: RNA mediated Toll-like receptor stimulation in health and disease., References: ['']\n",
      "DEBUG - Citing Paper: The role of immunostimulatory nucleic acids in septic shock., References: ['']\n",
      "DEBUG - Citing Paper: Identification of modifications in microbial, native tRNA that suppress immunostimulatory activity., References: ['']\n",
      "DEBUG - Citing Paper: J-LEAPS peptide and LEAPS dendritic cell vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Intranasal vaccination with messenger RNA as a new approach in gene therapy: use against tuberculosis., References: ['']\n",
      "DEBUG - Citing Paper: Bacterial recognition by TLR7 in the lysosomes of conventional dendritic cells., References: ['']\n",
      "DEBUG - Citing Paper: Phagocytosis of Borrelia burgdorferi, the Lyme disease spirochete, potentiates innate immune activation and induces apoptosis in human monocytes., References: ['']\n",
      "DEBUG - Citing Paper: Toll or toll-free adjuvant path toward the optimal vaccine development., References: ['']\n",
      "DEBUG - Citing Paper: The 3' CCACCA sequence of tRNAAla(UGC) is the motif that is important in inducing Th1-like immune response, and this motif can be recognized by Toll-like receptor 3., References: ['']\n",
      "DEBUG - Citing Paper: Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8., References: ['']\n",
      "DEBUG - Citing Paper: Synergistic effect of Nod1 and Nod2 agonists with toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells., References: ['']\n",
      "DEBUG - Citing Paper: Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients., References: ['']\n",
      "DEBUG - Citing Paper: Mammalian Toll-like receptors: to immunity and beyond., References: ['']\n",
      "DEBUG - Citing Paper: Dendritic cells in melanoma immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin., References: ['']\n",
      "DEBUG - Citing Paper: Both innate immunity and type 1 humoral immunity to Streptococcus pneumoniae are mediated by MyD88 but differ in their relative levels of dependence on toll-like receptor 2., References: ['']\n",
      "DEBUG - Citing Paper: The increased prevalence of allergy and the hygiene hypothesis: missing immune deviation, reduced immune suppression, or both?, References: ['']\n",
      "DEBUG - focal: Cutting edge: innate immune system discriminates between RNA containing bacterial versus eukaryotic structural features that prime for high-level IL-12 secretion by dendritic cells., NF: 0, NB: 0, NR: 0, D: 0\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DEBUG - Focal Paper: Inhibition of toll-like receptor and cytokine signaling--a unifying theme in ischemic tolerance., References: \n",
      "Abe T, Kunz A, Shimamura M, Zhou P, Anrather J\n",
      "et al. (2009) The neuroprotective effect of prostaglandin E2 EP1 receptor inhibition has a wide therapeutic window, is sustained in time and is not sexually dimorphic. J Cereb Blood Flow Metab\n",
      "29: 66-72. doi:10.1038/jcbfm.2008.88. PubMed: 18648380. \n",
      "DEBUG - Citing Paper: Impact of inflammatory preconditioning on murine microglial proteome response induced by focal ischemic brain injury., References: ['']\n",
      "DEBUG - Citing Paper: NaÃ¯ve Huntington's disease microglia mount a normal response to inflammatory stimuli but display a partially impaired development of innate immune tolerance that can be counteracted by ganglioside GM1., References: ['']\n",
      "DEBUG - Citing Paper: Novel Therapeutic Approaches to Prevent Atherothrombotic Ischemic Stroke in Patients with Carotid Atherosclerosis., References: ['']\n",
      "DEBUG - Citing Paper: Neuroinflammatory disorders of the brain and inner ear: a systematic review of auditory function in patients with migraine, multiple sclerosis, and neurodegeneration to support the idea of an innovative 'window of discovery'., References: ['']\n",
      "DEBUG - Citing Paper: Systemic Inflammation after Aneurysmal Subarachnoid Hemorrhage., References: ['']\n",
      "DEBUG - Citing Paper: A comprehensive review of stroke-related signaling pathways and treatment in western medicine and traditional Chinese medicine., References: ['']\n",
      "DEBUG - Citing Paper: Expression of Tie2 (angiopoietin receptor) on the monocyte subpopulations from ischemic stroke patients: Histological and flowcytometric studies., References: ['']\n",
      "DEBUG - Citing Paper: Ischemic Tolerance Induced by Glial Cells., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Interactions between remote ischemic conditioning and post-stroke sleep regulation., References: ['']\n",
      "DEBUG - Citing Paper: S100A8 Promotes Inflammation <i>via</i> Toll-Like Receptor 4 After Experimental Traumatic Brain Injury., References: ['']\n",
      "DEBUG - Citing Paper: Ischemia-Triggered Glutamate Excitotoxicity From the Perspective of Glial Cells., References: ['']\n",
      "DEBUG - Citing Paper: Glial Cells: Role of the Immune Response in Ischemic Stroke., References: ['']\n",
      "DEBUG - Citing Paper: Crosstalk between stressed brain cells: direct and indirect effects of ischemia and aglycemia on microglia., References: ['']\n",
      "DEBUG - Citing Paper: Prolonged Peripheral Hypoperfusion Promotes Neuroprotection in Ischemic Stroke., References: ['']\n",
      "DEBUG - Citing Paper: Memory-Like Inflammatory Responses of Microglia to Rising Doses of LPS: Key Role of PI3KÎ³., References: ['']\n",
      "DEBUG - Citing Paper: S-Layer Protein of <i>Lactobacillus helveticus</i> SBT2171 Promotes Human Î²-Defensin 2 Expression via TLR2-JNK Signaling., References: ['']\n",
      "DEBUG - Citing Paper: Ischemic preconditioning induces cortical microglial proliferation and a transcriptomic program of robust cell cycle activation., References: ['']\n",
      "DEBUG - Citing Paper: The role of microglia in ischemic preconditioning., References: ['']\n",
      "DEBUG - Citing Paper: Rab7b Overexpression-Ameliorated Ischemic Brain Damage Following tMCAO Involves Suppression of TLR4 and NF-ÎºB p65., References: ['']\n",
      "DEBUG - Citing Paper: Multidisciplinary Roles of LRRFIP1/GCF2 in Human Biological Systems and Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Dabrafenib, an inhibitor of RIP3 kinase-dependent necroptosis, reduces ischemic brain injury., References: ['']\n",
      "DEBUG - Citing Paper: Correction to: Neuroimmune Response in Ischemic Preconditioning., References: ['']\n",
      "DEBUG - Citing Paper: Crosstalk between TLR2 and Sphk1 in microglia in the cerebral ischemia/reperfusion-induced inflammatory response., References: ['']\n",
      "DEBUG - Citing Paper: The Focal-Focal Preconditioning Effect of Photothrombotic Impact on the Signaling Protein Profile in the Penumbra Surrounding the Ischemic Core Induced by Another Photothrombotic Impact., References: ['']\n",
      "DEBUG - Citing Paper: Ischemia/Reperfusion Induces Interferon-Stimulated Gene Expression in Microglia., References: ['']\n",
      "DEBUG - Citing Paper: Live imaging of the innate immune response in neonates reveals differential TLR2 dependent activation patterns in sterile inflammation and infection., References: ['']\n",
      "DEBUG - Citing Paper: Microglial Interferon Signaling and White Matter., References: ['']\n",
      "DEBUG - Citing Paper: Proinflammatory effects of S100A8/A9 via TLR4 and RAGE signaling pathways in BV-2 microglial cells., References: ['']\n",
      "DEBUG - Citing Paper: Molecular characterization and analysis of TLR-1 in rabbit tissues., References: ['']\n",
      "DEBUG - Citing Paper: Ethanol-Induced Neurodegeneration and Glial Activation in the Developing Brain., References: ['']\n",
      "DEBUG - Citing Paper: Neuroimmune Response in Ischemic Preconditioning., References: ['']\n",
      "DEBUG - Citing Paper: Heterogeneity of BÂ Cell Functions in Stroke-Related Risk, Prevention, Injury, and Repair., References: ['']\n",
      "DEBUG - Citing Paper: The Effects of Hypoxia and Inflammation on Synaptic Signaling in the CNS., References: ['']\n",
      "DEBUG - Citing Paper: Diphenyldifluoroketone EF24 Suppresses Pro-inflammatory Interleukin-1 receptor 1 and Toll-like Receptor 4 in lipopolysaccharide-stimulated dendritic cells., References: ['']\n",
      "DEBUG - Citing Paper: Identification of Sleep-Modulated Pathways Involved in Neuroprotection from Stroke., References: ['']\n",
      "DEBUG - Citing Paper: Phasic Treatment with Interferon Gamma Stimulates Release of Exosomes that Protect Against Spreading Depression., References: ['']\n",
      "DEBUG - Citing Paper: Cerebral Ischemic Preconditioning: the Road So Farâ¦., References: ['']\n",
      "DEBUG - Citing Paper: Novel Cellular Mechanisms for Neuroprotection in Ischemic Preconditioning: A View from Inside Organelles., References: ['']\n",
      "DEBUG - Citing Paper: Function and mechanism of toll-like receptors in cerebral ischemic tolerance: from preconditioning to treatment., References: ['']\n",
      "DEBUG - Citing Paper: Ischemic conditioning-induced endogenous brain protection: Applications pre-, per- or post-stroke., References: ['']\n",
      "DEBUG - Citing Paper: 'Preconditioning' with low dose lipopolysaccharide aggravates the organ injury / dysfunction caused by hemorrhagic shock in rats., References: ['']\n",
      "DEBUG - Citing Paper: Acetylbritannilactone Modulates MicroRNA-155-Mediated Inflammatory Response in Ischemic Cerebral Tissues., References: ['']\n",
      "DEBUG - Citing Paper: The Anti-Inflammatory Actions of Exercise Training., References: ['']\n",
      "DEBUG - Citing Paper: Clinical applications of remote ischaemic preconditioning in native and transplant acute kidney injury., References: ['']\n",
      "DEBUG - Citing Paper: Biological Effects of Space Radiation and Development of Effective Countermeasures., References: ['']\n",
      "DEBUG - Citing Paper: Postconditioning improvement effects of ulinastatin on brain injury following cardiopulmonary resuscitation., References: ['']\n",
      "DEBUG - Citing Paper: Ischemic tolerance modulates TRAIL expression and its receptors and generates a neuroprotected phenotype., References: ['']\n",
      "DEBUG - Citing Paper: Innate immune responses regulate morphogenesis and degeneration: roles of Toll-like receptors and Sarm1 in neurons., References: ['']\n",
      "DEBUG - Citing Paper: Neurotherapeutic activity of the recombinant heat shock protein Hsp70 in a model of focal cerebral ischemia in rats., References: ['']\n",
      "DEBUG - Citing Paper: Hemorrhage-induced interleukin-1 receptor pathway in lung is suppressed by 3,5-bis(2-fluorobenzylidene)-4-piperidone in a rat model of hypovolemic shock., References: ['']\n",
      "DEBUG - Citing Paper: Spreading depression requires microglia and is decreased by their M2a polarization from environmental enrichment., References: ['']\n",
      "DEBUG - Citing Paper: Curcumin inhibits TLR2/4-NF-ÎºB signaling pathway and attenuates brain damage in permanent focal cerebral ischemia in rats., References: ['']\n",
      "DEBUG - Citing Paper: Remote ischemic preconditioning as treatment for non-ischemic gastrointestinal disorders: beyond ischemia-reperfusion injury., References: ['']\n",
      "DEBUG - Citing Paper: Crosstalk between insulin and Toll-like receptor signaling pathways in the central nervous system., References: ['']\n",
      "DEBUG - Citing Paper: Trefoil factor 3 as an endocrine neuroprotective factor from the liver in experimental cerebral ischemia/reperfusion injury., References: ['']\n",
      "DEBUG - Citing Paper: A strategy for trade monitoring and substitution of the organs of threatened animals., References: ['']\n",
      "DEBUG - Citing Paper: TLR-3 receptor activation protects the very immature brain from ischemic injury., References: ['']\n",
      "DEBUG - Citing Paper: Innate immune regulation by toll-like receptors in the brain., References: ['']\n",
      "DEBUG - Citing Paper: Effect of solar particle event radiation and hindlimb suspension on gastrointestinal tract bacterial translocation and immune activation., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor 2 deficiency leads to delayed exacerbation of ischemic injury., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptors and opportunities for new sepsis therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Combination therapy with VELCADE and tissue plasminogen activator is neuroprotective in aged rats after stroke and targets microRNA-146a and the toll-like receptor signaling pathway., References: ['']\n",
      "DEBUG - Citing Paper: Role of heat shock protein 70 in innate alloimmunity., References: ['']\n",
      "DEBUG - Citing Paper: Effect of repeated ischaemic preconditioning on TLR4 and proinflammatory cytokines TNF-Î± and IL-1Î² in myocardial ischaemia-reperfusion injury in a rat model., References: ['']\n",
      "DEBUG - Citing Paper: The cytokine tumor necrosis factor-like weak inducer of apoptosis and its receptor fibroblast growth factor-inducible 14 have a neuroprotective effect in the central nervous system., References: ['']\n",
      "DEBUG - Citing Paper: Participation of MCP-induced protein 1 in lipopolysaccharide preconditioning-induced ischemic stroke tolerance by regulating the expression of proinflammatory cytokines., References: ['']\n",
      "DEBUG - Citing Paper: Pharmacophore modeling, molecular docking, QSAR, and in silico ADMET studies of gallic acid derivatives for immunomodulatory activity., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptors in cerebral ischemic inflammatory injury., References: ['']\n",
      "DEBUG - Citing Paper: The immunology of stroke: from mechanisms to translation., References: ['']\n",
      "DEBUG - Citing Paper: Protective conditioning of the brain: expressway or roadblock?, References: ['']\n",
      "DEBUG - Citing Paper: Multiple preconditioning paradigms converge on interferon regulatory factor-dependent signaling to promote tolerance to ischemic brain injury., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor expression and activation in astroglia: differential regulation by HIV-1 Tat, gp120, and morphine., References: ['']\n",
      "DEBUG - Citing Paper: The impact of chronic intrauterine inflammation on the physiologic and neurodevelopmental consequences of intermittent umbilical cord occlusion in fetal sheep., References: ['']\n",
      "DEBUG - Citing Paper: Progesterone administration modulates cortical TLR4/NF-ÎºB signaling pathway after subarachnoid hemorrhage in male rats., References: ['']\n",
      "DEBUG - Citing Paper: Spinal toll like receptor 3 is involved in chronic pancreatitis-induced mechanical allodynia of rat., References: ['']\n",
      "DEBUG - Citing Paper: Development of QSAR model for immunomodulatory activity of natural coumarinolignoids., References: ['']\n",
      "DEBUG - Citing Paper: Blocking TLR2 in vivo protects against accumulation of inflammatory cells and neuronal injury in experimental stroke., References: ['']\n",
      "DEBUG - Citing Paper: Neural injury following stroke: are Toll-like receptors the link between the immune system and the CNS?, References: ['']\n",
      "DEBUG - Citing Paper: Glycogen synthase kinase-3 regulates inflammatory tolerance in astrocytes., References: ['']\n",
      "DEBUG - Citing Paper: Transcriptomic responses in mouse brain exposed to chronic excess of the neurotransmitter glutamate., References: ['']\n",
      "DEBUG - Citing Paper: Microglia in ischemic brain injury., References: ['']\n",
      "DEBUG - Citing Paper: Preconditioning-induced ischemic tolerance: a window into endogenous gearing for cerebroprotection., References: ['']\n",
      "DEBUG - Citing Paper: Heterogeneity of microglial activation in the innate immune response in the brain., References: ['']\n",
      "DEBUG - Citing Paper: The neuroprotective mechanism of brain ischemic preconditioning., References: ['']\n",
      "DEBUG - Citing Paper: Preconditioning and tolerance against cerebral ischaemia: from experimental strategies to clinical use., References: ['']\n",
      "DEBUG - Citing Paper: Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease., References: ['']\n",
      "DEBUG - Citing Paper: TNF-alpha-mediated inflammation in cerebral aneurysms: a potential link to growth and rupture., References: ['']\n",
      "DEBUG - Citing Paper: Monomeric IgG is neuroprotective via enhancing microglial recycling endocytosis and TNF-alpha., References: ['']\n",
      "DEBUG - Citing Paper: A systems-theoretical framework for health and disease: inflammation and preconditioning from an abstract modeling point of view., References: ['']\n",
      "DEBUG - Citing Paper: Ischemic tolerance as an active and intrinsic neuroprotective mechanism., References: ['']\n",
      "DEBUG - Citing Paper: Influenza virus infection augments NK cell inhibition through reorganization of major histocompatibility complex class I proteins., References: ['']\n",
      "DEBUG - Citing Paper: A central role of connexin 43 in hypoxic preconditioning., References: ['']\n",
      "DEBUG - Citing Paper: Immunomodulation strategies for preventing vascular disease of the brain and heart: workshop summary., References: ['']\n",
      "DEBUG - Citing Paper: Mitochondria contribute to LPS-induced MAPK activation via uncoupling protein UCP2 in macrophages., References: ['']\n",
      "DEBUG - Citing Paper: Cerebral preconditioning using cortical application of hypertonic salt solutions: upregulation of mRNAs encoding inhibitors of inflammation., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptors in central nervous system glial inflammation and homeostasis., References: ['']\n",
      "DEBUG - Citing Paper: The harms and benefits of inflammatory and immune responses in vascular disease., References: ['']\n",
      "DEBUG - Citing Paper: T-cell cytokines in injury-induced neural damage and repair., References: ['']\n",
      "DEBUG - Citing Paper: Ischemic preconditioning prevents protein aggregation after transient cerebral ischemia., References: ['']\n",
      "DEBUG - focal: Inhibition of toll-like receptor and cytokine signaling--a unifying theme in ischemic tolerance., NF: 0, NB: 0, NR: 0, D: 0\n",
      "DEBUG - Focal Paper: Extracellular mRNA induces dendritic cell activation by stimulating tumor necrosis factor-alpha secretion and signaling through a nucleotide receptor., References: AP Ã¼yesinden Ã¶neri: Euro banknotlarÄ± Ã¼zerinde Ãzlem TÃ¼reci ve UÄur Åahinâin de fotoÄraflarÄ± olsun - BBC News TÃ¼rkÃ§e. (n.d.). Retrieved November 16, 2022, from https://www.bbc.com/turkce/haberler-dunya-59857624\n",
      "DEBUG - Citing Paper: Profile of Katalin KarikÃ³ and Drew Weissman: 2023 Nobel laureates in Physiology or Medicine., References: ['']\n",
      "DEBUG - Citing Paper: Nobel Prize for physiology or medicine in 2023: how to dupe the cellular innate immune system using modified RNA for therapeutic treatment., References: ['']\n",
      "DEBUG - Citing Paper: The forerunners and successful partnerships behind the BioNTech mRNA vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Extracellular Vesicle RNA Contents as Biomarkers for Ocular Diseases., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 and earlier pandemics, sepsis, and vaccines: A historical perspective., References: ['']\n",
      "DEBUG - Citing Paper: The legacy of mRNA engineering: A lineup of pioneers for the Nobel Prize., References: ['']\n",
      "DEBUG - Citing Paper: Advances in the design and development of SARS-CoV-2 vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Paving the Road for RNA Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Extracellular RNAs from lung cancer cells activate epithelial cells and induce neutrophil extracellular traps., References: ['']\n",
      "DEBUG - Citing Paper: Understanding the Role of Innate Immunity in the Response to Intracortical Microelectrodes., References: ['']\n",
      "DEBUG - Citing Paper: Large Differences in Small RNA Composition Between Human Biofluids., References: ['']\n",
      "DEBUG - Citing Paper: Electroporated Antigen-Encoding mRNA Is Not a Danger Signal to Human Mature Monocyte-Derived Dendritic Cells., References: ['']\n",
      "DEBUG - Citing Paper: Synthetic chemically modified mRNA (modRNA): toward a new technology platform for cardiovascular biology and medicine., References: ['']\n",
      "DEBUG - Citing Paper: Acute brain injury triggers MyD88-dependent, TLR2/4-independent inflammatory responses., References: ['']\n",
      "DEBUG - Citing Paper: A generic RNA-pulsed dendritic cell vaccine strategy for renal cell carcinoma., References: ['']\n",
      "DEBUG - focal: Extracellular mRNA induces dendritic cell activation by stimulating tumor necrosis factor-alpha secretion and signaling through a nucleotide receptor., NF: 0, NB: 0, NR: 0, D: 0\n",
      "DEBUG - Focal Paper: Platelet factor 4 binds to low-density lipoprotein receptors and disrupts the endocytic machinery, resulting in retention of low-density lipoprotein on the cell surface., References:   https://www.heartfoundation.org.au/images/uploads/main/Programs/Consumer_QA_Fish_Omega3_Cardiovascular_Health.pdf.\n",
      "DEBUG - Citing Paper: Proteomic analysis reveals activation of platelet- and fibrosis-related pathways in hearts of ApoE<sup>-/-</sup> mice exposed to diesel exhaust particles., References: ['']\n",
      "DEBUG - Citing Paper: Functions for platelet factor 4 (PF4/CXCL4) and its receptors in fibroblast-myofibroblast transition and fibrotic failure of arteriovenous fistulas (AVFs)., References: ['']\n",
      "DEBUG - Citing Paper: The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function., References: ['']\n",
      "DEBUG - Citing Paper: New perspectives on the induction and acceleration of immune-associated thrombosis by PF4 and VWF., References: ['']\n",
      "DEBUG - Citing Paper: Role of platelet factor 4 in arteriovenous fistula maturation failure: What do we know so far?, References: ['']\n",
      "DEBUG - Citing Paper: CXCL4 synergizes with TLR8 for TBK1-IRF5 activation, epigenomic remodeling and inflammatory response in human monocytes., References: ['']\n",
      "DEBUG - Citing Paper: <i>Panax ginseng</i>: Inflammation, platelet aggregation, thrombus formation, and atherosclerosis crosstalk., References: ['']\n",
      "DEBUG - Citing Paper: Differential Effects of Platelet Factor 4 (CXCL4) and Its Non-Allelic Variant (CXCL4L1) on Cultured Human Vascular Smooth Muscle Cells., References: ['']\n",
      "DEBUG - Citing Paper: Percutaneous coronary intervention in a patient with heparin resistance due to essential thrombocythaemia: a case report., References: ['']\n",
      "DEBUG - Citing Paper: Endothelial dysfunction in neuroprogressive disorders-causes and suggested treatments., References: ['']\n",
      "DEBUG - Citing Paper: Exploring the Extracellular Regulation of the Tumor Angiogenic Interaction Network Using a Systems Biology Model., References: ['']\n",
      "DEBUG - Citing Paper: Can Yellow Stripe Scad Compete with Salmon on Its Role in Platelet Phospholipid Membrane and Its Cardiovascular Benefits?, References: ['']\n",
      "DEBUG - Citing Paper: Interaction between platelets and endothelium: from pathophysiology to new therapeutic options., References: ['']\n",
      "DEBUG - Citing Paper: Obstructive Sleep Apnea: From Intermittent Hypoxia to Cardiovascular Complications via Blood Platelets., References: ['']\n",
      "DEBUG - Citing Paper: CXCL4/Platelet Factor 4 is an agonist of CCR1 and drives human monocyte migration., References: ['']\n",
      "DEBUG - Citing Paper: Platelet secretion in inflammatory and infectious diseases., References: ['']\n",
      "DEBUG - Citing Paper: Platelet-Specific Chemokines Contribute to the Pathogenesis of Acute Lung Injury., References: ['']\n",
      "DEBUG - Citing Paper: Genome-wide haplotypic testing in a Finnish cohort identifies a novel association with low-density lipoprotein cholesterol., References: ['']\n",
      "DEBUG - Citing Paper: Platelet factor 4 limits Th17 differentiation and cardiac allograft rejection., References: ['']\n",
      "DEBUG - Citing Paper: C-reactive protein/oxidised low-density lipoprotein/Î²2-glycoprotein I complex promotes atherosclerosis in diabetic BALB/c mice via p38mitogen-activated protein kinase signal pathway., References: ['']\n",
      "DEBUG - Citing Paper: Macrophage Phenotype Modulation by CXCL4 in Atherosclerosis., References: ['']\n",
      "DEBUG - Citing Paper: Hepatitis C virus E1 envelope glycoprotein interacts with apolipoproteins in facilitating entry into hepatocytes., References: ['']\n",
      "DEBUG - Citing Paper: CXC chemokine ligand 4 induces a unique transcriptome in monocyte-derived macrophages., References: ['']\n",
      "DEBUG - Citing Paper: CXCL4 downregulates the atheroprotective hemoglobin receptor CD163 in human macrophages., References: ['']\n",
      "DEBUG - Citing Paper: Platelet chemokines in vascular disease., References: ['']\n",
      "DEBUG - Citing Paper: Platelets in inflammation and atherogenesis., References: ['']\n",
      "DEBUG - Citing Paper: Endothelial expression of E-selectin is induced by the platelet-specific chemokine platelet factor 4 through LRP in an NF-kappaB-dependent manner., References: ['']\n",
      "DEBUG - Citing Paper: Human immunodeficiency virus type 1 enters primary human brain microvascular endothelial cells by a mechanism involving cell surface proteoglycans independent of lipid rafts., References: ['']\n",
      "DEBUG - focal: Platelet factor 4 binds to low-density lipoprotein receptors and disrupts the endocytic machinery, resulting in retention of low-density lipoprotein on the cell surface., NF: 0, NB: 0, NR: 0, D: 0\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DEBUG - Focal Paper: Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3., References: \n",
      "Baras B, Stittelaar KJ, Simon JH, Thoolen RJ, Mossman SP, Pistoor FH, van Amerongen G, Wettendorff MA, Hanon E, Osterhaus AD.\n",
      "2008. \n",
      "Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. \n",
      "PLoS One\n",
      "3:\n",
      "e1401\n",
      "doi:10.1371/journal.pone.0001401\n",
      "DEBUG - Citing Paper: RNAi-based drug design: considerations and future directions., References: ['']\n",
      "DEBUG - Citing Paper: Basic Principles of RNA Interference: Nucleic Acid Types and In Vitro Intracellular Delivery Methods., References: ['']\n",
      "DEBUG - Citing Paper: Encapsulation of miRNA and siRNA into Nanomaterials for Cancer Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: DNA double-strand break repair and nucleic acid-related immunity., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 and Lung Mast Cells: The Kallikrein-Kinin Activation Pathway., References: ['']\n",
      "DEBUG - Citing Paper: A Review of Human Coronaviruses' Receptors: The Host-Cell Targets for the Crown Bearing Viruses., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor 3 (TLR3) regulation mechanisms and roles in antiviral innate immune responses., References: ['']\n",
      "DEBUG - Citing Paper: Albumin Nanostructures for Nucleic Acid Delivery in Cancer: Current Trend, Emerging Issues, and Possible Solutions., References: ['']\n",
      "DEBUG - Citing Paper: Can SARS-CoV-2 Virus Use Multiple Receptors to Enter Host Cells?, References: ['']\n",
      "DEBUG - Citing Paper: <i>In situ</i> self-assembly of Au-antimiR-155 nanocomplexes mediates TLR3-dependent apoptosis in hepatocellular carcinoma cells., References: ['']\n",
      "DEBUG - Citing Paper: Distinct and Orchestrated Functions of RNA Sensors in Innate Immunity., References: ['']\n",
      "DEBUG - Citing Paper: Design, mechanism, delivery and therapeutics of canonical and Dicer-substrate siRNA., References: ['']\n",
      "DEBUG - Citing Paper: MicroRNAs in Ocular Infection., References: ['']\n",
      "DEBUG - Citing Paper: Heterozygous loss of keratinocyte TRIM16 expression increases melanocytic cell lesions and lymph node metastasis., References: ['']\n",
      "DEBUG - Citing Paper: Efficient reduction of synthetic mRNA induced immune activation by simultaneous delivery of B18R encoding mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Antisense peptide nucleic acids as a potential anti-infective agent., References: ['']\n",
      "DEBUG - Citing Paper: Lipopeptide Delivery of siRNA to the Central Nervous System., References: ['']\n",
      "DEBUG - Citing Paper: Increased expression of toll-like receptor 3, an anti-viral signaling molecule, and related genes in Alzheimer's disease brains., References: ['']\n",
      "DEBUG - Citing Paper: A novel animal model for neuroinflammation and white matter degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Reconstruction of Toll-like receptor 9-mediated responses in HEK-Blue hTLR9 cells by transfection of human macrophage scavenger receptor 1 gene., References: ['']\n",
      "DEBUG - Citing Paper: Luciferase shRNA Presents off-Target Effects on Voltage-Gated Ion Channels in Mouse Hippocampal Pyramidal Neurons., References: ['']\n",
      "DEBUG - Citing Paper: Gene suppression approaches to neurodegeneration., References: ['']\n",
      "DEBUG - Citing Paper: Identification of a novel p53 target, COL17A1, that inhibits breast cancer cell migration and invasion., References: ['']\n",
      "DEBUG - Citing Paper: Interleukin-like EMT inducer regulates partial phenotype switching in MITF-low melanoma cell lines., References: ['']\n",
      "DEBUG - Citing Paper: Therapeutic Effect of Novel Single-Stranded RNAi Agent Targeting Periostin in Eyes with Retinal Neovascularization., References: ['']\n",
      "DEBUG - Citing Paper: Nanoengineered strategies for siRNA delivery: from target assessment to cancer therapeutic efficacy., References: ['']\n",
      "DEBUG - Citing Paper: Molecular characterization and analysis of TLR-1 in rabbit tissues., References: ['']\n",
      "DEBUG - Citing Paper: Overexpression of Glutamate Decarboxylase in Mesenchymal Stem Cells Enhances Their Immunosuppressive Properties and Increases GABA and Nitric Oxide Levels., References: ['']\n",
      "DEBUG - Citing Paper: HDL and microRNA therapeutics in cardiovascular disease., References: ['']\n",
      "DEBUG - Citing Paper: Development of Novel Small Hairpin RNAs That do not Require Processing by Dicer or AGO2., References: ['']\n",
      "DEBUG - Citing Paper: Technologies for controlled, local delivery of siRNA., References: ['']\n",
      "DEBUG - Citing Paper: Identification of cellular microRNA-136 as a dual regulator of RIG-I-mediated innate immunity that antagonizes H5N1 IAV replication in A549 cells., References: ['']\n",
      "DEBUG - Citing Paper: Safety of Striatal Infusion of siRNA in a Transgenic Huntington's Disease Mouse Model., References: ['']\n",
      "DEBUG - Citing Paper: Design of a platform technology for systemic delivery of siRNA to tumours using rolling circle transcription., References: ['']\n",
      "DEBUG - Citing Paper: Inhibition of choroidal fibrovascular membrane formation by new class of RNA interference therapeutic agent targeting periostin., References: ['']\n",
      "DEBUG - Citing Paper: Hepatitis C virus induced endothelial inflammatory response depends on the functional expression of TNFÎ± receptor subtype 2., References: ['']\n",
      "DEBUG - Citing Paper: Therapeutic targeting of microRNAs: current status and future challenges., References: ['']\n",
      "DEBUG - Citing Paper: Recombinant AAV as a platform for translating the therapeutic potential of RNA interference., References: ['']\n",
      "DEBUG - Citing Paper: Dendrimers for siRNA Delivery., References: ['']\n",
      "DEBUG - Citing Paper: siRNA enhances DNA-mediated interferon lambda-1 response through crosstalk between RIG-I and IFI16 signalling pathway., References: ['']\n",
      "DEBUG - Citing Paper: Design of siRNA Therapeutics from the Molecular Scale., References: ['']\n",
      "DEBUG - Citing Paper: Nucleic acids and endosomal pattern recognition: how to tell friend from foe?, References: ['']\n",
      "DEBUG - Citing Paper: Heterogeneity in nanoparticles influences biodistribution and targeting., References: ['']\n",
      "DEBUG - Citing Paper: Liposome delivery of microRNA-145 to mesenchymal stem cells leads to immunological off-target effects mediated by RIG-I., References: ['']\n",
      "DEBUG - Citing Paper: Cytokines as biomarkers of nanoparticle immunotoxicity., References: ['']\n",
      "DEBUG - Citing Paper: The role of UNC93B1 protein in surface localization of TLR3 receptor and in cell priming to nucleic acid agonists., References: ['']\n",
      "DEBUG - Citing Paper: An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models., References: ['']\n",
      "DEBUG - Citing Paper: Iron regulator hepcidin exhibits antiviral activity against hepatitis C virus., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor sensing of human herpesvirus infection., References: ['']\n",
      "DEBUG - Citing Paper: Multi-level regulation of cellular recognition of viral dsRNA., References: ['']\n",
      "DEBUG - Citing Paper: Gene targeting in primary human trophoblasts., References: ['']\n",
      "DEBUG - Citing Paper: RNA mediated Toll-like receptor stimulation in health and disease., References: ['']\n",
      "DEBUG - Citing Paper: Lateral clustering of TLR3:dsRNA signaling units revealed by TLR3ecd:3Fabs quaternary structure., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor (TLR) 3 immune modulation by unformulated small interfering RNA or DNA and the role of CD14 (in TLR-mediated effects)., References: ['']\n",
      "DEBUG - Citing Paper: A window to innate neuroimmunity: Toll-like receptor-mediated cell responses in the retina., References: ['']\n",
      "DEBUG - Citing Paper: Involvement of activation of PKR in HBx-siRNA-mediated innate immune effects on HBV inhibition., References: ['']\n",
      "DEBUG - Citing Paper: LL37 and cationic peptides enhance TLR3 signaling by viral double-stranded RNAs., References: ['']\n",
      "DEBUG - Citing Paper: High-dose siRNAs upregulate mouse Eri-1 at both transcription and posttranscription levels., References: ['']\n",
      "DEBUG - Citing Paper: Short-interfering RNAs induce retinal degeneration via TLR3 and IRF3., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptors and myocardial inflammation., References: ['']\n",
      "DEBUG - Citing Paper: The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR-ABL tyrosine kinase inhibitors., References: ['']\n",
      "DEBUG - Citing Paper: Similar Structures but Different Roles - An Updated Perspective on TLR Structures., References: ['']\n",
      "DEBUG - Citing Paper: Chemical modification of siRNA bases to probe and enhance RNA interference., References: ['']\n",
      "DEBUG - Citing Paper: Direct visualization at the single-cell level of siRNA electrotransfer into cancer cells., References: ['']\n",
      "DEBUG - Citing Paper: Nucleobase and ribose modifications control immunostimulation by a microRNA-122-mimetic RNA., References: ['']\n",
      "DEBUG - Citing Paper: Modulation of Î³Î´ T cell responses by TLR ligands., References: ['']\n",
      "DEBUG - Citing Paper: Personalized cancer approach: using RNA interference technology., References: ['']\n",
      "DEBUG - Citing Paper: Cell penetrating peptide conjugated bioreducible polymer for siRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: Age-related macular degeneration and the other double helix. The Cogan Lecture., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor, RIG-I-like receptors and the NLRP3 inflammasome: key modulators of innate immune responses to double-stranded RNA viruses., References: ['']\n",
      "DEBUG - Citing Paper: Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Application of RNA interference in treating human diseases., References: ['']\n",
      "DEBUG - Citing Paper: dsRNA activation of endothelin-1 and markers of vascular activation in endothelial cells and fibroblasts., References: ['']\n",
      "DEBUG - Citing Paper: Minor-groove-modulating adenosine replacements control protein binding and RNAi activity in siRNAs., References: ['']\n",
      "DEBUG - Citing Paper: Kaposi's sarcoma-associated herpesvirus and innate immunity., References: ['']\n",
      "DEBUG - Citing Paper: Post-transcriptional regulation of miR-27 in murine cytomegalovirus infection., References: ['']\n",
      "DEBUG - Citing Paper: Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application., References: ['']\n",
      "DEBUG - Citing Paper: Effects of chemical modification on the potency, serum stability, and immunostimulatory properties of short shRNAs., References: ['']\n",
      "DEBUG - Citing Paper: Attenuation of the influenza virus sickness behavior in mice deficient in Toll-like receptor 3., References: ['']\n",
      "DEBUG - Citing Paper: Huntington's disease: silencing a brutal killer., References: ['']\n",
      "DEBUG - Citing Paper: Minimizing off-target effects by using diced siRNAs for RNA interference., References: ['']\n",
      "DEBUG - Citing Paper: Designer siRNAs to overcome the challenges from the RNAi pathway., References: ['']\n",
      "DEBUG - Citing Paper: Short-hairpin RNAs delivered by lentiviral vector transduction trigger RIG-I-mediated IFN activation., References: ['']\n",
      "DEBUG - Citing Paper: Combined genome-wide expression profiling and targeted RNA interference in primary mouse macrophages reveals perturbation of transcriptional networks associated with interferon signalling., References: ['']\n",
      "DEBUG - Citing Paper: Sequence determinants of innate immune activation by short interfering RNAs., References: ['']\n",
      "DEBUG - Citing Paper: Drug delivery-mediated control of RNA immunostimulation., References: ['']\n",
      "DEBUG - Citing Paper: Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer., References: ['']\n",
      "DEBUG - Citing Paper: Geographic atrophy in age-related macular degeneration and TLR3., References: ['']\n",
      "DEBUG - Citing Paper: Development of a chimeric DNA-RNA hammerhead ribozyme targeting SARS virus., References: ['']\n",
      "DEBUG - Citing Paper: Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth., References: ['']\n",
      "DEBUG - Citing Paper: Progress in the therapeutic applications of siRNAs against HIV-1., References: ['']\n",
      "DEBUG - Citing Paper: Polypurine hairpins directed against the template strand of DNA knock down the expression of mammalian genes., References: ['']\n",
      "DEBUG - Citing Paper: RNAi methodologies for the functional study of signaling molecules., References: ['']\n",
      "DEBUG - Citing Paper: Phototoxic aptamers selectively enter and kill epithelial cancer cells., References: ['']\n",
      "DEBUG - Citing Paper: Double-stranded RNA analog poly(I:C) inhibits human immunodeficiency virus amplification in dendritic cells via type I interferon-mediated activation of APOBEC3G., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor 3 and geographic atrophy in age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Cardiomyocyte-targeted siRNA delivery by prostaglandin E(2)-Fas siRNA polyplexes formulated with reducible poly(amido amine) for preventing cardiomyocyte apoptosis., References: ['']\n",
      "DEBUG - Citing Paper: Global gene expression profiling in cultured cells is strongly influenced by treatment with siRNA-cationic liposome complexes., References: ['']\n",
      "DEBUG - Citing Paper: Delivering small interfering RNA for novel therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Application of siRNA against SARS in the rhesus macaque model., References: ['']\n",
      "DEBUG - Citing Paper: Sequence- and target-independent angiogenesis suppression by siRNA via TLR3., References: ['']\n",
      "DEBUG - Citing Paper: Upregulation of the TLR3 pathway by Kaposi's sarcoma-associated herpesvirus during primary infection., References: ['']\n",
      "DEBUG - Citing Paper: Receptor-mediated delivery of siRNAs by tethered nucleic acid base-paired interactions., References: ['']\n",
      "DEBUG - Citing Paper: Short-hairpin RNAs synthesized by T7 phage polymerase do not induce interferon., References: ['']\n",
      "DEBUG - Citing Paper: Lack of interferon (IFN) response to T7 Transcribed pppG (n)(n = 2,3)-shRNA., References: ['']\n",
      "DEBUG - Citing Paper: SIRNA-directed in vivo silencing of androgen receptor inhibits the growth of castration-resistant prostate carcinomas., References: ['']\n",
      "DEBUG - Citing Paper: Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity., References: ['']\n",
      "DEBUG - Citing Paper: Modulating the expression of disease genes with RNA-based therapy., References: ['']\n",
      "DEBUG - Citing Paper: Immunological research using RNA interference technology., References: ['']\n",
      "DEBUG - Citing Paper: Toll or toll-free adjuvant path toward the optimal vaccine development., References: ['']\n",
      "DEBUG - Citing Paper: Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting., References: ['']\n",
      "DEBUG - Citing Paper: Chlamydia muridarum infection elicits a beta interferon response in murine oviduct epithelial cells dependent on interferon regulatory factor 3 and TRIF., References: ['']\n",
      "DEBUG - Citing Paper: Induction of interleukins IL-6 and IL-8 by siRNA., References: ['']\n",
      "DEBUG - Citing Paper: Molecular characterization of coding sequences and analysis of Toll-like receptor 3 mRNA expression in water buffalo (Bubalus bubalis) and nilgai (Boselaphus tragocamelus)., References: ['']\n",
      "DEBUG - Citing Paper: Molecular basis for the immunostimulatory potency of small interfering RNAs., References: ['']\n",
      "DEBUG - Citing Paper: Optimization of feline immunodeficiency virus vectors for RNA interference., References: ['']\n",
      "DEBUG - Citing Paper: Optimization and functional effects of stable short hairpin RNA expression in primary human lymphocytes via lentiviral vectors., References: ['']\n",
      "DEBUG - Citing Paper: RNA interference for antiviral therapy., References: ['']\n",
      "DEBUG - Citing Paper: Gangliosides trigger inflammatory responses via TLR4 in brain glia., References: ['']\n",
      "DEBUG - Citing Paper: Induction of the interferon response by siRNA is cell type- and duplex length-dependent., References: ['']\n",
      "DEBUG - Citing Paper: Progress towards in vivo use of siRNAs., References: ['']\n",
      "DEBUG - Citing Paper: Harnessing in vivo siRNA delivery for drug discovery and therapeutic development., References: ['']\n",
      "DEBUG - Citing Paper: Manifold mechanisms of Toll-like receptor-ligand recognition., References: ['']\n",
      "DEBUG - Citing Paper: Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque., References: ['']\n",
      "DEBUG - Citing Paper: The therapeutic potential of RNA interference., References: ['']\n",
      "DEBUG - Citing Paper: In vivo application of RNA interference: from functional genomics to therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: The molecular structure of the Toll-like receptor 3 ligand-binding domain., References: ['']\n",
      "DEBUG - Citing Paper: Mammalian Toll-like receptors: to immunity and beyond., References: ['']\n",
      "DEBUG - Citing Paper: RNA interference in biology and disease., References: ['']\n",
      "DEBUG - Citing Paper: Modulation of angiogenesis with siRNA inhibitors for novel therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Effects of length and location on the cellular response to double-stranded RNA., References: ['']\n",
      "DEBUG - focal: Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3., NF: 0, NB: 0, NR: 0, D: 0\n",
      "DEBUG - Focal Paper: Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference., References:  Available from:  http://www.reuters.com/article/euIpoNews/idUSLS22855520081128, [Accessed 2 April 2009]\n",
      "DEBUG - Citing Paper: Review: Recent Applications of Gene Editing in Fish Species and Aquatic Medicine., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: An insight on promising strategies hoping to cure HIV-1 infection by targeting Rev protein-short review., References: ['']\n",
      "DEBUG - Citing Paper: Design, mechanism, delivery and therapeutics of canonical and Dicer-substrate siRNA., References: ['']\n",
      "DEBUG - Citing Paper: Generation of HIV-Resistant Macrophages from IPSCs by Using Transcriptional Gene Silencing and Promoter-Targeted RNA., References: ['']\n",
      "DEBUG - Citing Paper: Are microRNAs Important Players in HIV-1 Infection? An Update., References: ['']\n",
      "DEBUG - Citing Paper: Six Highly Conserved Targets of RNAi Revealed in HIV-1-Infected Patients from Russia Are Also Present in Many HIV-1 Strains Worldwide., References: ['']\n",
      "DEBUG - Citing Paper: Polymers in the Delivery of siRNA for the Treatment of Virus Infections., References: ['']\n",
      "DEBUG - Citing Paper: Effect of surface properties on liposomal siRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: A Multiple siRNA-Based Anti-HIV/SHIV Microbicide Shows Protection in Both In Vitro and In Vivo Models., References: ['']\n",
      "DEBUG - Citing Paper: E6 and E7 gene silencing results in decreased methylation of tumor suppressor genes and induces phenotype transformation of human cervical carcinoma cell lines., References: ['']\n",
      "DEBUG - Citing Paper: Silencing sexually transmitted infections: topical siRNA-based interventions for the prevention of HIV and HSV., References: ['']\n",
      "DEBUG - Citing Paper: Antiviral Stratagems Against HIV-1 Using RNA Interference (RNAi) Technology., References: ['']\n",
      "DEBUG - Citing Paper: Durable knockdown and protection from HIV transmission in humanized mice treated with gel-formulated CD4 aptamer-siRNA chimeras., References: ['']\n",
      "DEBUG - Citing Paper: Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering., References: ['']\n",
      "DEBUG - Citing Paper: A transgenic Marc-145 cell line of piggyBac transposon-derived targeting shRNA interference against porcine reproductive and respiratory syndrome virus., References: ['']\n",
      "DEBUG - Citing Paper: Asymmetric siRNA: new strategy to improve specificity and reduce off-target gene expression., References: ['']\n",
      "DEBUG - Citing Paper: HIVsirDB: a database of HIV inhibiting siRNAs., References: ['']\n",
      "DEBUG - Citing Paper: Antiviral RNAi: translating science towards therapeutic success., References: ['']\n",
      "DEBUG - Citing Paper: Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras., References: ['']\n",
      "DEBUG - Citing Paper: Optimizing siRNA delivery to the genital mucosa., References: ['']\n",
      "DEBUG - Citing Paper: A mathematical model of HIV dynamics in the presence of a rescuing virus with replication deficiency., References: ['']\n",
      "DEBUG - Citing Paper: Application of RNA interference in treating human diseases., References: ['']\n",
      "DEBUG - Citing Paper: Stem cell-based anti-HIV gene therapy., References: ['']\n",
      "DEBUG - Citing Paper: DNAzyme-mediated recovery of small recombinant RNAs from a 5S rRNA-derived chimera expressed in Escherichia coli., References: ['']\n",
      "DEBUG - Citing Paper: In silico modeling indicates the development of HIV-1 resistance to multiple shRNA gene therapy differs to standard antiretroviral therapy., References: ['']\n",
      "DEBUG - Citing Paper: Intracellular localization and interaction of mRNA binding proteins as detected by FRET., References: ['']\n",
      "DEBUG - Citing Paper: RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA?, References: ['']\n",
      "DEBUG - Citing Paper: Hepatitis B virus inhibition in mice by lentiviral vector mediated short hairpin RNA., References: ['']\n",
      "DEBUG - Citing Paper: Toward a durable anti-HIV gene therapy based on RNA interference., References: ['']\n",
      "DEBUG - Citing Paper: Prolonged transcriptional silencing and CpG methylation induced by siRNAs targeted to the HIV-1 promoter region., References: ['']\n",
      "DEBUG - Citing Paper: A novel approach for inhibition of HIV-1 by RNA interference: counteracting viral escape with a second generation of siRNAs., References: ['']\n",
      "DEBUG - Citing Paper: Emerging drugs for respiratory syncytial virus infection., References: ['']\n",
      "DEBUG - Citing Paper: Lentiviral delivery of short hairpin RNAs., References: ['']\n",
      "DEBUG - Citing Paper: Lipid-based systemic delivery of siRNA., References: ['']\n",
      "DEBUG - Citing Paper: Optimization of linear double-stranded RNA for the production of multiple siRNAs targeting hepatitis C virus., References: ['']\n",
      "DEBUG - Citing Paper: Progress in the therapeutic applications of siRNAs against HIV-1., References: ['']\n",
      "DEBUG - Citing Paper: Consensus siRNA for inhibition of HCV genotype-4 replication., References: ['']\n",
      "DEBUG - Citing Paper: Inhibition of foot-and-mouth disease virus replication in vitro and in vivo by small interfering RNA., References: ['']\n",
      "DEBUG - Citing Paper: Maintaining the silence: reflections on long-term RNAi., References: ['']\n",
      "DEBUG - Citing Paper: Targets of small interfering RNA restriction during human immunodeficiency virus type 1 replication., References: ['']\n",
      "DEBUG - Citing Paper: RNA interference against viruses: strike and counterstrike., References: ['']\n",
      "DEBUG - Citing Paper: RNA interference and antiviral therapy., References: ['']\n",
      "DEBUG - Citing Paper: Silencing E1A mRNA by RNA interference inhibits adenovirus replication., References: ['']\n",
      "DEBUG - Citing Paper: Inhibition of porcine circovirus type 1 and type 2 production in PK-15 cells by small interfering RNAs targeting the Rep gene., References: ['']\n",
      "DEBUG - Citing Paper: RNAi therapeutics: principles, prospects and challenges., References: ['']\n",
      "DEBUG - Citing Paper: Small interfering RNAs against the TAR RNA binding protein, TRBP, a Dicer cofactor, inhibit human immunodeficiency virus type 1 long terminal repeat expression and viral production., References: ['']\n",
      "DEBUG - Citing Paper: Trans-inhibition of HIV-1 by a long hairpin RNA expressed within the viral genome., References: ['']\n",
      "DEBUG - Citing Paper: RNAi therapy for HIV infection: principles and practicalities., References: ['']\n",
      "DEBUG - Citing Paper: Simultaneously inhibition of HIV and HBV replication through a dual small interfering RNA expression system., References: ['']\n",
      "DEBUG - Citing Paper: Inhibition of hepatitis B virus expression and replication by RNA interference in HepG2.2.15., References: ['']\n",
      "DEBUG - Citing Paper: Optimization of feline immunodeficiency virus vectors for RNA interference., References: ['']\n",
      "DEBUG - Citing Paper: The virion-associated incoming HIV-1 RNA genome is not targeted by RNA interference., References: ['']\n",
      "DEBUG - Citing Paper: RNA interference for antiviral therapy., References: ['']\n",
      "DEBUG - Citing Paper: Inhibition of human immunodeficiency virus type 1 by RNA interference using long-hairpin RNA., References: ['']\n",
      "DEBUG - Citing Paper: RNA interference: its use as antiviral therapy., References: ['']\n",
      "DEBUG - Citing Paper: The interplay between virus infection and the cellular RNA interference machinery., References: ['']\n",
      "DEBUG - Citing Paper: Inhibition of porcine circovirus type 2 replication in mice by RNA interference., References: ['']\n",
      "DEBUG - Citing Paper: Inhibition of Anatid Herpes Virus-1 replication by small interfering RNAs in cell culture system., References: ['']\n",
      "DEBUG - Citing Paper: CXCR4 and CCR5 shRNA transgenic CD34+ cell derived macrophages are functionally normal and resist HIV-1 infection., References: ['']\n",
      "DEBUG - Citing Paper: Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer., References: ['']\n",
      "DEBUG - Citing Paper: Silence of the transcripts: RNA interference in medicine., References: ['']\n",
      "DEBUG - Citing Paper: Lentiviral delivery of short hairpin RNAs protects CD4 T cells from multiple clades and primary isolates of HIV., References: ['']\n",
      "DEBUG - Citing Paper: HIV-1 resistance conferred by siRNA cosuppression of CXCR4 and CCR5 coreceptors by a bispecific lentiviral vector., References: ['']\n",
      "DEBUG - Citing Paper: Inhibition of genes expression of SARS coronavirus by synthetic small interfering RNAs., References: ['']\n",
      "DEBUG - Citing Paper: siRNA targeting the leader sequence of SARS-CoV inhibits virus replication., References: ['']\n",
      "DEBUG - Citing Paper: Molecular strategies to inhibit HIV-1 replication., References: ['']\n",
      "DEBUG - Citing Paper: RNAi, a new therapeutic strategy against viral infection., References: ['']\n",
      "DEBUG - Citing Paper: Antiviral effects of human immunodeficiency virus type 1-specific small interfering RNAs against targets conserved in select neurotropic viral strains., References: ['']\n",
      "DEBUG - Citing Paper: Downregulation of transcription factors by ribonucleic acid interference. A novel approach to extend the multipotency of autologous adult stem cells?, References: ['']\n",
      "DEBUG - Citing Paper: siRNA-mediated inhibition of HBV replication and expression., References: ['']\n",
      "DEBUG - Citing Paper: Can RNA interference be used to expand the plasticity of autologous adult stem cells?, References: ['']\n",
      "DEBUG - Citing Paper: Short interfering RNA-mediated inhibition of herpes simplex virus type 1 gene expression and function during infection of human keratinocytes., References: ['']\n",
      "DEBUG - Citing Paper: Effects of length and location on the cellular response to double-stranded RNA., References: ['']\n",
      "DEBUG - Citing Paper: RNA interference directed against Poly(ADP-Ribose) polymerase 1 efficiently suppresses human immunodeficiency virus type 1 replication in human cells., References: ['']\n",
      "DEBUG - Citing Paper: RISC is a 5' phosphomonoester-producing RNA endonuclease., References: ['']\n",
      "DEBUG - Citing Paper: RNA silencing of rotavirus gene expression., References: ['']\n",
      "DEBUG - Citing Paper: Alternative approaches for efficient inhibition of hepatitis C virus RNA replication by small interfering RNAs., References: ['']\n",
      "DEBUG - Citing Paper: Silencing SARS-CoV Spike protein expression in cultured cells by RNA interference., References: ['']\n",
      "DEBUG - Citing Paper: Pharmaceutical prospects for RNA interference., References: ['']\n",
      "DEBUG - Citing Paper: Enhanced gene silencing of HIV-1 specific siRNA using microRNA designed hairpins., References: ['']\n",
      "DEBUG - Citing Paper: Human immunodeficiency virus type 1 escape from RNA interference., References: ['']\n",
      "DEBUG - Citing Paper: Interfering with disease: opportunities and roadblocks to harnessing RNA interference., References: ['']\n",
      "DEBUG - Citing Paper: RNA interference: antiviral weapon and beyond., References: ['']\n",
      "DEBUG - Citing Paper: Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages., References: ['']\n",
      "DEBUG - Citing Paper: Nucleic acid-based immune system: the antiviral potential of mammalian RNA silencing., References: ['']\n",
      "DEBUG - Citing Paper: Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs., References: ['']\n",
      "DEBUG - Citing Paper: Interference of hepatitis C virus RNA replication by short interfering RNAs., References: ['']\n",
      "DEBUG - focal: Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference., NF: 0, NB: 0, NR: 0, D: 0\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DEBUG - Focal Paper: Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination., References: \n",
      "\n",
      "Ahammad  I, Lira  SS. Designing a novel mrna vaccine against sars-cov-2: An immunoinformatics approach. International Journal of Biological Macromolecules  2020. ISSN 0141-8130; 162:820â37. doi: 10.1016/j.ijbiomac.2020.06.213. http://www.sciencedirect.com/science/article/pii/S0141813020336655.\n",
      "DEBUG - Citing Paper: Harnessing T-Cells for Enhanced Vaccine Development against Viral Infections., References: ['']\n",
      "DEBUG - Citing Paper: Evaluation of the immunogenicity of an mRNA vectored Nipah virus vaccine candidate in pigs., References: ['']\n",
      "DEBUG - Citing Paper: A tale of Science - The Nobel Prize in Physiology or Medicine 2023., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity., References: ['']\n",
      "DEBUG - Citing Paper: Safety, Immunogenicity, and Mechanism of a Rotavirus mRNA-LNP Vaccine in Mice., References: ['']\n",
      "DEBUG - Citing Paper: Zika Virus-A Reemerging Neurotropic Arbovirus Associated with Adverse Pregnancy Outcomes and Neuropathogenesis., References: ['']\n",
      "DEBUG - Citing Paper: Profile of Katalin KarikÃ³ and Drew Weissman: 2023 Nobel laureates in Physiology or Medicine., References: ['']\n",
      "DEBUG - Citing Paper: Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadth., References: ['']\n",
      "DEBUG - Citing Paper: Humanized mouse model for vaccine evaluation: an overview., References: ['']\n",
      "DEBUG - Citing Paper: Enhanced immunogenicity and protective efficacy in mice following a Zika DNA vaccine designed by modulation of membrane-anchoring regions and its association to adjuvants., References: ['']\n",
      "DEBUG - Citing Paper: Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine., References: ['']\n",
      "DEBUG - Citing Paper: Editorial: Post COVID-19: the nucleoside-modified messenger RNA (modRNA) platform., References: ['']\n",
      "DEBUG - Citing Paper: A review on Zika vaccine development., References: ['']\n",
      "DEBUG - Citing Paper: mRNA and Adenoviral Vector Vaccine Platforms Utilized in COVID-19 Vaccines: Technologies, Ecosystem, and Future Directions., References: ['']\n",
      "DEBUG - Citing Paper: The rise of epitranscriptomics: recent developments and future directions., References: ['']\n",
      "DEBUG - Citing Paper: A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax., References: ['']\n",
      "DEBUG - Citing Paper: Nobel Prize for physiology or medicine in 2023: how to dupe the cellular innate immune system using modified RNA for therapeutic treatment., References: ['']\n",
      "DEBUG - Citing Paper: Recruiting In Vitro Transcribed mRNA against Cancer Immunotherapy: A Contemporary Appraisal of the Current Landscape., References: ['']\n",
      "DEBUG - Citing Paper: Tributaries of the 2023 Nobel Prize in Physiology or Medicine, and lessons learned., References: ['']\n",
      "DEBUG - Citing Paper: EDIII-Fc induces protective immune responses against the Zika virus in mice and rhesus macaque., References: ['']\n",
      "DEBUG - Citing Paper: Clinical Analysis and Applications of mRNA Vaccines in Infectious Diseases and Cancer Treatment., References: ['']\n",
      "DEBUG - Citing Paper: In Vitro Transcribed RNA-Based Platform Vaccines: Past, Present, and Future., References: ['']\n",
      "DEBUG - Citing Paper: A Rift Valley fever mRNA vaccine elicits strong immune responses in mice and rhesus macaques., References: ['']\n",
      "DEBUG - Citing Paper: Reducing cell intrinsic immunity to mRNA vaccine alters adaptive immune responses in mice., References: ['']\n",
      "DEBUG - Citing Paper: A Prototype-Pathogen Approach for the Development of Flavivirus Countermeasures., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications., References: ['']\n",
      "DEBUG - Citing Paper: Recent Advances and Innovations in the Preparation and Purification of In Vitro-Transcribed-mRNA-Based Molecules., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines in disease prevention and treatment., References: ['']\n",
      "DEBUG - Citing Paper: Single-dose VSV-based vaccine protects against Kyasanur Forest disease in nonhuman primates., References: ['']\n",
      "DEBUG - Citing Paper: A Comprehensive Review on Cancer Vaccines and Vaccine Strategies in Hepatocellular Carcinoma., References: ['']\n",
      "DEBUG - Citing Paper: Next-Generation TB Vaccines: Progress, Challenges, and Prospects., References: ['']\n",
      "DEBUG - Citing Paper: Clinical applications of the CRISPR/Cas9 genome-editing system: Delivery options and challenges in precision medicine., References: ['']\n",
      "DEBUG - Citing Paper: Lipidic Formulations Inspired by COVID Vaccines as Smart Coatings to Enhance Nanoparticle-Based Cancer Therapy., References: ['']\n",
      "DEBUG - Citing Paper: Development of an mRNA-lipid nanoparticle vaccine against Lyme disease., References: ['']\n",
      "DEBUG - Citing Paper: Recent Advancement in mRNA Vaccine Development and Applications., References: ['']\n",
      "DEBUG - Citing Paper: Intratumoural Delivery of mRNA Loaded on a Cationic Hyper-Branched Cyclodextrin-Based Polymer Induced an Anti-Tumour Immunological Response in Melanoma., References: ['']\n",
      "DEBUG - Citing Paper: The use of RNA-based treatments in the field of cancer immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Evaluation of the immunogenicity and efficacy of an rVSV vaccine against Zika virus infection in macaca nemestrina., References: ['']\n",
      "DEBUG - Citing Paper: Vaccine development for mosquito-borne viral diseases., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV., References: ['']\n",
      "DEBUG - Citing Paper: Peptide-encoding mRNA barcodes for the high-throughput in vivo screening of libraries of lipid nanoparticles for mRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: Monkeypox virus quadrivalent mRNA vaccine induces immune response and protects against vaccinia virus., References: ['']\n",
      "DEBUG - Citing Paper: Diagnostic and vaccine potential of Zika virus envelope protein (E) derivates produced in bacterial and insect cells., References: ['']\n",
      "DEBUG - Citing Paper: Lipid-based colloidal nanoparticles for applications in targeted vaccine delivery., References: ['']\n",
      "DEBUG - Citing Paper: Lysine-Derived Charge-Altering Releasable Transporters: Targeted Delivery of mRNA and siRNA to the Lungs., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccines against SARS-CoV-2: Advantages and Caveats., References: ['']\n",
      "DEBUG - Citing Paper: Evaluation of repRNA vaccine for induction and in utero transfer of maternal antibodies in a pregnant rabbit model., References: ['']\n",
      "DEBUG - Citing Paper: Development of Novel siRNA Therapeutics: A Review with a Focus on Inclisiran for the Treatment of Hypercholesterolemia., References: ['']\n",
      "DEBUG - Citing Paper: Advanced delivery systems for peptide antibiotics., References: ['']\n",
      "DEBUG - Citing Paper: RNA modification in mRNA cancer vaccines., References: ['']\n",
      "DEBUG - Citing Paper: A single vaccination of nucleoside-modified Rabies mRNA vaccine induces prolonged highly protective immune responses in mice., References: ['']\n",
      "DEBUG - Citing Paper: Ionizable lipid nanoparticles deliver mRNA to pancreatic Î² cells via macrophage-mediated gene transfer., References: ['']\n",
      "DEBUG - Citing Paper: Engineered exosomes enriched in netrin-1 modRNA promote axonal growth in spinal cord injury by attenuating inflammation and pyroptosis., References: ['']\n",
      "DEBUG - Citing Paper: Race with virus evolution: The development and application of mRNA vaccines against SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: The mRNA Vaccine Technology Era and the Future Control of Parasitic Infections., References: ['']\n",
      "DEBUG - Citing Paper: In silico design and evaluation of a novel mRNA vaccine against BK virus: a reverse vaccinology approach., References: ['']\n",
      "DEBUG - Citing Paper: Nurturing Deep Tech to Solve Social Problems: Learning from COVID-19 mRNA Vaccine Development., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticles Delivering Constitutively Active STING mRNA to Stimulate Antitumor Immunity., References: ['']\n",
      "DEBUG - Citing Paper: Vaccination with a Zika virus envelope domain III protein induces neutralizing antibodies and partial protection against Asian genotype in immunocompetent mice., References: ['']\n",
      "DEBUG - Citing Paper: Lipid-Based Delivery Systems in Development of Genetic and Subunit Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Non-replicative antibiotic resistance-free DNA vaccine encoding S and N proteins induces full protection in mice against SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: Dendritic Cell-Derived Artificial Microvesicles Inhibit RLS<sub>40</sub> Lymphosarcoma Growth in Mice via Stimulation of Th1/Th17 Immune Response., References: ['']\n",
      "DEBUG - Citing Paper: Scope and challenges of nanoparticle-based mRNA delivery in cancer treatment., References: ['']\n",
      "DEBUG - Citing Paper: Current Advances in Zika Vaccine Development., References: ['']\n",
      "DEBUG - Citing Paper: Leishmaniasis Vaccines: Applications of RNA Technology and Targeted Clinical Trial Designs., References: ['']\n",
      "DEBUG - Citing Paper: The landscape of mRNA nanomedicine., References: ['']\n",
      "DEBUG - Citing Paper: Innate immune mechanisms of mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Unlocking the promise of mRNA therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: A systematic and thematic analysis of the top 100 cited articles on mRNA vaccine indexed in Scopus database., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-Based Approaches to Treating Liver Diseases., References: ['']\n",
      "DEBUG - Citing Paper: mRNA nanomedicine: Design and recent applications., References: ['']\n",
      "DEBUG - Citing Paper: Mice 3D testicular organoid system as a novel tool to study Zika virus pathogenesis., References: ['']\n",
      "DEBUG - Citing Paper: Modified Nucleotides for Chemical and Enzymatic Synthesis of Therapeutic RNA., References: ['']\n",
      "DEBUG - Citing Paper: Design Strategies for and Stability of mRNA-Lipid Nanoparticle COVID-19 Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Lipid-based nucleic acid therapeutics with in vivo efficacy., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines: Past, present, future., References: ['']\n",
      "DEBUG - Citing Paper: Synthesis of point-modified mRNA., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines in the prevention and treatment of diseases., References: ['']\n",
      "DEBUG - Citing Paper: Nano-multilamellar lipid vesicles promote the induction of SARS-CoV-2 immune responses by a protein-based vaccine formulation., References: ['']\n",
      "DEBUG - Citing Paper: Emerging trends of research on mRNA vaccines: A co-citation analysis., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-Loaded Lipid Nanoparticles Targeting Dendritic Cells for Cancer Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies., References: ['']\n",
      "DEBUG - Citing Paper: Nanoparticles in clinical trials of COVID-19: An update., References: ['']\n",
      "DEBUG - Citing Paper: Nanotechnology-facilitated vaccine development during the coronavirus disease 2019 (COVID-19) pandemic., References: ['']\n",
      "DEBUG - Citing Paper: Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIV <i>gag</i> conserved elements in macaques., References: ['']\n",
      "DEBUG - Citing Paper: The Pivotal Role of Chemical Modifications in mRNA Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Clinical Development of mRNA Vaccines: Challenges and Opportunities., References: ['']\n",
      "DEBUG - Citing Paper: A Single Dose of Anti-HBsAg Antibody-Encoding mRNA-LNPs Suppressed HBsAg Expression: a Potential Cure of Chronic Hepatitis B Virus Infection., References: ['']\n",
      "DEBUG - Citing Paper: The legacy of mRNA engineering: A lineup of pioneers for the Nobel Prize., References: ['']\n",
      "DEBUG - Citing Paper: A multiple-target mRNA-LNP vaccine induces protective immunity against experimental multi-serotype DENV in mice., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-based modalities for infectious disease management., References: ['']\n",
      "DEBUG - Citing Paper: Recent trends and advancements in electrochemiluminescence biosensors for human virus detection., References: ['']\n",
      "DEBUG - Citing Paper: Nucleic Acid Vaccine Platform for DENGUE and ZIKA Flaviviruses., References: ['']\n",
      "DEBUG - Citing Paper: Adenovirus vector-based vaccines as forefront approaches in fighting the battle against flaviviruses., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticle delivery of unmodified mRNAs encoding multiple monoclonal antibodies targeting poxviruses in rabbits., References: ['']\n",
      "DEBUG - Citing Paper: mRNA as a Therapeutics: Understanding mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Detection, prevention and treatment of COVID-19 and opportunities for nanobiotechnology., References: ['']\n",
      "DEBUG - Citing Paper: Accelerating clinical trial development in vaccinology: COVID-19 and beyond., References: ['']\n",
      "DEBUG - Citing Paper: The Progress and Promise of RNA MedicineâAn Arsenal of Targeted Treatments., References: ['']\n",
      "DEBUG - Citing Paper: Circular RNA vaccines against SARS-CoV-2 and emerging variants., References: ['']\n",
      "DEBUG - Citing Paper: Modified mRNA-Based Vaccines Against Coronavirus Disease 2019., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines: the most recent clinical applications of synthetic mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases., References: ['']\n",
      "DEBUG - Citing Paper: mRNA cancer vaccines: Advances, trends and challenges., References: ['']\n",
      "DEBUG - Citing Paper: Modification of Lipid-Based Nanoparticles: An Efficient Delivery System for Nucleic Acid-Based Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines for COVID-19 and diverse diseases., References: ['']\n",
      "DEBUG - Citing Paper: 3D Melanoma Cocultures as Improved Models for Nanoparticle-Mediated Delivery of RNA to Tumors., References: ['']\n",
      "DEBUG - Citing Paper: Advances in COVID-19 mRNA vaccine development., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice., References: ['']\n",
      "DEBUG - Citing Paper: Role of drug delivery technologies in the success of COVID-19 vaccines: a perspective., References: ['']\n",
      "DEBUG - Citing Paper: Messenger RNA vaccines for cancer immunotherapy: progress promotes promise., References: ['']\n",
      "DEBUG - Citing Paper: Microfluidic fabrication of lipid nanoparticles for the delivery of nucleic acids., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals., References: ['']\n",
      "DEBUG - Citing Paper: Current applications and future perspective of CRISPR/Cas9 gene editing in cancer., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 mRNA vaccines: Platforms and current developments., References: ['']\n",
      "DEBUG - Citing Paper: Nonhuman Primates in Translational Research., References: ['']\n",
      "DEBUG - Citing Paper: Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Phase-separating peptides for direct cytosolic delivery and redox-activated release of macromolecular therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Langerhans cells and cDC1s play redundant roles in mRNA-LNP induced protective anti-influenza and anti-SARS-CoV-2 immune responses., References: ['']\n",
      "DEBUG - Citing Paper: Dengue Virus and Vaccines: How Can DNA Immunization Contribute to This Challenge?, References: ['']\n",
      "DEBUG - Citing Paper: Enhanced Immune Responses and Protective Immunity to Zika Virus Induced by a DNA Vaccine Encoding a Chimeric NS1 Fused With Type 1 Herpes Virus gD Protein., References: ['']\n",
      "DEBUG - Citing Paper: Revisiting the Development of Vaccines Against Pathogenic <i>Leptospira</i>: Innovative Approaches, Present Challenges, and Future Perspectives., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccine Protects against Zika Virus., References: ['']\n",
      "DEBUG - Citing Paper: A Review of UK-Registered and Candidate Vaccines for Bovine Respiratory Disease., References: ['']\n",
      "DEBUG - Citing Paper: mRNA, a Revolution in Biomedicine., References: ['']\n",
      "DEBUG - Citing Paper: Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 - a review., References: ['']\n",
      "DEBUG - Citing Paper: An mRNA vaccine to prevent genital herpes., References: ['']\n",
      "DEBUG - Citing Paper: Added to pre-existing inflammation, mRNA-lipid nanoparticles induce inflammation exacerbation (IE)., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review., References: ['']\n",
      "DEBUG - Citing Paper: The Development of mRNA Vaccines for Infectious Diseases: Recent Updates., References: ['']\n",
      "DEBUG - Citing Paper: Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccines to Protect Against Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Challenges for Vaccinologists in the First Half of the Twenty-First Century., References: ['']\n",
      "DEBUG - Citing Paper: Advances in the design and development of SARS-CoV-2 vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Antigenic characterization of influenza and SARS-CoV-2 viruses., References: ['']\n",
      "DEBUG - Citing Paper: QnAs with Katalin KarikÃ³., References: ['']\n",
      "DEBUG - Citing Paper: Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials., References: ['']\n",
      "DEBUG - Citing Paper: Tick immunity using mRNA, DNA and protein-based Salp14 delivery strategies., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses., References: ['']\n",
      "DEBUG - Citing Paper: The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory., References: ['']\n",
      "DEBUG - Citing Paper: The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview., References: ['']\n",
      "DEBUG - Citing Paper: RNA Vaccines against Infectious Diseases: Vital Progress with Room for Improvement., References: ['']\n",
      "DEBUG - Citing Paper: Nucleoside-Modified mRNA Vaccines Protect IFNAR<sup>-/-</sup> Mice against Crimean-Congo Hemorrhagic Fever Virus Infection., References: ['']\n",
      "DEBUG - Citing Paper: Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis., References: ['']\n",
      "DEBUG - Citing Paper: Strategies for induction of HIV-1 envelope-reactive broadly neutralizing antibodies., References: ['']\n",
      "DEBUG - Citing Paper: The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticle chemistry determines how nucleoside base modifications alter mRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: Bioengineering Strategies for Developing Vaccines against Respiratory Viral Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Single-Cell Analysis of Antigen-Specific CD8+ T-Cell Transcripts Reveals Profiles Specific to mRNA or Adjuvanted Protein Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: A New Generation of Vaccines in the Age of Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticles for Organ-Specific mRNA Therapeutic Delivery., References: ['']\n",
      "DEBUG - Citing Paper: Application of Nanomaterials as an Advanced Strategy for the Diagnosis, Prevention, and Treatment of Viral Diseases., References: ['']\n",
      "DEBUG - Citing Paper: RNA Therapeutics - Research and Clinical Advancements., References: ['']\n",
      "DEBUG - Citing Paper: Cardiovascular consequences of viral infections: from COVID to other viral diseases., References: ['']\n",
      "DEBUG - Citing Paper: Current Progress in the Development of Zika Virus Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: An Update on mRNA-Based Viral Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions., References: ['']\n",
      "DEBUG - Citing Paper: A hitchhiker's guide through the COVID-19 galaxy., References: ['']\n",
      "DEBUG - Citing Paper: Vaccination induces rapid protection against bacterial pneumonia via training alveolar macrophage in mice., References: ['']\n",
      "DEBUG - Citing Paper: Severe Acute Respiratory Syndrome Coronavirus 2: Manifestations of Disease and Approaches to Treatment and Prevention in Humans., References: ['']\n",
      "DEBUG - Citing Paper: Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Review Article: vaccination for patients with inflammatory bowel disease during the COVID-19 pandemic., References: ['']\n",
      "DEBUG - Citing Paper: In Vitro Investigations on Optimizing and Nebulization of IVT-mRNA Formulations for Potential Pulmonary-Based Alpha-1-Antitrypsin Deficiency Treatment., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines for infectious diseases: principles, delivery and clinical translation., References: ['']\n",
      "DEBUG - Citing Paper: Ability of nucleoside-modified mRNA to encode HIV-1 envelope trimer nanoparticles., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticles for mRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: Langerhans cells and cDC1s play redundant roles in mRNA-LNP induced protective anti-influenza and anti-SARS-CoV-2 responses., References: ['']\n",
      "DEBUG - Citing Paper: Strategies to deliver RNA by nanoparticles for therapeutic potential., References: ['']\n",
      "DEBUG - Citing Paper: Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India., References: ['']\n",
      "DEBUG - Citing Paper: From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape., References: ['']\n",
      "DEBUG - Citing Paper: Non-human Primate Models to Investigate Mechanisms of Infection-Associated Fetal and Pediatric Injury, Teratogenesis and Stillbirth., References: ['']\n",
      "DEBUG - Citing Paper: Early approval of COVID-19 vaccines: Pros and cons., References: ['']\n",
      "DEBUG - Citing Paper: Flavivirus: From Structure to Therapeutics Development., References: ['']\n",
      "DEBUG - Citing Paper: Recommendations for dermatologists treating patients with atopic dermatitis during the Covid-19 pandemic: a look into the past for a conscious vaccination management., References: ['']\n",
      "DEBUG - Citing Paper: Cognizance of posttranslational modifications in vaccines: A way to enhanced immunogenicity., References: ['']\n",
      "DEBUG - Citing Paper: Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice., References: ['']\n",
      "DEBUG - Citing Paper: Synthetic modified messenger RNA for therapeutic applications., References: ['']\n",
      "DEBUG - Citing Paper: Implications of mRNA-based SARS-CoV-2 vaccination for cancer patients., References: ['']\n",
      "DEBUG - Citing Paper: Infectious disease mRNA vaccines and a review on epitope prediction for vaccine design., References: ['']\n",
      "DEBUG - Citing Paper: Development of a Vaccine against Human Cytomegalovirus: Advances, Barriers, and Implications for the Clinical Practice., References: ['']\n",
      "DEBUG - Citing Paper: Non-Immunotherapy Application of LNP-mRNA: Maximizing Efficacy and Safety., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Lipid-nanoparticle-encapsulated mRNA vaccines induce protective memory CD8 TÂ cells against a lethal viral infection., References: ['']\n",
      "DEBUG - Citing Paper: A vaccine inducing solely cytotoxic T lymphocytes fully prevents Zika virus infection and fetal damage., References: ['']\n",
      "DEBUG - Citing Paper: Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses., References: ['']\n",
      "DEBUG - Citing Paper: Editorial: mRNA Vaccines and Future Epidemic, Pandemic, and Endemic Zoonotic Virus Infections., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-Based Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: A Live-Attenuated Zika Virus Vaccine with High Production Capacity Confers Effective Protection in Neonatal Mice., References: ['']\n",
      "DEBUG - Citing Paper: Perspectives on RNA Vaccine Candidates for COVID-19., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccination compared to infection elicits an IgG-predominant response with greater SARS-CoV-2 specificity and similar decrease in variant spike recognition., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates., References: ['']\n",
      "DEBUG - Citing Paper: The Limitless Future of RNA Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: The dawn of mRNA vaccines: The COVID-19 case., References: ['']\n",
      "DEBUG - Citing Paper: Nano-Enabled COVID-19 Vaccines: Meeting the Challenges of Durable Antibody Plus Cellular Immunity and Immune Escape., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines manufacturing: Challenges and bottlenecks., References: ['']\n",
      "DEBUG - Citing Paper: CRISPR/Cas: Advances, Limitations, and Applications for Precision Cancer Research., References: ['']\n",
      "DEBUG - Citing Paper: Current Status of COVID-19 Vaccine Development: Focusing on Antigen Design and Clinical Trials on Later Stages., References: ['']\n",
      "DEBUG - Citing Paper: Clinical and immunological effects of mRNA vaccines in malignant diseases., References: ['']\n",
      "DEBUG - Citing Paper: Zika virus-like particle vaccine protects AG129 mice and rhesus macaques against Zika virus., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-encoded, constitutively active STING<sup>V155M</sup> is a potent genetic adjuvant of antigen-specific CD8<sup>+</sup> TÂ cell response., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccines against Flaviviruses., References: ['']\n",
      "DEBUG - Citing Paper: Analysis of Recent Bio-/Nanotechnologies for Coronavirus Diagnosis and Therapy., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform., References: ['']\n",
      "DEBUG - Citing Paper: Construction of a recombinant avipoxvirus expressing the env gene of Zika virus as a novel putative preventive vaccine., References: ['']\n",
      "DEBUG - Citing Paper: A genetically stable Zika virus vaccine candidate protects mice against virus infection and vertical transmission., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccine: a potential therapeutic strategy., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-Based Vaccines and Mode of Action., References: ['']\n",
      "DEBUG - Citing Paper: Self-assembled miRNA-switch nanoparticles target denuded regions and prevent restenosis., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: BNT162b vaccines protect rhesus macaques from SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: Promising Extracellular Vesicle-Based Vaccines against Viruses, Including SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?, References: ['']\n",
      "DEBUG - Citing Paper: Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans., References: ['']\n",
      "DEBUG - Citing Paper: Nanoparticles as Vaccines to Prevent Arbovirus Infection: A Long Road Ahead., References: ['']\n",
      "DEBUG - Citing Paper: RNA Vaccines: A Suitable Platform for Tackling Emerging Pandemics?, References: ['']\n",
      "DEBUG - Citing Paper: Self-assembled mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Vaccines for Perinatal and Congenital Infections-How Close Are We?, References: ['']\n",
      "DEBUG - Citing Paper: Platforms Exploited for SARS-CoV-2 Vaccine Development., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 vaccines: The status and perspectives in delivery points of view., References: ['']\n",
      "DEBUG - Citing Paper: Non-viral COVID-19 vaccine delivery systems., References: ['']\n",
      "DEBUG - Citing Paper: Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection., References: ['']\n",
      "DEBUG - Citing Paper: Integrating Biomaterials and Immunology to Improve Vaccines Against Infectious Diseases., References: ['']\n",
      "DEBUG - Citing Paper: N<sup>6</sup>-Methyladenosine Regulates Host Responses to Viral Infection., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation., References: ['']\n",
      "DEBUG - Citing Paper: Infectious RNA vaccine protects mice against chikungunya virus infection., References: ['']\n",
      "DEBUG - Citing Paper: Zika virus pathogenesis and current therapeutic advances., References: ['']\n",
      "DEBUG - Citing Paper: Insights from nanotechnology in COVID-19 treatment., References: ['']\n",
      "DEBUG - Citing Paper: Hybridization Networks of mRNA and Branched RNA Hybrids., References: ['']\n",
      "DEBUG - Citing Paper: A DNA Vaccine Encoding <i>Plasmodium falciparum</i> PfRH5 in Cationic Liposomes for Dermal Tattooing Immunization., References: ['']\n",
      "DEBUG - Citing Paper: Generation and preliminary characterization of vertebrate-specific replication-defective Zika virus., References: ['']\n",
      "DEBUG - Citing Paper: Live vaccine infection burden elicits adaptive humoral and cellular immunity required to prevent Zika virus infection., References: ['']\n",
      "DEBUG - Citing Paper: Zika Virus-Like Particles Bearing a Covalent Dimer of Envelope Protein Protect Mice from Lethal Challenge., References: ['']\n",
      "DEBUG - Citing Paper: Technological approaches to streamline vaccination schedules, progressing towards single-dose vaccines., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccine Era-Mechanisms, Drug Platform and Clinical Prospection., References: ['']\n",
      "DEBUG - Citing Paper: Modified mRNA-LNP Vaccines Confer Protection against Experimental DENV-2 Infection in Mice., References: ['']\n",
      "DEBUG - Citing Paper: Immunological considerations for COVID-19 vaccine strategies., References: ['']\n",
      "DEBUG - Citing Paper: Potential use of noncoding RNAs and innovative therapeutic strategies to target the 5'UTR of SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: Development of vaccines for SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: Identification of SARS-CoV-2 Vaccine Epitopes Predicted to Induce Long-Term Population-Scale Immunity., References: ['']\n",
      "DEBUG - Citing Paper: Development of a potent Zika virus vaccine using self-amplifying messenger RNA., References: ['']\n",
      "DEBUG - Citing Paper: Tick-Borne Encephalitis Virus: A Quest for Better Vaccines against a Virus on the Rise., References: ['']\n",
      "DEBUG - Citing Paper: A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice., References: ['']\n",
      "DEBUG - Citing Paper: Zika virus-an update on the current efforts for vaccine development., References: ['']\n",
      "DEBUG - Citing Paper: Cutaneous vaccination ameliorates Zika virus-induced neuro-ocular pathology via reduction of anti-ganglioside antibodies., References: ['']\n",
      "DEBUG - Citing Paper: A SARS-CoV-2 Vaccination Strategy Focused on Population-Scale Immunity., References: ['']\n",
      "DEBUG - Citing Paper: Zika vaccine pre-clinical and clinical data review with perspectives on the future development., References: ['']\n",
      "DEBUG - Citing Paper: Self-Amplifying RNA Viruses as RNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticle technology for therapeutic gene regulation in the liver., References: ['']\n",
      "DEBUG - Citing Paper: Designing a novel mRNA vaccine against SARS-CoV-2: An immunoinformatics approach., References: ['']\n",
      "DEBUG - Citing Paper: Modeling mosquito-borne and sexual transmission of Zika virus in an enzootic host, the African green monkey., References: ['']\n",
      "DEBUG - Citing Paper: Immunology of COVID-19: Current State of the Science., References: ['']\n",
      "DEBUG - Citing Paper: Vaccine Advances against Venezuelan, Eastern, and Western Equine Encephalitis Viruses., References: ['']\n",
      "DEBUG - Citing Paper: Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19., References: ['']\n",
      "DEBUG - Citing Paper: Current Status of Zika Virus Vaccines: Successes and Challenges., References: ['']\n",
      "DEBUG - Citing Paper: A Single Dose of NILV-Based Vaccine Provides Rapid and Durable Protection against Zika Virus., References: ['']\n",
      "DEBUG - Citing Paper: Formulation and Delivery Technologies for mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Baculovirus Surface Display of Zika Virus Envelope Protein Protects against Virus Challenge in Mouse Model., References: ['']\n",
      "DEBUG - Citing Paper: The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world., References: ['']\n",
      "DEBUG - Citing Paper: Anti-PfGARP activates programmed cell death of parasites and reduces severe malaria., References: ['']\n",
      "DEBUG - Citing Paper: An overview of functional nanoparticles as novel emerging antiviral therapeutic agents., References: ['']\n",
      "DEBUG - Citing Paper: Current Efforts in the Development of Vaccines for the Prevention of Zika and Chikungunya Virus Infections., References: ['']\n",
      "DEBUG - Citing Paper: A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice., References: ['']\n",
      "DEBUG - Citing Paper: Messenger RNA-Based Vaccines Against Infectious Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Vaccines to prevent genital herpes., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccines Encoding the HA Protein of Influenza A H1N1 Virus Delivered by Cationic Lipid Nanoparticles Induce Protective Immune Responses in Mice., References: ['']\n",
      "DEBUG - Citing Paper: Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection., References: ['']\n",
      "DEBUG - Citing Paper: Maternal-Fetal Interplay in Zika Virus Infection and Adverse Perinatal Outcomes., References: ['']\n",
      "DEBUG - Citing Paper: Characterization of a Species E Adenovirus Vector as a Zika virus vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives., References: ['']\n",
      "DEBUG - Citing Paper: Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization., References: ['']\n",
      "DEBUG - Citing Paper: The promise of mRNA vaccines: a biotech and industrial perspective., References: ['']\n",
      "DEBUG - Citing Paper: Innovations in HIV-1 Vaccine Design., References: ['']\n",
      "DEBUG - Citing Paper: Opportunities and Challenges in the Delivery of mRNA-based Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticles Potentiate CpG-Oligodeoxynucleotide-Based Vaccine for Influenza Virus., References: ['']\n",
      "DEBUG - Citing Paper: Cross-Reactive Antibodies during Zika Virus Infection: Protection, Pathogenesis, and Placental Seeding., References: ['']\n",
      "DEBUG - Citing Paper: Polylactide-Based Reactive Micelles as a Robust Platform for mRNA Delivery., References: ['']\n",
      "DEBUG - Citing Paper: NS1 DNA vaccination protects against Zika infection through T cell-mediated immunity in immunocompetent mice., References: ['']\n",
      "DEBUG - Citing Paper: An attenuated Zika virus NS4B protein mutant is a potent inducer of antiviral immune responses., References: ['']\n",
      "DEBUG - Citing Paper: Analysis Method of the Ion Current-Time Waveform Obtained from Low Aspect Ratio Solid-state Nanopores., References: ['']\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DEBUG - Citing Paper: Zika Vaccine Development: Current Status., References: ['']\n",
      "DEBUG - Citing Paper: Synthetic nucleic acid antibody prophylaxis confers rapid and durable protective immunity against Zika virus challenge., References: ['']\n",
      "DEBUG - Citing Paper: Strategies for inducing effective neutralizing antibody responses against HIV-1., References: ['']\n",
      "DEBUG - Citing Paper: Delivery strategies of cancer immunotherapy: recent advances and future perspectives., References: ['']\n",
      "DEBUG - Citing Paper: Evaluation of a Single-Dose Nucleoside-Modified Messenger RNA Vaccine Encoding Hendra Virus-Soluble Glycoprotein Against Lethal Nipah virus Challenge in Syrian Hamsters., References: ['']\n",
      "DEBUG - Citing Paper: A Trans-amplifying RNA Vaccine Strategy for Induction of Potent Protective Immunity., References: ['']\n",
      "DEBUG - Citing Paper: Establishing Preferred Product Characterization for the Evaluation of RNA Vaccine Antigens., References: ['']\n",
      "DEBUG - Citing Paper: Enlisting the mRNA Vaccine Platform to Combat Parasitic Infections., References: ['']\n",
      "DEBUG - Citing Paper: Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes., References: ['']\n",
      "DEBUG - Citing Paper: Immunogenicity of RNA Replicons Encoding HIV Env Immunogens Designed for Self-Assembly into Nanoparticles., References: ['']\n",
      "DEBUG - Citing Paper: A Gorilla Adenovirus-Based Vaccine against Zika Virus Induces Durable Immunity and Confers Protection in Pregnancy., References: ['']\n",
      "DEBUG - Citing Paper: Therapeutic Advances Against ZIKV: A Quick Response, a Long Way to Go., References: ['']\n",
      "DEBUG - Citing Paper: Immunogenicity and Protection Efficacy of a Naked Self-Replicating mRNA-Based Zika Virus Vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Neutral Lipopolyplexes for InÂ Vivo Delivery of Conventional and Replicative RNA Vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Correction of bleeding in experimental severe hemophilia A by systemic delivery of factor VIII-encoding mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Regulation of Viral Infection by the RNA Modification <i>N6</i>-Methyladenosine., References: ['']\n",
      "DEBUG - Citing Paper: Using Macaques to Address Critical Questions in Zika Virus Research., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticles for delivery of messenger RNA to the back of the eye., References: ['']\n",
      "DEBUG - Citing Paper: Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques., References: ['']\n",
      "DEBUG - Citing Paper: Advances in mRNA Vaccines for Infectious Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Pre-Clinical Pregnancy Models for Evaluating Zika Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Zika Virus-Specific IgY Results Are Therapeutic Following a Lethal Zika Virus Challenge without Inducing Antibody-Dependent Enhancement., References: ['']\n",
      "DEBUG - Citing Paper: Evaluation of alternative endpoints for ZIKV vaccine efficacy trials., References: ['']\n",
      "DEBUG - Citing Paper: Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery., References: ['']\n",
      "DEBUG - Citing Paper: A Vesicular Stomatitis Virus-Based Vaccine Carrying Zika Virus Capsid Protein Protects Mice from Viral Infection., References: ['']\n",
      "DEBUG - Citing Paper: mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Vaccine Development for Nipah Virus Infection in Pigs., References: ['']\n",
      "DEBUG - Citing Paper: The role of systems biology approaches in determining molecular signatures for the development of more effective vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Nucleotide Modification Alters MicroRNA-Dependent Silencing of MicroRNA Switches., References: ['']\n",
      "DEBUG - Citing Paper: Delivery of mRNA Therapeutics for the Treatment of Hepatic Diseases., References: ['']\n",
      "DEBUG - Citing Paper: A 'Furry-Tale' of Zika Virus Infection: What Have We Learned from Animal Models?, References: ['']\n",
      "DEBUG - Citing Paper: Efficacy of a T Cell-Biased Adenovirus Vector as a Zika Virus Vaccine., References: ['']\n",
      "DEBUG - Citing Paper: An mRNA Vaccine Protects Mice against Multiple Tick-Transmitted Flavivirus Infections., References: ['']\n",
      "DEBUG - Citing Paper: A yellow fever-Zika chimeric virus vaccine candidate protects against Zika infection and congenital malformations in mice., References: ['']\n",
      "DEBUG - Citing Paper: Efficient Induction of T Cells against Conserved HIV-1 Regions by Mosaic Vaccines Delivered as Self-Amplifying mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Fast Tracks and Roadblocks for Zika Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: A Recombinant Subunit Based Zika Virus Vaccine Is Efficacious in Non-human Primates., References: ['']\n",
      "DEBUG - Citing Paper: Recent Advances in Zika Virus Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Zika Virus Liquid Biopsy: A Dendritic Ru(bpy)<sub>3</sub> <sup>2+</sup>-Polymer-Amplified ECL Diagnosis Strategy Using a Drop of Blood., References: ['']\n",
      "DEBUG - Citing Paper: Purified Inactivated Zika Vaccine Candidates Afford Protection against Lethal Challenge in Mice., References: ['']\n",
      "DEBUG - Citing Paper: Heterologous Immunization With Defined RNA and Subunit Vaccines Enhances T Cell Responses That Protect Against <i>Leishmania donovani</i>., References: ['']\n",
      "DEBUG - Citing Paper: Research Models and Tools for the Identification of Antivirals and Therapeutics against Zika Virus Infection., References: ['']\n",
      "DEBUG - Citing Paper: Complementary Mechanisms Potentially Involved in the Pathology of Zika Virus., References: ['']\n",
      "DEBUG - Citing Paper: Biomaterials for vaccine-based cancer immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: A Single-Dose Live-Attenuated Zika Virus Vaccine with Controlled Infection Rounds that Protects against Vertical Transmission., References: ['']\n",
      "DEBUG - Citing Paper: New Vaccine Technologies to Combat Outbreak Situations., References: ['']\n",
      "DEBUG - Citing Paper: Live Zika virus chimeric vaccine candidate based on a yellow fever 17-D attenuated backbone., References: ['']\n",
      "DEBUG - Citing Paper: Zika Virus Vaccines: Challenges and Perspectives., References: ['']\n",
      "DEBUG - Citing Paper: The Challenges Imposed by Dengue, Zika, and Chikungunya to Brazil., References: ['']\n",
      "DEBUG - Citing Paper: A single-dose plasmid-launched live-attenuated Zika vaccine induces protective immunity., References: ['']\n",
      "DEBUG - Citing Paper: Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies., References: ['']\n",
      "DEBUG - Citing Paper: Role of Zika Virus prM Protein in Viral Pathogenicity and Use in Vaccine Development., References: ['']\n",
      "DEBUG - Citing Paper: E90 subunit vaccine protects mice from Zika virus infection and microcephaly., References: ['']\n",
      "DEBUG - Citing Paper: Disruption of glial cell development by Zika virus contributes to severe microcephalic newborn mice., References: ['']\n",
      "DEBUG - Citing Paper: A Nanostructured Lipid Carrier for Delivery of a Replicating Viral RNA Provides Single, Low-Dose Protection against Zika., References: ['']\n",
      "DEBUG - Citing Paper: A Zika virus vaccine expressing premembrane-envelope-NS1 polyprotein., References: ['']\n",
      "DEBUG - Citing Paper: Incorporation of NS1 and prM/M are important to confer effective protection of adenovirus-vectored Zika virus vaccine carrying E protein., References: ['']\n",
      "DEBUG - Citing Paper: Design and Development of Modified mRNA Encoding Core Antigen of Hepatitis C Virus: a Possible Application in Vaccine Production., References: ['']\n",
      "DEBUG - Citing Paper: A VSV-based Zika virus vaccine protects mice from lethal challenge., References: ['']\n",
      "DEBUG - Citing Paper: Zika Virus Vaccine: Progress and Challenges., References: ['']\n",
      "DEBUG - Citing Paper: Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors., References: ['']\n",
      "DEBUG - Citing Paper: Intraamniotic Zika virus inoculation of pregnant rhesus macaques produces fetal neurologic disease., References: ['']\n",
      "DEBUG - Citing Paper: Zika Virus Attenuation by Codon Pair Deoptimization Induces Sterilizing Immunity in Mouse Models., References: ['']\n",
      "DEBUG - Citing Paper: Zika virus vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Species-specific disruption of STING-dependent antiviral cellular defenses by the Zika virus NS2B3 protease., References: ['']\n",
      "DEBUG - Citing Paper: Areas with High Hazard Potential for Autochthonous Transmission of <i>Aedes albopictus</i>-Associated Arboviruses in Germany., References: ['']\n",
      "DEBUG - Citing Paper: Current status of Zika vaccine development: Zika vaccines advance into clinical evaluation., References: ['']\n",
      "DEBUG - Citing Paper: Zika vaccines and therapeutics: landscape analysis and challenges ahead., References: ['']\n",
      "DEBUG - Citing Paper: Therapeutic and protective efficacy of a dengue antibody against Zika infection in rhesus monkeys., References: ['']\n",
      "DEBUG - Citing Paper: Intradermal Delivery of Synthetic mRNA Using Hollow Microneedles for Efficient and Rapid Production of Exogenous Proteins in Skin., References: ['']\n",
      "DEBUG - Citing Paper: Latest development on RNA-based drugs and vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Zika Virus Baculovirus-Expressed Virus-Like Particles Induce Neutralizing Antibodies in Mice., References: ['']\n",
      "DEBUG - Citing Paper: Zika virus vaccines: immune response, current status, and future challenges., References: ['']\n",
      "DEBUG - Citing Paper: Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses., References: ['']\n",
      "DEBUG - Citing Paper: Nanoscale platforms for messenger RNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: Incorporation of Synthetic mRNA in Injectable Chitosan-Alginate Hybrid Hydrogels for Local and Sustained Expression of Exogenous Proteins in Cells., References: ['']\n",
      "DEBUG - Citing Paper: Tapping the RNA world for therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Messenger RNA Delivery for Tissue Engineering and Regenerative Medicine Applications., References: ['']\n",
      "DEBUG - Citing Paper: Zika Virus in the Male Reproductive Tract., References: ['']\n",
      "DEBUG - Citing Paper: New Kids on the Block: RNA-Based Influenza Virus Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Recombinant Zika virus envelope protein elicited protective immunity against Zika virus in immunocompetent mice., References: ['']\n",
      "DEBUG - Citing Paper: Cell-type- and region-specific restriction of neurotropic flavivirus infection by viperin., References: ['']\n",
      "DEBUG - Citing Paper: An origin of the immunogenicity of in vitro transcribed RNA., References: ['']\n",
      "DEBUG - Citing Paper: Adverse outcomes of pregnancy-associated Zika virus infection., References: ['']\n",
      "DEBUG - Citing Paper: Prevention and Control Strategies to Counter Zika Virus, a Special Focus on Intervention Approaches against Vector Mosquitoes-Current Updates., References: ['']\n",
      "DEBUG - Citing Paper: The Impact of IgG transplacental transfer on early life immunity., References: ['']\n",
      "DEBUG - Citing Paper: Development of a chimeric Zika vaccine using a licensed live-attenuated flavivirus vaccine as backbone., References: ['']\n",
      "DEBUG - Citing Paper: Pregnancy and infection: using disease pathogenesis to inform vaccine strategy., References: ['']\n",
      "DEBUG - Citing Paper: Critical neutralizing fragment of Zika virus EDIII elicits cross-neutralization and protection against divergent Zika viruses., References: ['']\n",
      "DEBUG - Citing Paper: Development of Zika Virus Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Cellular and Humoral Immunity Protect against Vaginal Zika Virus Infection in Mice., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines - a new era in vaccinology., References: ['']\n",
      "DEBUG - Citing Paper: Recombinant Chimpanzee Adenovirus Vaccine AdC7-M/E Protects against Zika Virus Infection and Testis Damage., References: ['']\n",
      "DEBUG - Citing Paper: Modified mRNA-Based Vaccines Elicit Robust Immune Responses and Protect Guinea Pigs From Ebola Virus Disease., References: ['']\n",
      "DEBUG - Citing Paper: Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses., References: ['']\n",
      "DEBUG - Citing Paper: Nonhuman Primate Models of Zika Virus Infection, Immunity, and Therapeutic Development., References: ['']\n",
      "DEBUG - Citing Paper: Zika Vaccines: Role for Controlled Human Infection., References: ['']\n",
      "DEBUG - Citing Paper: Zika Virus Vaccine Development., References: ['']\n",
      "DEBUG - Citing Paper: Small Molecules and Antibodies for Zika Therapy., References: ['']\n",
      "DEBUG - Citing Paper: Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Durability and correlates of vaccine protection against Zika virus in rhesus monkeys., References: ['']\n",
      "DEBUG - Citing Paper: Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials., References: ['']\n",
      "DEBUG - Citing Paper: Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic., References: ['']\n",
      "DEBUG - Citing Paper: Vaccines in 2017: Closing in on a Zika virus vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Induction of Robust B Cell Responses after Influenza mRNA Vaccination Is Accompanied by Circulating Hemagglutinin-Specific ICOS+ PD-1+ CXCR3+ T Follicular Helper Cells., References: ['']\n",
      "DEBUG - Citing Paper: Intranasal infection and contact transmission of Zika virus in guinea pigs., References: ['']\n",
      "DEBUG - Citing Paper: Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding., References: ['']\n",
      "DEBUG - Citing Paper: Preconceptual Zika virus asymptomatic infection protects against secondary prenatal infection., References: ['']\n",
      "DEBUG - Citing Paper: A DNA Vaccine Protects Human Immune Cells against Zika Virus Infection in Humanized Mice., References: ['']\n",
      "DEBUG - Citing Paper: Efficient Targeting and Activation of Antigen-Presenting Cells InÂ Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques., References: ['']\n",
      "DEBUG - Citing Paper: A single-dose live-attenuated vaccine prevents Zika virus pregnancy transmission and testis damage., References: ['']\n",
      "DEBUG - Citing Paper: Polyamine-Mediated Stoichiometric Assembly of Ribonucleoproteins for Enhanced mRNA Delivery., References: ['']\n",
      "DEBUG - Citing Paper: Nucleic acid-based vaccines targeting respiratory syncytial virus: Delivering the goods., References: ['']\n",
      "DEBUG - Citing Paper: Zika Virus Escapes NK Cell Detection by Upregulating Major Histocompatibility Complex Class I Molecules., References: ['']\n",
      "DEBUG - Citing Paper: Immunization with truncated envelope protein of Zika virus induces protective immune response in mice., References: ['']\n",
      "DEBUG - Citing Paper: The Zika threat to the periphery., References: ['']\n",
      "DEBUG - Citing Paper: Vaccines for emerging infectious diseases: Lessons from MERS coronavirus and Zika virus., References: ['']\n",
      "DEBUG - Citing Paper: Zika virus activates de novo and cross-reactive memory B cell responses in dengue-experienced donors., References: ['']\n",
      "DEBUG - Citing Paper: Development of Virus-Like-Particle Vaccine and Reporter Assay for Zika Virus., References: ['']\n",
      "DEBUG - Citing Paper: Personalized vaccinology: A review., References: ['']\n",
      "DEBUG - Citing Paper: Current trends in Zika vaccine development., References: ['']\n",
      "DEBUG - Citing Paper: DNA-immunisation with dengue virus E protein domains I/II, but not domain III, enhances Zika, West Nile and Yellow Fever virus infection., References: ['']\n",
      "DEBUG - Citing Paper: Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease., References: ['']\n",
      "DEBUG - Citing Paper: Impact of Zika virus for infertility specialists: current literature, guidelines, and resources., References: ['']\n",
      "DEBUG - Citing Paper: Immune Cell Dynamics in Rhesus Macaques Infected with a Brazilian Strain of Zika Virus., References: ['']\n",
      "DEBUG - Citing Paper: Advances in the delivery of RNA therapeutics: from concept to clinical reality., References: ['']\n",
      "DEBUG - Citing Paper: Zika Virus: Recent Advances towards the Development of Vaccines and Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Microcephaly., References: ['']\n",
      "DEBUG - Citing Paper: Zika in the Americas, year 2: What have we learned? What gaps remain? A report from the Global Virus Network., References: ['']\n",
      "DEBUG - Citing Paper: Transposon Mutagenesis of the Zika Virus Genome Highlights Regions Essential for RNA Replication and Restricted for Immune Evasion., References: ['']\n",
      "DEBUG - Citing Paper: Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses., References: ['']\n",
      "DEBUG - Citing Paper: Vaccination strategies against Zika virus., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticle Systems for Enabling Gene Therapies., References: ['']\n",
      "DEBUG - Citing Paper: Human Vaccines & Immunotherapeutics: News., References: ['']\n",
      "DEBUG - Citing Paper: Modified mRNA Vaccines Protect against Zika Virus Infection., References: ['']\n",
      "DEBUG - focal: Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination., NF: 0, NB: 0, NR: 0, D: 0\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DEBUG - Focal Paper: Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA., References: \n",
      "\n",
      " https://assets.thermofisher.com/TFSâAssets/LSG/manuals/65011_65012_Dynabeads_MyOne_Carboxylic_Acid_PI.pdf\n",
      "DEBUG - Citing Paper: Potential Application of Modified mRNA in Cardiac Regeneration., References: ['']\n",
      "DEBUG - Citing Paper: Expedient production of site specifically nucleobase-labelled or hypermodified RNA with engineered thermophilic DNA polymerases., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-Based Vaccines Are Highly Immunogenic and Confer Protection in the Gnotobiotic Pig Model of Human Rotavirus Diarrhea., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccine designs for optimal adjuvanticity and delivery., References: ['']\n",
      "DEBUG - Citing Paper: The clinical impact of mRNA therapeutics in the treatment of cancers, infections, genetic disorders, and autoimmune diseases., References: ['']\n",
      "DEBUG - Citing Paper: Gonadal androgens are associated with decreased type I interferon production by plasmacytoid dendritic cells and increased IgG titres to BNT162b2 following co-vaccination with live attenuated influenza vaccine in adolescents., References: ['']\n",
      "DEBUG - Citing Paper: Recent advances in nanoparticulate RNA delivery systems., References: ['']\n",
      "DEBUG - Citing Paper: Urea supplementation improves mRNA in vitro transcription by decreasing both shorter and longer RNA byproducts., References: ['']\n",
      "DEBUG - Citing Paper: Digital Twin Fundamentals of mRNA <i>In Vitro</i> Transcription in Variable Scale Toward Autonomous Operation., References: ['']\n",
      "DEBUG - Citing Paper: The mRNA-LNP vaccines - the good, the bad and the ugly?, References: ['']\n",
      "DEBUG - Citing Paper: Profile of Katalin KarikÃ³ and Drew Weissman: 2023 Nobel laureates in Physiology or Medicine., References: ['']\n",
      "DEBUG - Citing Paper: Comprehensive Impurity Profiling of mRNA: Evaluating Current Technologies and Advanced Analytical Techniques., References: ['']\n",
      "DEBUG - Citing Paper: Strategies to reduce the risks of mRNA drug and vaccine toxicity., References: ['']\n",
      "DEBUG - Citing Paper: Breaking the mold with RNA-a \"RNAissance\" of life science., References: ['']\n",
      "DEBUG - Citing Paper: Path towards mRNA delivery for cancer immunotherapy from bench to bedside., References: ['']\n",
      "DEBUG - Citing Paper: Formation of dsRNA by-products during <i>in vitro</i> transcription can be reduced by using low steady-state levels of UTP., References: ['']\n",
      "DEBUG - Citing Paper: mRNA and Adenoviral Vector Vaccine Platforms Utilized in COVID-19 Vaccines: Technologies, Ecosystem, and Future Directions., References: ['']\n",
      "DEBUG - Citing Paper: Global RNA modifications to the MALAT1 triple helix differentially affect thermostability and weaken binding to METTL16., References: ['']\n",
      "DEBUG - Citing Paper: Emerging delivery approaches for targeted pulmonary fibrosis treatment., References: ['']\n",
      "DEBUG - Citing Paper: mRNA as a medicine in nephrology: the future is now., References: ['']\n",
      "DEBUG - Citing Paper: In Vitro Transcribed RNA-Based Platform Vaccines: Past, Present, and Future., References: ['']\n",
      "DEBUG - Citing Paper: Enabling mRNA Therapeutics: Current Landscape and Challenges in Manufacturing., References: ['']\n",
      "DEBUG - Citing Paper: The advances of adjuvants in mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Small interfering RNA (siRNA)-based therapeutic applications against viruses: principles, potential, and challenges., References: ['']\n",
      "DEBUG - Citing Paper: Purification of linearized template plasmid DNA decreases double-stranded RNA formation during IVT reaction., References: ['']\n",
      "DEBUG - Citing Paper: Administration of an excessive dosage of covid-19 pfizer vaccine in an infant: Case report of clinical and immune responses., References: ['']\n",
      "DEBUG - Citing Paper: The Dual Role of the Innate Immune System in the Effectiveness of mRNA Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability., References: ['']\n",
      "DEBUG - Citing Paper: Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Real-time monitoring strategies for optimization of <i>in vitro</i> transcription and quality control of RNA., References: ['']\n",
      "DEBUG - Citing Paper: Recent Advances and Innovations in the Preparation and Purification of In Vitro-Transcribed-mRNA-Based Molecules., References: ['']\n",
      "DEBUG - Citing Paper: High Recovery Chromatographic Purification of mRNA at Room Temperature and Neutral pH., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccine quality analysis using RNA sequencing., References: ['']\n",
      "DEBUG - Citing Paper: RNA-based medicine: from molecular mechanisms to therapy., References: ['']\n",
      "DEBUG - Citing Paper: Circular RNA vaccine in disease prevention and treatment., References: ['']\n",
      "DEBUG - Citing Paper: Co-administration of an effector antibody enhances the half-life and therapeutic potential of RNA-encoded nanobodies., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-Based Nanomedicine: A New Strategy for Treating Infectious Diseases and Beyond., References: ['']\n",
      "DEBUG - Citing Paper: Efficient circular RNA engineering by end-to-end self-targeting and splicing reaction using <i>Tetrahymena</i> group I intron ribozyme., References: ['']\n",
      "DEBUG - Citing Paper: Mesenchymal stem cell engineering by ARCA analog-capped mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Targeting cancer with mRNA-lipid nanoparticles: key considerations and future prospects., References: ['']\n",
      "DEBUG - Citing Paper: Class switch towards spike protein-specific IgG4 antibodies after SARS-CoV-2 mRNA vaccination depends on prior infection history., References: ['']\n",
      "DEBUG - Citing Paper: Mesoporous Silica Particle as an RNA Adsorbent for Facile Purification of In Vitro-Transcribed RNA., References: ['']\n",
      "DEBUG - Citing Paper: Recent Advances in Messenger Ribonucleic Acid (mRNA) Vaccines and Their Delivery Systems: A Review., References: ['']\n",
      "DEBUG - Citing Paper: CMC Strategies and Advanced Technologies for Vaccine Development to Boost Acceleration and Pandemic Preparedness., References: ['']\n",
      "DEBUG - Citing Paper: Advances in saRNA Vaccine Research against Emerging/Re-Emerging Viruses., References: ['']\n",
      "DEBUG - Citing Paper: Development of an Alcohol Dilution-Lyophilization Method for the Preparation of mRNA-LNPs with Improved Storage Stability., References: ['']\n",
      "DEBUG - Citing Paper: In vivo hematopoietic stem cell modification by mRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: Expanding the Reach of Monoclonal Antibodies: A Review of Synthetic Nucleic Acid Delivery in Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Knife's edge: Balancing immunogenicity and reactogenicity in mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Comb-structured mRNA vaccine tethered with short double-stranded RNA adjuvants maximizes cellular immunity for cancer treatment., References: ['']\n",
      "DEBUG - Citing Paper: Learning from cancer to address COVID-19., References: ['']\n",
      "DEBUG - Citing Paper: A localizing nanocarrier formulation enables multi-target immune responses to multivalent replicating RNA with limited systemic inflammation., References: ['']\n",
      "DEBUG - Citing Paper: ASL mRNA-LNP Therapeutic for the Treatment of Argininosuccinic Aciduria Enables Survival Benefit in a Mouse Model., References: ['']\n",
      "DEBUG - Citing Paper: Regulation and functions of non-m<sup>6</sup>A mRNA modifications., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-based cancer therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 bivalent mRNA vaccine with broad protection against variants of concern., References: ['']\n",
      "DEBUG - Citing Paper: Factors, enablers and challenges for COVID-19 vaccine development., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccine Platform: mRNA Production and Delivery., References: ['']\n",
      "DEBUG - Citing Paper: Innovation in the 21st century: following the footsteps of Katalin KarikÃ³., References: ['']\n",
      "DEBUG - Citing Paper: Lateral flow immunoassay for rapid and sensitive detection of dsRNA contaminants in <i>inÂ vitro</i>-transcribed mRNA products., References: ['']\n",
      "DEBUG - Citing Paper: Cap analogs with a hydrophobic photocleavable tag enable facile purification of fully capped mRNA with various cap structures., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV., References: ['']\n",
      "DEBUG - Citing Paper: mRNA melanoma vaccine revolution spurred by the COVID-19 pandemic., References: ['']\n",
      "DEBUG - Citing Paper: Could artificial intelligence revolutionize the development of nanovectors for gene therapy and mRNA vaccines?, References: ['']\n",
      "DEBUG - Citing Paper: Revolutionizing viral disease vaccination: the promising clinical advancements of non-replicating mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Construction and immunogenicity of an mRNA vaccine against chikungunya virus., References: ['']\n",
      "DEBUG - Citing Paper: Intraduodenal Delivery of Exosome-Loaded SARS-CoV-2 RBD mRNA Induces a Neutralizing Antibody Response in Mice., References: ['']\n",
      "DEBUG - Citing Paper: The Combination of an mRNA Immunogen, a TLR7 Agonist and a PD1 Blocking Agent Enhances In-Vitro HIV T-Cell Immune Responses., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-Based Therapeutics in Cancer Treatment., References: ['']\n",
      "DEBUG - Citing Paper: Safe and Effective Delivery of mRNA Using Modified PEI-Based Lipopolymers., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-From COVID-19 Treatment to Cancer Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Advanced delivery systems for peptide antibiotics., References: ['']\n",
      "DEBUG - Citing Paper: Current Status and Challenges of Vaccination Therapy for Glioblastoma., References: ['']\n",
      "DEBUG - Citing Paper: A Comprehensive Review of mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: A single vaccination of nucleoside-modified Rabies mRNA vaccine induces prolonged highly protective immune responses in mice., References: ['']\n",
      "DEBUG - Citing Paper: High-salt transcription from enzymatically gapped promoters nets higher yields and purity of transcribed RNAs., References: ['']\n",
      "DEBUG - Citing Paper: Self-Amplifying RNA Vaccine Candidates: Alternative Platforms for mRNA Vaccine Development., References: ['']\n",
      "DEBUG - Citing Paper: Screening of Tumor Antigens and Construction of Immune Subtypes for mRNA Vaccine Development in Head and Neck Squamous Cell Carcinoma., References: ['']\n",
      "DEBUG - Citing Paper: Advances of mRNA vaccine in tumor: a maze of opportunities and challenges., References: ['']\n",
      "DEBUG - Citing Paper: Structural basis of transcription recognition of a hydrophobic unnatural base pair by T7 RNA polymerase., References: ['']\n",
      "DEBUG - Citing Paper: The mRNA Vaccine Technology Era and the Future Control of Parasitic Infections., References: ['']\n",
      "DEBUG - Citing Paper: Comparison between viral vector and mRNA based COVID-19 vaccination in prevalence and severity of regional immune reactions, and <sup>18</sup>F-FDG PET/CT features., References: ['']\n",
      "DEBUG - Citing Paper: ESCRT recruitment to mRNA-encoded SARS-CoV-2 spike induces virus-like particles and enhanced antibody responses., References: ['']\n",
      "DEBUG - Citing Paper: Exploring <i>in vitro</i> expression and immune potency in mice using mRNA encoding the <i>Plasmodium falciparum</i> malaria antigen, CelTOS., References: ['']\n",
      "DEBUG - Citing Paper: A new dawn for monoclonal antibodies against antimicrobial resistant bacteria., References: ['']\n",
      "DEBUG - Citing Paper: In silico design and evaluation of a novel mRNA vaccine against BK virus: a reverse vaccinology approach., References: ['']\n",
      "DEBUG - Citing Paper: Liquid Chromatography-Mass Spectrometry-Based Qualitative Profiling of mRNA Therapeutic Reagents Using Stable Isotope-Labeled Standards Followed by the Automatic Quantitation Software Ariadne., References: ['']\n",
      "DEBUG - Citing Paper: Recent Advances in Lipid Nanoparticles for Delivery of mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Structural Elements of DNA and RNA Eukaryotic Expression Vectors for In Vitro and In Vivo Genome Editor Delivery., References: ['']\n",
      "DEBUG - Citing Paper: Lessons learned from COVID-19 pandemic: Vaccine platform is a key player., References: ['']\n",
      "DEBUG - Citing Paper: Impact of disease-modifying therapy on dendritic cells and exploring their immunotherapeutic potential in multiple sclerosis., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticles Delivering Constitutively Active STING mRNA to Stimulate Antitumor Immunity., References: ['']\n",
      "DEBUG - Citing Paper: Nanoformulations targeting immune cells for cancer therapy: mRNA therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Challenges and emerging trends in liquid chromatography-based analyses of mRNA pharmaceuticals., References: ['']\n",
      "DEBUG - Citing Paper: Hydrogel-guided strategies to stimulate an effective immune response for vaccine-based cancer immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Developing New Tools to Fight Human Pathogens: A Journey through the Advances in RNA Technologies., References: ['']\n",
      "DEBUG - Citing Paper: RNA sensor response in HeLa cells for transfected mRNAs prepared <i>in vitro</i> by SP6 and HiT7 RNA polymerases: A comparative study., References: ['']\n",
      "DEBUG - Citing Paper: Pros and Cons of In Vitro Methods for Circular RNA Preparation., References: ['']\n",
      "DEBUG - Citing Paper: An engineered T7 RNA polymerase that produces mRNA free of immunostimulatory byproducts., References: ['']\n",
      "DEBUG - Citing Paper: The landscape of mRNA nanomedicine., References: ['']\n",
      "DEBUG - Citing Paper: Advancing mRNA technologies for therapies and vaccines: An African context., References: ['']\n",
      "DEBUG - Citing Paper: Innate immune mechanisms of mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 mRNA-based vaccines in the Aicardi GoutiÃ¨res Syndrome., References: ['']\n",
      "DEBUG - Citing Paper: Psychrophilic phage VSW-3 RNA polymerase reduces both terminal and full-length dsRNA byproducts in <i>in vitro</i> transcription., References: ['']\n",
      "DEBUG - Citing Paper: Immunization with a Prefusion SARS-CoV-2 Spike Protein Vaccine (RBMRNA-176) Protects against Viral Challenge in Mice and Nonhuman Primates., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-Based Approaches to Treating Liver Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Fast-track development of vaccines for SARS-CoV-2: The shots that saved the world., References: ['']\n",
      "DEBUG - Citing Paper: Design Strategies for and Stability of mRNA-Lipid Nanoparticle COVID-19 Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Cutting-Edge Delivery Systems and Adjuvants in Tolerogenic Vaccines: A Review., References: ['']\n",
      "DEBUG - Citing Paper: A critical overview of current progress for COVID-19: development of vaccines, antiviralÂ drugs, and therapeutic antibodies., References: ['']\n",
      "DEBUG - Citing Paper: Double-stranded RNA reduction by chaotropic agents during <i>inÂ vitro</i> transcription of messenger RNA., References: ['']\n",
      "DEBUG - Citing Paper: Applications and challenges of biomaterial mediated mRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: Synthesis of point-modified mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Pre-exposure to mRNA-LNP inhibits adaptive immune responses and alters innate immune fitness in an inheritable fashion., References: ['']\n",
      "DEBUG - Citing Paper: The life and death of RNA across temperatures., References: ['']\n",
      "DEBUG - Citing Paper: Design and Immunoinformatic Assessment of Candidate Multivariant mRNA Vaccine Construct against Immune Escape Variants of SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: Analysis of melanoma tumor antigens and immune subtypes for the development of mRNA vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Recent Advances in the Molecular Design and Delivery Technology of mRNA for Vaccination Against Infectious Diseases., References: ['']\n",
      "DEBUG - Citing Paper: The Pivotal Role of Chemical Modifications in mRNA Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: The legacy of mRNA engineering: A lineup of pioneers for the Nobel Prize., References: ['']\n",
      "DEBUG - Citing Paper: Message in a bottle: mRNA vaccination for influenza., References: ['']\n",
      "DEBUG - Citing Paper: Structure Characterization of <i>Escherichia coli</i> Pseudouridine Kinase PsuK., References: ['']\n",
      "DEBUG - Citing Paper: Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials., References: ['']\n",
      "DEBUG - Citing Paper: A circular RNA derived from the insulin receptor locus protects against doxorubicin-induced cardiotoxicity., References: ['']\n",
      "DEBUG - Citing Paper: Nanomedicine for the Delivery of RNA in Cancer., References: ['']\n",
      "DEBUG - Citing Paper: Stronger together for in-cell translation: natural and unnatural base modified mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Universal Flu mRNA Vaccine: Promises, Prospects, and Problems., References: ['']\n",
      "DEBUG - Citing Paper: mRNA as a Therapeutics: Understanding mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Best practice standards for circular RNA research., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-based therapeutics: powerful and versatile tools to combat diseases., References: ['']\n",
      "DEBUG - Citing Paper: RNA in Cancer Immunotherapy: Unlocking the Potential of the Immune System., References: ['']\n",
      "DEBUG - Citing Paper: An imidazole modified lipid confers enhanced mRNA-LNP stability and strong immunization properties in mice and non-human primates., References: ['']\n",
      "DEBUG - Citing Paper: The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: A systematic dissection of determinants and consequences of snoRNA-guided pseudouridylation of human mRNA., References: ['']\n",
      "DEBUG - Citing Paper: The clinical progress of mRNA vaccines and immunotherapies., References: ['']\n",
      "DEBUG - Citing Paper: mRNA- and Adenovirus-Based Vaccines against SARS-CoV-2 in HIV-Positive People., References: ['']\n",
      "DEBUG - Citing Paper: Uniting Disciplines to Develop Therapeutics: Targeted mRNA Lipid Nanoparticles Reprogram the Immune System <i>In Vivo</i> to Treat Heart Disease., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines: the most recent clinical applications of synthetic mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Anti-coronavirus vaccines will not accelerate the transition of humanity to a non-pandemic period, but the pandemic will take fewer victims., References: ['']\n",
      "DEBUG - Citing Paper: mRNA cancer vaccines: Advances, trends and challenges., References: ['']\n",
      "DEBUG - Citing Paper: Advances in COVID-19 mRNA vaccine development., References: ['']\n",
      "DEBUG - Citing Paper: Cancer vaccines as promising immuno-therapeutics: platforms and current progress., References: ['']\n",
      "DEBUG - Citing Paper: Novel In Silico mRNA vaccine design exploiting proteins of M. tuberculosis that modulates host immune responses by inducing epigenetic modifications., References: ['']\n",
      "DEBUG - Citing Paper: Messenger RNA vaccines for cancer immunotherapy: progress promotes promise., References: ['']\n",
      "DEBUG - Citing Paper: Selective Xi reactivation and alternative methods to restore MECP2 function in Rett syndrome., References: ['']\n",
      "DEBUG - Citing Paper: The Potential of Nanomedicine to Unlock the Limitless Applications of mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 mRNA vaccines: Platforms and current developments., References: ['']\n",
      "DEBUG - Citing Paper: Chemical modification of uridine modulates mRNA-mediated proinflammatory and antiviral response in primary human macrophages., References: ['']\n",
      "DEBUG - Citing Paper: CIMT 2021: report on the 18th Annual Meeting of the Association for Cancer Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Hantavirus Induced Kidney Disease., References: ['']\n",
      "DEBUG - Citing Paper: Langerhans cells and cDC1s play redundant roles in mRNA-LNP induced protective anti-influenza and anti-SARS-CoV-2 immune responses., References: ['']\n",
      "DEBUG - Citing Paper: Nanotechnologies in Delivery of DNA and mRNA Vaccines to the Nasal and Pulmonary Mucosa., References: ['']\n",
      "DEBUG - Citing Paper: Microneedle systems for delivering nucleic acid drugs., References: ['']\n",
      "DEBUG - Citing Paper: A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models., References: ['']\n",
      "DEBUG - Citing Paper: Intracellular RNase activity dampens zinc finger nuclease-mediated gene editing in hematopoietic stem and progenitor cells., References: ['']\n",
      "DEBUG - Citing Paper: Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities., References: ['']\n",
      "DEBUG - Citing Paper: A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues., References: ['']\n",
      "DEBUG - Citing Paper: mRNA, a Revolution in Biomedicine., References: ['']\n",
      "DEBUG - Citing Paper: Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 - a review., References: ['']\n",
      "DEBUG - Citing Paper: Membrane-dependent relief of translation elongationÂ arrest on pseudouridine- and N1-methyl-pseudouridine-modified mRNAs., References: ['']\n",
      "DEBUG - Citing Paper: Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza., References: ['']\n",
      "DEBUG - Citing Paper: Current view on novel vaccine technologies to combat human infectious diseases., References: ['']\n",
      "DEBUG - Citing Paper: Myocarditis and COVID-19 mRNA vaccines: a mechanistic hypothesis involving dsRNA., References: ['']\n",
      "DEBUG - Citing Paper: Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials., References: ['']\n",
      "DEBUG - Citing Paper: Nucleic Acid-Based Treatments Against COVID-19: Potential Efficacy of Aptamers and siRNAs., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses., References: ['']\n",
      "DEBUG - Citing Paper: The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory., References: ['']\n",
      "DEBUG - Citing Paper: The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview., References: ['']\n",
      "DEBUG - Citing Paper: The Current Status of COVID-19 Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Development of a 3D-printed single-use separation chamber for use in mRNA-based vaccine production with magnetic microparticles., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticles for Organ-Specific mRNA Therapeutic Delivery., References: ['']\n",
      "DEBUG - Citing Paper: Immunogenicity of <i>In Vitro</i>-Transcribed RNA., References: ['']\n",
      "DEBUG - Citing Paper: mRNA - A game changer in regenerative medicine, cell-based therapy and reprogramming strategies., References: ['']\n",
      "DEBUG - Citing Paper: Rapid development of analytical methods for evaluating pandemic vaccines: a COVID-19 perspective., References: ['']\n",
      "DEBUG - Citing Paper: RNA Therapeutics - Research and Clinical Advancements., References: ['']\n",
      "DEBUG - Citing Paper: CRISPR-derived genome editing therapies: Progress from bench to bedside., References: ['']\n",
      "DEBUG - Citing Paper: Cardiovascular consequences of viral infections: from COVID to other viral diseases., References: ['']\n",
      "DEBUG - Citing Paper: To Be or Not To Be Vaccinated: That Is a Question in Myasthenia Gravis., References: ['']\n",
      "DEBUG - Citing Paper: Ethylenediamine derivatives efficiently react with oxidized RNA 3' ends providing access to mono and dually labelled RNA probes for enzymatic assays and in vivo translation., References: ['']\n",
      "DEBUG - Citing Paper: An Update on mRNA-Based Viral Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Pharma 4.0 Continuous mRNA Drug Products Manufacturing., References: ['']\n",
      "DEBUG - Citing Paper: Cationic Liposomes as Vectors for Nucleic Acid and Hydrophobic Drug Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Nucleic acid delivery and nanoparticle design for COVID vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Influenza Viruses: Innate Immunity and mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Pseudouridines in RNAs: switching atoms means shifting paradigms., References: ['']\n",
      "DEBUG - Citing Paper: In Vitro Investigations on Optimizing and Nebulization of IVT-mRNA Formulations for Potential Pulmonary-Based Alpha-1-Antitrypsin Deficiency Treatment., References: ['']\n",
      "DEBUG - Citing Paper: Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticles for mRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: Induced endothelial cells from peripheral arterial disease patients and neonatal fibroblasts have comparable angiogenic properties., References: ['']\n",
      "DEBUG - Citing Paper: Langerhans cells and cDC1s play redundant roles in mRNA-LNP induced protective anti-influenza and anti-SARS-CoV-2 responses., References: ['']\n",
      "DEBUG - Citing Paper: Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: Delivery of nucleic acid therapeutics for cancer immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across., References: ['']\n",
      "DEBUG - Citing Paper: A single mutation attenuates both the transcription termination and RNA-dependent RNA polymerase activity of T7 RNA polymerase., References: ['']\n",
      "DEBUG - Citing Paper: From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape., References: ['']\n",
      "DEBUG - Citing Paper: Serological response to a single dose of a SARS-CoV-2 mRNA vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Intracellular Routing and Recognition of Lipid-Based mRNA Nanoparticles., References: ['']\n",
      "DEBUG - Citing Paper: From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases., References: ['']\n",
      "DEBUG - Citing Paper: A Guide to Nucleic Acid Vaccines in the Prevention and Treatment of Infectious Diseases and Cancers: From Basic Principles to Current Applications., References: ['']\n",
      "DEBUG - Citing Paper: Opportunities for innovation: Building on the success of lipid nanoparticle vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2: One Year in the Pandemic. What Have We Learned, the New Vaccine Era and the Threat of SARS-CoV-2 Variants., References: ['']\n",
      "DEBUG - Citing Paper: Non-Immunotherapy Application of LNP-mRNA: Maximizing Efficacy and Safety., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 vaccine platforms: Delivering on a promise?, References: ['']\n",
      "DEBUG - Citing Paper: Lipid-nanoparticle-encapsulated mRNA vaccines induce protective memory CD8 TÂ cells against a lethal viral infection., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-Based Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Rational Vaccine Design in Times of Emerging Diseases: The Critical Choices of Immunological Correlates of Protection, Vaccine Antigen and Immunomodulation., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines for COVID-19: what, why and how., References: ['']\n",
      "DEBUG - Citing Paper: Future considerations for the mRNA-lipid nanoparticle vaccine platform., References: ['']\n",
      "DEBUG - Citing Paper: Self-amplifying mRNA-Based Vaccine Technology and Its Mode of Action., References: ['']\n",
      "DEBUG - Citing Paper: mRNA therapeutics in cancer immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: RNA ImmunoGenic Assay: A Method to Detect Immunogenicity of <i>in vitro</i> Transcribed mRNA in Human Whole Blood., References: ['']\n",
      "DEBUG - Citing Paper: Emerging Therapeutics for Immune Tolerance: Tolerogenic Vaccines, T cell Therapy, and IL-2 Therapy., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates., References: ['']\n",
      "DEBUG - Citing Paper: In the Era of mRNA Vaccines, Is There Any Hope for HIV Functional Cure?, References: ['']\n",
      "DEBUG - Citing Paper: An Overview on the Development of mRNA-Based Vaccines and Their Formulation Strategies for Improved Antigen Expression In Vivo., References: ['']\n",
      "DEBUG - Citing Paper: The dawn of mRNA vaccines: The COVID-19 case., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines manufacturing: Challenges and bottlenecks., References: ['']\n",
      "DEBUG - Citing Paper: A Dengue Virus Serotype 1 mRNA-LNP Vaccine Elicits Protective Immune Responses., References: ['']\n",
      "DEBUG - Citing Paper: Novel approaches for vaccine development., References: ['']\n",
      "DEBUG - Citing Paper: Clinical and immunological effects of mRNA vaccines in malignant diseases., References: ['']\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DEBUG - Citing Paper: mRNA Vaccines against Flaviviruses., References: ['']\n",
      "DEBUG - Citing Paper: mRNA in cancer immunotherapy: beyond a source of antigen., References: ['']\n",
      "DEBUG - Citing Paper: The Regulation of RNA Modification Systems: The Next Frontier in Epitranscriptomics?, References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccine for cancer immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Tricks and threats of RNA viruses - towards understanding the fate of viral RNA., References: ['']\n",
      "DEBUG - Citing Paper: Synthetic biology in the clinic: engineering vaccines, diagnostics, and therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: HIV mRNA Vaccines-Progress and Future Paths., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis., References: ['']\n",
      "DEBUG - Citing Paper: Murine liver repair via transient activation of regenerative pathways in hepatocytes using lipid nanoparticle-complexed nucleoside-modified mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Improved efficiency of genome editing by constitutive expression of Cas9 endonuclease in genetically-modified mice., References: ['']\n",
      "DEBUG - Citing Paper: Corticosteroids and cellulose purification improve, respectively, the inÂ vivo translation and vaccination efficacy of sa-mRNAs., References: ['']\n",
      "DEBUG - Citing Paper: Nanomaterial Delivery Systems for mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Neo-Antigen mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Nucleic Acid-Based Technologies Targeting Coronaviruses., References: ['']\n",
      "DEBUG - Citing Paper: The Opposing Effect of Type I IFN on the T Cell Response by Non-modified mRNA-Lipoplex Vaccines Is Determined by the Route of Administration., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19: A review of therapeutic strategies and vaccine candidates., References: ['']\n",
      "DEBUG - Citing Paper: Advances in Lipid Nanoparticles for mRNA-Based Cancer Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: High resolution biosensor to test the capping level and integrity of mRNAs., References: ['']\n",
      "DEBUG - Citing Paper: Self-amplifying RNA vaccines for infectious diseases., References: ['']\n",
      "DEBUG - Citing Paper: Engineering Antiviral Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: tRNA Modification Detection Using Graphene Nanopores: A Simulation Study., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccine Era-Mechanisms, Drug Platform and Clinical Prospection., References: ['']\n",
      "DEBUG - Citing Paper: Phosphodiester modifications in mRNA poly(A) tail prevent deadenylation without compromising protein expression., References: ['']\n",
      "DEBUG - Citing Paper: Delivery of hepatocyte growth factor mRNA from nanofibrillar scaffolds in a pig model of peripheral arterial disease., References: ['']\n",
      "DEBUG - Citing Paper: Intramuscular Delivery of Replicon RNA Encoding ZIKV-117 Human Monoclonal Antibody Protects against Zika Virus Infection., References: ['']\n",
      "DEBUG - Citing Paper: Advances in Development of mRNA-Based Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Opportunities and challenges for the clinical translation of structured DNA assemblies as gene therapeutic delivery and vaccine vectors., References: ['']\n",
      "DEBUG - Citing Paper: Regulatory Considerations on the Development of mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Impact of mRNA chemistry and manufacturing process on innate immune activation., References: ['']\n",
      "DEBUG - Citing Paper: Designing a novel mRNA vaccine against SARS-CoV-2: An immunoinformatics approach., References: ['']\n",
      "DEBUG - Citing Paper: Controlling timing and location in vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Preparing for Pandemics: RNA Vaccines at the Forefront., References: ['']\n",
      "DEBUG - Citing Paper: Formulation and Delivery Technologies for mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Messenger RNA-Based Vaccines Against Infectious Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives., References: ['']\n",
      "DEBUG - Citing Paper: Strong Immune Responses Induced by Direct Local Injections of Modified mRNA-Lipid Nanocomplexes., References: ['']\n",
      "DEBUG - Citing Paper: The promise of mRNA vaccines: a biotech and industrial perspective., References: ['']\n",
      "DEBUG - Citing Paper: The identity and methylation status of the first transcribed nucleotide in eukaryotic mRNA 5' cap modulates protein expression in living cells., References: ['']\n",
      "DEBUG - Citing Paper: Synthesis of low immunogenicity RNA with high-temperature in vitro transcription., References: ['']\n",
      "DEBUG - Citing Paper: Establishing Preferred Product Characterization for the Evaluation of RNA Vaccine Antigens., References: ['']\n",
      "DEBUG - Citing Paper: Enlisting the mRNA Vaccine Platform to Combat Parasitic Infections., References: ['']\n",
      "DEBUG - Citing Paper: Immunological Analysis of a CCHFV mRNA Vaccine Candidate in Mouse Models., References: ['']\n",
      "DEBUG - Citing Paper: Immunogenicity of RNA Replicons Encoding HIV Env Immunogens Designed for Self-Assembly into Nanoparticles., References: ['']\n",
      "DEBUG - Citing Paper: Expression Kinetics and Innate Immune Response after Electroporation and LNP-Mediated Delivery of a Self-Amplifying mRNA in the Skin., References: ['']\n",
      "DEBUG - Citing Paper: Efficient inhibition of RNA self-primed extension by addition of competing 3'-capture DNA-improved RNA synthesis by T7 RNA polymerase., References: ['']\n",
      "DEBUG - Citing Paper: Intranodal administration of mRNA encoding nucleoprotein provides cross-strain immunity against influenza in mice., References: ['']\n",
      "DEBUG - Citing Paper: Correction of bleeding in experimental severe hemophilia A by systemic delivery of factor VIII-encoding mRNA., References: ['']\n",
      "DEBUG - Citing Paper: RNA therapeutics - The potential treatment for myocardial infarction., References: ['']\n",
      "DEBUG - Citing Paper: A Comparison of Plasmid DNA and mRNA as Vaccine Technologies., References: ['']\n",
      "DEBUG - Citing Paper: Advances in mRNA Vaccines for Infectious Diseases., References: ['']\n",
      "DEBUG - Citing Paper: A Facile Method for the Removal of dsRNA Contaminant from InÂ Vitro-Transcribed mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Precise Gene Editing Preserves Hematopoietic Stem Cell Function following Transient p53-Mediated DNA Damage Response., References: ['']\n",
      "DEBUG - Citing Paper: Non-viral Delivery of Zinc Finger Nuclease mRNA Enables Highly Efficient InÂ Vivo Genome Editing of Multiple Therapeutic Gene Targets., References: ['']\n",
      "DEBUG - Citing Paper: RNA Circularization Diminishes Immunogenicity and Can Extend Translation Duration InÂ Vivo., References: ['']\n",
      "DEBUG - Citing Paper: mRNA: A Novel Avenue to Antibody Therapy?, References: ['']\n",
      "DEBUG - Citing Paper: mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases., References: ['']\n",
      "DEBUG - Citing Paper: How mRNA therapeutics are entering the monoclonal antibody field., References: ['']\n",
      "DEBUG - Citing Paper: Multiple covalent fluorescence labeling of eukaryotic mRNA at the poly(A) tail enhances translation and can be performed in living cells., References: ['']\n",
      "DEBUG - Citing Paper: Local Delivery of <i>Ox40l</i>, <i>Cd80</i>, and <i>Cd86</i> mRNA Kindles Global Anticancer Immunity., References: ['']\n",
      "DEBUG - Citing Paper: Eukaryotic Translation Elongation is Modulated by Single Natural Nucleotide Derivatives in the Coding Sequences of mRNAs., References: ['']\n",
      "DEBUG - Citing Paper: Nucleotide Modification Alters MicroRNA-Dependent Silencing of MicroRNA Switches., References: ['']\n",
      "DEBUG - Citing Paper: Delivery of mRNA Therapeutics for the Treatment of Hepatic Diseases., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-Based Genetic Reprogramming., References: ['']\n",
      "DEBUG - Citing Paper: Proximity Ligation Assays for In Situ Detection of Innate Immune Activation: Focus on InÂ Vitro-Transcribed mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Exploitation of Synthetic mRNA To Drive Immune Effector Cell Recruitment and Functional Reprogramming In Vivo., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma., References: ['']\n",
      "DEBUG - Citing Paper: PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake., References: ['']\n",
      "DEBUG - Citing Paper: mRNA as novel technology for passive immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Biomaterials for vaccine-based cancer immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: New Vaccine Technologies to Combat Outbreak Situations., References: ['']\n",
      "DEBUG - Citing Paper: Uridine Depletion and Chemical Modification Increase Cas9 mRNA Activity and Reduce Immunogenicity without HPLC Purification., References: ['']\n",
      "DEBUG - Citing Paper: An RNA toolbox for cancer immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies., References: ['']\n",
      "DEBUG - Citing Paper: Biocompatible, Purified <i>VEGF-A</i> mRNA Improves Cardiac Function after Intracardiac Injection 1 Week Post-myocardial Infarction in Swine., References: ['']\n",
      "DEBUG - Citing Paper: Purification of mRNA Encoding Chimeric Antigen Receptor Is Critical for Generation of a Robust T-Cell Response., References: ['']\n",
      "DEBUG - Citing Paper: Engineering circular RNA for potent and stable translation in eukaryotic cells., References: ['']\n",
      "DEBUG - Citing Paper: De Novo Synthesis of Elastin by Exogenous Delivery of Synthetic Modified mRNA into Skin and Elastin-Deficient Cells., References: ['']\n",
      "DEBUG - Citing Paper: Latest development on RNA-based drugs and vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses., References: ['']\n",
      "DEBUG - Citing Paper: Nanoscale platforms for messenger RNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: New Kids on the Block: RNA-Based Influenza Virus Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: An origin of the immunogenicity of in vitro transcribed RNA., References: ['']\n",
      "DEBUG - Citing Paper: Targeted mRNA Therapy for Ornithine Transcarbamylase Deficiency., References: ['']\n",
      "DEBUG - Citing Paper: Challenges of influenza A viruses in humans and animals and current animal vaccines as an effective control measure., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines - a new era in vaccinology., References: ['']\n",
      "DEBUG - Citing Paper: Design, Assembly, Production, and Transfection of Synthetic Modified mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Cationic Nanoliposomes Meet mRNA: Efficient Delivery of Modified mRNA Using Hemocompatible and Stable Vectors for Therapeutic Applications., References: ['']\n",
      "DEBUG - Citing Paper: Synthetic mRNA is a more reliable tool for the delivery of DNA-targeting proteins into the cell nucleus than fusion with a protein transduction domain., References: ['']\n",
      "DEBUG - Citing Paper: Elimination of large tumors in mice by mRNA-encoded bispecific antibodies., References: ['']\n",
      "DEBUG - Citing Paper: Understanding RNA modifications: the promises and technological bottlenecks of the 'epitranscriptome'., References: ['']\n",
      "DEBUG - Citing Paper: Characterizing exogenous mRNA delivery, trafficking, cytoplasmic release and RNA-protein correlations at the level of single cells., References: ['']\n",
      "DEBUG - Citing Paper: N1-methyl-pseudouridine in mRNA enhances translation through eIF2Î±-dependent and independent mechanisms by increasing ribosome density., References: ['']\n",
      "DEBUG - Citing Paper: Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge., References: ['']\n",
      "DEBUG - Citing Paper: Efficacy and immunogenicity of unmodified and pseudouridine-modified mRNA delivered systemically with lipid nanoparticles inÂ vivo., References: ['']\n",
      "DEBUG - Citing Paper: RNAs Containing Modified Nucleotides Fail To Trigger RIG-I Conformational Changes for Innate Immune Signaling., References: ['']\n",
      "DEBUG - Citing Paper: The notorious R.N.A. in the spotlight - drug or target for the treatment of disease., References: ['']\n",
      "DEBUG - Citing Paper: V-Maf Musculoaponeurotic Fibrosarcoma Oncogene Homolog A Synthetic Modified mRNA Drives Reprogramming of Human Pancreatic Duct-Derived Cells Into Insulin-Secreting Cells., References: ['']\n",
      "DEBUG - Citing Paper: Viral and Synthetic RNA Vector Technologies and Applications., References: ['']\n",
      "DEBUG - Citing Paper: Translating the epitranscriptome., References: ['']\n",
      "DEBUG - Citing Paper: Reprogramming of Pancreatic Exocrine Cells AR42J Into Insulin-producing Cells Using mRNAs for Pdx1, Ngn3, and MafA Transcription Factors., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-Mediated Gene Supplementation of Toll-Like Receptors as Treatment Strategy for Asthma In Vivo., References: ['']\n",
      "DEBUG - Citing Paper: RNA-Based Vaccines in Cancer Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Nucleotide modifications within bacterial messenger RNAs regulate their translation and are able to rewire the genetic code., References: ['']\n",
      "DEBUG - Citing Paper: mRNA: Fulfilling the Promise of Gene Therapy., References: ['']\n",
      "DEBUG - Citing Paper: Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes., References: ['']\n",
      "DEBUG - Citing Paper: Screening of mRNA Chemical Modification to Maximize Protein Expression with Reduced Immunogenicity., References: ['']\n",
      "DEBUG - Citing Paper: Modified mRNA as an alternative to plasmid DNA (pDNA) for transcript replacement and vaccination therapy., References: ['']\n",
      "DEBUG - Citing Paper: Identification of Cyclobutane Pyrimidine Dimer-Responsive Genes Using UVB-Irradiated Human Keratinocytes Transfected with In Vitro-Synthesized Photolyase mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals., References: ['']\n",
      "DEBUG - Citing Paper: In vivo genome editing using nuclease-encoding mRNA corrects SP-B deficiency., References: ['']\n",
      "DEBUG - Citing Paper: Synthetic chemically modified mRNA (modRNA): toward a new technology platform for cardiovascular biology and medicine., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-based therapeutics--developing a new class of drugs., References: ['']\n",
      "DEBUG - Citing Paper: Transfection of pseudouridine-modified mRNA encoding CPD-photolyase leads to repair of DNA damage in human keratinocytes: a new approach with future therapeutic potential., References: ['']\n",
      "DEBUG - Citing Paper: Augmentation of epithelial resistance to invading bacteria by using mRNA transfections., References: ['']\n",
      "DEBUG - Citing Paper: Evaluation of RNA Amplification Methods to Improve DC Immunotherapy Antigen Presentation and Immune Response., References: ['']\n",
      "DEBUG - Citing Paper: Single-nucleotide resolution of RNAs up to 59 nucleotides by high-performance liquid chromatography., References: ['']\n",
      "DEBUG - Citing Paper: Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy., References: ['']\n",
      "DEBUG - Citing Paper: Developing mRNA-vaccine technologies., References: ['']\n",
      "DEBUG - Citing Paper: Feeder-free derivation of human induced pluripotent stem cells with messenger RNA., References: ['']\n",
      "DEBUG - Citing Paper: mRNA leapfrogs DNA to show promise for therapeutic gene transfer., References: ['']\n",
      "DEBUG - Citing Paper: Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin., References: ['']\n",
      "DEBUG - Citing Paper: Nucleofection induces transient eIF2Î± phosphorylation by GCN2 and PERK., References: ['']\n",
      "DEBUG - focal: Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA., NF: 0, NB: 0, NR: 0, D: 0\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DEBUG - Focal Paper: DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration., References: \n",
      "AREDS Home Page. Age-related eye disease study. https://web.emmes.com/study/areds/ (accessed May 2012).\n",
      "DEBUG - Citing Paper: The mechanisms of natural products for eye disorders by targeting mitochondrial dysfunction., References: ['']\n",
      "DEBUG - Citing Paper: Cancer-derived exosomal Alu RNA promotes colorectal cancer progression., References: ['']\n",
      "DEBUG - Citing Paper: The contribution of pattern recognition receptor signalling in the development of age related macular degeneration: the role of toll-like-receptors and the NLRP3-inflammasome., References: ['']\n",
      "DEBUG - Citing Paper: Selection on synonymous sites: the unwanted transcript hypothesis., References: ['']\n",
      "DEBUG - Citing Paper: Regulated cell death pathways in the sodium iodate model: Insights and implications for AMD., References: ['']\n",
      "DEBUG - Citing Paper: Emerging Roles of cGAS-STING Signaling in Mediating Ocular Inflammation., References: ['']\n",
      "DEBUG - Citing Paper: Comparison between sodium iodate and lipid peroxide murine models of age-related macular degeneration for drug evaluation-a narrative review., References: ['']\n",
      "DEBUG - Citing Paper: Interplay between RNA interference and transposable elements in mammals., References: ['']\n",
      "DEBUG - Citing Paper: Emerging role of the RNA-editing enzyme ADAR1 in stem cell fate and function., References: ['']\n",
      "DEBUG - Citing Paper: The essential role of N6-methyladenosine RNA methylation in complex eye diseases., References: ['']\n",
      "DEBUG - Citing Paper: The RNA polymerase III-RIG-I axis in antiviral immunity and inflammation., References: ['']\n",
      "DEBUG - Citing Paper: The 3' UTR polymorphisms rs3742330 in DICER1 and rs10719 in DROSHA genes are not associated with primary open-angle and angle-closure glaucoma: As case-control study., References: ['']\n",
      "DEBUG - Citing Paper: Oxidative stress in retinal pigment epithelium degeneration: from pathogenesis to therapeutic targets in dry age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Immunogenicity in renal cell carcinoma: shifting focus to alternative sources of tumour-specific antigens., References: ['']\n",
      "DEBUG - Citing Paper: MAPK Pathways in Ocular Pathophysiology: Potential Therapeutic Drugs and Challenges., References: ['']\n",
      "DEBUG - Citing Paper: Non-Coding RNAs Regulating Mitochondrial Functions and the Oxidative Stress Response as Putative Targets against Age-Related Macular Degeneration (AMD)., References: ['']\n",
      "DEBUG - Citing Paper: The Pol III transcriptome: Basic features, recurrent patterns, and emerging roles in cancer., References: ['']\n",
      "DEBUG - Citing Paper: Murine Gammaherpesvirus 68 ORF45 Stimulates B2 Retrotransposon and Pre-tRNA Activation in a Manner Dependent on Mitogen-Activated Protein Kinase (MAPK) Signaling., References: ['']\n",
      "DEBUG - Citing Paper: Dimethyl Fumarate Protects Retinal Pigment Epithelium from Blue Light-Induced Oxidative Damage via the Nrf2 Pathway., References: ['']\n",
      "DEBUG - Citing Paper: Pathogenic tau-induced transposable element-derived dsRNA drives neuroinflammation., References: ['']\n",
      "DEBUG - Citing Paper: WiFi Related Radiofrequency Electromagnetic Fields Promote Transposable Element Dysregulation and Genomic Instability in <i>Drosophila melanogaster</i>., References: ['']\n",
      "DEBUG - Citing Paper: Reduced RNA adenosine-to-inosine editing in hippocampus vasculature associated with Alzheimer's disease., References: ['']\n",
      "DEBUG - Citing Paper: <i>Dicer1</i> deficient mice exhibit premature aging and metabolic perturbations in adipocytes., References: ['']\n",
      "DEBUG - Citing Paper: UBE3D Is Involved in Blue Light-Induced Retinal Damage by Regulating Double-Strand Break Repair., References: ['']\n",
      "DEBUG - Citing Paper: Non-coding RNAs: The Neuroinflammatory Regulators in Neurodegenerative Diseases., References: ['']\n",
      "DEBUG - Citing Paper: cGAS inhibition alleviates Alu RNA-induced immune responses and cytotoxicity in retinal pigmented epithelium., References: ['']\n",
      "DEBUG - Citing Paper: DNA damage and repair in age-related inflammation., References: ['']\n",
      "DEBUG - Citing Paper: Inflammasome Activation in Retinal Pigment Epithelium from Human Donors with Age-Related Macular Degeneration., References: ['']\n",
      "DEBUG - Citing Paper: The Role of Transposable Elements of the Human Genome in Neuronal Function and Pathology., References: ['']\n",
      "DEBUG - Citing Paper: Animal models of age-related macular degeneration and their translatability into the clinic., References: ['']\n",
      "DEBUG - Citing Paper: Dicer and PKR as Novel Regulators of Embryonic Stem Cell Fate and Antiviral Innate Immunity., References: ['']\n",
      "DEBUG - Citing Paper: Nutraceuticals/Drugs Promoting Mitophagy and Mitochondrial Biogenesis May Combat the Mitochondrial Dysfunction Driving Progression of Dry Age-Related Macular Degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Neuroprotective Effects of PARP Inhibitors in <i>Drosophila</i> Models of Alzheimer's Disease., References: ['']\n",
      "DEBUG - Citing Paper: Subretinal injection in mice to study retinal physiology and disease., References: ['']\n",
      "DEBUG - Citing Paper: AMD Genomics: Non-Coding RNAs as Biomarkers and Therapeutic Targets., References: ['']\n",
      "DEBUG - Citing Paper: Polymorphism rs3742330 in microRNA Biogenesis Gene <i>DICER1</i> Is Associated with Pseudoexfoliation Glaucoma in Saudi Cohort., References: ['']\n",
      "DEBUG - Citing Paper: The Learning Curve of Murine Subretinal Injection Among Clinically Trained Ophthalmic Surgeons., References: ['']\n",
      "DEBUG - Citing Paper: Exudative versus Nonexudative Age-Related Macular Degeneration: Physiopathology and Treatment Options., References: ['']\n",
      "DEBUG - Citing Paper: Damage-Associated Molecular Patterns (DAMPs) in Retinal Disorders., References: ['']\n",
      "DEBUG - Citing Paper: A comprehensive WGS-based pipeline for the identification of new candidate genes in inherited retinal dystrophies., References: ['']\n",
      "DEBUG - Citing Paper: Alu RNA Structural Features Modulate Immune Cell Activation and A-to-I Editing of Alu RNAs Is Diminished in Human Inflammatory Bowel Disease., References: ['']\n",
      "DEBUG - Citing Paper: Analysis of LINE1 Retrotransposons in Huntington's Disease., References: ['']\n",
      "DEBUG - Citing Paper: A <i>Gypsy</i> element contributes to the nuclear retention and transcriptional regulation of the resident lncRNA in locusts., References: ['']\n",
      "DEBUG - Citing Paper: Targeting Pyroptotic Cell Death Pathways in Retinal Disease., References: ['']\n",
      "DEBUG - Citing Paper: Transposable element activation promotes neurodegeneration in a <i>Drosophila</i> model of Huntington's disease., References: ['']\n",
      "DEBUG - Citing Paper: Malondialdehyde-Modified Photoreceptor Outer Segments Promote Choroidal Neovascularization in Mice., References: ['']\n",
      "DEBUG - Citing Paper: DDX17 is an essential mediator of sterile NLRC4 inflammasome activation by retrotransposon RNAs., References: ['']\n",
      "DEBUG - Citing Paper: Molecular Mechanisms of Retinal Pigment Epithelium Dysfunction in Age-Related Macular Degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Cellular origins of dsRNA, their recognition and consequences., References: ['']\n",
      "DEBUG - Citing Paper: Targeting Lipid Metabolism for the Treatment of Age-Related Macular Degeneration: Insights from Preclinical Mouse Models., References: ['']\n",
      "DEBUG - Citing Paper: Introns encode dsRNAs undetected by RIG-I/MDA5/interferons and sensed via RNase L., References: ['']\n",
      "DEBUG - Citing Paper: MicroRNA regulation of critical retinal pigment epithelial functions., References: ['']\n",
      "DEBUG - Citing Paper: Cytoplasmic DNA: sources, sensing, and role in aging and disease., References: ['']\n",
      "DEBUG - Citing Paper: Biochemical and Immunological implications of Lutein and Zeaxanthin., References: ['']\n",
      "DEBUG - Citing Paper: Alu RNA and their roles in human disease states., References: ['']\n",
      "DEBUG - Citing Paper: Identification of fluoxetine as a direct NLRP3 inhibitor to treat atrophic macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Targeting senescent retinal pigment epithelial cells facilitates retinal regeneration in mouse models of age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: DICER1 tumor predisposition syndrome: an evolving story initiated with the pleuropulmonary blastoma., References: ['']\n",
      "DEBUG - Citing Paper: <i>Alu</i> complementary DNA is enriched in atrophic macular degeneration and triggers retinal pigmented epithelium toxicity via cytosolic innate immunity., References: ['']\n",
      "DEBUG - Citing Paper: Corticosterone dynamically regulates retrotransposable element expression in the rat hippocampus and C6 cells., References: ['']\n",
      "DEBUG - Citing Paper: Inducible and reversible inhibition of miRNA-mediated gene repression in vivo., References: ['']\n",
      "DEBUG - Citing Paper: RNA structure probing reveals the structural basis of Dicer binding and cleavage., References: ['']\n",
      "DEBUG - Citing Paper: Intercellular viral spread and intracellular transposition of Drosophila gypsy., References: ['']\n",
      "DEBUG - Citing Paper: Nucleoside reverse transcriptase inhibitors and Kamuvudines inhibit amyloid-Î² induced retinal pigmented epithelium degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Immunological Aspects of Age-Related Macular Degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Dicer represses the interferon response and the double-stranded RNA-activated protein kinase pathway inÂ mouse embryonic stem cells., References: ['']\n",
      "DEBUG - Citing Paper: RNA and DNA G-quadruplexes bind to human dicer and inhibit its activity., References: ['']\n",
      "DEBUG - Citing Paper: The L1-dependant and Pol III transcribed Alu retrotransposon, from its discovery to innate immunity., References: ['']\n",
      "DEBUG - Citing Paper: Increased Alu RNA processing in Alzheimer brains is linked to gene expression changes., References: ['']\n",
      "DEBUG - Citing Paper: Transposable Element Landscape in Drosophila Populations Selected for Longevity., References: ['']\n",
      "DEBUG - Citing Paper: Cytoplasmic synthesis of endogenous <i>Alu</i> complementary DNA via reverse transcription and implications in age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: The Impact of miRNAs in Health and Disease of Retinal Pigment Epithelium., References: ['']\n",
      "DEBUG - Citing Paper: Neovascular Macular Degeneration: A Review of Etiology, Risk Factors, and Recent Advances in Research and Therapy., References: ['']\n",
      "DEBUG - Citing Paper: Recognize Yourself-Innate Sensing of Non-LTR Retrotransposons., References: ['']\n",
      "DEBUG - Citing Paper: Not All Stressors Are Equal: Mechanism of Stressors on RPE Cell Degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Mitochondrial dysfunction induces RNA interference in C. elegans through a pathway homologous to the mammalian RIG-I antiviral response., References: ['']\n",
      "DEBUG - Citing Paper: MicroRNAs Regulating Cytoskeleton Dynamics, Endocytosis, and Cell Motility-A Link Between Neurodegeneration and Cancer?, References: ['']\n",
      "DEBUG - Citing Paper: Modulation of Tmem135 Leads to Retinal Pigmented Epithelium Pathologies in Mice., References: ['']\n",
      "DEBUG - Citing Paper: Adenosine-to-Inosine RNA Editing of Alu Double-Stranded (ds)RNAs Is Markedly Decreased in Multiple Sclerosis and Unedited Alu dsRNAs Are Potent Activators of Proinflammatory Transcriptional Responses., References: ['']\n",
      "DEBUG - Citing Paper: Decreased expression of miR-29 family associated with autoimmune myasthenia gravis., References: ['']\n",
      "DEBUG - Citing Paper: An Updated Review of the Epigenetic Mechanism Underlying the Pathogenesis of Age-related Macular Degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Dicing the Disease with Dicer: The Implications of Dicer Ribonuclease in Human Pathologies., References: ['']\n",
      "DEBUG - Citing Paper: Deficiency of C-X-C chemokine receptor type 5 (CXCR5) gene causes dysfunction of retinal pigment epithelium cells., References: ['']\n",
      "DEBUG - Citing Paper: Protective Effects and Molecular Signaling of n-3 Fatty Acids on Oxidative Stress and Inflammation in Retinal Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Repurposing anti-inflammasome NRTIs for improving insulin sensitivity and reducing type 2 diabetes development., References: ['']\n",
      "DEBUG - Citing Paper: Caveolin-1 Promotes Cellular Senescence in Exchange for Blocking Subretinal Fibrosis in Age-Related Macular Degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Spiropyran as a potential molecular diagnostic tool for double-stranded RNA detection., References: ['']\n",
      "DEBUG - Citing Paper: Lamivudine Inhibits <i>Alu</i> RNA-induced Retinal Pigment Epithelium Degeneration via Anti-inflammatory and Anti-senescence Activities., References: ['']\n",
      "DEBUG - Citing Paper: Processing of <i>Alu</i> small RNAs by DICER/ADAR1 complexes and their RNAi targets., References: ['']\n",
      "DEBUG - Citing Paper: DICER1 in the Pathogenesis of Age-related Macular Degeneration (AMD) - <i>Alu</i> RNA Accumulation versus miRNA Dysregulation., References: ['']\n",
      "DEBUG - Citing Paper: A Clinical Metabolite of Azidothymidine Inhibits Experimental Choroidal Neovascularization and Retinal Pigmented Epithelium Degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Retinal pigment epithelium and age-related macular degeneration: A review of major disease mechanisms., References: ['']\n",
      "DEBUG - Citing Paper: RNA polymerase III transcription as a disease factor., References: ['']\n",
      "DEBUG - Citing Paper: DICER regulates the expression of major satellite repeat transcripts and meiotic chromosome segregation during spermatogenesis., References: ['']\n",
      "DEBUG - Citing Paper: AP-TSS: A New Method for the Analysis of RNA Expression from Particular and Challenging Transcription Start Sites., References: ['']\n",
      "DEBUG - Citing Paper: Conserved Herpesvirus Kinase ORF36 Activates B2 Retrotransposons during Murine Gammaherpesvirus Infection., References: ['']\n",
      "DEBUG - Citing Paper: <i>Caenorhabditis elegans</i> ADAR editing and the ERI-6/7/MOV10 RNAi pathway silence endogenous viral elements and LTR retrotransposons., References: ['']\n",
      "DEBUG - Citing Paper: The role of the redox/miR-6855-3p/PRDX5A axis in reversing SLUG-mediated BRCA2 silencing in breast cancer cells., References: ['']\n",
      "DEBUG - Citing Paper: Chronic Dicer1 deficiency promotes atrophic and neovascular outer retinal pathologies in mice., References: ['']\n",
      "DEBUG - Citing Paper: Epigenetics in age-related macular degeneration: new discoveries and future perspectives., References: ['']\n",
      "DEBUG - Citing Paper: Biomarker potential of repetitive-element transcriptome in lung cancer., References: ['']\n",
      "DEBUG - Citing Paper: B2 and ALU retrotransposons are self-cleaving ribozymes whose activity is enhanced by EZH2., References: ['']\n",
      "DEBUG - Citing Paper: Interplay between MicroRNAs and Oxidative Stress in Neurodegenerative Diseases., References: ['']\n",
      "DEBUG - Citing Paper: New Therapies of Neovascular AMD-Beyond Anti-VEGFs., References: ['']\n",
      "DEBUG - Citing Paper: The microphthalmia-associated transcription factor (Mitf) gene and its role in regulating eye function., References: ['']\n",
      "DEBUG - Citing Paper: Systemic expression of Alu RNA in patients with geographic atrophy secondary to age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: A systems biology approach towards understanding and treating non-neovascular age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: <i>Alu</i> RNA Modulates the Expression of Cell Cycle Genes in Human Fibroblasts., References: ['']\n",
      "DEBUG - Citing Paper: Early life exposures, neurodevelopmental disorders, and transposable elements., References: ['']\n",
      "DEBUG - Citing Paper: Quantifying Retinal Pigment Epithelium Dysmorphia and Loss of Histologic Autofluorescence in Age-Related Macular Degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Cellular labeling of endogenous retrovirus replication (CLEVR) reveals de novo insertions of the gypsy retrotransposable element in cell culture and in both neurons and glial cells of aging fruit flies., References: ['']\n",
      "DEBUG - Citing Paper: Ro60 and Y RNAs: structure, functions, and roles in autoimmunity., References: ['']\n",
      "DEBUG - Citing Paper: Heat shock in C. elegans induces downstream of gene transcription and accumulation of double-stranded RNA., References: ['']\n",
      "DEBUG - Citing Paper: Mapping the dsRNA World., References: ['']\n",
      "DEBUG - Citing Paper: Conditional Dicer1 depletion using Chrnb4-Cre leads to cone cell death and impaired photopic vision., References: ['']\n",
      "DEBUG - Citing Paper: Dgcr8 knockout approaches to understand microRNA functions in vitro and in vivo., References: ['']\n",
      "DEBUG - Citing Paper: Double-Stranded RNA Sensors and Modulators in Innate Immunity., References: ['']\n",
      "DEBUG - Citing Paper: Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: <i>Drosophila</i> as a Model to Study Brain Innate Immunity in Health and Disease., References: ['']\n",
      "DEBUG - Citing Paper: RIG-I like receptor sensing of host RNAs facilitates the cell-intrinsic immune response to KSHV infection., References: ['']\n",
      "DEBUG - Citing Paper: Regulating gene expression in animals through RNA endonucleolytic cleavage., References: ['']\n",
      "DEBUG - Citing Paper: Calcified nodules in retinal drusen are associated with disease progression in age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: DICER1 Syndrome: Characterization of the Ocular Phenotype in a Family-Based Cohort Study., References: ['']\n",
      "DEBUG - Citing Paper: The impact of lipids, lipid oxidation, and inflammation on AMD, and the potential role of miRNAs on lipid metabolism in the RPE., References: ['']\n",
      "DEBUG - Citing Paper: Remodeling of Retinal Architecture in Diabetic Retinopathy: Disruption of Ocular Physiology and Visual Functions by Inflammatory Gene Products and Pyroptosis., References: ['']\n",
      "DEBUG - Citing Paper: Modulation of three key innate immune pathways for the most common retinal degenerative diseases., References: ['']\n",
      "DEBUG - Citing Paper: DICER1 regulates antibacterial function of epididymis by modulating transcription of Î²-defensins., References: ['']\n",
      "DEBUG - Citing Paper: Non-coding RNAs in retinal development and function., References: ['']\n",
      "DEBUG - Citing Paper: Function of HNRNPC in breast cancer cells by controlling the dsRNA-induced interferon response., References: ['']\n",
      "DEBUG - Citing Paper: Oxidative stress causes Alu RNA accumulation via PIWIL4 sequestration into stress granules., References: ['']\n",
      "DEBUG - Citing Paper: DICER1: A Key Player in Rheumatoid Arthritis, at the Crossroads of Cellular Stress, Innate Immunity, and Chronic Inflammation in Aging., References: ['']\n",
      "DEBUG - Citing Paper: Characterization of Human iPSC-RPE on a Prosthetic Bruch's Membrane Manufactured From Silk Fibroin., References: ['']\n",
      "DEBUG - Citing Paper: L1 retrotransposition in the soma: a field jumping ahead., References: ['']\n",
      "DEBUG - Citing Paper: JNK-mediated microglial DICER degradation potentiates inflammatory responses to induce dopaminergic neuron loss., References: ['']\n",
      "DEBUG - Citing Paper: AMP-Activated Protein Kinase Mediates the Effect of Leptin on Avian Autophagy in a Tissue-Specific Manner., References: ['']\n",
      "DEBUG - Citing Paper: Protective paraspeckle hyper-assembly downstream of TDP-43 loss of function in amyotrophic lateral sclerosis., References: ['']\n",
      "DEBUG - Citing Paper: Mitochondrial quality control in AMD: does mitophagy play a pivotal role?, References: ['']\n",
      "DEBUG - Citing Paper: The Retrotransposon storm and the dangers of a Collyer's genome., References: ['']\n",
      "DEBUG - Citing Paper: Epigenetic and Transcriptional Modifications in Repetitive Elements in Petrol Station Workers Exposed to Benzene and MTBE., References: ['']\n",
      "DEBUG - Citing Paper: Heterochromatin protects retinal pigment epithelium cells from oxidative damage by silencing p53 target genes., References: ['']\n",
      "DEBUG - Citing Paper: Warning SINEs: Alu elements, evolution of the human brain, and the spectrum of neurological disease., References: ['']\n",
      "DEBUG - Citing Paper: RNA Biology in Retinal Development and Disease., References: ['']\n",
      "DEBUG - Citing Paper: Breaching Self-Tolerance to Alu Duplex RNA Underlies MDA5-Mediated Inflammation., References: ['']\n",
      "DEBUG - Citing Paper: Evidence for the activation of pyroptotic and apoptotic pathways in RPE cells associated with NLRP3 inflammasome in the rodent eye., References: ['']\n",
      "DEBUG - Citing Paper: Issues with the Specificity of Immunological Reagents for NLRP3: Implications for Age-related Macular Degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Recognizing the SINEs of Infection: Regulation of Retrotransposon Expression and Modulation of Host Cell Processes., References: ['']\n",
      "DEBUG - Citing Paper: MiR-211 is essential for adult cone photoreceptor maintenance and visual function., References: ['']\n",
      "DEBUG - Citing Paper: Oxidative Stress Induces an Interactive Decline in Wnt and Nrf2 Signaling in Degenerating Retinal Pigment Epithelium., References: ['']\n",
      "DEBUG - Citing Paper: cGAS drives noncanonical-inflammasome activation in age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Noncoding RNA Surveillance: The Ends Justify the Means., References: ['']\n",
      "DEBUG - Citing Paper: Enhanced Detection of Sub-Retinal Pigment Epithelial Cell Layer Deposits in Human and Murine Tissue: Imaging Zinc as a Biomarker for Age-Related Macular Degeneration (An American Ophthalmological Society Thesis)., References: ['']\n",
      "DEBUG - Citing Paper: Suppression of microRNA Activity in Kidney Collecting Ducts Induces Partial Loss of Epithelial Phenotype and Renal Fibrosis., References: ['']\n",
      "DEBUG - Citing Paper: Alu RNA accumulation induces epithelial-to-mesenchymal transition by modulating miR-566 and is associated with cancer progression., References: ['']\n",
      "DEBUG - Citing Paper: DIP1 modulates stem cell homeostasis in Drosophila through regulation of sisR-1., References: ['']\n",
      "DEBUG - Citing Paper: Host Noncoding Retrotransposons Induced by DNA Viruses: a SINE of Infection?, References: ['']\n",
      "DEBUG - Citing Paper: Recent developments in age-related macular degeneration: a review., References: ['']\n",
      "DEBUG - Citing Paper: Mobile DNA in Health and Disease., References: ['']\n",
      "DEBUG - Citing Paper: A glimpse at the aging eye., References: ['']\n",
      "DEBUG - Citing Paper: Repetitive element transcripts are elevated in the brain of C9orf72 ALS/FTLD patients., References: ['']\n",
      "DEBUG - Citing Paper: Altered bioenergetics and enhanced resistance to oxidative stress in human retinal pigment epithelial cells from donors with age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Dicer and microRNAs protect adult dopamine neurons., References: ['']\n",
      "DEBUG - Citing Paper: Molecular mechanisms of Dicer: endonuclease and enzymatic activity., References: ['']\n",
      "DEBUG - Citing Paper: Genome-wide mapping of infection-induced SINE RNAs reveals a role in selective mRNA export., References: ['']\n",
      "DEBUG - Citing Paper: Retrotransposon activation contributes to neurodegeneration in a Drosophila TDP-43 model of ALS., References: ['']\n",
      "DEBUG - Citing Paper: DUSP11 - An RNA phosphatase that regulates host and viral non-coding RNAs in mammalian cells., References: ['']\n",
      "DEBUG - Citing Paper: Nutritional Supplementation Inhibits the Increase in Serum Malondialdehyde in Patients with Wet Age-Related Macular Degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Shortcuts to a functional adipose tissue: The role of small non-coding RNAs., References: ['']\n",
      "DEBUG - Citing Paper: Signal Factors Secreted by 2D and Spheroid Mesenchymal Stem Cells and by Cocultures of Mesenchymal Stem Cells Derived Microvesicles and Retinal Photoreceptor Neurons., References: ['']\n",
      "DEBUG - Citing Paper: MicroRNA-processing Enzymes Are Essential for Survival and Function of Mature Retinal Pigmented Epithelial Cells in Mice., References: ['']\n",
      "DEBUG - Citing Paper: Polycomb repressive complex 1 provides a molecular explanation for repeat copy number dependency in FSHD muscular dystrophy., References: ['']\n",
      "DEBUG - Citing Paper: VISUALIZING RETINAL PIGMENT EPITHELIUM PHENOTYPES IN THE TRANSITION TO GEOGRAPHIC ATROPHY IN AGE-RELATED MACULAR DEGENERATION., References: ['']\n",
      "DEBUG - Citing Paper: Accumulation of cholesterol and increased demand for zinc in serum-deprived RPE cells., References: ['']\n",
      "DEBUG - Citing Paper: Dicer maintains the identity and function of proprioceptive sensory neurons., References: ['']\n",
      "DEBUG - Citing Paper: THE PATHOPHYSIOLOGY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION AND THE COMPLEMENT PATHWAY AS A THERAPEUTIC TARGET., References: ['']\n",
      "DEBUG - Citing Paper: Dry Age-Related Macular Degeneration Pharmacology., References: ['']\n",
      "DEBUG - Citing Paper: Autophagy regulates death of retinal pigment epithelium cells in age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Splicing repression allows the gradual emergence of new Alu-exons in primate evolution., References: ['']\n",
      "DEBUG - Citing Paper: DUSP11 activity on triphosphorylated transcripts promotes Argonaute association with noncanonical viral microRNAs and regulates steady-state levels of cellular noncoding RNAs., References: ['']\n",
      "DEBUG - Citing Paper: A network-biology perspective of microRNA function and dysfunction in cancer., References: ['']\n",
      "DEBUG - Citing Paper: Nuclear Factor (Erythroid-Derived)-Related Factor 2-Associated Retinal Pigment Epithelial Cell Protection under Blue Light-Induced Oxidative Stress., References: ['']\n",
      "DEBUG - Citing Paper: Endogenous Retroelements and the Host Innate Immune Sensors., References: ['']\n",
      "DEBUG - Citing Paper: Retinal expression of small non-coding RNAs in a murine model of proliferative retinopathy., References: ['']\n",
      "DEBUG - Citing Paper: Alu-miRNA interactions modulate transcript isoform diversity in stress response and reveal signatures of positive selection., References: ['']\n",
      "DEBUG - Citing Paper: Restricting retrotransposons: a review., References: ['']\n",
      "DEBUG - Citing Paper: MicroRNA-29b Overexpression Decreases Extracellular Matrix mRNA and Protein Production in Human Corneal Endothelial Cells., References: ['']\n",
      "DEBUG - Citing Paper: A Revised Hemodynamic Theory of Age-Related Macular Degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Targeting MAPK Signaling in Age-Related Macular Degeneration., References: ['']\n",
      "DEBUG - Citing Paper: AMD Genetics in India: The Missing Links., References: ['']\n",
      "DEBUG - Citing Paper: Roles for retrotransposon insertions in human disease., References: ['']\n",
      "DEBUG - Citing Paper: Risk factors and biomarkers of age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Age-associated de-repression of retrotransposons in the Drosophila fat body, its potential cause and consequence., References: ['']\n",
      "DEBUG - Citing Paper: Production of small RNAs by mammalian Dicer., References: ['']\n",
      "DEBUG - Citing Paper: Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs., References: ['']\n",
      "DEBUG - Citing Paper: Update on Clinical Trials in Dry Age-related Macular Degeneration., References: ['']\n",
      "DEBUG - Citing Paper: The Complete Genome Sequences, Unique Mutational Spectra, and Developmental Potency of Adult Neurons Revealed by Cloning., References: ['']\n",
      "DEBUG - Citing Paper: Selective repression of SINE transcription by RNA polymerase III., References: ['']\n",
      "DEBUG - Citing Paper: Functional single nucleotide polymorphism in IL-17A 3' untranslated region is targeted by miR-4480 in vitro and may be associated with age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: A Small RNA-Based Immune System Defends Germ Cells against Mobile Genetic Elements., References: ['']\n",
      "DEBUG - Citing Paper: Non-Coding RNA: Sequence-Specific Guide for Chromatin Modification and DNA Damage Signaling., References: ['']\n",
      "DEBUG - Citing Paper: Infection-Induced Retrotransposon-Derived Noncoding RNAs Enhance Herpesviral Gene Expression via the NF-ÎºB Pathway., References: ['']\n",
      "DEBUG - Citing Paper: What might retrotransposons teach us about aging?, References: ['']\n",
      "DEBUG - Citing Paper: Alu element-containing RNAs maintain nucleolar structure and function., References: ['']\n",
      "DEBUG - Citing Paper: The impact of microRNA gene regulation on the survival and function of mature cell types in the eye., References: ['']\n",
      "DEBUG - Citing Paper: RNA interference machinery-mediated gene regulation in mouse adult neural stem cells., References: ['']\n",
      "DEBUG - Citing Paper: RPE necroptosis in response to oxidative stress and in AMD., References: ['']\n",
      "DEBUG - Citing Paper: Gene expression regulation in retinal pigment epithelial cells induced by viral RNA and viral/bacterial DNA., References: ['']\n",
      "DEBUG - Citing Paper: Dysregulated miRNA biogenesis downstream of cellular stress and ALS-causing mutations: a new mechanism for ALS., References: ['']\n",
      "DEBUG - Citing Paper: Microprocessor complex subunit DiGeorge syndrome critical region gene 8 (Dgcr8) is required for schwann cell myelination and myelin maintenance., References: ['']\n",
      "DEBUG - Citing Paper: NLRP3 Inflammasome and Pathobiology in AMD., References: ['']\n",
      "DEBUG - Citing Paper: The stereotypical molecular cascade in neovascular age-related macular degeneration: the role of dynamic reciprocity., References: ['']\n",
      "DEBUG - Citing Paper: MicroRNA-103a-3p controls proliferation and osteogenic differentiation of human adipose tissue-derived stromal cells., References: ['']\n",
      "DEBUG - Citing Paper: Double-Stranded RNA Is Detected by Immunofluorescence Analysis in RNA and DNA Virus Infections, Including Those by Negative-Stranded RNA Viruses., References: ['']\n",
      "DEBUG - Citing Paper: Histological Characterization of the Dicer1 Mutant Zebrafish Retina., References: ['']\n",
      "DEBUG - Citing Paper: Dicer Is Required for Normal Cerebellar Development and to Restrain Medulloblastoma Formation., References: ['']\n",
      "DEBUG - Citing Paper: Deletion of autophagy inducer RB1CC1 results in degeneration of the retinal pigment epithelium., References: ['']\n",
      "DEBUG - Citing Paper: Iron Toxicity in the Retina Requires Alu RNA and the NLRP3 Inflammasome., References: ['']\n",
      "DEBUG - Citing Paper: Retinal phagocytes in age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Aicardi-GoutiÃ¨res syndrome and the type I interferonopathies., References: ['']\n",
      "DEBUG - Citing Paper: Inflammatory Mechanisms of Age-related Macular Degeneration., References: ['']\n",
      "DEBUG - Citing Paper: A chimeric Cfh transgene leads to increased retinal oxidative stress, inflammation, and accumulation of activated subretinal microglia in mice., References: ['']\n",
      "DEBUG - Citing Paper: Swiss army knives: non-canonical functions of nuclear Drosha and Dicer., References: ['']\n",
      "DEBUG - Citing Paper: The role of Dicer1 in the male reproductive tract., References: ['']\n",
      "DEBUG - Citing Paper: Barrier Function of the Repaired Skin Is Disrupted Following Arrest of Dicer in Keratinocytes., References: ['']\n",
      "DEBUG - Citing Paper: The Project MACULA Retinal Pigment Epithelium Grading System for Histology and Optical Coherence Tomography in Age-Related Macular Degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Genome-wide profiling of the C. elegans dsRNAome., References: ['']\n",
      "DEBUG - Citing Paper: Gossypol Acetic Acid Prevents Oxidative Stress-Induced Retinal Pigment Epithelial Necrosis by Regulating the FoxO3/Sestrin2 Pathway., References: ['']\n",
      "DEBUG - Citing Paper: SINE transcription by RNA polymerase III is suppressed by histone methylation but not by DNA methylation., References: ['']\n",
      "DEBUG - Citing Paper: NLRP3 inflammasome: activation and regulation in age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Vision from next generation sequencing: multi-dimensional genome-wide analysis for producing gene regulatory networks underlying retinal development, aging and disease., References: ['']\n",
      "DEBUG - Citing Paper: Inflammation and Cell Death in Age-Related Macular Degeneration: An Immunopathological and Ultrastructural Model., References: ['']\n",
      "DEBUG - Citing Paper: Transposable elements modulate human RNA abundance and splicing via specific RNA-protein interactions., References: ['']\n",
      "DEBUG - Citing Paper: IL-18 is not therapeutic for neovascular age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity., References: ['']\n",
      "DEBUG - Citing Paper: TDP-1, the Caenorhabditis elegans ortholog of TDP-43, limits the accumulation of double-stranded RNA., References: ['']\n",
      "DEBUG - Citing Paper: A cytoplasmic RNA virus generates functional viral small RNAs and regulates viral IRES activity in mammalian cells., References: ['']\n",
      "DEBUG - Citing Paper: DICER1/Alu RNA dysmetabolism induces Caspase-8-mediated cell death in age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Dry age-related macular degeneration: A currently unmet clinical need., References: ['']\n",
      "DEBUG - Citing Paper: Iron upregulates melanogenesis in cultured retinal pigment epithelial cells., References: ['']\n",
      "DEBUG - Citing Paper: Dynamic Alu methylation during normal development, aging, and tumorigenesis., References: ['']\n",
      "DEBUG - Citing Paper: The role of epigenetics in age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Evolutionary conservation and expression of human RNA-binding proteins and their role in human genetic disease., References: ['']\n",
      "DEBUG - Citing Paper: Direct binding of the Alu binding protein dimer SRP9/14 to 40S ribosomal subunits promotes stress granule formation and is regulated by Alu RNA., References: ['']\n",
      "DEBUG - Citing Paper: Selective impairment of a subset of Ran-GTP-binding domains of ran-binding protein 2 (Ranbp2) suffices to recapitulate the degeneration of the retinal pigment epithelium (RPE) triggered by Ranbp2 ablation., References: ['']\n",
      "DEBUG - Citing Paper: The RNA-centred view of the synapse: non-coding RNAs and synaptic plasticity., References: ['']\n",
      "DEBUG - Citing Paper: Using current data to define new approach in age related macular degeneration: need to accelerate translational research., References: ['']\n",
      "DEBUG - Citing Paper: Regulation of microRNA biogenesis., References: ['']\n",
      "DEBUG - Citing Paper: Mitochondrial oxidative stress in the retinal pigment epithelium leads to localized retinal degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Studying age-related macular degeneration using animal models., References: ['']\n",
      "DEBUG - Citing Paper: Protection of retina by Î±B crystallin in sodium iodate induced retinal degeneration., References: ['']\n",
      "DEBUG - Citing Paper: miRNAs at the interface of cellular stress and disease., References: ['']\n",
      "DEBUG - Citing Paper: The RIDL hypothesis: transposable elements as functional domains of long noncoding RNAs., References: ['']\n",
      "DEBUG - Citing Paper: Human nuclear Dicer restricts the deleterious accumulation of endogenous double-stranded RNA., References: ['']\n",
      "DEBUG - Citing Paper: DICER1 is essential for survival of postmitotic rod photoreceptor cells in mice., References: ['']\n",
      "DEBUG - Citing Paper: Transcription-independent functions of an RNA polymerase II subunit, Rpb2, during genome rearrangement in the ciliate, Oxytricha trifallax., References: ['']\n",
      "DEBUG - Citing Paper: Histamine H4 receptor as a new therapeutic target for choroidal neovascularization in age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: A universal small molecule, inorganic phosphate, restricts the substrate specificity of Dicer-2 in small RNA biogenesis., References: ['']\n",
      "DEBUG - Citing Paper: Interleukin-17 retinotoxicity is prevented by gene transfer of a soluble interleukin-17 receptor acting as a cytokine blocker: implications for age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Reduced insulin/IGF-1 signaling restores germ cell immortality to Caenorhabditis elegans Piwi mutants., References: ['']\n",
      "DEBUG - Citing Paper: Immune responses in age-related macular degeneration and a possible long-term therapeutic strategy for prevention., References: ['']\n",
      "DEBUG - Citing Paper: The Rpe65 rd12 allele exerts a semidominant negative effect on vision in mice., References: ['']\n",
      "DEBUG - Citing Paper: Inorganic phosphate blocks binding of pre-miRNA to Dicer-2 via its PAZ domain., References: ['']\n",
      "DEBUG - Citing Paper: Drosha-independent DGCR8/Pasha pathway regulates neuronal morphogenesis., References: ['']\n",
      "DEBUG - Citing Paper: Alu- and 7SL RNA Analogues Suppress MCF-7 Cell Viability through Modulating the Transcription of Endoplasmic Reticulum Stress Response Genes., References: ['']\n",
      "DEBUG - Citing Paper: Chromatin structure and transposable elements in organismal aging., References: ['']\n",
      "DEBUG - Citing Paper: Valproic acid causes proteasomal degradation of DICER and influences miRNA expression., References: ['']\n",
      "DEBUG - Citing Paper: Endothelial cell microRNA expression in human late-onset Fuchs' dystrophy., References: ['']\n",
      "DEBUG - Citing Paper: TE-array--a high throughput tool to study transposon transcription., References: ['']\n",
      "DEBUG - Citing Paper: Dicer in immune cell development and function., References: ['']\n",
      "DEBUG - Citing Paper: In vivo imaging of retinal pigment epithelium cells in age related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Recognizing the enemy within: licensing RNA-guided genome defense., References: ['']\n",
      "DEBUG - Citing Paper: Alu mobile elements: from junk DNA to genomic gems., References: ['']\n",
      "DEBUG - Citing Paper: Dicer expression exhibits a tissue-specific diurnal pattern that is lost during aging and in diabetes., References: ['']\n",
      "DEBUG - Citing Paper: Functional microRNAs and target sites are created by lineage-specific transposition., References: ['']\n",
      "DEBUG - Citing Paper: The role of transposable elements in health and diseases of the central nervous system., References: ['']\n",
      "DEBUG - Citing Paper: Epigenetics in ocular diseases., References: ['']\n",
      "DEBUG - Citing Paper: MicroRNA-independent roles of the RNase III enzymes Drosha and Dicer., References: ['']\n",
      "DEBUG - Citing Paper: Functional principal component analysis reveals discriminating categories of retinal pigment epithelial morphology in mice., References: ['']\n",
      "DEBUG - Citing Paper: Association between geographic atrophy progression and reticular pseudodrusen in eyes with dry age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: TLR-independent and P2X7-dependent signaling mediate Alu RNA-induced NLRP3 inflammasome activation in geographic atrophy., References: ['']\n",
      "DEBUG - Citing Paper: Genetic architecture of retinal and macular degenerative diseases: the promise and challenges of next-generation sequencing., References: ['']\n",
      "DEBUG - Citing Paper: Role of antioxidant enzymes and small molecular weight antioxidants in the pathogenesis of age-related macular degeneration (AMD)., References: ['']\n",
      "DEBUG - Citing Paper: Next-generation therapeutic solutions for age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: NLRP3 inflammasome blockade inhibits VEGF-A-induced age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Loss of functional Dicer in mouse radial glia cell-autonomously prolongs cortical neurogenesis., References: ['']\n",
      "DEBUG - Citing Paper: Photoreceptor cell death and rescue in retinal detachment and degenerations., References: ['']\n",
      "DEBUG - Citing Paper: Disruption of microRNA biogenesis confers resistance to ER stress-induced cell death upstream of the mitochondrion., References: ['']\n",
      "DEBUG - Citing Paper: Programmed necrosis, not apoptosis, is a key mediator of cell loss and DAMP-mediated inflammation in dsRNA-induced retinal degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Aging is not a disease: distinguishing age-related macular degeneration from aging., References: ['']\n",
      "DEBUG - Citing Paper: Interaction of complement factor h and fibulin3 in age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Long non-coding RNAs: novel targets for nervous system disease diagnosis and therapy., References: ['']\n",
      "DEBUG - Citing Paper: Photoreceptor avascular privilege is shielded by soluble VEGF receptor-1., References: ['']\n",
      "DEBUG - Citing Paper: Immunology of age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: A gene expression restriction network mediated by sense and antisense Alu sequences located on protein-coding messenger RNAs., References: ['']\n",
      "DEBUG - Citing Paper: An eye on the future of inflammasomes and drug development in AMD., References: ['']\n",
      "DEBUG - Citing Paper: Non-coding RNAs in the development of sensory organs and related diseases., References: ['']\n",
      "DEBUG - Citing Paper: Activation of transposable elements during aging and neuronal decline in Drosophila., References: ['']\n",
      "DEBUG - Citing Paper: Review: Epigenetic mechanisms in ocular disease., References: ['']\n",
      "DEBUG - Citing Paper: Exploring the RNA world in hematopoietic cells through the lens of RNA-binding proteins., References: ['']\n",
      "DEBUG - Citing Paper: Functional impact of the human mobilome., References: ['']\n",
      "DEBUG - Citing Paper: Dicer deficiency reveals microRNAs predicted to control gene expression in the developing adrenal cortex., References: ['']\n",
      "DEBUG - Citing Paper: Targeting inflammation in emerging therapies for genetic retinal disease., References: ['']\n",
      "DEBUG - Citing Paper: \"Seq-ing\" insights into the epigenetics of neuronal gene regulation., References: ['']\n",
      "DEBUG - Citing Paper: Histologic basis of variations in retinal pigment epithelium autofluorescence in eyes with geographic atrophy., References: ['']\n",
      "DEBUG - Citing Paper: Deep sequencing of small RNAs identifies canonical and non-canonical miRNA and endogenous siRNAs in mammalian somatic tissues., References: ['']\n",
      "DEBUG - Citing Paper: Virus-encoded microRNAs: an overview and a look to the future., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor 3 (TLR3) protects retinal pigmented epithelium (RPE) cells from oxidative stress through a STAT3-dependent mechanism., References: ['']\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DEBUG - Citing Paper: Genetic mechanisms and age-related macular degeneration: common variants, rare variants, copy number variations, epigenetics, and mitochondrial genetics., References: ['']\n",
      "DEBUG - Citing Paper: Good news-bad news: the Yin and Yang of immune privilege in the eye., References: ['']\n",
      "DEBUG - Citing Paper: The role of dicer in DNA damage repair., References: ['']\n",
      "DEBUG - Citing Paper: Egr2::cre mediated conditional ablation of dicer disrupts histogenesis of mammalian central auditory nuclei., References: ['']\n",
      "DEBUG - Citing Paper: DICER- and AGO3-dependent generation of retinoic acid-induced DR2 Alu RNAs regulates human stem cell proliferation., References: ['']\n",
      "DEBUG - Citing Paper: A repetitive elements perspective in Polycomb epigenetics., References: ['']\n",
      "DEBUG - Citing Paper: A novel molecular mechanism in human genetic disease: a DNA repeat-derived lncRNA., References: ['']\n",
      "DEBUG - Citing Paper: Convergent transcription induces transcriptional gene silencing in fission yeast and mammalian cells., References: ['']\n",
      "DEBUG - Citing Paper: Genetic studies of age-related macular degeneration: lessons, challenges, and opportunities for disease management., References: ['']\n",
      "DEBUG - Citing Paper: Extensive somatic L1 retrotransposition in colorectal tumors., References: ['']\n",
      "DEBUG - Citing Paper: Role of microRNA processing in adipose tissue in stress defense and longevity., References: ['']\n",
      "DEBUG - Citing Paper: Transposable elements in TDP-43-mediated neurodegenerative disorders., References: ['']\n",
      "DEBUG - Citing Paper: miR-3928 activates ATR pathway by targeting Dicer., References: ['']\n",
      "DEBUG - Citing Paper: Human intron-encoded Alu RNAs are processed and packaged into Wdr79-associated nucleoplasmic box H/ACA RNPs., References: ['']\n",
      "DEBUG - Citing Paper: ERK1/2 activation is a therapeutic target in age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Identification of miRNA signatures during the differentiation of hESCs into retinal pigment epithelial cells., References: ['']\n",
      "DEBUG - Citing Paper: Emerging roles of non-coding RNAs in brain evolution, development, plasticity and disease., References: ['']\n",
      "DEBUG - Citing Paper: Dicer-dependent biogenesis of small RNAs derived from 7SL RNA., References: ['']\n",
      "DEBUG - Citing Paper: Mechanisms of age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Protein interactions with piALU RNA indicates putative participation of retroRNA in the cell cycle, DNA repair and chromatin assembly., References: ['']\n",
      "DEBUG - Citing Paper: Do human transposable element small RNAs serve primarily as genome defenders or genome regulators?, References: ['']\n",
      "DEBUG - Citing Paper: Loss of microRNAs in pyramidal neurons leads to specific changes in inhibitory synaptic transmission in the prefrontal cortex., References: ['']\n",
      "DEBUG - Citing Paper: Drosha regulates neurogenesis by controlling neurogenin 2 expression independent of microRNAs., References: ['']\n",
      "DEBUG - Citing Paper: Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma., References: ['']\n",
      "DEBUG - Citing Paper: The RNase III enzyme DROSHA is essential for microRNA production and spermatogenesis., References: ['']\n",
      "DEBUG - Citing Paper: MicroRNAs and fibrosis., References: ['']\n",
      "DEBUG - Citing Paper: Reduced mature microRNA levels in association with dicer loss in human temporal lobe epilepsy with hippocampal sclerosis., References: ['']\n",
      "DEBUG - Citing Paper: Human transposon tectonics., References: ['']\n",
      "DEBUG - Citing Paper: Genetic insights into age-related macular degeneration: controversies addressing risk, causality, and therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Uncovering the role of genomic \"dark matter\" in human disease., References: ['']\n",
      "DEBUG - Citing Paper: Understanding age-related macular degeneration (AMD): relationships between the photoreceptor/retinal pigment epithelium/Bruch's membrane/choriocapillaris complex., References: ['']\n",
      "DEBUG - Citing Paper: DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88., References: ['']\n",
      "DEBUG - Citing Paper: A long ncRNA links copy number variation to a polycomb/trithorax epigenetic switch in FSHD muscular dystrophy., References: ['']\n",
      "DEBUG - Citing Paper: Nuclear noncoding RNA surveillance: is the end in sight?, References: ['']\n",
      "DEBUG - Citing Paper: The physiological impact of microRNA gene regulation in the retina., References: ['']\n",
      "DEBUG - Citing Paper: miRNAs as potential therapeutic targets for age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Transcriptional regulation of translocator protein (Tspo) via a SINE B2-mediated natural antisense transcript in MA-10 Leydig cells., References: ['']\n",
      "DEBUG - Citing Paper: Systems-level analysis of age-related macular degeneration reveals global biomarkers and phenotype-specific functional networks., References: ['']\n",
      "DEBUG - Citing Paper: Mobile elements in the human genome: implications for disease., References: ['']\n",
      "DEBUG - Citing Paper: Functional Studies of microRNAs in Neural Stem Cells: Problems and Perspectives., References: ['']\n",
      "DEBUG - Citing Paper: Genetics of immunological and inflammatory components in age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Non-coding RNAs in retinal development., References: ['']\n",
      "DEBUG - Citing Paper: Alu elements: know the SINEs., References: ['']\n",
      "DEBUG - Citing Paper: The search for endogenous siRNAs in the mammalian brain., References: ['']\n",
      "DEBUG - Citing Paper: Dicer1 depletion in male germ cells leads to infertility due to cumulative meiotic and spermiogenic defects., References: ['']\n",
      "DEBUG - Citing Paper: Short-interfering RNAs induce retinal degeneration via TLR3 and IRF3., References: ['']\n",
      "DEBUG - Citing Paper: Dicer is required for haploid male germ cell differentiation in mice., References: ['']\n",
      "DEBUG - Citing Paper: Retrotransposon activation contributes to fragile X premutation rCGG-mediated neurodegeneration., References: ['']\n",
      "DEBUG - Citing Paper: Alternative miRNA biogenesis pathways and the interpretation of core miRNA pathway mutants., References: ['']\n",
      "DEBUG - Citing Paper: Retrotransposon-centered analysis of piRNA targeting shows a shift from active to passive retrotransposon transcription in developing mouse testes., References: ['']\n",
      "DEBUG - Citing Paper: Inhibition of activated pericentromeric SINE/Alu repeat transcription in senescent human adult stem cells reinstates self-renewal., References: ['']\n",
      "DEBUG - Citing Paper: A role for noncanonical microRNAs in the mammalian brain revealed by phenotypic differences in Dgcr8 versus Dicer1 knockouts and small RNA sequencing., References: ['']\n",
      "DEBUG - Citing Paper: Retinal pigment epithelial expression of complement regulator CD46 is altered early in the course of geographic atrophy., References: ['']\n",
      "DEBUG - Citing Paper: Induced pluripotent stem cell therapies for geographic atrophy of age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Age-related macular degeneration and the other double helix. The Cogan Lecture., References: ['']\n",
      "DEBUG - Citing Paper: Vision: Dicer leaps into view., References: ['']\n",
      "DEBUG - focal: DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration., NF: 0, NB: 0, NR: 0, D: 0\n",
      "DEBUG - Focal Paper: Sequence- and target-independent angiogenesis suppression by siRNA via TLR3., References: \n",
      "<\n",
      "http://www.sec.gov/Archives/edgar/data/879407/\n",
      "000119312511277913/d246656d8k.htm\n",
      ">\n",
      "\n",
      "DEBUG - Citing Paper: Precise genome-editing in human diseases: mechanisms, strategies and applications., References: ['']\n",
      "DEBUG - Citing Paper: pH-Responsive polymer boosts cytosolic siRNA release for retinal neovascularization therapy., References: ['']\n",
      "DEBUG - Citing Paper: Advancing cancer treatment: <i>in vivo</i> delivery of therapeutic small noncoding RNAs., References: ['']\n",
      "DEBUG - Citing Paper: Connective tissue growth factor: Role in trabecular meshwork remodeling and intraocular pressure lowering., References: ['']\n",
      "DEBUG - Citing Paper: HIF-1-Induced hsa-miR-429: Understanding Its Direct Targets as the Key to Developing Cancer Diagnostics and Therapies., References: ['']\n",
      "DEBUG - Citing Paper: Innate immune regulations and various siRNA modalities., References: ['']\n",
      "DEBUG - Citing Paper: Hyaluronic acid-based nanoparticles to deliver drugs to the ocular posterior segment., References: ['']\n",
      "DEBUG - Citing Paper: RNAi for the Treatment of People with Hemophilia: Current Evidence and Patient Selection., References: ['']\n",
      "DEBUG - Citing Paper: Calling for continuous surgical support in Ukraine., References: ['']\n",
      "DEBUG - Citing Paper: Chemistry, structureÂ and function of approved oligonucleotide therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: MiR-34a induces myofibroblast differentiation from renal fibroblasts., References: ['']\n",
      "DEBUG - Citing Paper: Effective treatment of retinal neovascular leakage with fusogenic porous silicon nanoparticles delivering VEGF-siRNA., References: ['']\n",
      "DEBUG - Citing Paper: A p53-TLR3 axis ameliorates pulmonary hypertension by inducing BMPR2 via IRF3., References: ['']\n",
      "DEBUG - Citing Paper: Long noncoding RNA uc007nnj.1 mediates neuronal death induced by retinal ischemia/reperfusion in mice via the miR-155-5p/Tle4 axis., References: ['']\n",
      "DEBUG - Citing Paper: MicroRNA mimics can distort physiological microRNA effects on immune checkpoints by triggering an antiviral interferon response., References: ['']\n",
      "DEBUG - Citing Paper: Nanoparticles-Based Strategies to Improve the Delivery of Therapeutic Small Interfering RNA in Precision Oncology., References: ['']\n",
      "DEBUG - Citing Paper: Therapeutic siRNA: State-of-the-Art and Future Perspectives., References: ['']\n",
      "DEBUG - Citing Paper: Current advancements and future perspectives of long noncoding RNAs in lipid metabolism and signaling., References: ['']\n",
      "DEBUG - Citing Paper: Gene Therapy: Will the Promise of Optimizing Lung Allografts Become Reality?, References: ['']\n",
      "DEBUG - Citing Paper: Engineering bioactive nanoparticles to rejuvenate vascular progenitor cells., References: ['']\n",
      "DEBUG - Citing Paper: PAI-1 is a vascular cell-specific HIF-2-dependent angiogenic factor that promotes retinal neovascularization in diabetic patients., References: ['']\n",
      "DEBUG - Citing Paper: Introduction and History of the Chemistry of Nucleic Acids Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Therapeutic RNA-silencing oligonucleotides in metabolic diseases., References: ['']\n",
      "DEBUG - Citing Paper: Gene-Based Therapeutics for Acquired Retinal Disease: Opportunities and Progress., References: ['']\n",
      "DEBUG - Citing Paper: Retinal Pigment Epithelium Expressed Toll-like Receptors and Their Potential Role in Age-Related Macular Degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor 3 (TLR3) regulation mechanisms and roles in antiviral innate immune responses., References: ['']\n",
      "DEBUG - Citing Paper: Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Self-assembled fluorescent hybrid nanoparticles-mediated collaborative lncRNA CCAT1 silencing and curcumin delivery for synchronous colorectal cancer theranostics., References: ['']\n",
      "DEBUG - Citing Paper: Delivery of nucleic acid therapeutics for cancer immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Role of interferons in diabetic retinopathy., References: ['']\n",
      "DEBUG - Citing Paper: Local application of Usag-1 siRNA can promote tooth regeneration in Runx2-deficient mice., References: ['']\n",
      "DEBUG - Citing Paper: siRNAs Targeting Mouse-Specific lncRNA AA388235 Induce Human Tumor Cell Pyroptosis/Apoptosis., References: ['']\n",
      "DEBUG - Citing Paper: Noncoding RNA therapeutics - challenges and potential solutions., References: ['']\n",
      "DEBUG - Citing Paper: HIF-1Î± and HIF-2Î± redundantly promote retinal neovascularization in patients with ischemic retinal disease., References: ['']\n",
      "DEBUG - Citing Paper: siRNA Therapeutics in Ocular Diseases., References: ['']\n",
      "DEBUG - Citing Paper: siRNA Design and GalNAc-Empowered Hepatic Targeted Delivery., References: ['']\n",
      "DEBUG - Citing Paper: Prolyl 3-Hydroxylase 2 Is a Molecular Player of Angiogenesis., References: ['']\n",
      "DEBUG - Citing Paper: Silencing of SARS-CoV-2 with modified siRNA-peptide dendrimer formulation., References: ['']\n",
      "DEBUG - Citing Paper: Multi-Functionalized Nanomaterials and Nanoparticles for Diagnosis and Treatment of Retinoblastoma., References: ['']\n",
      "DEBUG - Citing Paper: Rationale and Application of PEGylated Lipid-Based System for Advanced Target Delivery of siRNA., References: ['']\n",
      "DEBUG - Citing Paper: lncRNA Ttc3-209 Promotes the Apoptosis of Retinal Ganglion Cells in Retinal Ischemia Reperfusion Injury by Targeting the miR-484/Wnt8a Axis., References: ['']\n",
      "DEBUG - Citing Paper: Cytoplasmic synthesis of endogenous <i>Alu</i> complementary DNA via reverse transcription and implications in age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: siRNA Therapeutics against Respiratory Viral Infections-What Have We Learned for Potential COVID-19 Therapies?, References: ['']\n",
      "DEBUG - Citing Paper: PDGF Receptor Alpha Signaling Is Key for MÃ¼ller Cell Homeostasis Functions., References: ['']\n",
      "DEBUG - Citing Paper: The Effects of Single Nucleotide Polymorphisms in Cancer RNAi Therapies., References: ['']\n",
      "DEBUG - Citing Paper: Overcoming Barriers for siRNA Therapeutics: From Bench to Bedside., References: ['']\n",
      "DEBUG - Citing Paper: RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges., References: ['']\n",
      "DEBUG - Citing Paper: When Innate Immunity Meets Angiogenesis-The Role of Toll-Like Receptors in Endothelial Cells and Pulmonary Hypertension., References: ['']\n",
      "DEBUG - Citing Paper: Distinct and Orchestrated Functions of RNA Sensors in Innate Immunity., References: ['']\n",
      "DEBUG - Citing Paper: Gene Therapy Intervention in Neovascular Eye Disease: A Recent Update., References: ['']\n",
      "DEBUG - Citing Paper: Therapeutic siRNA: state of the art., References: ['']\n",
      "DEBUG - Citing Paper: Rational design of antisense oligonucleotides modulating the activity of TLR7/8 agonists., References: ['']\n",
      "DEBUG - Citing Paper: The Delivery of RNA-Interference Therapies Based on Engineered Hydrogels for Bone Tissue Regeneration., References: ['']\n",
      "DEBUG - Citing Paper: Transcription and Translation Inhibitors in Cancer Treatment., References: ['']\n",
      "DEBUG - Citing Paper: RNA Signaling in Pulmonary Arterial Hypertension-A Double-Stranded Sword., References: ['']\n",
      "DEBUG - Citing Paper: Regulation of virus-triggered type I interferon signaling by cellular and viral proteins., References: ['']\n",
      "DEBUG - Citing Paper: Altered Long Non-coding RNAs Involved in Immunological Regulation and Associated with Choroidal Neovascularization in Mice., References: ['']\n",
      "DEBUG - Citing Paper: Editorial focus: understanding off-target effects as the key to successful RNAi therapy., References: ['']\n",
      "DEBUG - Citing Paper: Nucleic Acid Sensors and Programmed Cell Death., References: ['']\n",
      "DEBUG - Citing Paper: Theranostic small interfering RNA nanoparticles in cancer precision nanomedicine., References: ['']\n",
      "DEBUG - Citing Paper: MicroRNAs in Ocular Infection., References: ['']\n",
      "DEBUG - Citing Paper: Tunicamycin-induced photoreceptor atrophy precedes degeneration of retinal capillaries with minimal effects on retinal ganglion and pigment epithelium cells., References: ['']\n",
      "DEBUG - Citing Paper: Clinical Cancer Nanomedicine., References: ['']\n",
      "DEBUG - Citing Paper: Harnessing host-virus evolution in antiviral therapy and immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Suppression of Choroidal Neovascularization and Fibrosis by a Novel RNAi Therapeutic Agent against (Pro)renin Receptor., References: ['']\n",
      "DEBUG - Citing Paper: IRF3 and IRF7 mediate neovascularization via inflammatory cytokines., References: ['']\n",
      "DEBUG - Citing Paper: Intratracheal Administration of siRNA Triggers mRNA Silencing in the Lung to Modulate T Cell Immune Response and Lung Inflammation., References: ['']\n",
      "DEBUG - Citing Paper: Below the surface: The inner lives of TLR4 and TLR9., References: ['']\n",
      "DEBUG - Citing Paper: Releasing the Immune System Brakes Using siRNAs Enhances Cancer Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Brain Theranostics and Radiotheranostics: Exosomes and Graphenes In Vivo as Novel Brain Theranostics., References: ['']\n",
      "DEBUG - Citing Paper: Interferon priming is essential for human CD34+ cell-derived plasmacytoid dendritic cell maturation and function., References: ['']\n",
      "DEBUG - Citing Paper: Gelofusine Attenuates Tubulointerstitial Injury Induced by cRGD-Conjugated siRNA by Regulating the TLR3 Signaling Pathway., References: ['']\n",
      "DEBUG - Citing Paper: CRISPR GENOME SURGERY IN THE RETINA IN LIGHT OF OFF-TARGETING., References: ['']\n",
      "DEBUG - Citing Paper: Stimulation of TLR3 triggers release of lysosomal ATP in astrocytes and epithelial cells that requires TRPML1 channels., References: ['']\n",
      "DEBUG - Citing Paper: (Pro)renin receptor: Involvement in diabetic retinopathy and development of molecular targeted therapy., References: ['']\n",
      "DEBUG - Citing Paper: Oligonucleotide therapeutics in neurodegenerative diseases., References: ['']\n",
      "DEBUG - Citing Paper: Age-Related Macular Degeneration: New Paradigms for Treatment and Management of AMD., References: ['']\n",
      "DEBUG - Citing Paper: Diverse roles of macrophages in intraocular neovascular diseases: a review., References: ['']\n",
      "DEBUG - Citing Paper: cGAS drives noncanonical-inflammasome activation in age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Oligonucleotide Therapies for the Lung: Ready to Return to the Clinic?, References: ['']\n",
      "DEBUG - Citing Paper: Reconstruction of Toll-like receptor 9-mediated responses in HEK-Blue hTLR9 cells by transfection of human macrophage scavenger receptor 1 gene., References: ['']\n",
      "DEBUG - Citing Paper: NLRC4 regulates caspase-1 and IL-1beta production in a CD11blowLy6Glow population of cells required for resistance to Pseudomonas aeruginosa keratitis., References: ['']\n",
      "DEBUG - Citing Paper: Periostin in vitreoretinal diseases., References: ['']\n",
      "DEBUG - Citing Paper: Evaluation and control of miRNA-like off-target repression for RNA interference., References: ['']\n",
      "DEBUG - Citing Paper: Improving miRNA Delivery by Optimizing miRNA Expression Cassettes in Diverse Virus Vectors., References: ['']\n",
      "DEBUG - Citing Paper: Advances in the delivery of RNA therapeutics: from concept to clinical reality., References: ['']\n",
      "DEBUG - Citing Paper: A Novel Single-Strand RNAi Therapeutic Agent Targeting the (Pro)renin Receptor Suppresses Ocular Inflammation., References: ['']\n",
      "DEBUG - Citing Paper: The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market., References: ['']\n",
      "DEBUG - Citing Paper: Differential Induction of Immunogenic Cell Death and Interferon Expression in Cancer Cells by Structured ssRNAs., References: ['']\n",
      "DEBUG - Citing Paper: Therapeutic Effect of Novel Single-Stranded RNAi Agent Targeting Periostin in Eyes with Retinal Neovascularization., References: ['']\n",
      "DEBUG - Citing Paper: Oligonucleotide therapies for disorders of the nervous system., References: ['']\n",
      "DEBUG - Citing Paper: A tumor-targeting cRGD-EGFR siRNA conjugate and its anti-tumor effect on glioblastoma in vitro and in vivo., References: ['']\n",
      "DEBUG - Citing Paper: Human CD64-targeted non-viral siRNA delivery system for blood monocyte gene modulation., References: ['']\n",
      "DEBUG - Citing Paper: High Interleukin-12 Levels May Prevent an Increase in the Amount of Fungi in the Gastrointestinal Tract during the First Years of Diabetes Mellitus Type 1., References: ['']\n",
      "DEBUG - Citing Paper: Interplay of extracellular matrix and leukocytes in lung inflammation., References: ['']\n",
      "DEBUG - Citing Paper: Evaluating side effects of nanoparticle-mediated siRNA delivery to mesenchymal stem cells using next generation sequencing and enrichment analysis., References: ['']\n",
      "DEBUG - Citing Paper: Off Target, but Sequence-Specific, shRNA-Associated Trans-Activation of Promoter Reporters in Transient Transfection Assays., References: ['']\n",
      "DEBUG - Citing Paper: Intramyocardial Injection of siRNAs Can Efficiently Establish Myocardial Tissue-Specific Renalase Knockdown Mouse Model., References: ['']\n",
      "DEBUG - Citing Paper: The role of Toll-like receptors in retinal ischemic diseases., References: ['']\n",
      "DEBUG - Citing Paper: Dual targeted immunotherapy via <i>in vivo</i> delivery of biohybrid RNAi-peptide nanoparticles to tumour-associated macrophages and cancer cells., References: ['']\n",
      "DEBUG - Citing Paper: Interleukin-12 inhibits pathological neovascularization in mouse model of oxygen-induced retinopathy., References: ['']\n",
      "DEBUG - Citing Paper: Delivery strategies and potential targets for siRNA in major cancer types., References: ['']\n",
      "DEBUG - Citing Paper: Poly (I:C) enhances the anti-tumor activity of canine parvovirus NS1 protein by inducing a potent anti-tumor immune response., References: ['']\n",
      "DEBUG - Citing Paper: Strand and Cell Type-specific Function of microRNA-126 in Angiogenesis., References: ['']\n",
      "DEBUG - Citing Paper: Downregulation of c-Myc is involved in TLR3-mediated tumor death of neuroblastoma xenografts., References: ['']\n",
      "DEBUG - Citing Paper: Plant microRNAs as novel immunomodulatory agents., References: ['']\n",
      "DEBUG - Citing Paper: Topical Use of Angiopoietin-like Protein 2 RNAi-loaded Lipid Nanoparticles Suppresses Corneal Neovascularization., References: ['']\n",
      "DEBUG - Citing Paper: Development of Novel Small Hairpin RNAs That do not Require Processing by Dicer or AGO2., References: ['']\n",
      "DEBUG - Citing Paper: Efficacy of rintatolimod in the treatment of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME)., References: ['']\n",
      "DEBUG - Citing Paper: Detection of siRNA-mediated target mRNA cleavage activities in human cells by a novel stem-loop array RT-PCR analysis., References: ['']\n",
      "DEBUG - Citing Paper: Intravenous immune globulin suppresses angiogenesis in mice and humans., References: ['']\n",
      "DEBUG - Citing Paper: Human IgG1 antibodies suppress angiogenesis in a target-independent manner., References: ['']\n",
      "DEBUG - Citing Paper: Peptide- and Amine-Modified Glucan Particles for the Delivery of Therapeutic siRNA., References: ['']\n",
      "DEBUG - Citing Paper: Association of toll-like receptor 3 polymorphism rs3775291 with age-related macular degeneration: a systematic review and meta-analysis., References: ['']\n",
      "DEBUG - Citing Paper: EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model., References: ['']\n",
      "DEBUG - Citing Paper: Short-interference RNAs: becoming medicines., References: ['']\n",
      "DEBUG - Citing Paper: Nucleoside Reverse Transcriptase Inhibitors Suppress Laser-Induced Choroidal Neovascularization in Mice., References: ['']\n",
      "DEBUG - Citing Paper: Novel Types of Small RNA Exhibit Sequence- and Target-dependent Angiogenesis Suppression Without Activation of Toll-like Receptor 3 in an Age-related Macular Degeneration (AMD) Mouse Model., References: ['']\n",
      "DEBUG - Citing Paper: Technologies for controlled, local delivery of siRNA., References: ['']\n",
      "DEBUG - Citing Paper: Safety of Striatal Infusion of siRNA in a Transgenic Huntington's Disease Mouse Model., References: ['']\n",
      "DEBUG - Citing Paper: siRNA Versus miRNA as Therapeutics for Gene Silencing., References: ['']\n",
      "DEBUG - Citing Paper: Knocking down disease: a progress report on siRNA therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Oligonucleotide Therapies: The Past and the Present., References: ['']\n",
      "DEBUG - Citing Paper: Harnessing RNAi nanomedicine for precision therapy., References: ['']\n",
      "DEBUG - Citing Paper: Multigenic lentiviral vectors for combined and tissue-specific expression of miRNA- and protein-based antiangiogenic factors., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticle delivery of a microRNA-145 inhibitor improves experimental pulmonary hypertension., References: ['']\n",
      "DEBUG - Citing Paper: Both MicroRNA-155 and Virus-Encoded MiR-155 Ortholog Regulate TLR3 Expression., References: ['']\n",
      "DEBUG - Citing Paper: Liposomally encapsulated CDC20 siRNA inhibits both solid melanoma tumor growth and spontaneous growth of intravenously injected melanoma cells on mouse lung., References: ['']\n",
      "DEBUG - Citing Paper: Clinical translation of RNAi-based treatments for respiratory diseases., References: ['']\n",
      "DEBUG - Citing Paper: The application of RNAi-based treatments for inflammatory bowel disease., References: ['']\n",
      "DEBUG - Citing Paper: Suppression of Laser-Induced Choroidal Neovascularization by the Oral Medicine Targeting Histamine Receptor H4 in Mice., References: ['']\n",
      "DEBUG - Citing Paper: Development of small RNA delivery systems for lung cancer therapy., References: ['']\n",
      "DEBUG - Citing Paper: Vision from next generation sequencing: multi-dimensional genome-wide analysis for producing gene regulatory networks underlying retinal development, aging and disease., References: ['']\n",
      "DEBUG - Citing Paper: High-mobility group box 1: a novel target for treatment of Pseudomonas aeruginosa keratitis., References: ['']\n",
      "DEBUG - Citing Paper: Activation of TLR3 promotes the degeneration of retinal ganglion cells by upregulating the protein levels of JNK3., References: ['']\n",
      "DEBUG - Citing Paper: Cytokine-modulating strategies and newer cytokine targets for arthritis therapy., References: ['']\n",
      "DEBUG - Citing Paper: Inhibition of choroidal fibrovascular membrane formation by new class of RNA interference therapeutic agent targeting periostin., References: ['']\n",
      "DEBUG - Citing Paper: Reply to IL-18 is not therapeutic for neovascular age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: IL-18 is not therapeutic for neovascular age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: TLR3 engagement induces IRF-3-dependent apoptosis in androgen-sensitive prostate cancer cells and inhibits tumour growth in vivo., References: ['']\n",
      "DEBUG - Citing Paper: Hepatitis C virus induced endothelial inflammatory response depends on the functional expression of TNFÎ± receptor subtype 2., References: ['']\n",
      "DEBUG - Citing Paper: Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity., References: ['']\n",
      "DEBUG - Citing Paper: Tumor-targeted in vivo gene silencing via systemic delivery of cRGD-conjugated siRNA., References: ['']\n",
      "DEBUG - Citing Paper: The Immune System and AMD., References: ['']\n",
      "DEBUG - Citing Paper: Tyrosine phosphorylation in Toll-like receptor signaling., References: ['']\n",
      "DEBUG - Citing Paper: Therapeutic targeting of microRNAs: current status and future challenges., References: ['']\n",
      "DEBUG - Citing Paper: Mitochondrial oxidative stress in the retinal pigment epithelium leads to localized retinal degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Assessment of anti-scarring therapies in exÂ vivo organ cultured rabbit corneas., References: ['']\n",
      "DEBUG - Citing Paper: dsRNA-activation of TLR3 and RLR signaling: gene induction-dependent and independent effects., References: ['']\n",
      "DEBUG - Citing Paper: Histamine H4 receptor as a new therapeutic target for choroidal neovascularization in age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Clusterin silencing inhibits proliferation and reduces invasion in human laryngeal squamous carcinoma cells., References: ['']\n",
      "DEBUG - Citing Paper: Development of nucleic acid vaccines: use of self-amplifying RNA in lipid nanoparticles., References: ['']\n",
      "DEBUG - Citing Paper: Adeno-associated virus type 8 vector-mediated expression of siRNA targeting vascular endothelial growth factor efficiently inhibits neovascularization in a murine choroidal neovascularization model., References: ['']\n",
      "DEBUG - Citing Paper: Does toll-like receptor-3 (TLR-3) have any role in Indian AMD phenotype?, References: ['']\n",
      "DEBUG - Citing Paper: Blockade of TLR3 protects mice from lethal radiation-induced gastrointestinal syndrome., References: ['']\n",
      "DEBUG - Citing Paper: Silencing sexually transmitted infections: topical siRNA-based interventions for the prevention of HIV and HSV., References: ['']\n",
      "DEBUG - Citing Paper: Discordant biological and toxicological species responses to TLR3 activation., References: ['']\n",
      "DEBUG - Citing Paper: Identification of age-related macular degeneration related genes by applying shortest path algorithm in protein-protein interaction network., References: ['']\n",
      "DEBUG - Citing Paper: IL-10 is significantly involved in HSP70-regulation of experimental subretinal fibrosis., References: ['']\n",
      "DEBUG - Citing Paper: Development of a Positive-readout Mouse Model of siRNA Pharmacodynamics., References: ['']\n",
      "DEBUG - Citing Paper: Challenging the future of siRNA therapeutics against cancer: the crucial role of nanotechnology., References: ['']\n",
      "DEBUG - Citing Paper: A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo., References: ['']\n",
      "DEBUG - Citing Paper: Induced DNA demethylation by targeting Ten-Eleven Translocation 2 to the human ICAM-1 promoter., References: ['']\n",
      "DEBUG - Citing Paper: Therapeutic expression of hairpins targeting apolipoprotein B100 induces phenotypic and transcriptome changes in murine liver., References: ['']\n",
      "DEBUG - Citing Paper: Lentiviral vector-mediated RNA silencing in the central nervous system., References: ['']\n",
      "DEBUG - Citing Paper: Innate immunity activation involved in unprotected porcine auto-transplant kidneys preserved by naked caspase-3 siRNA., References: ['']\n",
      "DEBUG - Citing Paper: In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma., References: ['']\n",
      "DEBUG - Citing Paper: Retinal angiogenesis suppression through small molecule activation of p53., References: ['']\n",
      "DEBUG - Citing Paper: VEGF receptor blockade markedly reduces retinal microglia/macrophage infiltration into laser-induced CNV., References: ['']\n",
      "DEBUG - Citing Paper: Design of siRNA Therapeutics from the Molecular Scale., References: ['']\n",
      "DEBUG - Citing Paper: Short hairpin RNA-mediated knockdown of VEGFA in MÃ¼ller cells reduces intravitreal neovascularization in a rat model of retinopathy of prematurity., References: ['']\n",
      "DEBUG - Citing Paper: Increase in peripheral blood mononuclear cell Toll-like receptor 2/3 expression and reactivity to their ligands in a cohort of patients with wet age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy., References: ['']\n",
      "DEBUG - Citing Paper: Nucleic acids and endosomal pattern recognition: how to tell friend from foe?, References: ['']\n",
      "DEBUG - Citing Paper: Bevasiranib for the treatment of wet, age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Lentiviral miR30-based RNA interference against heparanase suppresses melanoma metastasis with lower liver and lung toxicity., References: ['']\n",
      "DEBUG - Citing Paper: Circulating miRNAs: cell-cell communication function?, References: ['']\n",
      "DEBUG - Citing Paper: Photoreceptor avascular privilege is shielded by soluble VEGF receptor-1., References: ['']\n",
      "DEBUG - Citing Paper: Toll like receptor 3 plays a critical role in the progression and severity of acetaminophen-induced hepatotoxicity., References: ['']\n",
      "DEBUG - Citing Paper: Immunology of age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Retinal pigment epithelium (RPE) exosomes contain signaling phosphoproteins affected by oxidative stress., References: ['']\n",
      "DEBUG - Citing Paper: Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges., References: ['']\n",
      "DEBUG - Citing Paper: Efficient delivery of RNA interference oligonucleotides to polarized airway epithelia in vitro., References: ['']\n",
      "DEBUG - Citing Paper: Nanomedicines for back of the eye drug delivery, gene delivery, and imaging., References: ['']\n",
      "DEBUG - Citing Paper: Gene silencing via RNAi and siRNA quantification in tumor tissue using MEND, a liposomal siRNA delivery system., References: ['']\n",
      "DEBUG - Citing Paper: RNA viruses and the host microRNA machinery., References: ['']\n",
      "DEBUG - Citing Paper: Targeting the IRE1Î±/XBP1 and ATF6 arms of the unfolded protein response enhances VEGF blockade to prevent retinal and choroidal neovascularization., References: ['']\n",
      "DEBUG - Citing Paper: Suitability of endogenous reference genes for gene expression studies with human intraocular endothelial cells., References: ['']\n",
      "DEBUG - Citing Paper: Induced pluripotent stem cells in cardiovascular drug discovery., References: ['']\n",
      "DEBUG - Citing Paper: Recognition of pathogen-associated nucleic acids by endosomal nucleic acid-sensing toll-like receptors., References: ['']\n",
      "DEBUG - Citing Paper: The Business of RNAi Therapeutics in 2012., References: ['']\n",
      "DEBUG - Citing Paper: Oligonucleotide delivery to the lung: waiting to inhale., References: ['']\n",
      "DEBUG - Citing Paper: Antiviral innate immunity disturbs podocyte cell function., References: ['']\n",
      "DEBUG - Citing Paper: Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia., References: ['']\n",
      "DEBUG - Citing Paper: Buffering capacity and size of siRNA polyplexes influence cytokine levels., References: ['']\n",
      "DEBUG - Citing Paper: Epigenetic Editing: targeted rewriting of epigenetic marks to modulate expression of selected target genes., References: ['']\n",
      "DEBUG - Citing Paper: Small interfering RNA-mediated suppression of Ccl2 in MÃ¼ller cells attenuates microglial recruitment and photoreceptor death following retinal degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Multi-level regulation of cellular recognition of viral dsRNA., References: ['']\n",
      "DEBUG - Citing Paper: Trial Watch: Experimental Toll-like receptor agonists for cancer therapy., References: ['']\n",
      "DEBUG - Citing Paper: Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering., References: ['']\n",
      "DEBUG - Citing Paper: Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy., References: ['']\n",
      "DEBUG - Citing Paper: Proteolytic processing regulates Toll-like receptor 3 stability and endosomal localization., References: ['']\n",
      "DEBUG - Citing Paper: Reduced retinal microvascular density, improved forepaw reach, comparative microarray and gene set enrichment analysis with c-jun targeting DNA enzyme., References: ['']\n",
      "DEBUG - Citing Paper: Epidermal growth factor receptor is essential for Toll-like receptor 3 signaling., References: ['']\n",
      "DEBUG - Citing Paper: Mechanisms of age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: RNA interference trigger variants: getting the most out of RNA for RNA interference-based therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma., References: ['']\n",
      "DEBUG - Citing Paper: Strategies for ocular siRNA delivery: Potential and limitations of non-viral nanocarriers., References: ['']\n",
      "DEBUG - Citing Paper: Loss-of-function of inositol polyphosphate-4-phosphatase reversibly increases the severity of allergic airway inflammation., References: ['']\n",
      "DEBUG - Citing Paper: PV1 down-regulation via shRNA inhibits the growth of pancreatic adenocarcinoma xenografts., References: ['']\n",
      "DEBUG - Citing Paper: Genetic insights into age-related macular degeneration: controversies addressing risk, causality, and therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Nanovector delivery of siRNA for cancer therapy., References: ['']\n",
      "DEBUG - Citing Paper: DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88., References: ['']\n",
      "DEBUG - Citing Paper: TGF-Î²1 induces endothelial cell apoptosis by shifting VEGF activation of p38(MAPK) from the prosurvival p38Î² to proapoptotic p38Î±., References: ['']\n",
      "DEBUG - Citing Paper: Inhibition of connective tissue growth factor by small interfering ribonucleic acid prevents increase in extracellular matrix molecules in a rodent model of diabetic retinopathy., References: ['']\n",
      "DEBUG - Citing Paper: Lentiviral vectors encoding short hairpin RNAs efficiently transduce and knockdown LINGO-1 but induce an interferon response and cytotoxicity in central nervous system neurones., References: ['']\n",
      "DEBUG - Citing Paper: Nanoparticle-mediated delivery of shRNA.VEGF-a plasmids regresses corneal neovascularization., References: ['']\n",
      "DEBUG - Citing Paper: Promoter-associated RNAs and promoter-targeted RNAs., References: ['']\n",
      "DEBUG - Citing Paper: RNAimmuno: a database of the nonspecific immunological effects of RNA interference and microRNA reagents., References: ['']\n",
      "DEBUG - Citing Paper: Targeting pattern recognition receptors in cancer immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: A TRIF-independent branch of TLR3 signaling., References: ['']\n",
      "DEBUG - Citing Paper: In vivo screening of modified siRNAs for non-specific antiviral effect in a small fish model: number and localization in the strands are important., References: ['']\n",
      "DEBUG - Citing Paper: RNA-based therapeutics: current progress and future prospects., References: ['']\n",
      "DEBUG - Citing Paper: Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor (TLR) 3 immune modulation by unformulated small interfering RNA or DNA and the role of CD14 (in TLR-mediated effects)., References: ['']\n",
      "DEBUG - Citing Paper: Asymmetric siRNA: new strategy to improve specificity and reduce off-target gene expression., References: ['']\n",
      "DEBUG - Citing Paper: Progress toward in vivo use of siRNAs-II., References: ['']\n",
      "DEBUG - Citing Paper: A window to innate neuroimmunity: Toll-like receptor-mediated cell responses in the retina., References: ['']\n",
      "DEBUG - Citing Paper: ÎÎ³â134.5 herpes simplex viruses encoding human cytomegalovirus IRS1 or TRS1 induce interferon regulatory factor 3 phosphorylation and an interferon-stimulated gene response., References: ['']\n",
      "DEBUG - Citing Paper: Silencing disease genes in the laboratory and the clinic., References: ['']\n",
      "DEBUG - Citing Paper: Selection and optimization of asymmetric siRNA targeting the human c-MET gene., References: ['']\n",
      "DEBUG - Citing Paper: Long-term RNA interference gene therapy in a dominant retinitis pigmentosa mouse model., References: ['']\n",
      "DEBUG - Citing Paper: Subcellular fate and off-target effects of siRNA, shRNA, and miRNA., References: ['']\n",
      "DEBUG - Citing Paper: RNA interference and cancer therapy., References: ['']\n",
      "DEBUG - Citing Paper: The herpes simplex virus-1 transactivator infected cell protein-4 drives VEGF-A dependent neovascularization., References: ['']\n",
      "DEBUG - Citing Paper: Possibilities for RNA interference in developing hepatitis C virus therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Short-interfering RNAs induce retinal degeneration via TLR3 and IRF3., References: ['']\n",
      "DEBUG - Citing Paper: Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisense., References: ['']\n",
      "DEBUG - Citing Paper: Oxidation as \"the stress of life\"., References: ['']\n",
      "DEBUG - Citing Paper: Using drug-excipient interactions for siRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: RNA therapeutics targeting osteoclast-mediated excessive bone resorption., References: ['']\n",
      "DEBUG - Citing Paper: Delivery of RNAi mediators., References: ['']\n",
      "DEBUG - Citing Paper: The great regulator. Basic research into the roles of RNA is steaming ahead, but its commercial exploitation has stalled., References: ['']\n",
      "DEBUG - Citing Paper: Similar Structures but Different Roles - An Updated Perspective on TLR Structures., References: ['']\n",
      "DEBUG - Citing Paper: Chemical modification of siRNA bases to probe and enhance RNA interference., References: ['']\n",
      "DEBUG - Citing Paper: Variables and strategies in development of therapeutic post-transcriptional gene silencing agents., References: ['']\n",
      "DEBUG - Citing Paper: Protein kinase CÎ± downregulation via siRNA-PKCÎ± released from foldable capsular vitreous body in cultured human retinal pigment epithelium cells., References: ['']\n",
      "DEBUG - Citing Paper: Structural diversity repertoire of gene silencing small interfering RNAs., References: ['']\n",
      "DEBUG - Citing Paper: Immunostimulatory motifs enhance antiviral siRNAs targeting highly pathogenic avian influenza H5N1., References: ['']\n",
      "DEBUG - Citing Paper: Current progress of siRNA/shRNA therapeutics in clinical trials., References: ['']\n",
      "DEBUG - Citing Paper: Targeting key signalling pathways in oesophageal adenocarcinoma: a reality for personalised medicine?, References: ['']\n",
      "DEBUG - Citing Paper: In vivo efficacy and off-target effects of locked nucleic acid (LNA) and unlocked nucleic acid (UNA) modified siRNA and small internally segmented interfering RNA (sisiRNA) in mice bearing human tumor xenografts., References: ['']\n",
      "DEBUG - Citing Paper: Ocular neuroprotection by siRNA targeting caspase-2., References: ['']\n",
      "DEBUG - Citing Paper: Developing therapeutic microRNAs for cancer., References: ['']\n",
      "DEBUG - Citing Paper: The importance of RT-qPCR primer design for the detection of siRNA-mediated mRNA silencing., References: ['']\n",
      "DEBUG - Citing Paper: Nucleobase and ribose modifications control immunostimulation by a microRNA-122-mimetic RNA., References: ['']\n",
      "DEBUG - Citing Paper: New short interfering RNA-based therapies for glomerulonephritis., References: ['']\n",
      "DEBUG - Citing Paper: Transcriptional mechanisms regulating skeletal muscle differentiation, growth and homeostasis., References: ['']\n",
      "DEBUG - Citing Paper: RNAi-based therapeutic strategies for metabolic disease., References: ['']\n",
      "DEBUG - Citing Paper: Current prospects for RNA interference-based therapies., References: ['']\n",
      "DEBUG - Citing Paper: Age-related macular degeneration and the other double helix. The Cogan Lecture., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor, RIG-I-like receptors and the NLRP3 inflammasome: key modulators of innate immune responses to double-stranded RNA viruses., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor 3 is required for development of retinopathy caused by impaired all-trans-retinal clearance in mice., References: ['']\n",
      "DEBUG - Citing Paper: Horizons in therapy for corneal angiogenesis., References: ['']\n",
      "DEBUG - Citing Paper: RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer., References: ['']\n",
      "DEBUG - Citing Paper: Delivery of intracellular-acting biologics in pro-apoptotic therapies., References: ['']\n",
      "DEBUG - Citing Paper: DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: The alternative pathway is required, but not alone sufficient, for retinal pathology in mouse laser-induced choroidal neovascularization., References: ['']\n",
      "DEBUG - Citing Paper: Rapid, cell-based toxicity screen of potentially therapeutic post-transcriptional gene silencing agents., References: ['']\n",
      "DEBUG - Citing Paper: Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo., References: ['']\n",
      "DEBUG - Citing Paper: Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells., References: ['']\n",
      "DEBUG - Citing Paper: Engagement of toll-like receptor 3 induces vascular endothelial growth factor and interleukin-8 in human rheumatoid synovial fibroblasts., References: ['']\n",
      "DEBUG - Citing Paper: Emerging therapeutic approaches in the management of retinal angiogenesis and edema., References: ['']\n",
      "DEBUG - Citing Paper: RNA interference in the clinic: challenges and future directions., References: ['']\n",
      "DEBUG - Citing Paper: Vigilance and validation: Keys to success in RNAi screening., References: ['']\n",
      "DEBUG - Citing Paper: dsRNA activation of endothelin-1 and markers of vascular activation in endothelial cells and fibroblasts., References: ['']\n",
      "DEBUG - Citing Paper: Small interfering RNAs induce target-independent inhibition of tumor growth and vasculature remodeling in a mouse model of hepatocellular carcinoma., References: ['']\n",
      "DEBUG - Citing Paper: Quantitative evaluation of siRNA delivery in vivo., References: ['']\n",
      "DEBUG - Citing Paper: Non-viral siRNA delivery into the mouse retina in vivo., References: ['']\n",
      "DEBUG - Citing Paper: Minor-groove-modulating adenosine replacements control protein binding and RNAi activity in siRNAs., References: ['']\n",
      "DEBUG - Citing Paper: Synthetic double-stranded RNA oligonucleotides are immunostimulatory for chicken spleen cells., References: ['']\n",
      "DEBUG - Citing Paper: [siRNA in macular degeneration]., References: ['']\n",
      "DEBUG - Citing Paper: Gene regulation by small RNAs., References: ['']\n",
      "DEBUG - Citing Paper: A status report on RNAi therapeutics., References: ['']\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DEBUG - Citing Paper: Poly(I:C) drives type I IFN- and TGFÎ²-mediated inflammation and dermal fibrosis simulating altered gene expression in systemic sclerosis., References: ['']\n",
      "DEBUG - Citing Paper: Important aspects of Toll-like receptors, ligands and their signaling pathways., References: ['']\n",
      "DEBUG - Citing Paper: Knockdown of FcÎ³ receptor III in an arthritic temporomandibular joint reduces the nociceptive response in rats., References: ['']\n",
      "DEBUG - Citing Paper: Poly(I:C) induces intense expression of c-IAP2 and cooperates with an IAP inhibitor in induction of apoptosis in cancer cells., References: ['']\n",
      "DEBUG - Citing Paper: Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34., References: ['']\n",
      "DEBUG - Citing Paper: Delivery of siRNA therapeutics: barriers and carriers., References: ['']\n",
      "DEBUG - Citing Paper: Local arterial nanoparticle delivery of siRNA for NOX2 knockdown to prevent restenosis in an atherosclerotic rat model., References: ['']\n",
      "DEBUG - Citing Paper: RNAi reduces expression and intracellular retention of mutant cartilage oligomeric matrix protein., References: ['']\n",
      "DEBUG - Citing Paper: A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus., References: ['']\n",
      "DEBUG - Citing Paper: Clinical status of duplex RNA., References: ['']\n",
      "DEBUG - Citing Paper: RNA interference in three humans., References: ['']\n",
      "DEBUG - Citing Paper: siRNA-based topical microbicides targeting sexually transmitted infections., References: ['']\n",
      "DEBUG - Citing Paper: Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles., References: ['']\n",
      "DEBUG - Citing Paper: Engineering RNA for targeted siRNA delivery and medical application., References: ['']\n",
      "DEBUG - Citing Paper: Advances in Systemic siRNA Delivery., References: ['']\n",
      "DEBUG - Citing Paper: Transglutaminase-2: a new endostatin partner in the extracellular matrix of endothelial cells., References: ['']\n",
      "DEBUG - Citing Paper: Antisense oligonucleotide therapy in diabetic retinopathy., References: ['']\n",
      "DEBUG - Citing Paper: Mediators of ocular angiogenesis., References: ['']\n",
      "DEBUG - Citing Paper: Immune regulation in the retina., References: ['']\n",
      "DEBUG - Citing Paper: Lipid-like materials for low-dose, in vivo gene silencing., References: ['']\n",
      "DEBUG - Citing Paper: RNAi-based therapeutics-current status, challenges and prospects., References: ['']\n",
      "DEBUG - Citing Paper: Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application., References: ['']\n",
      "DEBUG - Citing Paper: VEGF-A expression by HSV-1-infected cells drives corneal lymphangiogenesis., References: ['']\n",
      "DEBUG - Citing Paper: Inhibition of Vascular Endothelial Growth Factor Receptor-1/Wnt/{beta}-catenin Crosstalk Leads to Tumor Cell Death., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor 2 ligand-induced protection against bacterial endophthalmitis., References: ['']\n",
      "DEBUG - Citing Paper: RNA interference inhibits hepatitis E virus mRNA accumulation and protein synthesis in vitro., References: ['']\n",
      "DEBUG - Citing Paper: A rapid and sensitive method to detect siRNA-mediated mRNA cleavage in vivo using 5' RACE and a molecular beacon probe., References: ['']\n",
      "DEBUG - Citing Paper: First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder., References: ['']\n",
      "DEBUG - Citing Paper: Selective inhibition of retinal angiogenesis by targeting PI3 kinase., References: ['']\n",
      "DEBUG - Citing Paper: Inhibition of human retinal pigment epithelial cell attachment, spreading, and migration by the human lectin galectin-1., References: ['']\n",
      "DEBUG - Citing Paper: Strategies for targeted nonviral delivery of siRNAs in vivo., References: ['']\n",
      "DEBUG - Citing Paper: Sequence-non-specific effects of RNA interference triggers and microRNA regulators., References: ['']\n",
      "DEBUG - Citing Paper: siRNA delivery not Toll-free., References: ['']\n",
      "DEBUG - Citing Paper: Development of universal antidotes to control aptamer activity., References: ['']\n",
      "DEBUG - Citing Paper: Toward a durable anti-HIV gene therapy based on RNA interference., References: ['']\n",
      "DEBUG - Citing Paper: Identification of novel host-oriented targets for Human Immunodeficiency Virus type 1 using Random Homozygous Gene Perturbation., References: ['']\n",
      "DEBUG - Citing Paper: Huntington's disease: silencing a brutal killer., References: ['']\n",
      "DEBUG - Citing Paper: Lipidic systems for in vivo siRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: RNA interference technologies and therapeutics: from basic research to products., References: ['']\n",
      "DEBUG - Citing Paper: RNA interference and micro RNA-oriented therapy in cancer: rationales, promises, and challenges., References: ['']\n",
      "DEBUG - Citing Paper: Combined genome-wide expression profiling and targeted RNA interference in primary mouse macrophages reveals perturbation of transcriptional networks associated with interferon signalling., References: ['']\n",
      "DEBUG - Citing Paper: Sequence determinants of innate immune activation by short interfering RNAs., References: ['']\n",
      "DEBUG - Citing Paper: Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity., References: ['']\n",
      "DEBUG - Citing Paper: Drug delivery-mediated control of RNA immunostimulation., References: ['']\n",
      "DEBUG - Citing Paper: Amelioration of psoriasis by anti-TNF-alpha RNAi in the xenograft transplantation model., References: ['']\n",
      "DEBUG - Citing Paper: [New aspects in the therapy of neovascular age related macular degeneration. Current position of the Retinological Society, the Germany Ophthalmologic Society and the Professional Union of Eye Doctors of Germany]., References: ['']\n",
      "DEBUG - Citing Paper: CCR3 is a target for age-related macular degeneration diagnosis and therapy., References: ['']\n",
      "DEBUG - Citing Paper: RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy., References: ['']\n",
      "DEBUG - Citing Paper: Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer., References: ['']\n",
      "DEBUG - Citing Paper: Geographic atrophy in age-related macular degeneration and TLR3., References: ['']\n",
      "DEBUG - Citing Paper: KLF6-SV1 is a novel antiapoptotic protein that targets the BH3-only protein NOXA for degradation and whose inhibition extends survival in an ovarian cancer model., References: ['']\n",
      "DEBUG - Citing Paper: Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth., References: ['']\n",
      "DEBUG - Citing Paper: A novel high-throughput cell-based method for integrated quantification of type I interferons and in vitro screening of immunostimulatory RNA drug delivery., References: ['']\n",
      "DEBUG - Citing Paper: Lipid-based systemic delivery of siRNA., References: ['']\n",
      "DEBUG - Citing Paper: The use of Random Homozygous Gene Perturbation to identify novel host-oriented targets for influenza., References: ['']\n",
      "DEBUG - Citing Paper: Gene silencing below the immune radar., References: ['']\n",
      "DEBUG - Citing Paper: Short non-coding RNA biology and neurodegenerative disorders: novel disease targets and therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Regulated and multiple miRNA and siRNA delivery into primary cells by a lentiviral platform., References: ['']\n",
      "DEBUG - Citing Paper: Detection of siRNA administered to cells and animals by using a fluorescence intensity distribution analysis polarization system., References: ['']\n",
      "DEBUG - Citing Paper: A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Glioma angiogenesis: Towards novel RNA therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: The roles of TLRs, RLRs and NLRs in pathogen recognition., References: ['']\n",
      "DEBUG - Citing Paper: RNA and disease., References: ['']\n",
      "DEBUG - Citing Paper: RNAi methodologies for the functional study of signaling molecules., References: ['']\n",
      "DEBUG - Citing Paper: Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice., References: ['']\n",
      "DEBUG - Citing Paper: Knocking down barriers: advances in siRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: The promises and pitfalls of RNA-interference-based therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Asymmetric shorter-duplex siRNA structures trigger efficient gene silencing with reduced nonspecific effects., References: ['']\n",
      "DEBUG - Citing Paper: Durable protection from Herpes Simplex Virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene., References: ['']\n",
      "DEBUG - Citing Paper: RNA interference: from basic research to therapeutic applications., References: ['']\n",
      "DEBUG - Citing Paper: Human corneal epithelium-derived thymic stromal lymphopoietin links the innate and adaptive immune responses via TLRs and Th2 cytokines., References: ['']\n",
      "DEBUG - Citing Paper: MicroRNA-like off-target transcript regulation by siRNAs is species specific., References: ['']\n",
      "DEBUG - Citing Paper: Polymersome delivery of siRNA and antisense oligonucleotides., References: ['']\n",
      "DEBUG - Citing Paper: Nucleic acids-based therapeutics in the battle against pathogenic viruses., References: ['']\n",
      "DEBUG - Citing Paper: Age-related macular degeneration: activation of innate immunity system via pattern recognition receptors., References: ['']\n",
      "DEBUG - Citing Paper: Permanent silencing of NKG2A expression for cell-based therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy., References: ['']\n",
      "DEBUG - Citing Paper: Epigenetic principles and mechanisms underlying nervous system functions in health and disease., References: ['']\n",
      "DEBUG - Citing Paper: Innate immune recognition of nucleic acids., References: ['']\n",
      "DEBUG - Citing Paper: A RNA transcript (Heg) in mononuclear cells is negatively correlated with CD14 mRNA and TSH receptor autoantibodies., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor 3 and geographic atrophy in age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer., References: ['']\n",
      "DEBUG - Citing Paper: Maintaining the silence: reflections on long-term RNAi., References: ['']\n",
      "DEBUG - Citing Paper: Ethical perspectives on RNA interference therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides., References: ['']\n",
      "DEBUG - focal: Sequence- and target-independent angiogenesis suppression by siRNA via TLR3., NF: 0, NB: 0, NR: 0, D: 0\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DEBUG - Focal Paper: mRNA is an endogenous ligand for Toll-like receptor 3., References: \n",
      "DEBUG - Citing Paper: Transcriptional control of metabolism by interferon regulatory factors., References: ['']\n",
      "DEBUG - Citing Paper: Frameworks for transformational breakthroughs in RNA-based medicines., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor 4 in pancreatic damage and immune infiltration in acute pancreatitis., References: ['']\n",
      "DEBUG - Citing Paper: Cell Reprogramming and Differentiation Utilizing Messenger RNA for Regenerative Medicine., References: ['']\n",
      "DEBUG - Citing Paper: ACE mRNA (Additional Chimeric Element incorporated IVT mRNA) for Enhancing Protein Expression by Modulating Immunogenicity., References: ['']\n",
      "DEBUG - Citing Paper: Profile of Katalin KarikÃ³ and Drew Weissman: 2023 Nobel laureates in Physiology or Medicine., References: ['']\n",
      "DEBUG - Citing Paper: Strategies to reduce the risks of mRNA drug and vaccine toxicity., References: ['']\n",
      "DEBUG - Citing Paper: Breaking the mold with RNA-a \"RNAissance\" of life science., References: ['']\n",
      "DEBUG - Citing Paper: Novel immunotherapeutic options for BCG-unresponsive high-risk non-muscle-invasive bladder cancer., References: ['']\n",
      "DEBUG - Citing Paper: Mesenchymal Stromal Cells Primed by Toll-like Receptors 3 and 4 Enhanced Anti-Inflammatory Effects against LPS-Induced Macrophages via Extracellular Vesicles., References: ['']\n",
      "DEBUG - Citing Paper: Hypoxia-inducible Factor-1Î± Suppresses the Innate Immune Response in Cultured Human Proximal Tubular Cells., References: ['']\n",
      "DEBUG - Citing Paper: Necrotic Cells from Head and Neck Carcinomas Release Biomolecules That Are Activating Toll-like Receptor 3., References: ['']\n",
      "DEBUG - Citing Paper: The Role of the Oxidative State and Innate Immunity Mediated by TLR7 and TLR9 in Lupus Nephritis., References: ['']\n",
      "DEBUG - Citing Paper: Challenges in developing personalized neoantigen cancer vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: From Bench to Bedside: Implications of Lipid Nanoparticle Carrier Reactogenicity for Advancing Nucleic Acid Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Gastrointestinal Delivery of an mRNA Vaccine Using Immunostimulatory Polymeric Nanoparticles., References: ['']\n",
      "DEBUG - Citing Paper: Targeting cancer with mRNA-lipid nanoparticles: key considerations and future prospects., References: ['']\n",
      "DEBUG - Citing Paper: Brain alarm by self-extracellular nucleic acids: from neuroinflammation to neurodegeneration., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like Receptors as Pro-Thrombotic Drivers in Viral Infections: A Narrative Review., References: ['']\n",
      "DEBUG - Citing Paper: Learning from cancer to address COVID-19., References: ['']\n",
      "DEBUG - Citing Paper: A comparative analysis on serious adverse events reported for COVID-19 vaccines in adolescents and young adults., References: ['']\n",
      "DEBUG - Citing Paper: The impact of nucleoside base modification in mRNA vaccine is influenced by the chemistry of its lipid nanoparticle delivery system., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccine Platform: mRNA Production and Delivery., References: ['']\n",
      "DEBUG - Citing Paper: Recent Advancements in Mosquito-Borne Flavivirus Vaccine Development., References: ['']\n",
      "DEBUG - Citing Paper: Advances in Vaccine Adjuvants: Nanomaterials and Small Molecules., References: ['']\n",
      "DEBUG - Citing Paper: New insights into the immune functions of podocytes: the role of complement., References: ['']\n",
      "DEBUG - Citing Paper: Toll-Like Receptor 3 Mediates Aortic Stenosis Through a Conserved Mechanism of Calcification., References: ['']\n",
      "DEBUG - Citing Paper: Dialog beyond the Grave: Necrosis in the Tumor Microenvironment and Its Contribution to Tumor Growth., References: ['']\n",
      "DEBUG - Citing Paper: Case Report: mRNA vaccination-mediated STAT3 overactivation with agranulocytosis and clonal T-LGL expansion., References: ['']\n",
      "DEBUG - Citing Paper: Immunogenic cell death: The cornerstone of oncolytic viro-immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Review: Current trends, challenges, and success stories in adjuvant research., References: ['']\n",
      "DEBUG - Citing Paper: Modulating the expression of tumor suppressor genes using activating oligonucleotide technologies as a therapeutic approach in cancer., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like Receptor 3 in the Hybrid Yellow Catfish (<i>Pelteobagrus fulvidraco â Ã P. vachelli â</i>): Protein Structure, Evolution and Immune Response to Exogenous <i>Aeromonas hydrophila</i> and Poly (I:C) Stimuli., References: ['']\n",
      "DEBUG - Citing Paper: Race with virus evolution: The development and application of mRNA vaccines against SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: TLR3 forms a laterally aligned multimeric complex along double-stranded RNA for efficient signal transduction., References: ['']\n",
      "DEBUG - Citing Paper: Nucleobase-modified nucleosides and nucleotides: Applications in biochemistry, synthetic biology, and drug discovery., References: ['']\n",
      "DEBUG - Citing Paper: Lessons learned from COVID-19 pandemic: Vaccine platform is a key player., References: ['']\n",
      "DEBUG - Citing Paper: Is There a Role for Immunoregulatory and Antiviral Oligonucleotides Acting in the Extracellular Space? A Review and Hypothesis., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor-targeted anti-tumor therapies: Advances and challenges., References: ['']\n",
      "DEBUG - Citing Paper: Current progress in the development of prophylactic and therapeutic vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Scope and challenges of nanoparticle-based mRNA delivery in cancer treatment., References: ['']\n",
      "DEBUG - Citing Paper: Minor Changes for a Major Impact: A Review of Epigenetic Modifications in Cell-Based Therapies for Stroke., References: ['']\n",
      "DEBUG - Citing Paper: Advancing mRNA technologies for therapies and vaccines: An African context., References: ['']\n",
      "DEBUG - Citing Paper: Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Translational and Clinical Significance of DAMPs, PAMPs, and PRRs in Trauma-induced Inflammation., References: ['']\n",
      "DEBUG - Citing Paper: Synthesis of point-modified mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Hypoxic human proximal tubular epithelial cells undergo ferroptosis and elicit an NLRP3 inflammasome response in CD1c<sup>+</sup> dendritic cells., References: ['']\n",
      "DEBUG - Citing Paper: Toll-Like Receptor 3 (TLR3) Is Engaged in the Intracellular Survival of the Protozoan Parasite <i>Leishmania (Leishmania) amazonensis</i>., References: ['']\n",
      "DEBUG - Citing Paper: TBK1-mTOR Signaling Attenuates Obesity-Linked Hyperglycemia and Insulin Resistance., References: ['']\n",
      "DEBUG - Citing Paper: DNA double-strand break repair and nucleic acid-related immunity., References: ['']\n",
      "DEBUG - Citing Paper: The legacy of mRNA engineering: A lineup of pioneers for the Nobel Prize., References: ['']\n",
      "DEBUG - Citing Paper: Animal Models of Preeclampsia: Mechanistic Insights and Promising Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Oral mRNA Vaccines Against Infectious Diseases- A Bacterial Perspective [Invited]., References: ['']\n",
      "DEBUG - Citing Paper: Nucleic Acid Sensing Pathways in DNA Repair Targeted Cancer Therapy., References: ['']\n",
      "DEBUG - Citing Paper: Mobilization of innate and adaptive antitumor immune responses by the RNP-targeting antibody ATRC-101., References: ['']\n",
      "DEBUG - Citing Paper: Epitranscriptomics of SARS-CoV-2 Infection., References: ['']\n",
      "DEBUG - Citing Paper: Modification of Lipid-Based Nanoparticles: An Efficient Delivery System for Nucleic Acid-Based Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Targeting DAMPs with nucleic acid scavengers to treat lupus., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: LL-37 and Double-Stranded RNA Synergistically Upregulate Bronchial Epithelial TLR3 Involving Enhanced Import of Double-Stranded RNA and Downstream TLR3 Signaling., References: ['']\n",
      "DEBUG - Citing Paper: Frequency and Associations of Adverse Reactions of COVID-19 Vaccines Reported to Pharmacovigilance Systems in the European Union and the United States., References: ['']\n",
      "DEBUG - Citing Paper: Cytidine acetylation yields a hypoinflammatory synthetic messenger RNA., References: ['']\n",
      "DEBUG - Citing Paper: The Nanoparticle-Enabled Success of COVID-19 mRNA Vaccines and the Promise of Microneedle Platforms for Pandemic Vaccine Response., References: ['']\n",
      "DEBUG - Citing Paper: Epigenetic Regulation of Endothelial Dysfunction and Inflammation in Pulmonary Arterial Hypertension., References: ['']\n",
      "DEBUG - Citing Paper: The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticle chemistry determines how nucleoside base modifications alter mRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: B cells support the repair of injured tissues by adopting MyD88-dependent regulatory functions and phenotype., References: ['']\n",
      "DEBUG - Citing Paper: A Review of Human Coronaviruses' Receptors: The Host-Cell Targets for the Crown Bearing Viruses., References: ['']\n",
      "DEBUG - Citing Paper: Principles for designing an optimal mRNA lipid nanoparticle vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Immunogenicity of <i>In Vitro</i>-Transcribed RNA., References: ['']\n",
      "DEBUG - Citing Paper: Immunology of SARS-CoV-2 infections and vaccines., References: ['']\n",
      "DEBUG - Citing Paper: An Update on mRNA-Based Viral Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Nucleic acid delivery and nanoparticle design for COVID vaccines., References: ['']\n",
      "DEBUG - Citing Paper: The tangled history of mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: A Guide to Nucleic Acid Vaccines in the Prevention and Treatment of Infectious Diseases and Cancers: From Basic Principles to Current Applications., References: ['']\n",
      "DEBUG - Citing Paper: Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: PEGylation of mRNA by Hybridization of Complementary PEG-RNA Oligonucleotides Stabilizes mRNA without Using Cationic Materials., References: ['']\n",
      "DEBUG - Citing Paper: Multifunctional Immunoadjuvants for Use in Minimalist Nucleic Acid Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: New epigenetic players in stroke pathogenesis: From non-coding RNAs to exosomal non-coding RNAs., References: ['']\n",
      "DEBUG - Citing Paper: Examining the evidence for extracellular RNA function in mammals., References: ['']\n",
      "DEBUG - Citing Paper: The dawn of mRNA vaccines: The COVID-19 case., References: ['']\n",
      "DEBUG - Citing Paper: Treatment of Cystic Fibrosis: From Gene- to Cell-Based Therapies., References: ['']\n",
      "DEBUG - Citing Paper: Roles of RNA Methylation on Tumor Immunity and Clinical Implications., References: ['']\n",
      "DEBUG - Citing Paper: RNA-based therapies: A cog in the wheel of lung cancer defense., References: ['']\n",
      "DEBUG - Citing Paper: Exosomes for mRNA delivery: a novel biotherapeutic strategy with hurdles and hope., References: ['']\n",
      "DEBUG - Citing Paper: Alternative oxidase encoded by sequence-optimized and chemically-modified RNA transfected into mammalian cells is catalytically active., References: ['']\n",
      "DEBUG - Citing Paper: mRNA in cancer immunotherapy: beyond a source of antigen., References: ['']\n",
      "DEBUG - Citing Paper: Targeting Toll-Like Receptors in Sepsis: From Bench to Clinical Trials., References: ['']\n",
      "DEBUG - Citing Paper: The immune-inflammatory response of oligodendrocytes in a murine model of preterm white matter injury: the role of TLR3 activation., References: ['']\n",
      "DEBUG - Citing Paper: A Population of Radio-Resistant Macrophages in the Deep Myenteric Plexus Contributes to Postoperative Ileus <i>Via</i> Toll-Like Receptor 3 Signaling., References: ['']\n",
      "DEBUG - Citing Paper: TLR3-Activated Monocyte-Derived Dendritic Cells Trigger Progression from Acute Viral Infection to Chronic Disease in the Lung., References: ['']\n",
      "DEBUG - Citing Paper: Can SARS-CoV-2 Virus Use Multiple Receptors to Enter Host Cells?, References: ['']\n",
      "DEBUG - Citing Paper: Self-assembled mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: TLR3 controls constitutive IFN-Î² antiviral immunity in human fibroblasts and cortical neurons., References: ['']\n",
      "DEBUG - Citing Paper: Damage-Associated Molecular Patterns in Myocardial Infarction and Heart Transplantation: The Road to Translational Success., References: ['']\n",
      "DEBUG - Citing Paper: Neo-Antigen mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Toll-Like Receptor 3 as a Recurrence Risk Factor and a Potential Molecular Therapeutic Target in Colorectal Cancer., References: ['']\n",
      "DEBUG - Citing Paper: Role of astroglial toll-like receptors (TLRs) in central nervous system infections, injury and neurodegenerative diseases., References: ['']\n",
      "DEBUG - Citing Paper: Receptor-interacting protein kinase 1 is a key mediator in TLR3 ligand and Smac mimetic-induced cell death and suppresses TLR3 ligand-promoted invasion in cholangiocarcinoma., References: ['']\n",
      "DEBUG - Citing Paper: Theoretical basis for stabilizing messenger RNA through secondary structure design., References: ['']\n",
      "DEBUG - Citing Paper: When Innate Immunity Meets Angiogenesis-The Role of Toll-Like Receptors in Endothelial Cells and Pulmonary Hypertension., References: ['']\n",
      "DEBUG - Citing Paper: Necroptosis in Hepatosteatotic Ischaemia-Reperfusion Injury., References: ['']\n",
      "DEBUG - Citing Paper: Metabolic Flexibility and Innate Immunity in Renal Ischemia Reperfusion Injury: The Fine Balance Between Adaptive Repair and Tissue Degeneration., References: ['']\n",
      "DEBUG - Citing Paper: Microglia: Agents of the CNS Pro-Inflammatory Response., References: ['']\n",
      "DEBUG - Citing Paper: Innate Immune Sensing of Influenza A Virus., References: ['']\n",
      "DEBUG - Citing Paper: Immune Sensing Mechanisms that Discriminate Self from Altered Self and Foreign Nucleic Acids., References: ['']\n",
      "DEBUG - Citing Paper: Distinct and Orchestrated Functions of RNA Sensors in Innate Immunity., References: ['']\n",
      "DEBUG - Citing Paper: The Role of Danger Associated Molecular Patterns in Human Fetal Membrane Weakening., References: ['']\n",
      "DEBUG - Citing Paper: Hypoxia induced up-regulation of tissue factor is mediated through extracellular RNA activated Toll-like receptor 3-activated protein 1 signalling., References: ['']\n",
      "DEBUG - Citing Paper: RNA-Binding Proteins in Pulmonary Hypertension., References: ['']\n",
      "DEBUG - Citing Paper: Chemical multi-fingerprinting of exogenous ultrafine particles in human serum and pleural effusion., References: ['']\n",
      "DEBUG - Citing Paper: Protein Kinase C Î´ (PKCÎ´) Attenuates Bleomycin Induced Pulmonary Fibrosis via Inhibiting NF-ÎºB Signaling Pathway., References: ['']\n",
      "DEBUG - Citing Paper: Hepatic Macrophages in Liver Injury., References: ['']\n",
      "DEBUG - Citing Paper: RNA Signaling in Pulmonary Arterial Hypertension-A Double-Stranded Sword., References: ['']\n",
      "DEBUG - Citing Paper: HIV infection suppresses TLR3 activation-mediated antiviral immunity in microglia and macrophages., References: ['']\n",
      "DEBUG - Citing Paper: Double-stranded RNA and Toll-like receptor activation: a novel mechanism for blood pressure regulation., References: ['']\n",
      "DEBUG - Citing Paper: Molecular Mechanism of the Antiproliferative Activity of Short Immunostimulating dsRNA., References: ['']\n",
      "DEBUG - Citing Paper: Synthesis of low immunogenicity RNA with high-temperature in vitro transcription., References: ['']\n",
      "DEBUG - Citing Paper: Activation of Toll-Like Receptor 3 Induces Interleukin-1 Receptor Antagonist Expression by Activating the Interferon Regulatory Factor 3., References: ['']\n",
      "DEBUG - Citing Paper: Mitochondrial Double-Stranded RNA in Exosome Promotes Interleukin-17 Production Through Toll-Like Receptor 3 in Alcohol-associated Liver Injury., References: ['']\n",
      "DEBUG - Citing Paper: A Bioinformatic Approach for the Identification of Molecular Determinants of Resistance/Sensitivity to Cancer Thermotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Inflammation associated with noise-induced hearing loss., References: ['']\n",
      "DEBUG - Citing Paper: Nucleic Acid Sensors and Programmed Cell Death., References: ['']\n",
      "DEBUG - Citing Paper: Efficient reduction of synthetic mRNA induced immune activation by simultaneous delivery of B18R encoding mRNA., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Delivery for Therapeutic Anti-HER2 Antibody Expression InÂ Vivo., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor 3 acts as a suppressor gene in breast cancer initiation and progression: a two-stage association study and functional investigation., References: ['']\n",
      "DEBUG - Citing Paper: Biomedical applications of mRNA nanomedicine., References: ['']\n",
      "DEBUG - Citing Paper: Advances in mRNA Vaccines for Infectious Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Evidence for Sexual Dimorphism in the Response to TLR3 Activation in the Developing Neonatal Mouse Brain: A Pilot Study., References: ['']\n",
      "DEBUG - Citing Paper: Recent Developments in mRNA-Based Protein Supplementation Therapy to Target Lung Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Understanding the Role of Innate Immunity in the Response to Intracortical Microelectrodes., References: ['']\n",
      "DEBUG - Citing Paper: A literature review for the mechanisms of stress-induced liver injury., References: ['']\n",
      "DEBUG - Citing Paper: Recent Advances in Zika Virus Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Extracellular RNA Sensing by Pattern Recognition Receptors., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like Receptor 3 Is a Therapeutic Target for Pulmonary Hypertension., References: ['']\n",
      "DEBUG - Citing Paper: Increased expression of toll-like receptor 3, an anti-viral signaling molecule, and related genes in Alzheimer's disease brains., References: ['']\n",
      "DEBUG - Citing Paper: Biocompatible, Purified <i>VEGF-A</i> mRNA Improves Cardiac Function after Intracardiac Injection 1 Week Post-myocardial Infarction in Swine., References: ['']\n",
      "DEBUG - Citing Paper: Dual Effect of Hepatic Macrophages on Liver Ischemia and Reperfusion Injury during Liver Transplantation., References: ['']\n",
      "DEBUG - Citing Paper: Trauma-Induced Damage-Associated Molecular Patterns-Mediated Remote Organ Injury and Immunosuppression in the Acutely Ill Patient., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis., References: ['']\n",
      "DEBUG - Citing Paper: The Roles of MicroRNAs in Stroke: Possible Therapeutic Targets., References: ['']\n",
      "DEBUG - Citing Paper: Modulation of mRNA Translation and Cell Viability by Influenza A Virus Derived Nonstructural Protein 1., References: ['']\n",
      "DEBUG - Citing Paper: Recognition of Double-Stranded RNA and Regulation of Interferon Pathway by Toll-Like Receptor 10., References: ['']\n",
      "DEBUG - Citing Paper: Innate immune system activation in zebrafish and cellular models of Diamond Blackfan Anemia., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor 3 modulates the behavioral effects of cocaine in mice., References: ['']\n",
      "DEBUG - Citing Paper: Deficiency of Toll-like receptors 2, 3 or 4 extends life expectancy in Huntington's disease mice., References: ['']\n",
      "DEBUG - Citing Paper: The Multirole of Liposomes in Therapy and Prevention of Infectious Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Shuttling Tolerogenic Dendritic Cells across the Blood-Brain Barrier <i>In Vitro via</i> the Introduction of <i>De Novo</i> C-C Chemokine Receptor 5 Expression Using Messenger RNA Electroporation., References: ['']\n",
      "DEBUG - Citing Paper: Toll-Like Receptor 4 on both Myeloid Cells and Dendritic Cells Is Required for Systemic Inflammation and Organ Damage after Hemorrhagic Shock with Tissue Trauma in Mice., References: ['']\n",
      "DEBUG - Citing Paper: Oxidative stress diseases unique to the perinatal period: A window into the developing innate immune response., References: ['']\n",
      "DEBUG - Citing Paper: Toll-Like Receptor-3 Mediates HIV-1-Induced Interleukin-6 Expression in the Human Brain Endothelium via TAK1 and JNK Pathways: Implications for Viral Neuropathogenesis., References: ['']\n",
      "DEBUG - Citing Paper: Knockout of toll-like receptor impairs nerve regeneration after a crush injury., References: ['']\n",
      "DEBUG - Citing Paper: Design, Assembly, Production, and Transfection of Synthetic Modified mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Higher Expression of Toll-Like Receptors 2 and 4 in Blood Cells of Keratoconus Patiens., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptors and their role in persistent pain., References: ['']\n",
      "DEBUG - Citing Paper: The Role of Danger Signals in the Pathogenesis and Perpetuation of Critical Illness., References: ['']\n",
      "DEBUG - Citing Paper: Natural Modulators of Endosomal Toll-Like Receptor-Mediated Psoriatic Skin Inflammation., References: ['']\n",
      "DEBUG - Citing Paper: Surface Toll-like receptor 3 expression in metastatic intestinal epithelial cells induces inflammatory cytokine production and promotes invasiveness., References: ['']\n",
      "DEBUG - Citing Paper: Neuroinflammation and Infection: Molecular Mechanisms Associated with Dysfunction of Neurovascular Unit., References: ['']\n",
      "DEBUG - Citing Paper: Small RNAs induce the activation of the pro-inflammatory TLR7 signaling pathway in aged rat kidney., References: ['']\n",
      "DEBUG - Citing Paper: The Role of Toll-Like Receptors in Autoimmune Diseases through Failure of the Self-Recognition Mechanism., References: ['']\n",
      "DEBUG - Citing Paper: Emerging Roles of microRNAs in Ischemic Stroke: As Possible Therapeutic Agents., References: ['']\n",
      "DEBUG - Citing Paper: Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses., References: ['']\n",
      "DEBUG - Citing Paper: Poly I:C induces collective migration of HaCaT keratinocytes via IL-8., References: ['']\n",
      "DEBUG - Citing Paper: Pathogenic mechanisms following ischemic stroke., References: ['']\n",
      "DEBUG - Citing Paper: Bioconjugation of Small Molecules to RNA Impedes Its Recognition by Toll-Like Receptor 7., References: ['']\n",
      "DEBUG - Citing Paper: The viral innate immune antagonism and an alternative vaccine design for PRRS virus., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor-associated keratitis and strategies for its management., References: ['']\n",
      "DEBUG - Citing Paper: Particulate Air pollution mediated effects on insulin resistance in mice are independent of CCR2., References: ['']\n",
      "DEBUG - Citing Paper: Modified mRNA Vaccines Protect against Zika Virus Infection., References: ['']\n",
      "DEBUG - Citing Paper: TLR4 signaling induces TLR3 up-regulation in alveolar macrophages during acute lung injury., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor 3 activation selectively reverses HIV latency in microglial cells., References: ['']\n",
      "DEBUG - Citing Paper: Central role of the TIR-domain-containing adaptor-inducing interferon-Î² (TRIF) adaptor protein in murine sterile liver injury., References: ['']\n",
      "DEBUG - Citing Paper: Interplay between Inflammation and Stemness in Cancer Cells: The Role of Toll-Like Receptor Signaling., References: ['']\n",
      "DEBUG - Citing Paper: TLR3 downregulates expression of schizophrenia gene Disc1 via MYD88 to control neuronal morphology., References: ['']\n",
      "DEBUG - Citing Paper: TLR3-Induced Maturation of Murine Dendritic Cells Regulates CTL Responses by Modulating PD-L1 Trafficking., References: ['']\n",
      "DEBUG - Citing Paper: Stimulation of the toll-like receptor 3 promotes metabolic reprogramming in head and neck carcinoma cells., References: ['']\n",
      "DEBUG - Citing Paper: Endogenous Retroelements and the Host Innate Immune Sensors., References: ['']\n",
      "DEBUG - Citing Paper: A specific anti-citrullinated protein antibody profile identifies a group of rheumatoid arthritis patients with a toll-like receptor 4-mediated disease., References: ['']\n",
      "DEBUG - Citing Paper: Efficacy and immunogenicity of unmodified and pseudouridine-modified mRNA delivered systemically with lipid nanoparticles inÂ vivo., References: ['']\n",
      "DEBUG - Citing Paper: Double-Stranded RNA Interacts With Toll-Like Receptor 3 in Driving the Acute Inflammatory Response Following Lung Contusion., References: ['']\n",
      "DEBUG - Citing Paper: Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose., References: ['']\n",
      "DEBUG - Citing Paper: Viral and Synthetic RNA Vector Technologies and Applications., References: ['']\n",
      "DEBUG - Citing Paper: RNA is an Adjuvanticity Mediator for the Lipid-Based Mucosal Adjuvant, Endocine., References: ['']\n",
      "DEBUG - Citing Paper: Particle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I Interferon., References: ['']\n",
      "DEBUG - Citing Paper: Immune evasion of porcine enteric coronaviruses and viral modulation of antiviral innate signaling., References: ['']\n",
      "DEBUG - Citing Paper: Profiling of the dynamically alteredgene expression in peripheral nerve injury using NGS RNA sequencing technique., References: ['']\n",
      "DEBUG - Citing Paper: Preconditioning Vaccine Sites for mRNA-Transfected Dendritic Cell Therapy and Antitumor Efficacy., References: ['']\n",
      "DEBUG - Citing Paper: Non-coding Double-stranded RNA and Antimicrobial Peptide LL-37 Induce Growth Factor Expression from Keratinocytes and Endothelial Cells., References: ['']\n",
      "DEBUG - Citing Paper: Splenic RNA and MicroRNA Mimics Promote Complement Factor B Production and Alternative Pathway Activation via Innate Immune Signaling., References: ['']\n",
      "DEBUG - Citing Paper: The Effect of Estradiol and Progesterone on Toll Like Receptor Gene Expression in A Human Fallopian Tube Epithelial Cell Line., References: ['']\n",
      "DEBUG - Citing Paper: Electroporated Antigen-Encoding mRNA Is Not a Danger Signal to Human Mature Monocyte-Derived Dendritic Cells., References: ['']\n",
      "DEBUG - Citing Paper: 2'Fluoro Modification Differentially Modulates the Ability of RNAs to Activate Pattern Recognition Receptors., References: ['']\n",
      "DEBUG - Citing Paper: Poly(I:C) increases the expression of mPGES-1 and COX-2 in rat primary microglia., References: ['']\n",
      "DEBUG - Citing Paper: Poly(glycoamidoamine) Brushes Formulated Nanomaterials for Systemic siRNA and mRNA Delivery in Vivo., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor-3 mediates HIV-1 transactivation via NFÎºB and JNK pathways and histone acetylation, but prolonged activation suppresses Tat and HIV-1 replication., References: ['']\n",
      "DEBUG - Citing Paper: Periostin is critical for improving the therapeutic properties of adipocyte-derived stem cells., References: ['']\n",
      "DEBUG - Citing Paper: Expression of CCL20 and Its Corresponding Receptor CCR6 Is Enhanced in Active Inflammatory Bowel Disease, and TLR3 Mediates CCL20 Expression in Colonic Epithelial Cells., References: ['']\n",
      "DEBUG - Citing Paper: Chemically modified RNA activated matrices enhance bone regeneration., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor 3 regulates NK cell responses to cytokines and controls experimental metastasis., References: ['']\n",
      "DEBUG - Citing Paper: Cardiac RNA induces inflammatory responses in cardiomyocytes and immune cells via Toll-like receptor 7 signaling., References: ['']\n",
      "DEBUG - Citing Paper: Epilepsy and innate immune system: A possible immunogenic predisposition and related therapeutic implications., References: ['']\n",
      "DEBUG - Citing Paper: dsRNA Released by Tissue Damage Activates TLR3 to Drive Skin Regeneration., References: ['']\n",
      "DEBUG - Citing Paper: Screening of mRNA Chemical Modification to Maximize Protein Expression with Reduced Immunogenicity., References: ['']\n",
      "DEBUG - Citing Paper: Pattern recognition receptors in microbial keratitis., References: ['']\n",
      "DEBUG - Citing Paper: Modified mRNA as an alternative to plasmid DNA (pDNA) for transcript replacement and vaccination therapy., References: ['']\n",
      "DEBUG - Citing Paper: The sterile inflammation in the exacerbation of HBV-associated liver injury., References: ['']\n",
      "DEBUG - Citing Paper: TLR-3 is present in human adipocytes, but its signalling is not required for obesity-induced inflammation in adipose tissue in vivo., References: ['']\n",
      "DEBUG - Citing Paper: An LXR-NCOA5 gene regulatory complex directs inflammatory crosstalk-dependent repression of macrophage cholesterol efflux., References: ['']\n",
      "DEBUG - Citing Paper: Antimicrobial peptides and complement in neonatal hypoxia-ischemia induced brain damage., References: ['']\n",
      "DEBUG - Citing Paper: Cellular mechanisms of toll-like receptor-3 activation in the thalamus are associated with white matter injury in the developing brain., References: ['']\n",
      "DEBUG - Citing Paper: Friend retrovirus drives cytotoxic effectors through Toll-like receptor 3., References: ['']\n",
      "DEBUG - Citing Paper: Synthetic chemically modified mRNA (modRNA): toward a new technology platform for cardiovascular biology and medicine., References: ['']\n",
      "DEBUG - Citing Paper: Self DNA from lymphocytes that have undergone activation-induced cell death enhances murine B cell proliferation and antibody production., References: ['']\n",
      "DEBUG - Citing Paper: Immunogenicity of necrotic cell death., References: ['']\n",
      "DEBUG - Citing Paper: A novel protective role for the innate immunity Toll-Like Receptor 3 (TLR3) in the retina via Stat3., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor 3 increases allergic and irritant contact dermatitis., References: ['']\n",
      "DEBUG - Citing Paper: Expression of toll-like receptors and co-stimulatory molecules in lymphoid tissue during experimental infection of beef calves with bovine viral diarrhea virus of low and high virulence., References: ['']\n",
      "DEBUG - Citing Paper: A long-awaited merger of the pathways mediating host defence and programmed cell death., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor 3 activation is required for normal skin barrier repair following UV damage., References: ['']\n",
      "DEBUG - Citing Paper: The intricate interplay between RNA viruses and NF-ÎºB., References: ['']\n",
      "DEBUG - Citing Paper: Pattern recognition receptors and central nervous system repair., References: ['']\n",
      "DEBUG - Citing Paper: The same and not the same: heterogeneous functional activation of prostate tumor cells by TLR ligation., References: ['']\n",
      "DEBUG - Citing Paper: Repair of the Peripheral Nerve-Remyelination that Works., References: ['']\n",
      "DEBUG - Citing Paper: UVB radiation illuminates the role of TLR3 in the epidermis., References: ['']\n",
      "DEBUG - Citing Paper: Differential MSC activation leads to distinct mononuclear leukocyte binding mechanisms., References: ['']\n",
      "DEBUG - Citing Paper: Does toll-like receptor-3 (TLR-3) have any role in Indian AMD phenotype?, References: ['']\n",
      "DEBUG - Citing Paper: Defects in TLR3 expression and RNase L activation lead to decreased MnSOD expression and insulin resistance in muscle cells of obese people., References: ['']\n",
      "DEBUG - Citing Paper: Blockade of TLR3 protects mice from lethal radiation-induced gastrointestinal syndrome., References: ['']\n",
      "DEBUG - Citing Paper: Type-1 interferons contribute to oxygen glucose deprivation induced neuro-inflammation in BE(2)M17 human neuroblastoma cells., References: ['']\n",
      "DEBUG - Citing Paper: Hyaluronan digestion controls DC migration from the skin., References: ['']\n",
      "DEBUG - Citing Paper: TLR3 plays significant roles against hepatitis B virus., References: ['']\n",
      "DEBUG - Citing Paper: Necrosis-dependent and independent signaling of the RIP kinases in inflammation., References: ['']\n",
      "DEBUG - Citing Paper: Immunopathology of lupus nephritis., References: ['']\n",
      "DEBUG - Citing Paper: Role of extracellular RNA and TLR3-Trif signaling in myocardial ischemia-reperfusion injury., References: ['']\n",
      "DEBUG - Citing Paper: Danger signals in the initiation of the inflammatory response after myocardial infarction., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor signaling adapter proteins govern spread of neuropathic pain and recovery following nerve injury in male mice., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor 3 plays a role in myocardial infarction and ischemia/reperfusion injury., References: ['']\n",
      "DEBUG - Citing Paper: TLR and NKG2D signaling pathways mediate CS-induced pulmonary pathologies., References: ['']\n",
      "DEBUG - Citing Paper: The pathogenesis of lupus nephritis., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor 3 in viral pathogenesis: friend or foe?, References: ['']\n",
      "DEBUG - Citing Paper: Nucleic acids and endosomal pattern recognition: how to tell friend from foe?, References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptors in atherosclerosis., References: ['']\n",
      "DEBUG - Citing Paper: Adenosine triphosphate hydrolysis reduces neutrophil infiltration and necrosis in partial-thickness scald burns in mice., References: ['']\n",
      "DEBUG - Citing Paper: Nuclear factor ÎºB2 p52 protein has a role in antiviral immunity through IÎºB kinase epsilon-dependent induction of Sp1 protein and interleukin 15., References: ['']\n",
      "DEBUG - Citing Paper: Toll like receptor 3 plays a critical role in the progression and severity of acetaminophen-induced hepatotoxicity., References: ['']\n",
      "DEBUG - Citing Paper: Danger signalling during cancer cell death: origins, plasticity and regulation., References: ['']\n",
      "DEBUG - Citing Paper: Damage-associated molecular patterns and their receptors in upper airway pathologies., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor 3 recognizes incomplete stem structures in single-stranded viral RNA., References: ['']\n",
      "DEBUG - Citing Paper: Expression of Toll-like receptor-3 is enhanced in active inflammatory bowel disease and mediates the excessive release of lipocalin 2., References: ['']\n",
      "DEBUG - Citing Paper: Rhinovirus and dsRNA induce RIG-I-like receptors and expression of interferon Î² and Î»1 in human bronchial smooth muscle cells., References: ['']\n",
      "DEBUG - Citing Paper: Hypothermia reduces toll-like receptor 3-activated microglial interferon-Î² and nitric oxide production., References: ['']\n",
      "DEBUG - Citing Paper: Immunogenic cell death: can it be exploited in PhotoDynamic Therapy for cancer?, References: ['']\n",
      "DEBUG - Citing Paper: Spinal toll-like receptor signaling and nociceptive processing: regulatory balance between TIRAP and TRIF cascades mediated by TNF and IFNÎ²., References: ['']\n",
      "DEBUG - Citing Paper: In vivo messenger RNA introduction into the central nervous system using polyplex nanomicelle., References: ['']\n",
      "DEBUG - Citing Paper: Lung CD8+ T cells in COPD have increased expression of bacterial TLRs., References: ['']\n",
      "DEBUG - Citing Paper: Recognition of damage-associated molecular patterns related to nucleic acids during inflammation and vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor expression and induction of type I and type III interferons in primary airway epithelial cells., References: ['']\n",
      "DEBUG - Citing Paper: mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic., References: ['']\n",
      "DEBUG - Citing Paper: TLR3 immunity to infection in mice and humans., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor 3 (TLR3) protects retinal pigmented epithelium (RPE) cells from oxidative stress through a STAT3-dependent mechanism., References: ['']\n",
      "DEBUG - Citing Paper: TLR3, TRIF, and caspase 8 determine double-stranded RNA-induced epithelial cell death and survival in vivo., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor 3 in Epstein-Barr virus-associated nasopharyngeal carcinomas: consistent expression and cytotoxic effects of its synthetic ligand poly(A:U) combined to a Smac-mimetic., References: ['']\n",
      "DEBUG - Citing Paper: Primary sterile necrotic cells fail to cross-prime CD8(+) T cells., References: ['']\n",
      "DEBUG - Citing Paper: TLR3/TICAM-1 signaling in tumor cell RIP3-dependent necroptosis., References: ['']\n",
      "DEBUG - Citing Paper: Immunogenic cell death and DAMPs in cancer therapy., References: ['']\n",
      "DEBUG - Citing Paper: Innate immune regulation by toll-like receptors in the brain., References: ['']\n",
      "DEBUG - Citing Paper: Developing mRNA-vaccine technologies., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor sensing of human herpesvirus infection., References: ['']\n",
      "DEBUG - Citing Paper: Human endogenous RNAs: Implications for the immunomodulation of Toll-like receptor 3., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like Receptors in Chronic Lymphocytic Leukemia., References: ['']\n",
      "DEBUG - Citing Paper: DAMP signaling in fungal infections and diseases., References: ['']\n",
      "DEBUG - Citing Paper: Multi-level regulation of cellular recognition of viral dsRNA., References: ['']\n",
      "DEBUG - Citing Paper: Placental Toll-like receptor 3 and Toll-like receptor 7/8 activation contributes to preeclampsia in humans and mice., References: ['']\n",
      "DEBUG - Citing Paper: Mechanisms of age-related macular degeneration., References: ['']\n",
      "DEBUG - Citing Paper: The immunology of acute stroke., References: ['']\n",
      "DEBUG - Citing Paper: A Distinct Profile of Tryptophan Metabolism along the Kynurenine Pathway Downstream of Toll-Like Receptor Activation in Irritable Bowel Syndrome., References: ['']\n",
      "DEBUG - Citing Paper: Toll/interleukin-1 receptor domain-containing adapter inducing interferon-Î² mediates microglial phagocytosis of degenerating axons., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor 3 plays a central role in cardiac dysfunction during polymicrobial sepsis., References: ['']\n",
      "DEBUG - Citing Paper: RNA mediated Toll-like receptor stimulation in health and disease., References: ['']\n",
      "DEBUG - Citing Paper: Interplay between interferon-mediated innate immunity and porcine reproductive and respiratory syndrome virus., References: ['']\n",
      "DEBUG - Citing Paper: Triggering of the dsRNA sensors TLR3, MDA5, and RIG-I induces CD55 expression in synovial fibroblasts., References: ['']\n",
      "DEBUG - Citing Paper: Lateral clustering of TLR3:dsRNA signaling units revealed by TLR3ecd:3Fabs quaternary structure., References: ['']\n",
      "DEBUG - Citing Paper: Induction and activation of antiviral enzyme 2',5'-oligoadenylate synthetase by in vitro transcribed insulin mRNA and other cellular RNAs., References: ['']\n",
      "DEBUG - Citing Paper: Eicosanoid receptor subtype-mediated opposing regulation of TLR-stimulated expression of astrocyte glial-derived neurotrophic factor., References: ['']\n",
      "DEBUG - Citing Paper: mRNA leapfrogs DNA to show promise for therapeutic gene transfer., References: ['']\n",
      "DEBUG - Citing Paper: Emerging role of Toll-like receptors in the control of pain and itch., References: ['']\n",
      "DEBUG - Citing Paper: The bacterial preparation OK432 induces IL-12p70 secretion in human dendritic cells in a TLR3 dependent manner., References: ['']\n",
      "DEBUG - Citing Paper: Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin., References: ['']\n",
      "DEBUG - Citing Paper: A TRIF-independent branch of TLR3 signaling., References: ['']\n",
      "DEBUG - Citing Paper: Mucins and toll-like receptors: kith and kin in infection and cancer., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor (TLR) 3 immune modulation by unformulated small interfering RNA or DNA and the role of CD14 (in TLR-mediated effects)., References: ['']\n",
      "DEBUG - Citing Paper: Bench-to-bedside review: Damage-associated molecular patterns in the onset of ventilator-induced lung injury., References: ['']\n",
      "DEBUG - Citing Paper: Two microRNAs encoded within the bovine herpesvirus 1 latency-related gene promote cell survival by interacting with RIG-I and stimulating NF-ÎºB-dependent transcription and beta interferon signaling pathways., References: ['']\n",
      "DEBUG - Citing Paper: Many stimuli pull the necrotic trigger, an overview., References: ['']\n",
      "DEBUG - Citing Paper: Exogenous or endogenous Toll-like receptor ligands: which is the MVP in tumorigenesis?, References: ['']\n",
      "DEBUG - Citing Paper: Viral double-strand RNA-binding proteins can enhance innate immune signaling by toll-like Receptor 3., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptors and myocardial inflammation., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor 2 contributes to chemokine gene expression and macrophage infiltration in the dorsal root ganglia after peripheral nerve injury., References: ['']\n",
      "DEBUG - Citing Paper: Apolipoprotein E isoforms and regulation of the innate immune response in brain of patients with Alzheimer's disease., References: ['']\n",
      "DEBUG - Citing Paper: Wallerian degeneration: gaining perspective on inflammatory events after peripheral nerve injury., References: ['']\n",
      "DEBUG - Citing Paper: Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase resistance to cleavage by RNase L., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptors in health and disease in the brain: mechanisms and therapeutic potential., References: ['']\n",
      "DEBUG - Citing Paper: The ribonucleotide reductase R1 subunits of herpes simplex virus 1 and 2 protect cells against poly(I Â· C)-induced apoptosis., References: ['']\n",
      "DEBUG - Citing Paper: Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4., References: ['']\n",
      "DEBUG - Citing Paper: Regulation of toll-like receptor 1 and -2 in neonatal mice brains after hypoxia-ischemia., References: ['']\n",
      "DEBUG - Citing Paper: Innate immunity and monocyte-macrophage activation in atherosclerosis., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor 3 signaling enables human esophageal epithelial cells to sense endogenous danger signals released by necrotic cells., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor, RIG-I-like receptors and the NLRP3 inflammasome: key modulators of innate immune responses to double-stranded RNA viruses., References: ['']\n",
      "DEBUG - Citing Paper: The danger signal S100B integrates pathogen- and danger-sensing pathways to restrain inflammation., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor signaling in neural plasticity and disease., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor 3 is required for development of retinopathy caused by impaired all-trans-retinal clearance in mice., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptors and signalling in spermatogenesis and testicular responses to inflammation--a perspective., References: ['']\n",
      "DEBUG - Citing Paper: Differential activation of Toll-like receptor-mediated apoptosis induced by hypoxia., References: ['']\n",
      "DEBUG - Citing Paper: Suppressed microglial E prostanoid receptor 1 signaling selectively reduces tumor necrosis factor alpha and interleukin 6 secretion from toll-like receptor 3 activation., References: ['']\n",
      "DEBUG - Citing Paper: Toll in the vessel wall--for better or worse?, References: ['']\n",
      "DEBUG - Citing Paper: Role of TLR2-dependent inflammation in metastatic progression., References: ['']\n",
      "DEBUG - Citing Paper: Unexpected protective role for Toll-like receptor 3 in the arterial wall., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptors 2 and 4 in ischemic stroke: outcome and therapeutic values., References: ['']\n",
      "DEBUG - Citing Paper: Mechanical ventilation modulates Toll-like receptor-3-induced lung inflammation via a MyD88-dependent, TLR4-independent pathway: a controlled animal study., References: ['']\n",
      "DEBUG - Citing Paper: Sterile inflammation: sensing and reacting to damage., References: ['']\n",
      "DEBUG - Citing Paper: Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts., References: ['']\n",
      "DEBUG - Citing Paper: Microglial Toll-like receptor 2 contributes to kainic acid-induced glial activation and hippocampal neuronal cell death., References: ['']\n",
      "DEBUG - Citing Paper: DAMPening inflammation by modulating TLR signalling., References: ['']\n",
      "DEBUG - Citing Paper: Immunomodulatory effects of dsRNA and its potential as vaccine adjuvant., References: ['']\n",
      "DEBUG - Citing Paper: Simian immunodeficiency virus infection alters chemokine networks in lung tissues of cynomolgus macaques: association with Pneumocystis carinii infection., References: ['']\n",
      "DEBUG - Citing Paper: Innate immune suppression enables frequent transfection with RNA encoding reprogramming proteins., References: ['']\n",
      "DEBUG - Citing Paper: The expression and functions of toll-like receptors in atherosclerosis., References: ['']\n",
      "DEBUG - Citing Paper: Neural injury following stroke: are Toll-like receptors the link between the immune system and the CNS?, References: ['']\n",
      "DEBUG - Citing Paper: Endogenous toll-like receptor ligands and their biological significance., References: ['']\n",
      "DEBUG - Citing Paper: Poly(I:C) drives type I IFN- and TGFÎ²-mediated inflammation and dermal fibrosis simulating altered gene expression in systemic sclerosis., References: ['']\n",
      "DEBUG - Citing Paper: IFN-gamma primes intact human coronary arteries and cultured coronary smooth muscle cells to double-stranded RNA- and self-RNA-induced inflammatory responses by upregulating TLR3 and melanoma differentiation-associated gene 5., References: ['']\n",
      "DEBUG - Citing Paper: Expression of toll-like receptors in genital tract tissues from normal and HIV-infected men., References: ['']\n",
      "DEBUG - Citing Paper: Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens., References: ['']\n",
      "DEBUG - Citing Paper: Kaposi's sarcoma-associated herpesvirus and innate immunity., References: ['']\n",
      "DEBUG - Citing Paper: Pattern recognition via the toll-like receptor system in the human female genital tract., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor 9 inhibition confers protection from liver ischemia-reperfusion injury., References: ['']\n",
      "DEBUG - Citing Paper: Murine pancreatic beta TC3 cells show greater 2', 5'-oligoadenylate synthetase (2'5'AS) antiviral enzyme activity and apoptosis following IFN-alpha or poly(I:C) treatment than pancreatic alpha TC3 cells., References: ['']\n",
      "DEBUG - Citing Paper: It's all in the family: multiple Toll-like receptors offer promise as novel therapeutic targets for stroke neuroprotection., References: ['']\n",
      "DEBUG - Citing Paper: Attenuation of the influenza virus sickness behavior in mice deficient in Toll-like receptor 3., References: ['']\n",
      "DEBUG - Citing Paper: Immune activation in brain aging and neurodegeneration: too much or too little?, References: ['']\n",
      "DEBUG - Citing Paper: A clear and present danger: endogenous ligands of Toll-like receptors., References: ['']\n",
      "DEBUG - Citing Paper: TLR3-mediated NF-{kappa}B signaling in human esophageal epithelial cells., References: ['']\n",
      "DEBUG - Citing Paper: Inflammatory regulation by TLR3 in acute hepatitis., References: ['']\n",
      "DEBUG - Citing Paper: Gene silencing in the therapy of influenza and other respiratory diseases: Targeting to RNase P by use of External Guide Sequences (EGS)., References: ['']\n",
      "DEBUG - Citing Paper: Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment., References: ['']\n",
      "DEBUG - Citing Paper: Increased expression of Toll-like receptor 3 in intrahepatic biliary epithelial cells at sites of ductular reaction in diseased livers., References: ['']\n",
      "DEBUG - Citing Paper: Innate immunity in heart transplantation., References: ['']\n",
      "DEBUG - Citing Paper: Long-term activation of TLR3 by poly(I:C) induces inflammation and impairs lung function in mice., References: ['']\n",
      "DEBUG - Citing Paper: Alteration of TLR3 pathways by glucocorticoids may be responsible for immunosusceptibility of human corneal epithelial cells to viral infections., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptors in kidney disease., References: ['']\n",
      "DEBUG - Citing Paper: Translational mini-review series on immunology of vascular disease: inflammation, infections and Toll-like receptors in cardiovascular disease., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor 3 (TLR3) plays a major role in the formation of rabies virus Negri Bodies., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptors and their role in carcinogenesis and anti-tumor treatment., References: ['']\n",
      "DEBUG - Citing Paper: Dendritic cell-based human immunodeficiency virus vaccine., References: ['']\n",
      "DEBUG - Citing Paper: TLR3 modulates immunopathology during a Schistosoma mansoni egg-driven Th2 response in the lung., References: ['']\n",
      "DEBUG - Citing Paper: Activation of Toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors., References: ['']\n",
      "DEBUG - Citing Paper: TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory events., References: ['']\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DEBUG - Citing Paper: Pathogenic anti-DNA antibodies modulate gene expression in mesangial cells: involvement of HMGB1 in anti-DNA antibody-induced renal injury., References: ['']\n",
      "DEBUG - Citing Paper: Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability., References: ['']\n",
      "DEBUG - Citing Paper: TLR3 and TLR4 expression in healthy and diseased human endometrium., References: ['']\n",
      "DEBUG - Citing Paper: No longer an innocent bystander: epithelial toll-like receptor signaling in the development of mucosal inflammation., References: ['']\n",
      "DEBUG - Citing Paper: Single-stranded oligonucleotides can inhibit cytokine production induced by human toll-like receptor 3., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor 3 regulates Mx expression in rare minnow Gobiocypris rarus after viral infection., References: ['']\n",
      "DEBUG - Citing Paper: Upregulation of the TLR3 pathway by Kaposi's sarcoma-associated herpesvirus during primary infection., References: ['']\n",
      "DEBUG - Citing Paper: Involvement of innate immunity in the pathogenesis of intestinal BehÃ§et's disease., References: ['']\n",
      "DEBUG - Citing Paper: Double-stranded RNA mediates interferon regulatory factor 3 activation and interleukin-6 production by engaging Toll-like receptor 3 in human brain astrocytes., References: ['']\n",
      "DEBUG - Citing Paper: Sensing of viral infection and activation of innate immunity by toll-like receptor 3., References: ['']\n",
      "DEBUG - Citing Paper: Macrophage activation by endogenous danger signals., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptors in defense and damage of the central nervous system., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor 3 is a potent negative regulator of axonal growth in mammals., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptors: novel pharmacological targets for the treatment of neurological diseases., References: ['']\n",
      "DEBUG - Citing Paper: Antiviral responses of human Fallopian tube epithelial cells to toll-like receptor 3 agonist poly(I:C)., References: ['']\n",
      "DEBUG - Citing Paper: Acute brain injury triggers MyD88-dependent, TLR2/4-independent inflammatory responses., References: ['']\n",
      "DEBUG - Citing Paper: Epithelia: lymphocyte interactions in the gut., References: ['']\n",
      "DEBUG - Citing Paper: The Toll-like receptor adaptor proteins MyD88 and Mal/TIRAP contribute to the inflammatory and destructive processes in a human model of rheumatoid arthritis., References: ['']\n",
      "DEBUG - Citing Paper: Translational mini-review series on Toll-like receptors: networks regulated by Toll-like receptors mediate innate and adaptive immunity., References: ['']\n",
      "DEBUG - Citing Paper: Chlamydia muridarum infection elicits a beta interferon response in murine oviduct epithelial cells dependent on interferon regulatory factor 3 and TRIF., References: ['']\n",
      "DEBUG - Citing Paper: Molecular characterization of coding sequences and analysis of Toll-like receptor 3 mRNA expression in water buffalo (Bubalus bubalis) and nilgai (Boselaphus tragocamelus)., References: ['']\n",
      "DEBUG - Citing Paper: The role of toll-like receptors in systemic lupus erythematosus., References: ['']\n",
      "DEBUG - Citing Paper: The TLR3 ligand polyI: C downregulates connexin 43 expression and function in astrocytes by a mechanism involving the NF-kappaB and PI3 kinase pathways., References: ['']\n",
      "DEBUG - Citing Paper: The role of Toll-like receptors in CNS response to microbial challenge., References: ['']\n",
      "DEBUG - Citing Paper: The 3' CCACCA sequence of tRNAAla(UGC) is the motif that is important in inducing Th1-like immune response, and this motif can be recognized by Toll-like receptor 3., References: ['']\n",
      "DEBUG - Citing Paper: A comprehensive map of the toll-like receptor signaling network., References: ['']\n",
      "DEBUG - Citing Paper: Characterization of the ribonuclease activity on the skin surface., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptors in central nervous system glial inflammation and homeostasis., References: ['']\n",
      "DEBUG - Citing Paper: Manifold mechanisms of Toll-like receptor-ligand recognition., References: ['']\n",
      "DEBUG - Citing Paper: The GRIP1:IRF3 interaction as a target for glucocorticoid receptor-mediated immunosuppression., References: ['']\n",
      "DEBUG - Citing Paper: Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus., References: ['']\n",
      "DEBUG - Citing Paper: NKG2D function protects the host from tumor initiation., References: ['']\n",
      "DEBUG - Citing Paper: The molecular structure of the Toll-like receptor 3 ligand-binding domain., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus., References: ['']\n",
      "DEBUG - Citing Paper: Mammalian Toll-like receptors: to immunity and beyond., References: ['']\n",
      "DEBUG - Citing Paper: Differential role for TLR3 in respiratory syncytial virus-induced chemokine expression., References: ['']\n",
      "DEBUG - Citing Paper: Interferon regulatory factor 3-independent double-stranded RNA-induced inhibition of hepatitis C virus replicons in human embryonic kidney 293 cells., References: ['']\n",
      "DEBUG - Citing Paper: Reading the viral signature by Toll-like receptors and other pattern recognition receptors., References: ['']\n",
      "DEBUG - Citing Paper: Effects of length and location on the cellular response to double-stranded RNA., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes., References: ['']\n",
      "DEBUG - Citing Paper: Toll-like receptor (TLR) expression and TLR-mediated cytokine/chemokine production by human uterine epithelial cells., References: ['']\n",
      "DEBUG - Citing Paper: TLR7: A new sensor of viral infection., References: ['']\n",
      "DEBUG - focal: mRNA is an endogenous ligand for Toll-like receptor 3., NF: 0, NB: 0, NR: 0, D: 0\n",
      "DEBUG - Focal Paper: Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes., References: \n",
      "Academy of Breastfeeding Medicine (ABM) . ABM Statement. Considerations for COVID-19 Vaccination in Lactation. Available at: https://www.bfmed.org/abm-statement-considerations-for-covid-19-vaccination-in-lactation?fbclid=IwAR1qG7rS66IyTDyDlxGIOrwQsoSqDRuXWMWnjgBXwhOJuSofk13veeT3jl8.\n",
      "DEBUG - Citing Paper: Antitumor activity of Z15-0-2, a bispecific nanobody targeting PD-1 and CTLA-4., References: ['']\n",
      "DEBUG - Citing Paper: Sustained antigen delivery improves germinal center reaction and increases antibody responses in neonatal mice., References: ['']\n",
      "DEBUG - Citing Paper: Novel Efficient Lipid-Based Delivery Systems Enable a Delayed Uptake and Sustained Expression of mRNA in Human Cells and Mouse Tissues., References: ['']\n",
      "DEBUG - Citing Paper: B cell somatic hypermutation following COVID-19 vaccination with Ad26.COV2.S., References: ['']\n",
      "DEBUG - Citing Paper: Recent SARS-CoV-2 Outlook and Implications in a COVID-19 Vaccination Era., References: ['']\n",
      "DEBUG - Citing Paper: Physiologically based modeling of LNP-mediated delivery of mRNA in the vascular system., References: ['']\n",
      "DEBUG - Citing Paper: Carrier-free mRNA vaccine induces robust immunity against SARS-CoV-2 in mice and non-human primates without systemic reactogenicity., References: ['']\n",
      "DEBUG - Citing Paper: The Role of Biological Sex in Pre-Clinical (Mouse) mRNA Vaccine Studies., References: ['']\n",
      "DEBUG - Citing Paper: Targeting lipid nanoparticles to the blood-brain barrier to ameliorate acute ischemic stroke., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticle structure and delivery route during pregnancy dictate mRNA potency, immunogenicity, and maternal and fetal outcomes., References: ['']\n",
      "DEBUG - Citing Paper: Correlating Stability-Indicating Biochemical and Biophysical Characteristics with In Vitro Cell Potency in mRNA LNP Vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Durable cross-protective neutralizing antibody responses elicited by lipid nanoparticle-formulated SARS-CoV-2 mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: The mRNA-LNP vaccines - the good, the bad and the ugly?, References: ['']\n",
      "DEBUG - Citing Paper: Profile of Katalin KarikÃ³ and Drew Weissman: 2023 Nobel laureates in Physiology or Medicine., References: ['']\n",
      "DEBUG - Citing Paper: Lipid-Encapsulated mRNAs Encoding Complex Fusion Proteins Potentiate Antitumor Immune Responses., References: ['']\n",
      "DEBUG - Citing Paper: Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadth., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticle-Based Delivery System-A Competing Place for mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Recent progress in mRNA cancer vaccines., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccine boosters and impaired immune system response in immune compromised individuals: a narrative review., References: ['']\n",
      "DEBUG - Citing Paper: Strategies to reduce the risks of mRNA drug and vaccine toxicity., References: ['']\n",
      "DEBUG - Citing Paper: Biodistribution of RNA Vaccines and of Their Products: Evidence from Human and Animal Studies., References: ['']\n",
      "DEBUG - Citing Paper: Dynamics of technology emergence in innovation networks., References: ['']\n",
      "DEBUG - Citing Paper: Modulating Antigen Availability in Lymphoid Organs to Shape the Humoral Immune Response to Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Bile acid-containing lipid nanoparticles enhance extrahepatic mRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: Association between sleep duration and antibody acquisition after mRNA vaccination against SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax., References: ['']\n",
      "DEBUG - Citing Paper: Unlocking the potential of RNA-based therapeutics in the lung: current status and future directions., References: ['']\n",
      "DEBUG - Citing Paper: VEGFA mRNA-LNP promotes biliary epithelial cell-to-hepatocyte conversion in acute and chronic liver diseases and reverses steatosis and fibrosis., References: ['']\n",
      "DEBUG - Citing Paper: Low-sugar universal mRNA vaccine against coronavirus variants with deletion of glycosites in the S2 or stem of SARS-CoV-2 spike messenger RNA (mRNA)., References: ['']\n",
      "DEBUG - Citing Paper: Evolution of global scientific collaboration in mRNA vaccine research: Insights from bibliometric and social network analysis (2010~2023)., References: ['']\n",
      "DEBUG - Citing Paper: B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity., References: ['']\n",
      "DEBUG - Citing Paper: <i>InÂ vivo</i> genome editing using 244-<i>cis</i> LNPs and low-dose AAV achieves therapeutic threshold in hemophilia A mice., References: ['']\n",
      "DEBUG - Citing Paper: The Expression Kinetics and Immunogenicity of Lipid Nanoparticles Delivering Plasmid DNA and mRNA in Mice., References: ['']\n",
      "DEBUG - Citing Paper: Blood Coagulation and Thrombotic Disorders following SARS-CoV-2 Infection and COVID-19 Vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Enabling mRNA Therapeutics: Current Landscape and Challenges in Manufacturing., References: ['']\n",
      "DEBUG - Citing Paper: Highly efficient cellular expression of circular mRNA enables prolonged protein expression., References: ['']\n",
      "DEBUG - Citing Paper: Dendritic Cell-Mimicking Nanoparticles Promote mRNA Delivery to Lymphoid Organs., References: ['']\n",
      "DEBUG - Citing Paper: Looking to the Future: Drug Delivery and Targeting in the Prophylaxis and Therapy of Severe and Chronic Diseases., References: ['']\n",
      "DEBUG - Citing Paper: A single immunization with core-shell structured lipopolyplex mRNA vaccine against rabies induces potent humoral immunity in mice and dogs., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 mRNA vaccination-induced immunological memory in human nonlymphoid and lymphoid tissues., References: ['']\n",
      "DEBUG - Citing Paper: Delivery of gene editing therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Updated Considerations for the Immunopharmacological Aspects of the \"Talented mRNA Vaccines\"., References: ['']\n",
      "DEBUG - Citing Paper: Sending a Message: Use of mRNA Vaccines to Target the Tumor Immune Microenvironment., References: ['']\n",
      "DEBUG - Citing Paper: Comprehensive Evaluation of Lipid Nanoparticles and Polyplex Nanomicelles for Muscle-Targeted mRNA Delivery., References: ['']\n",
      "DEBUG - Citing Paper: Emerging Applications of Nanotechnology in Healthcare and Medicine., References: ['']\n",
      "DEBUG - Citing Paper: Biodistribution of mRNA COVID-19 vaccines in human breast milk., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticles Deliver mRNA to the Brain after an Intracerebral Injection., References: ['']\n",
      "DEBUG - Citing Paper: Circular RNA vaccine in disease prevention and treatment., References: ['']\n",
      "DEBUG - Citing Paper: Induction of liver-resident memory T cells and protection at liver-stage malaria by mRNA-containing lipid nanoparticles., References: ['']\n",
      "DEBUG - Citing Paper: Editorial: Delivery systems in biologics-based therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: An Overview of Nanostructured Lipid Carriers and its Application in Drug Delivery through Different Routes., References: ['']\n",
      "DEBUG - Citing Paper: From Bench to Bedside: Implications of Lipid Nanoparticle Carrier Reactogenicity for Advancing Nucleic Acid Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Alt-RNAtive vaccines elicit anti-malarial T<sub>RM</sub> cells., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticle mRNA systems containing high levels of sphingomyelin engender higher protein expression in hepatic and extra-hepatic tissues., References: ['']\n",
      "DEBUG - Citing Paper: Recent Advances in Messenger Ribonucleic Acid (mRNA) Vaccines and Their Delivery Systems: A Review., References: ['']\n",
      "DEBUG - Citing Paper: Orthogonal Design of Experiments for Engineering of Lipid Nanoparticles for mRNA Delivery to the Placenta., References: ['']\n",
      "DEBUG - Citing Paper: Development of an mRNA-lipid nanoparticle vaccine against Lyme disease., References: ['']\n",
      "DEBUG - Citing Paper: Dissecting the Protective Effect of CD8<sup>+</sup> T Cells in Response to SARS-CoV-2 mRNA Vaccination and the Potential Link with Lymph Node CD8<sup>+</sup> T Cells., References: ['']\n",
      "DEBUG - Citing Paper: Ionizable Amino Lipids Distribution and Effects on DSPC/Cholesterol Membranes: Implications for Lipid Nanoparticle Structure., References: ['']\n",
      "DEBUG - Citing Paper: Delivery and Expression of mRNA in the Secondary Lymphoid Organs Drive Immune Responses to Lipid Nanoparticle-mRNA Vaccines after Intramuscular Injection., References: ['']\n",
      "DEBUG - Citing Paper: Expanding the Reach of Monoclonal Antibodies: A Review of Synthetic Nucleic Acid Delivery in Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Immunogenicity and efficacy of vaccine boosters against SARS-CoV-2 Omicron subvariant BA.5 in male Syrian hamsters., References: ['']\n",
      "DEBUG - Citing Paper: Ionizable Lipid Nanoparticles for Therapeutic Base Editing of Congenital Brain Disease., References: ['']\n",
      "DEBUG - Citing Paper: In Situ Programming of CAR-T Cells: A Pressing Need in Modern Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Transitional Insight into the RNA-Based Oligonucleotides in Cancer Treatment., References: ['']\n",
      "DEBUG - Citing Paper: Non-interfacial self-assembly of synthetic protocells., References: ['']\n",
      "DEBUG - Citing Paper: Treatment mechanism of immune triad from the repurposing drug against COVID-19., References: ['']\n",
      "DEBUG - Citing Paper: Exploiting Unique Features of Microneedles to Modulate Immunity., References: ['']\n",
      "DEBUG - Citing Paper: The impact of nucleoside base modification in mRNA vaccine is influenced by the chemistry of its lipid nanoparticle delivery system., References: ['']\n",
      "DEBUG - Citing Paper: [Vaccination approach in patients with an allergic reaction to COVID-19 vaccines or at risk of developing allergic reactions]., References: ['']\n",
      "DEBUG - Citing Paper: Applications of advances in mRNA-based platforms as therapeutics and diagnostics in reproductive technologies., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccine Platform: mRNA Production and Delivery., References: ['']\n",
      "DEBUG - Citing Paper: Hybrid immunity expands the functional humoral footprint of both mRNA and vector-based SARS-CoV-2 vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Messenger RNA rescues medium-chain acyl-CoA dehydrogenase deficiency in fibroblasts from patients and a murine model., References: ['']\n",
      "DEBUG - Citing Paper: Proof-of-concept for effective antiviral activity of an <i>in silico</i> designed decoy synthetic mRNA against SARS-CoV-2 in the Vero E6 cell-based infection model., References: ['']\n",
      "DEBUG - Citing Paper: An Overview of Nanoparticle Protein Corona Literature., References: ['']\n",
      "DEBUG - Citing Paper: A SARS-CoV-2 Vaccine Designed for Manufacturability Results in Unexpected Potency and Non-Waning Humoral Response., References: ['']\n",
      "DEBUG - Citing Paper: Immunogenicity and protective efficacy of SARS-CoV-2 mRNA vaccine encoding secreted non-stabilized spike in female mice., References: ['']\n",
      "DEBUG - Citing Paper: <i>InÂ vivo</i> genome editing for hemophilia B therapy by the combination of rebalancing and therapeutic gene knockin using a viral and non-viral vector., References: ['']\n",
      "DEBUG - Citing Paper: Advances in Vaccine Adjuvants: Nanomaterials and Small Molecules., References: ['']\n",
      "DEBUG - Citing Paper: Revolutionizing viral disease vaccination: the promising clinical advancements of non-replicating mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Self-driving laboratories: A paradigm shift in nanomedicine development., References: ['']\n",
      "DEBUG - Citing Paper: Analysis of PEG-lipid anchor length on lipid nanoparticle pharmacokinetics and activity in a mouse model of traumatic brain injury., References: ['']\n",
      "DEBUG - Citing Paper: DLin-MC3-Containing mRNA Lipid Nanoparticles Induce an Antibody Th2-Biased Immune Response Polarization in a Delivery Route-Dependent Manner in Mice., References: ['']\n",
      "DEBUG - Citing Paper: Antigen presentation dynamics shape the antibody response to variants like SARS-CoV-2 Omicron after multiple vaccinations with the original strain., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticle-encapsulated mRNA therapy corrects serum total bilirubin level in Crigler-Najjar syndrome mouse model., References: ['']\n",
      "DEBUG - Citing Paper: Restoration of Motor Function through Delayed Intraspinal Delivery of Human IL-10-Encoding Nucleoside-Modified mRNA after Spinal Cord Injury., References: ['']\n",
      "DEBUG - Citing Paper: Single-domain antibody delivery using an mRNA platform protects against lethal doses of botulinum neurotoxin A., References: ['']\n",
      "DEBUG - Citing Paper: Impact of BNT162b2 Booster Dose on SARS-CoV-2 Anti-Trimeric Spike Antibody Dynamics in a Large Cohort of Italian Health Care Workers., References: ['']\n",
      "DEBUG - Citing Paper: Toxicological Assessments of a Pandemic COVID-19 Vaccine-Demonstrating the Suitability of a Platform Approach for mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Safe and Effective Delivery of mRNA Using Modified PEI-Based Lipopolymers., References: ['']\n",
      "DEBUG - Citing Paper: Employing T-Cell Memory to Effectively Target SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-From COVID-19 Treatment to Cancer Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Advanced delivery systems for peptide antibiotics., References: ['']\n",
      "DEBUG - Citing Paper: A Comprehensive Review of mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 vaccines and a perspective on Africa., References: ['']\n",
      "DEBUG - Citing Paper: Ionizable lipid nanoparticles deliver mRNA to pancreatic Î² cells via macrophage-mediated gene transfer., References: ['']\n",
      "DEBUG - Citing Paper: Low protease activity in B cell follicles promotes retention of intact antigens after immunization., References: ['']\n",
      "DEBUG - Citing Paper: Modulating the expression of tumor suppressor genes using activating oligonucleotide technologies as a therapeutic approach in cancer., References: ['']\n",
      "DEBUG - Citing Paper: Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs., References: ['']\n",
      "DEBUG - Citing Paper: Nanotechnology-Based RNA Vaccines: Fundamentals, Advantages and Challenges., References: ['']\n",
      "DEBUG - Citing Paper: Membrane-Mediated Interactions Between Nonspherical Elastic Particles., References: ['']\n",
      "DEBUG - Citing Paper: Advances of mRNA vaccine in tumor: a maze of opportunities and challenges., References: ['']\n",
      "DEBUG - Citing Paper: Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 spike mRNA vaccine sequences circulate in blood up to 28âdays after COVID-19 vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticle-mediated mRNA delivery in lung fibrosis., References: ['']\n",
      "DEBUG - Citing Paper: Critical point for membrane bilayer formation., References: ['']\n",
      "DEBUG - Citing Paper: The mRNA vaccine BNT162b2 demonstrates impaired T<sub>H</sub>1 immunogenicity in human elders <i>in vitro</i> and aged mice <i>in vivo</i>., References: ['']\n",
      "DEBUG - Citing Paper: ESCRT recruitment to mRNA-encoded SARS-CoV-2 spike induces virus-like particles and enhanced antibody responses., References: ['']\n",
      "DEBUG - Citing Paper: Effect of Cholesterol Content of Lipid Composition in mRNA-LNPs on the Protein Expression in the Injected Site and Liver After Local Administration in Mice., References: ['']\n",
      "DEBUG - Citing Paper: Exploring <i>in vitro</i> expression and immune potency in mice using mRNA encoding the <i>Plasmodium falciparum</i> malaria antigen, CelTOS., References: ['']\n",
      "DEBUG - Citing Paper: Synthetic mRNA rescues very long-chain acyl-CoA dehydrogenase deficiency in patient fibroblasts and a murine model., References: ['']\n",
      "DEBUG - Citing Paper: Recent Advances in Cancer Vaccines: Challenges, Achievements, and Futuristic Prospects., References: ['']\n",
      "DEBUG - Citing Paper: Recent Advances in Lipid Nanoparticles for Delivery of mRNA., References: ['']\n",
      "DEBUG - Citing Paper: A universal influenza mRNA vaccine candidate boosts T cell responses and reduces zoonotic influenza virus disease in ferrets., References: ['']\n",
      "DEBUG - Citing Paper: Long-term durability of immune responses to the BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Microparticles Show Similar Efficacy With Lipid Nanoparticles in Delivering mRNA and Preventing Cancer., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of <i>in vivo</i> imaging., References: ['']\n",
      "DEBUG - Citing Paper: Scope and challenges of nanoparticle-based mRNA delivery in cancer treatment., References: ['']\n",
      "DEBUG - Citing Paper: Nanoparticles for vaccine and gene therapy: Overcoming the barriers to nucleic acid delivery., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticle Delivery System for mRNA Encoding B7H3-redirected Bispecific Antibody Displays Potent Antitumor Effects on Malignant Tumors., References: ['']\n",
      "DEBUG - Citing Paper: Mechanisms and challenges of nanocarriers as non-viral vectors of therapeutic genes for enhanced pulmonary delivery., References: ['']\n",
      "DEBUG - Citing Paper: Nucleic Acid Vaccines against SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: Stability Study of mRNA-Lipid Nanoparticles Exposed to Various Conditions Based on the Evaluation between Physicochemical Properties and Their Relation with Protein Expression Ability., References: ['']\n",
      "DEBUG - Citing Paper: Self-Amplifying RNA Approach for Protein Replacement Therapy., References: ['']\n",
      "DEBUG - Citing Paper: Advancing mRNA technologies for therapies and vaccines: An African context., References: ['']\n",
      "DEBUG - Citing Paper: Innate immune mechanisms of mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 mRNA-based vaccines in the Aicardi GoutiÃ¨res Syndrome., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-Based Approaches to Treating Liver Diseases., References: ['']\n",
      "DEBUG - Citing Paper: mRNA nanomedicine: Design and recent applications., References: ['']\n",
      "DEBUG - Citing Paper: Immediate protein expression from exogenous mRNAs in embryonic brain., References: ['']\n",
      "DEBUG - Citing Paper: <i>In vivo</i> assessment of triazine lipid nanoparticles as transfection agents for plasmid DNA., References: ['']\n",
      "DEBUG - Citing Paper: Nanotechnology for the management of COVID-19 during the pandemic and in the post-pandemic era., References: ['']\n",
      "DEBUG - Citing Paper: Membrane-bound mRNA immunogens lower the threshold to activate HIV Env V2 apex-directed broadly neutralizing B cell precursors in humanized mice., References: ['']\n",
      "DEBUG - Citing Paper: Formulation of Lipid-Free Polymeric Mesoscale Nanoparticles Encapsulating mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Anti-Inflammatory Therapy for Temporomandibular Joint Osteoarthritis Using mRNA Medicine Encoding Interleukin-1 Receptor Antagonist., References: ['']\n",
      "DEBUG - Citing Paper: Understanding the Pharmacology of COVID-19 mRNA Vaccines: Playing Dice with the Spike?, References: ['']\n",
      "DEBUG - Citing Paper: Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial., References: ['']\n",
      "DEBUG - Citing Paper: The spike hypothesis in vaccine-induced adverse effects: questions and answers., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticles for mRNA Delivery to Enhance Cancer Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Applications and challenges of biomaterial mediated mRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: Antigen presentation dynamics shape the response to emergent variants like SARS-CoV-2 Omicron strain after multiple vaccinations with wild type strain., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines in the prevention and treatment of diseases., References: ['']\n",
      "DEBUG - Citing Paper: Emerging trends of research on mRNA vaccines: A co-citation analysis., References: ['']\n",
      "DEBUG - Citing Paper: The Delivery of mRNA Vaccines for Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Antigen transfer and its effect on vaccine-induced immune amplification and tolerance., References: ['']\n",
      "DEBUG - Citing Paper: Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-based therapy proves superior to the standard of care for treating hereditary tyrosinemia 1 in a mouse model., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines induce rapid antibody responses in mice., References: ['']\n",
      "DEBUG - Citing Paper: Analyzing the Systems Biology Effects of COVID-19 mRNA Vaccines to Assess Their Safety and Putative Side Effects., References: ['']\n",
      "DEBUG - Citing Paper: \"Don't Look Up\" Your Science-Herd Immunity or Herd Mentality?, References: ['']\n",
      "DEBUG - Citing Paper: mRNA-LNP vaccines tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cells., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 and plasma cells: Is there long-lived protection?, References: ['']\n",
      "DEBUG - Citing Paper: Towards the future exploration of mucosal mRNA vaccines against emerging viral diseases; lessons from existing next-generation mucosal vaccine strategies., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticle delivery of unmodified mRNAs encoding multiple monoclonal antibodies targeting poxviruses in rabbits., References: ['']\n",
      "DEBUG - Citing Paper: Rapidly Progressive Dementia with Asymmetric Rigidity Following ChAdOx1 nCoV-19 Vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Comparison of DLin-MC3-DMA and ALC-0315 for siRNA Delivery to Hepatocytes and Hepatic Stellate Cells., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccines: Why Is the Biology of Retroposition Ignored?, References: ['']\n",
      "DEBUG - Citing Paper: mRNA as a Therapeutics: Understanding mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Optimization of Lipid Nanoparticles for saRNA Expression and Cellular Activation Using a Design-of-Experiment Approach., References: ['']\n",
      "DEBUG - Citing Paper: Antigen targeting to dendritic cells: Still a place in future immunotherapy?, References: ['']\n",
      "DEBUG - Citing Paper: Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis., References: ['']\n",
      "DEBUG - Citing Paper: The Progress and Promise of RNA MedicineâAn Arsenal of Targeted Treatments., References: ['']\n",
      "DEBUG - Citing Paper: mRNA- and Adenovirus-Based Vaccines against SARS-CoV-2 in HIV-Positive People., References: ['']\n",
      "DEBUG - Citing Paper: Nucleic Acids as Biotools at the Interface between Chemistry and Nanomedicine in the COVID-19 Era., References: ['']\n",
      "DEBUG - Citing Paper: Delivery Systems of Plasmid DNA and Messenger RNA for Advanced Therapies., References: ['']\n",
      "DEBUG - Citing Paper: Current trends in delivery of non-viral nucleic acid-based therapeutics for improved efficacy., References: ['']\n",
      "DEBUG - Citing Paper: Anaphylaxis to Pfizer/BioNTech mRNA COVID-19 Vaccine in a Patient With Clinically Confirmed PEG Allergy., References: ['']\n",
      "DEBUG - Citing Paper: Recent advances in lipid nanoparticles for delivery of nucleic acid, mRNA, and gene editing-based therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Absence of SARS-CoV-2 Spike glycoprotein expression in placentas from individuals after mRNA SARS-CoV-2 vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Regulatory guidelines and preclinical tools to study the biodistribution of RNA therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Advances in COVID-19 mRNA vaccine development., References: ['']\n",
      "DEBUG - Citing Paper: Novel In Silico mRNA vaccine design exploiting proteins of M. tuberculosis that modulates host immune responses by inducing epigenetic modifications., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice., References: ['']\n",
      "DEBUG - Citing Paper: Messenger RNA vaccines for cancer immunotherapy: progress promotes promise., References: ['']\n",
      "DEBUG - Citing Paper: Microfluidic fabrication of lipid nanoparticles for the delivery of nucleic acids., References: ['']\n",
      "DEBUG - Citing Paper: Anti-COVID-19 Nanomaterials: Directions to Improve Prevention, Diagnosis, and Treatment., References: ['']\n",
      "DEBUG - Citing Paper: Insights into the immune responses of SARS-CoV-2 in relation to COVID-19 vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Glycosite-deleted mRNA of SARS-CoV-2 spike protein as a broad-spectrum vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Neutralizing Activity and SARS-CoV-2 Vaccine mRNA Persistence in Serum and Breastmilk After BNT162b2 Vaccination in Lactating Women., References: ['']\n",
      "DEBUG - Citing Paper: Researchers getting closer to a \"universal\" flu vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Biodistribution and Non-linear Gene Expression of mRNA LNPs Affected by Delivery Route and Particle Size., References: ['']\n",
      "DEBUG - Citing Paper: DOCK2 regulates antifungal immunity by regulating RAC GTPase activity., References: ['']\n",
      "DEBUG - Citing Paper: Supramolecular Nanostructures for Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Rational design of anti-inflammatory lipid nanoparticles for mRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: Nanotechnologies in Delivery of DNA and mRNA Vaccines to the Nasal and Pulmonary Mucosa., References: ['']\n",
      "DEBUG - Citing Paper: Engineered adipose-derived stem cells with IGF-1-modified mRNA ameliorates osteoarthritis development., References: ['']\n",
      "DEBUG - Citing Paper: From high-throughput to therapeutic: host-directed interventions against influenza viruses., References: ['']\n",
      "DEBUG - Citing Paper: Runx1 Messenger RNA Delivered by Polyplex Nanomicelles Alleviate Spinal Disc Hydration Loss in a Rat Disc Degeneration Model., References: ['']\n",
      "DEBUG - Citing Paper: CAR T cells produced in vivo to treat cardiac injury., References: ['']\n",
      "DEBUG - Citing Paper: Drug delivery systems for RNA therapeutics., References: ['']\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DEBUG - Citing Paper: Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities., References: ['']\n",
      "DEBUG - Citing Paper: A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues., References: ['']\n",
      "DEBUG - Citing Paper: Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 - a review., References: ['']\n",
      "DEBUG - Citing Paper: An mRNA vaccine to prevent genital herpes., References: ['']\n",
      "DEBUG - Citing Paper: Added to pre-existing inflammation, mRNA-lipid nanoparticles induce inflammation exacerbation (IE)., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 infection: efficacy of extensive vaccination of the healthcare workforce in a large Italian hospital., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccines to Protect Against Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Optimization of phospholipid chemistry for improved lipid nanoparticle (LNP) delivery of messenger RNA (mRNA)., References: ['']\n",
      "DEBUG - Citing Paper: RNA Secondary Structures Regulate Adsorption of Fragments onto Flat Substrates., References: ['']\n",
      "DEBUG - Citing Paper: The role of nanoparticle format and route of administration on self-amplifying mRNA vaccine potency., References: ['']\n",
      "DEBUG - Citing Paper: Engineered mRNA-expressed bispecific antibody prevent intestinal cancer via lipid nanoparticle delivery., References: ['']\n",
      "DEBUG - Citing Paper: Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses., References: ['']\n",
      "DEBUG - Citing Paper: The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory., References: ['']\n",
      "DEBUG - Citing Paper: Pneumococcal Vaccines: Past Findings, Present Work, and Future Strategies., References: ['']\n",
      "DEBUG - Citing Paper: Nucleoside-Modified mRNA Vaccines Protect IFNAR<sup>-/-</sup> Mice against Crimean-Congo Hemorrhagic Fever Virus Infection., References: ['']\n",
      "DEBUG - Citing Paper: Development of a microchip capillary electrophoresis method for determination of the purity and integrity of mRNA in lipid nanoparticle vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Bioengineering Strategies for Developing Vaccines against Respiratory Viral Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Emerging importance of nanotechnology-based approaches to control the COVID-19 pandemic; focus on nanomedicine iterance in diagnosis and treatment of COVID-19 patients., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccines Induce Rapid Antibody Responses in Mice., References: ['']\n",
      "DEBUG - Citing Paper: A New Generation of Vaccines in the Age of Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Vaccine development and technology for SARS-CoV-2: Current insight., References: ['']\n",
      "DEBUG - Citing Paper: Rational preparation and application of a mRNA delivery system with cytidinyl/cationic lipid., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticles for Organ-Specific mRNA Therapeutic Delivery., References: ['']\n",
      "DEBUG - Citing Paper: Review: Development of SARS-CoV-2 immuno-enhanced COVID-19 vaccines with nano-platform., References: ['']\n",
      "DEBUG - Citing Paper: mRNA - A game changer in regenerative medicine, cell-based therapy and reprogramming strategies., References: ['']\n",
      "DEBUG - Citing Paper: The quest for a better fight: How can nanomaterials address the current therapeutic and diagnostic obstacles in the fight against COVID-19?, References: ['']\n",
      "DEBUG - Citing Paper: Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Self-Assemblies under the Atomic Force Microscope., References: ['']\n",
      "DEBUG - Citing Paper: Challenges and Scientific Prospects of the Newest Generation of mRNA-Based Vaccines against SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: Nucleic acid delivery and nanoparticle design for COVID vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months., References: ['']\n",
      "DEBUG - Citing Paper: Comparison of Antibody and T Cell Responses Induced by Single Doses of ChAdOx1 nCoV-19 and BNT162b2 Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Antigen modifications improve nucleoside-modified mRNA-based influenza virus vaccines in mice., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 Pathogenesis: From Molecular Pathway to Vaccine Administration., References: ['']\n",
      "DEBUG - Citing Paper: Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Codominant IgG and IgA expression with minimal vaccine mRNA in milk of BNT162b2 vaccinees., References: ['']\n",
      "DEBUG - Citing Paper: Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticles for mRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: Development and Delivery Systems of mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration., References: ['']\n",
      "DEBUG - Citing Paper: Functionalized DMP-039 Hybrid Nanoparticle as a Novel mRNA Vector for Efficient Cancer Suicide Gene Therapy., References: ['']\n",
      "DEBUG - Citing Paper: Increasing the Power of Polyphenols through Nanoencapsulation for Adjuvant Therapy against Cardiovascular Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Detailed Dissection and Critical Evaluation of the Pfizer/BioNTech and Moderna mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Inadequate deltoid muscle penetration and concerns of improper COVID mRNA vaccine administration can be avoided by injection technique modification., References: ['']\n",
      "DEBUG - Citing Paper: [Subjective well-being and ability to work of hospital staff after SARS-CoV2 immunization with the mRNA vaccine BNT162b2]., References: ['']\n",
      "DEBUG - Citing Paper: Immunological mechanisms of vaccine-induced protection against COVID-19 in humans., References: ['']\n",
      "DEBUG - Citing Paper: Intracellular Routing and Recognition of Lipid-Based mRNA Nanoparticles., References: ['']\n",
      "DEBUG - Citing Paper: From Recoding to Peptides for MHC Class I Immune Display: Enriching Viral Expression, Virus Vulnerability and Virus Evasion., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses., References: ['']\n",
      "DEBUG - Citing Paper: From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases., References: ['']\n",
      "DEBUG - Citing Paper: Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice., References: ['']\n",
      "DEBUG - Citing Paper: Nucleoside-modified VEGFC mRNA induces organ-specific lymphatic growth and reverses experimental lymphedema., References: ['']\n",
      "DEBUG - Citing Paper: A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity., References: ['']\n",
      "DEBUG - Citing Paper: Lack of effects on female fertility and prenatal and postnatal offspring development in rats with BNT162b2, a mRNA-based COVID-19 vaccine., References: ['']\n",
      "DEBUG - Citing Paper: BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 vaccine platforms: Delivering on a promise?, References: ['']\n",
      "DEBUG - Citing Paper: Coronavirus Disease-19 Vaccines Best Reflect Effective Pharmaceuticals., References: ['']\n",
      "DEBUG - Citing Paper: Cell-Based Delivery Approaches for DNA-Binding Domains to the Central Nervous System., References: ['']\n",
      "DEBUG - Citing Paper: Lipid-nanoparticle-encapsulated mRNA vaccines induce protective memory CD8 TÂ cells against a lethal viral infection., References: ['']\n",
      "DEBUG - Citing Paper: Enhanced target cell specificity and uptake of lipid nanoparticles using RNA aptamers and peptides., References: ['']\n",
      "DEBUG - Citing Paper: Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?, References: ['']\n",
      "DEBUG - Citing Paper: Impact of Ribosome Activity on SARS-CoV-2 LNP - Based mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Cationic Nanoparticle-Based Cancer Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Future considerations for the mRNA-lipid nanoparticle vaccine platform., References: ['']\n",
      "DEBUG - Citing Paper: The Importance of Apparent pKa in the Development of Nanoparticles Encapsulating siRNA and mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Functionalized lipid nanoparticles for subcutaneous administration of mRNA to achieve systemic exposures of a therapeutic protein., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates., References: ['']\n",
      "DEBUG - Citing Paper: Role of nanotechnology behind the success of mRNA vaccines for COVID-19., References: ['']\n",
      "DEBUG - Citing Paper: The dawn of mRNA vaccines: The COVID-19 case., References: ['']\n",
      "DEBUG - Citing Paper: Treatment of Cystic Fibrosis: From Gene- to Cell-Based Therapies., References: ['']\n",
      "DEBUG - Citing Paper: Clinical and immunological effects of mRNA vaccines in malignant diseases., References: ['']\n",
      "DEBUG - Citing Paper: The conundrum of current anti-SARS-CoV-2 vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Nanotechnology against the novel coronavirus (severe acute respiratory syndrome coronavirusÂ 2): diagnosis, treatment, therapy and future perspectives., References: ['']\n",
      "DEBUG - Citing Paper: The significance of bioengineered nanoplatforms against SARS-CoV-2: From detection to genome editing., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccines against Flaviviruses., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccine for cancer immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccine: a potential therapeutic strategy., References: ['']\n",
      "DEBUG - Citing Paper: HIV mRNA Vaccines-Progress and Future Paths., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Polymer-Lipid Pharmaceutical Nanocarriers: Innovations by New Formulations and Production Technologies., References: ['']\n",
      "DEBUG - Citing Paper: A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: BNT162b vaccines protect rhesus macaques from SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: Murine liver repair via transient activation of regenerative pathways in hepatocytes using lipid nanoparticle-complexed nucleoside-modified mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Strategies for Vaccination: Conventional Vaccine Approaches Versus New-Generation Strategies in Combination with Adjuvants., References: ['']\n",
      "DEBUG - Citing Paper: Corticosteroids and cellulose purification improve, respectively, the inÂ vivo translation and vaccination efficacy of sa-mRNAs., References: ['']\n",
      "DEBUG - Citing Paper: Nanomaterial Delivery Systems for mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Anionic Complex with Efficient Expression and Good Safety Profile for mRNA Delivery., References: ['']\n",
      "DEBUG - Citing Paper: Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans., References: ['']\n",
      "DEBUG - Citing Paper: Current State of the First COVID-19 Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19: Coronavirus Vaccine Development Updates., References: ['']\n",
      "DEBUG - Citing Paper: Self-assembled mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Novel coronavirus disease (COVID-19) pandemic: A recent mini review., References: ['']\n",
      "DEBUG - Citing Paper: Non-viral COVID-19 vaccine delivery systems., References: ['']\n",
      "DEBUG - Citing Paper: D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization., References: ['']\n",
      "DEBUG - Citing Paper: Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation., References: ['']\n",
      "DEBUG - Citing Paper: Location of a single histidine within peptide carriers increases mRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccine Era-Mechanisms, Drug Platform and Clinical Prospection., References: ['']\n",
      "DEBUG - Citing Paper: Inhaled RNA Therapy: From Promise to Reality., References: ['']\n",
      "DEBUG - Citing Paper: A Thermostable mRNA Vaccine against COVID-19., References: ['']\n",
      "DEBUG - Citing Paper: A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice., References: ['']\n",
      "DEBUG - Citing Paper: Delivery of hepatocyte growth factor mRNA from nanofibrillar scaffolds in a pig model of peripheral arterial disease., References: ['']\n",
      "DEBUG - Citing Paper: Application of advances in endocytosis and membrane trafficking to drug delivery., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticle technology for therapeutic gene regulation in the liver., References: ['']\n",
      "DEBUG - Citing Paper: Designing a novel mRNA vaccine against SARS-CoV-2: An immunoinformatics approach., References: ['']\n",
      "DEBUG - Citing Paper: Controlling timing and location in vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Role of Lipid-Based and Polymer-Based Non-Viral Vectors in Nucleic Acid Delivery for Next-Generation Gene Therapy., References: ['']\n",
      "DEBUG - Citing Paper: Active immunoprophylaxis with a synthetic DNA-encoded monoclonal anti-respiratory syncytial virus scFv-Fc fusion protein confers protection against infection and durable activity., References: ['']\n",
      "DEBUG - Citing Paper: Formulation and Delivery Technologies for mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Protein and mRNA Delivery Enabled by Cholesteryl-Based Biodegradable Lipidoid Nanoparticles., References: ['']\n",
      "DEBUG - Citing Paper: A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice., References: ['']\n",
      "DEBUG - Citing Paper: Optimization of 5' Untranslated Region of Modified mRNA for Use in Cardiac or Hepatic Ischemic Injury., References: ['']\n",
      "DEBUG - Citing Paper: Vaccines to prevent genital herpes., References: ['']\n",
      "DEBUG - Citing Paper: Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization., References: ['']\n",
      "DEBUG - Citing Paper: Opportunities and Challenges in the Delivery of mRNA-based Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Selective targeting of nanomedicine to inflamed cerebral vasculature to enhance the blood-brain barrier., References: ['']\n",
      "DEBUG - Citing Paper: Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering., References: ['']\n",
      "DEBUG - Citing Paper: Nucleoside-modified mRNA vaccination partially overcomes maternal antibody inhibition of de novo immune responses in mice., References: ['']\n",
      "DEBUG - Citing Paper: Nanoparticles versus Dendritic Cells as Vehicles to Deliver mRNA Encoding Multiple Epitopes for Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: mRNA as a Novel Treatment Strategy for Hereditary Spastic Paraplegia Type 5., References: ['']\n",
      "DEBUG - Citing Paper: Therapeutic Prospects of mRNA-Based Gene Therapy for Glioblastoma., References: ['']\n",
      "DEBUG - Citing Paper: Evaluation of a Single-Dose Nucleoside-Modified Messenger RNA Vaccine Encoding Hendra Virus-Soluble Glycoprotein Against Lethal Nipah virus Challenge in Syrian Hamsters., References: ['']\n",
      "DEBUG - Citing Paper: Enlisting the mRNA Vaccine Platform to Combat Parasitic Infections., References: ['']\n",
      "DEBUG - Citing Paper: Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes., References: ['']\n",
      "DEBUG - Citing Paper: Immunological Analysis of a CCHFV mRNA Vaccine Candidate in Mouse Models., References: ['']\n",
      "DEBUG - Citing Paper: Expression Kinetics and Innate Immune Response after Electroporation and LNP-Mediated Delivery of a Self-Amplifying mRNA in the Skin., References: ['']\n",
      "DEBUG - Citing Paper: Improving the Repeatability and Efficacy of Intradermal Electroporated Self-Replicating mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Long-term efficacy and safety of mRNA therapy in two murine models of methylmalonic acidemia., References: ['']\n",
      "DEBUG - Citing Paper: High Pressure Nebulization (PIPAC) Versus Injection for the Intraperitoneal Administration of mRNA Complexes., References: ['']\n",
      "DEBUG - Citing Paper: Antibody responses to crucial functional epitopes as a novel approach to assess immunogenicity of vaccine adjuvants., References: ['']\n",
      "DEBUG - Citing Paper: Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques., References: ['']\n",
      "DEBUG - Citing Paper: Advances in mRNA Vaccines for Infectious Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Using macropinocytosis for intracellular delivery of therapeutic nucleic acids to tumour cells., References: ['']\n",
      "DEBUG - Citing Paper: Recent Developments in mRNA-Based Protein Supplementation Therapy to Target Lung Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Non-viral Delivery of Zinc Finger Nuclease mRNA Enables Highly Efficient InÂ Vivo Genome Editing of Multiple Therapeutic Gene Targets., References: ['']\n",
      "DEBUG - Citing Paper: mRNA: A Novel Avenue to Antibody Therapy?, References: ['']\n",
      "DEBUG - Citing Paper: Improved Efficacy in a Fabry Disease Model Using a Systemic mRNA Liver Depot System as Compared to Enzyme Replacement Therapy., References: ['']\n",
      "DEBUG - Citing Paper: Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery., References: ['']\n",
      "DEBUG - Citing Paper: mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases., References: ['']\n",
      "DEBUG - Citing Paper: How mRNA therapeutics are entering the monoclonal antibody field., References: ['']\n",
      "DEBUG - Citing Paper: Local Delivery of <i>Ox40l</i>, <i>Cd80</i>, and <i>Cd86</i> mRNA Kindles Global Anticancer Immunity., References: ['']\n",
      "DEBUG - Citing Paper: Delivery of mRNA Therapeutics for the Treatment of Hepatic Diseases., References: ['']\n",
      "DEBUG - Citing Paper: The delivery of mRNA to colon inflammatory lesions by lipid-nano-particles containing environmentally-sensitive lipid-like materials with oleic acid scaffolds., References: ['']\n",
      "DEBUG - Citing Paper: Increasing lean muscle mass in mice via nanoparticle-mediated hepatic delivery of follistatin mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Chemically modified hCFTR mRNAs recuperate lung function in a mouse model of cystic fibrosis., References: ['']\n",
      "DEBUG - Citing Paper: PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake., References: ['']\n",
      "DEBUG - Citing Paper: mRNA as novel technology for passive immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Biomaterials for vaccine-based cancer immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: New Vaccine Technologies to Combat Outbreak Situations., References: ['']\n",
      "DEBUG - Citing Paper: Kinetics of mRNA delivery and protein translation in dendritic cells using lipid-coated PLGA nanoparticles., References: ['']\n",
      "DEBUG - Citing Paper: Uridine Depletion and Chemical Modification Increase Cas9 mRNA Activity and Reduce Immunogenicity without HPLC Purification., References: ['']\n",
      "DEBUG - Citing Paper: Metabolically stabilized double-stranded mRNA polyplexes., References: ['']\n",
      "DEBUG - Citing Paper: Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis., References: ['']\n",
      "DEBUG - Citing Paper: mRNA treatment produces sustained expression of enzymatically active human ADAMTS13 in mice., References: ['']\n",
      "DEBUG - Citing Paper: Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses., References: ['']\n",
      "DEBUG - Citing Paper: Nanoscale platforms for messenger RNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: Aligned Nanofibrillar Scaffolds for Controlled Delivery of Modified mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Prolonging pulse duration in ultrasound-mediated gene delivery lowers acoustic pressure threshold for efficient gene transfer to cells and small animals., References: ['']\n",
      "DEBUG - Citing Paper: Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles., References: ['']\n",
      "DEBUG - Citing Paper: Optimization of mRNA untranslated regions for improved expression of therapeutic mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Rapid, Single-Cell Analysis and Discovery of Vectored mRNA Transfection InÂ Vivo with a loxP-Flanked tdTomato Reporter Mouse., References: ['']\n",
      "DEBUG - Citing Paper: Targeted mRNA Therapy for Ornithine Transcarbamylase Deficiency., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines - a new era in vaccinology., References: ['']\n",
      "DEBUG - Citing Paper: Engineering the Delivery System for CRISPR-Based Genome Editing., References: ['']\n",
      "DEBUG - Citing Paper: Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Design, Assembly, Production, and Transfection of Synthetic Modified mRNA., References: ['']\n",
      "DEBUG - Citing Paper: InÂ Vivo Production of Monoclonal Antibodies by Gene Transfer via Electroporation Protects against Lethal Influenza and Ebola Infections., References: ['']\n",
      "DEBUG - Citing Paper: Efficient Targeting and Activation of Antigen-Presenting Cells InÂ Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques., References: ['']\n",
      "DEBUG - Citing Paper: Polyamine-Mediated Stoichiometric Assembly of Ribonucleoproteins for Enhanced mRNA Delivery., References: ['']\n",
      "DEBUG - Citing Paper: Cationic Nanoliposomes Meet mRNA: Efficient Delivery of Modified mRNA Using Hemocompatible and Stable Vectors for Therapeutic Applications., References: ['']\n",
      "DEBUG - Citing Paper: Boosting Intracellular Delivery of Lipid Nanoparticle-Encapsulated mRNA., References: ['']\n",
      "DEBUG - Citing Paper: mRNA mediates passive vaccination against infectious agents, toxins, and tumors., References: ['']\n",
      "DEBUG - Citing Paper: State of play and clinical prospects of antibody gene transfer., References: ['']\n",
      "DEBUG - Citing Paper: Optimizing Cardiac Delivery of Modified mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge., References: ['']\n",
      "DEBUG - Citing Paper: Structurally Programmed Assembly of Translation Initiation Nanoplex for Superior mRNA Delivery., References: ['']\n",
      "DEBUG - Citing Paper: Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems., References: ['']\n",
      "DEBUG - Citing Paper: Efficacy and immunogenicity of unmodified and pseudouridine-modified mRNA delivered systemically with lipid nanoparticles inÂ vivo., References: ['']\n",
      "DEBUG - Citing Paper: mRNA capping: biological functions and applications., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccine delivery using lipid nanoparticles., References: ['']\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DEBUG - Citing Paper: Intrathecal delivery of frataxin mRNA encapsulated in lipid nanoparticles to dorsal root ganglia as a potential therapeutic for Friedreich's ataxia., References: ['']\n",
      "DEBUG - Citing Paper: Modified mRNA as a new therapeutic option for pediatric respiratory diseases and hemoglobinopathies., References: ['']\n",
      "DEBUG - focal: Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes., NF: 0, NB: 0, NR: 0, D: 0\n",
      "DEBUG - Focal Paper: Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability., References: \n",
      "\n",
      "Tollervey, D.\n",
      ", \n",
      "Lehtonen, H.\n",
      ", \n",
      "CarmoâFonseca, M.\n",
      ", & \n",
      "Hurt, E. C.\n",
      " (1991). The small nucleolar RNP protein NOP1 (fibrillarin) is required for preârRNA processing in yeast. The EMBO Journal, 10(3), 573â583. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/1825809\n",
      "\n",
      "DEBUG - Citing Paper: Antibody Response after Homologous and Heterologous Prime-Boost COVID-19 Vaccination in a Bangladeshi Residential University Cohort., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 Variants and Vaccine Development., References: ['']\n",
      "DEBUG - Citing Paper: RNA-based programmable DNA cleavage., References: ['']\n",
      "DEBUG - Citing Paper: Potential Application of Modified mRNA in Cardiac Regeneration., References: ['']\n",
      "DEBUG - Citing Paper: Transient pacing in pigs with complete heart block via myocardial injection of mRNA coding for the T-box transcription factor 18., References: ['']\n",
      "DEBUG - Citing Paper: Assembling the RNA therapeutics toolbox., References: ['']\n",
      "DEBUG - Citing Paper: Innate Responses to the Former COVID-19 Vaccine Candidate CVnCoV and Their Relation to Reactogenicity and Adaptive Immunogenicity., References: ['']\n",
      "DEBUG - Citing Paper: Comprehensive evaluation of T7 promoter for enhanced yield and quality in mRNA production., References: ['']\n",
      "DEBUG - Citing Paper: Does the SARS-CoV-2 mRNA vaccine and its serum IgG levels affect fertility treatments and obstetric outcomes? An observational cohort study., References: ['']\n",
      "DEBUG - Citing Paper: A review on Gaucher disease: therapeutic potential of Î²-glucocerebrosidase-targeted mRNA/saRNA approach., References: ['']\n",
      "DEBUG - Citing Paper: Codon-optimization in gene therapy: promises, prospects and challenges., References: ['']\n",
      "DEBUG - Citing Paper: Co-delivery of Cas9 mRNA and guide RNAs for editing of LGMN gene represses breast cancer cell metastasis., References: ['']\n",
      "DEBUG - Citing Paper: RNA nanostructures for targeted drug delivery and imaging., References: ['']\n",
      "DEBUG - Citing Paper: The mRNACalc webserver accounts for the N1-methylpseudouridine hypochromicity to enable precise nucleoside-modified mRNA quantification., References: ['']\n",
      "DEBUG - Citing Paper: Nucleic Acid Vaccines Encoding Proteins and Virus-like Particles for HIV Prevention., References: ['']\n",
      "DEBUG - Citing Paper: Exploring HIV Vaccine Progress in the Pre-Clinical and Clinical Setting: From History to Future Prospects., References: ['']\n",
      "DEBUG - Citing Paper: Cholesterol-Bearing Polysaccharide-Based Nanogels for Development of Novel Immunotherapy and Regenerative Medicine., References: ['']\n",
      "DEBUG - Citing Paper: RNA modifications in cellular metabolism: implications for metabolism-targeted therapy and immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Stabilized 5' Cap Analogue for Optochemical Activation of mRNA Translation., References: ['']\n",
      "DEBUG - Citing Paper: Branched chemically modified poly(A) tails enhance the translation capacity of mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Optimizing the Delivery of mRNA to Mesenchymal Stem Cells for Tissue Engineering Applications., References: ['']\n",
      "DEBUG - Citing Paper: A tale of Science - The Nobel Prize in Physiology or Medicine 2023., References: ['']\n",
      "DEBUG - Citing Paper: mRNAid, an open-source platform for therapeutic mRNA design and optimization strategies., References: ['']\n",
      "DEBUG - Citing Paper: Recent Progress in Nucleic Acid Pulmonary Delivery toward Overcoming Physiological Barriers and Improving Transfection Efficiency., References: ['']\n",
      "DEBUG - Citing Paper: ACE mRNA (Additional Chimeric Element incorporated IVT mRNA) for Enhancing Protein Expression by Modulating Immunogenicity., References: ['']\n",
      "DEBUG - Citing Paper: Trinucleotide mRNA Cap Analogue <i>N</i>6-Benzylated at the Site of Posttranscriptional <sup>m6</sup>A<sub>m</sub> Mark Facilitates mRNA Purification and Confers Superior Translational Properties In Vitro and In Vivo., References: ['']\n",
      "DEBUG - Citing Paper: Programmable RNA base editing via targeted modifications., References: ['']\n",
      "DEBUG - Citing Paper: Can the Revolution in mRNA-Based Vaccine Technologies Solve the Intractable Health Issues of Current Ruminant Production Systems?, References: ['']\n",
      "DEBUG - Citing Paper: Advances in Poultry Vaccines: Leveraging Biotechnology for Improving Vaccine Development, Stability, and Delivery., References: ['']\n",
      "DEBUG - Citing Paper: The Effect of Cholesterol Content on the Adjuvant Activity of Nucleic-Acid-Free Lipid Nanoparticles., References: ['']\n",
      "DEBUG - Citing Paper: Durable cross-protective neutralizing antibody responses elicited by lipid nanoparticle-formulated SARS-CoV-2 mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Cell-Specific mRNA Therapeutics for Cardiovascular Diseases and Regeneration., References: ['']\n",
      "DEBUG - Citing Paper: The mRNA-LNP vaccines - the good, the bad and the ugly?, References: ['']\n",
      "DEBUG - Citing Paper: Profile of Katalin KarikÃ³ and Drew Weissman: 2023 Nobel laureates in Physiology or Medicine., References: ['']\n",
      "DEBUG - Citing Paper: Bacteriophages and their unique components provide limitless resources for exploitation., References: ['']\n",
      "DEBUG - Citing Paper: Next-generation direct reprogramming., References: ['']\n",
      "DEBUG - Citing Paper: Acute interstitial nephritis with acute kidney injury after COVID-19 vaccination: a case report., References: ['']\n",
      "DEBUG - Citing Paper: Single-Stranded DNA with Internal Base Modifications Mediates Highly Efficient Gene Insertion in Primary Cells., References: ['']\n",
      "DEBUG - Citing Paper: Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine., References: ['']\n",
      "DEBUG - Citing Paper: Novel Lipid Nanoparticles Stable and Efficient for mRNA Transfection to Antigen-Presenting Cells., References: ['']\n",
      "DEBUG - Citing Paper: Simultaneous nanopore profiling of mRNA m<sup>6</sup>A and pseudouridine reveals translation coordination., References: ['']\n",
      "DEBUG - Citing Paper: The implication of integrative multiple RNA modification-based subtypes in gastric cancer immunotherapy and prognosis., References: ['']\n",
      "DEBUG - Citing Paper: Recent progress in mRNA cancer vaccines., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccine Nanoplatforms and Innate Immunity., References: ['']\n",
      "DEBUG - Citing Paper: Engineering approaches for RNA-based and cell-based osteoarthritis therapies., References: ['']\n",
      "DEBUG - Citing Paper: Cancer vaccines: from an immunology perspective., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines expressing malaria transmission-blocking antigens Pfs25 and Pfs230D1 induce a functional immune response., References: ['']\n",
      "DEBUG - Citing Paper: mRNA and Adenoviral Vector Vaccine Platforms Utilized in COVID-19 Vaccines: Technologies, Ecosystem, and Future Directions., References: ['']\n",
      "DEBUG - Citing Paper: A Comprehensive Review of Small Interfering RNAs (siRNAs): Mechanism, Therapeutic Targets, and Delivery Strategies for Cancer Therapy., References: ['']\n",
      "DEBUG - Citing Paper: The rise of epitranscriptomics: recent developments and future directions., References: ['']\n",
      "DEBUG - Citing Paper: Modified messenger-RNA components alter the encoded protein., References: ['']\n",
      "DEBUG - Citing Paper: Global RNA modifications to the MALAT1 triple helix differentially affect thermostability and weaken binding to METTL16., References: ['']\n",
      "DEBUG - Citing Paper: Straight to the point: targeted mRNA-delivery to immune cells for improved vaccine design., References: ['']\n",
      "DEBUG - Citing Paper: Nobel Prize for physiology or medicine in 2023: how to dupe the cellular innate immune system using modified RNA for therapeutic treatment., References: ['']\n",
      "DEBUG - Citing Paper: Influence of N1-Methylpseudouridine in Guide RNAs on CRISPR/Cas9 Activity., References: ['']\n",
      "DEBUG - Citing Paper: Nucleic Acid-Based Approaches to Tackle KRAS Mutant Cancers., References: ['']\n",
      "DEBUG - Citing Paper: In Situ Stability Test for mRNA Vaccines Based on Deep-UV Resonance Raman Spectroscopy., References: ['']\n",
      "DEBUG - Citing Paper: tRNA therapeutics for genetic diseases., References: ['']\n",
      "DEBUG - Citing Paper: Genetically engineered transfusable platelets using mRNA lipid nanoparticles., References: ['']\n",
      "DEBUG - Citing Paper: Future of biotherapeutics: Harnessing mRNA to enhance elastin expression., References: ['']\n",
      "DEBUG - Citing Paper: Do RNA modifications contribute to modulation of immune responses in allergic diseases?, References: ['']\n",
      "DEBUG - Citing Paper: From rejection to the Nobel Prize: KarikÃ³ and Weissman's pioneering work on mRNA vaccines, and the need for diversity and inclusion in translational immunology., References: ['']\n",
      "DEBUG - Citing Paper: Recruiting In Vitro Transcribed mRNA against Cancer Immunotherapy: A Contemporary Appraisal of the Current Landscape., References: ['']\n",
      "DEBUG - Citing Paper: Tributaries of the 2023 Nobel Prize in Physiology or Medicine, and lessons learned., References: ['']\n",
      "DEBUG - Citing Paper: Evolution of global scientific collaboration in mRNA vaccine research: Insights from bibliometric and social network analysis (2010~2023)., References: ['']\n",
      "DEBUG - Citing Paper: Non-viral and viral delivery systems for hemophilia A therapy: recent development and prospects., References: ['']\n",
      "DEBUG - Citing Paper: Blood Coagulation and Thrombotic Disorders following SARS-CoV-2 Infection and COVID-19 Vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Enabling mRNA Therapeutics: Current Landscape and Challenges in Manufacturing., References: ['']\n",
      "DEBUG - Citing Paper: Large-scale manufacturing of base-edited chimeric antigen receptor TÂ cells., References: ['']\n",
      "DEBUG - Citing Paper: The advances of adjuvants in mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Reducing cell intrinsic immunity to mRNA vaccine alters adaptive immune responses in mice., References: ['']\n",
      "DEBUG - Citing Paper: The Nobel Prize awarded to pioneers of mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: The forerunners and successful partnerships behind the BioNTech mRNA vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Seasonal quadrivalent mRNA vaccine prevents and mitigates influenza infection., References: ['']\n",
      "DEBUG - Citing Paper: Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability., References: ['']\n",
      "DEBUG - Citing Paper: A single immunization with core-shell structured lipopolyplex mRNA vaccine against rabies induces potent humoral immunity in mice and dogs., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications., References: ['']\n",
      "DEBUG - Citing Paper: Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Chemical Modifications of mRNA Ends for Therapeutic Applications., References: ['']\n",
      "DEBUG - Citing Paper: Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Application of Lung-Targeted Lipid Nanoparticle-delivered mRNA of soluble PD-L1 via SORT Technology in Acute Respiratory Distress Syndrome., References: ['']\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DEBUG - Citing Paper: Modified mRNA Formulation and Stability for Cardiac and Skeletal Muscle Delivery., References: ['']\n",
      "DEBUG - Citing Paper: Tolerogenic Lipid Nanoparticles for Delivering Self-Antigen mRNA for the Treatment of Experimental Autoimmune Encephalomyelitis., References: ['']\n",
      "DEBUG - Citing Paper: What Is the Impact of the Novel Coronavirus and the Vaccination on Guillain-Barre Syndrome?, References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines in disease prevention and treatment., References: ['']\n",
      "DEBUG - Citing Paper: Incorporation of noncanonical base Z yields modified mRNA with minimal immunogenicity and improved translational capacity in mammalian cells., References: ['']\n",
      "DEBUG - Citing Paper: RNA modifications in physiology and disease: towards clinical applications., References: ['']\n",
      "DEBUG - Citing Paper: A Lassa virus mRNA vaccine confers protection but does not require neutralizing antibody in a guinea pig model of infection., References: ['']\n",
      "DEBUG - Citing Paper: Enhancing the immunogenicity of lipid-nanoparticle mRNA vaccines by adjuvanting the ionizable lipid and the mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Making the Next Generation of Therapeutics: mRNA Meets Synthetic Biology., References: ['']\n",
      "DEBUG - Citing Paper: Research progress in mRNA drug modification and delivery systems., References: ['']\n",
      "DEBUG - Citing Paper: Polysarcosine-Functionalized mRNA Lipid Nanoparticles Tailored for Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: 'Spikeopathy': COVID-19 Spike Protein Is Pathogenic, from Both Virus and Vaccine mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Targeting cancer with mRNA-lipid nanoparticles: key considerations and future prospects., References: ['']\n",
      "DEBUG - Citing Paper: Anti-CD117 CAR TÂ cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells., References: ['']\n",
      "DEBUG - Citing Paper: Class switch towards spike protein-specific IgG4 antibodies after SARS-CoV-2 mRNA vaccination depends on prior infection history., References: ['']\n",
      "DEBUG - Citing Paper: Recent Advances in Messenger Ribonucleic Acid (mRNA) Vaccines and Their Delivery Systems: A Review., References: ['']\n",
      "DEBUG - Citing Paper: Transgene-free direct conversion of murine fibroblasts into functional muscle stem cells., References: ['']\n",
      "DEBUG - Citing Paper: Repetitive mRNA vaccination is required to improve the quality of broad-spectrum anti-SARS-CoV-2 antibodies in the absence of CXCL13., References: ['']\n",
      "DEBUG - Citing Paper: Advances in saRNA Vaccine Research against Emerging/Re-Emerging Viruses., References: ['']\n",
      "DEBUG - Citing Paper: Recent Advancement in mRNA Vaccine Development and Applications., References: ['']\n",
      "DEBUG - Citing Paper: Practical Considerations for Next-Generation Adjuvant Development and Translation., References: ['']\n",
      "DEBUG - Citing Paper: Control of protein synthesis through mRNA pseudouridylation by dyskerin., References: ['']\n",
      "DEBUG - Citing Paper: Expanding the Reach of Monoclonal Antibodies: A Review of Synthetic Nucleic Acid Delivery in Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Immunogenicity and efficacy of vaccine boosters against SARS-CoV-2 Omicron subvariant BA.5 in male Syrian hamsters., References: ['']\n",
      "DEBUG - Citing Paper: Fulfilling the Promise of RNA Therapies for Cardiac Repair and Regeneration., References: ['']\n",
      "DEBUG - Citing Paper: Knife's edge: Balancing immunogenicity and reactogenicity in mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Emerging Progress of RNA-Based Antitumor Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Learning from cancer to address COVID-19., References: ['']\n",
      "DEBUG - Citing Paper: State-of-the-art 2023 on gene therapy for phenylketonuria., References: ['']\n",
      "DEBUG - Citing Paper: ASL mRNA-LNP Therapeutic for the Treatment of Argininosuccinic Aciduria Enables Survival Benefit in a Mouse Model., References: ['']\n",
      "DEBUG - Citing Paper: Regulation and functions of non-m<sup>6</sup>A mRNA modifications., References: ['']\n",
      "DEBUG - Citing Paper: Protective RNA nanovaccines against <i>Mycobacterium avium</i> subspecies <i>hominissuis</i>., References: ['']\n",
      "DEBUG - Citing Paper: Decoding the 'Fifth' Nucleotide: Impact of RNA Pseudouridylation on Gene Expression and Human Disease., References: ['']\n",
      "DEBUG - Citing Paper: Deciphering glioma epitranscriptome: focus on RNA modifications., References: ['']\n",
      "DEBUG - Citing Paper: SINE RNA of the imprinted miRNA clusters mediates constitutive type III interferon expression and antiviral protection in hemochorial placentas., References: ['']\n",
      "DEBUG - Citing Paper: mt-LAF3 is a pseudouridine synthase ortholog required for mitochondrial rRNA and mRNA gene expression in Trypanosoma brucei., References: ['']\n",
      "DEBUG - Citing Paper: A tool for optimizing messenger RNA sequence., References: ['']\n",
      "DEBUG - Citing Paper: RNA Therapeutics: A Healthcare Paradigm Shift., References: ['']\n",
      "DEBUG - Citing Paper: Innate immune regulations and various siRNA modalities., References: ['']\n",
      "DEBUG - Citing Paper: Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets., References: ['']\n",
      "DEBUG - Citing Paper: Innovation in the 21st century: following the footsteps of Katalin KarikÃ³., References: ['']\n",
      "DEBUG - Citing Paper: Aging-induced pseudouridine synthase 10 impairs hematopoietic stem cells., References: ['']\n",
      "DEBUG - Citing Paper: Algorithm for optimized mRNA design improves stability and immunogenicity., References: ['']\n",
      "DEBUG - Citing Paper: Establishment of an Antiplasmodial Vaccine Based on PfRH5-Encoding RNA Replicons Stabilized by Cationic Liposomes., References: ['']\n",
      "DEBUG - Citing Paper: Promoter-independent synthesis of chemically modified RNA by human DNA polymerase Î¸ variants., References: ['']\n",
      "DEBUG - Citing Paper: A selective and atom-economic rearrangement of uridine by cascade biocatalysis for production of pseudouridine., References: ['']\n",
      "DEBUG - Citing Paper: Engineering cytokine therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Could artificial intelligence revolutionize the development of nanovectors for gene therapy and mRNA vaccines?, References: ['']\n",
      "DEBUG - Citing Paper: Immune-mediated liver injury following COVID-19 vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Revolutionizing viral disease vaccination: the promising clinical advancements of non-replicating mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Biomimetic Nanotechnology for SARS-CoV-2 Treatment., References: ['']\n",
      "DEBUG - Citing Paper: Intraduodenal Delivery of Exosome-Loaded SARS-CoV-2 RBD mRNA Induces a Neutralizing Antibody Response in Mice., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19-Induced Myocarditis: Pathophysiological Roles of ACE2 and Toll-like Receptors., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 and earlier pandemics, sepsis, and vaccines: A historical perspective., References: ['']\n",
      "DEBUG - Citing Paper: Restoration of Motor Function through Delayed Intraspinal Delivery of Human IL-10-Encoding Nucleoside-Modified mRNA after Spinal Cord Injury., References: ['']\n",
      "DEBUG - Citing Paper: Single-domain antibody delivery using an mRNA platform protects against lethal doses of botulinum neurotoxin A., References: ['']\n",
      "DEBUG - Citing Paper: A comparative study of the COVID-19 vaccine efficacy among cancer patients: mRNA versus non-mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Use of a Liver-Targeting Immune-Tolerogenic mRNA Lipid Nanoparticle Platform to Treat Peanut-Induced Anaphylaxis by Single- and Multiple-Epitope Nucleotide Sequence Delivery., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 Vaccine-Induced Lichenoid Eruptions-Clinical and Histopathologic Spectrum in a Case Series of Fifteen Patients with Review of the Literature., References: ['']\n",
      "DEBUG - Citing Paper: The Combination of an mRNA Immunogen, a TLR7 Agonist and a PD1 Blocking Agent Enhances In-Vitro HIV T-Cell Immune Responses., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-Based Therapeutics in Cancer Treatment., References: ['']\n",
      "DEBUG - Citing Paper: Safe and Effective Delivery of mRNA Using Modified PEI-Based Lipopolymers., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-From COVID-19 Treatment to Cancer Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Terminal hairpins improve protein expression in IRES-initiated mRNA in the absence of a cap and polyadenylated tail., References: ['']\n",
      "DEBUG - Citing Paper: Advanced delivery systems for peptide antibiotics., References: ['']\n",
      "DEBUG - Citing Paper: Protein expression/secretion boost by a novel unique 21-mer cis-regulatory motif (Exin21) via mRNA stabilization., References: ['']\n",
      "DEBUG - Citing Paper: RNA modification in mRNA cancer vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Identification of tumor antigens and immune subtypes of acute myeloid leukemia for mRNA vaccine development., References: ['']\n",
      "DEBUG - Citing Paper: A single vaccination of nucleoside-modified Rabies mRNA vaccine induces prolonged highly protective immune responses in mice., References: ['']\n",
      "DEBUG - Citing Paper: Review: Current trends, challenges, and success stories in adjuvant research., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 vaccines and a perspective on Africa., References: ['']\n",
      "DEBUG - Citing Paper: Modulating the expression of tumor suppressor genes using activating oligonucleotide technologies as a therapeutic approach in cancer., References: ['']\n",
      "DEBUG - Citing Paper: Hematopoietic stem and progenitors cells gene editing: Beyond blood disorders., References: ['']\n",
      "DEBUG - Citing Paper: Development of mRNA Vaccines/Therapeutics and Their Delivery System., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccine Mitigates SARS-CoV-2 Infections and COVID-19., References: ['']\n",
      "DEBUG - Citing Paper: Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs., References: ['']\n",
      "DEBUG - Citing Paper: mRNA in the Context of Protein Replacement Therapy., References: ['']\n",
      "DEBUG - Citing Paper: Self-Amplifying RNA Vaccine Candidates: Alternative Platforms for mRNA Vaccine Development., References: ['']\n",
      "DEBUG - Citing Paper: Screening of Tumor Antigens and Construction of Immune Subtypes for mRNA Vaccine Development in Head and Neck Squamous Cell Carcinoma., References: ['']\n",
      "DEBUG - Citing Paper: Race with virus evolution: The development and application of mRNA vaccines against SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: Structural basis of transcription recognition of a hydrophobic unnatural base pair by T7 RNA polymerase., References: ['']\n",
      "DEBUG - Citing Paper: Molecular elements: novel approaches for molecular building., References: ['']\n",
      "DEBUG - Citing Paper: Comparison between viral vector and mRNA based COVID-19 vaccination in prevalence and severity of regional immune reactions, and <sup>18</sup>F-FDG PET/CT features., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 vaccines adverse events: potential molecular mechanisms., References: ['']\n",
      "DEBUG - Citing Paper: ESCRT recruitment to mRNA-encoded SARS-CoV-2 spike induces virus-like particles and enhanced antibody responses., References: ['']\n",
      "DEBUG - Citing Paper: In silico design and evaluation of a novel mRNA vaccine against BK virus: a reverse vaccinology approach., References: ['']\n",
      "DEBUG - Citing Paper: Deep learning models for predicting RNA degradation via dual crowdsourcing., References: ['']\n",
      "DEBUG - Citing Paper: Enhancing the Effect of Nucleic Acid Vaccines in the Treatment of HPV-Related Cancers: An Overview of Delivery Systems., References: ['']\n",
      "DEBUG - Citing Paper: Modified mRNA Therapeutics for Heart Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Lessons learned from COVID-19 pandemic: Vaccine platform is a key player., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticles Delivering Constitutively Active STING mRNA to Stimulate Antitumor Immunity., References: ['']\n",
      "DEBUG - Citing Paper: Low Resource Integrated Platform for Production and Analysis of Capped mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Nanoformulations targeting immune cells for cancer therapy: mRNA therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Emerging roles of noncoding micro RNAs and circular RNAs in bovine mastitis: Regulation, breeding, diagnosis, and therapy., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Microparticles Show Similar Efficacy With Lipid Nanoparticles in Delivering mRNA and Preventing Cancer., References: ['']\n",
      "DEBUG - Citing Paper: Challenges and emerging trends in liquid chromatography-based analyses of mRNA pharmaceuticals., References: ['']\n",
      "DEBUG - Citing Paper: siRNA Functionalized Lipid Nanoparticles (LNPs) in Management of Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Scope and challenges of nanoparticle-based mRNA delivery in cancer treatment., References: ['']\n",
      "DEBUG - Citing Paper: Developing New Tools to Fight Human Pathogens: A Journey through the Advances in RNA Technologies., References: ['']\n",
      "DEBUG - Citing Paper: RNA sensor response in HeLa cells for transfected mRNAs prepared <i>in vitro</i> by SP6 and HiT7 RNA polymerases: A comparative study., References: ['']\n",
      "DEBUG - Citing Paper: Current strategies employed in the manipulation of gene expression for clinical purposes., References: ['']\n",
      "DEBUG - Citing Paper: Strategy of developing nucleic acid-based universal monkeypox vaccine candidates., References: ['']\n",
      "DEBUG - Citing Paper: Self-Amplifying RNA Approach for Protein Replacement Therapy., References: ['']\n",
      "DEBUG - Citing Paper: The landscape of mRNA nanomedicine., References: ['']\n",
      "DEBUG - Citing Paper: Internal RNA 2'O-methylation in the HIV-1 genome counteracts ISG20 nuclease-mediated antiviral effect., References: ['']\n",
      "DEBUG - Citing Paper: Advancing mRNA technologies for therapies and vaccines: An African context., References: ['']\n",
      "DEBUG - Citing Paper: Innate immune mechanisms of mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 mRNA-based vaccines in the Aicardi GoutiÃ¨res Syndrome., References: ['']\n",
      "DEBUG - Citing Paper: Unlocking the promise of mRNA therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Promising strategy for developing mRNA-based universal influenza virus vaccine for human population, poultry, and pigs- focus on the bigger picture., References: ['']\n",
      "DEBUG - Citing Paper: Delivery strategies for CRISPR/Cas genome editing tool for retinal dystrophies: challenges and opportunities., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model., References: ['']\n",
      "DEBUG - Citing Paper: Quantitative sequencing using BID-seq uncovers abundant pseudouridines in mammalian mRNA at base resolution., References: ['']\n",
      "DEBUG - Citing Paper: Immunization with a Prefusion SARS-CoV-2 Spike Protein Vaccine (RBMRNA-176) Protects against Viral Challenge in Mice and Nonhuman Primates., References: ['']\n",
      "DEBUG - Citing Paper: Detection technologies for RNA modifications., References: ['']\n",
      "DEBUG - Citing Paper: Construction and evaluation of a self-replicative RNA vaccine against SARS-CoV-2 using yellow fever virus replicon., References: ['']\n",
      "DEBUG - Citing Paper: Fast-track development of vaccines for SARS-CoV-2: The shots that saved the world., References: ['']\n",
      "DEBUG - Citing Paper: mRNA nanomedicine: Design and recent applications., References: ['']\n",
      "DEBUG - Citing Paper: Immediate protein expression from exogenous mRNAs in embryonic brain., References: ['']\n",
      "DEBUG - Citing Paper: Delivering the CRISPR/Cas9 system for engineering gene therapies: Recent cargo and delivery approaches for clinical translation., References: ['']\n",
      "DEBUG - Citing Paper: Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Lipid-based nucleic acid therapeutics with in vivo efficacy., References: ['']\n",
      "DEBUG - Citing Paper: Nucleic acid-protein condensates in innate immune signaling., References: ['']\n",
      "DEBUG - Citing Paper: Clinical advances and ongoing trials on mRNA vaccines for cancer treatment., References: ['']\n",
      "DEBUG - Citing Paper: Robust genome editing via modRNA-based Cas9 or base editor in human pluripotent stem cells., References: ['']\n",
      "DEBUG - Citing Paper: Phase I Study to Assess the Safety and Immunogenicity of an Intradermal COVID-19 DNA Vaccine Administered Using a Pyro-Drive Jet Injector in Healthy Adults., References: ['']\n",
      "DEBUG - Citing Paper: Role of Epitranscriptomic and Epigenetic Modifications during the Lytic and Latent Phases of Herpesvirus Infections., References: ['']\n",
      "DEBUG - Citing Paper: RNA modifications: importance in immune cell biology and related diseases., References: ['']\n",
      "DEBUG - Citing Paper: The role of RNA modification in hepatocellular carcinoma., References: ['']\n",
      "DEBUG - Citing Paper: Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial., References: ['']\n",
      "DEBUG - Citing Paper: Exploring the epitranscriptome by native RNA sequencing., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticle-based mRNA vaccines in cancers: Current advances and future prospects., References: ['']\n",
      "DEBUG - Citing Paper: Chemically modified <i>in-vitro</i>-transcribed mRNA encoding thrombopoietin stimulates thrombopoiesis in mice., References: ['']\n",
      "DEBUG - Citing Paper: Double-stranded RNA reduction by chaotropic agents during <i>inÂ vitro</i> transcription of messenger RNA., References: ['']\n",
      "DEBUG - Citing Paper: Anti-atherosclerotic therapies: Milestones, challenges, and emerging innovations., References: ['']\n",
      "DEBUG - Citing Paper: Advances in mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Synthesis of point-modified mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Pre-exposure to mRNA-LNP inhibits adaptive immune responses and alters innate immune fitness in an inheritable fashion., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines in the prevention and treatment of diseases., References: ['']\n",
      "DEBUG - Citing Paper: Emerging trends of research on mRNA vaccines: A co-citation analysis., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8<sup>+</sup> T cell response., References: ['']\n",
      "DEBUG - Citing Paper: Analysis of melanoma tumor antigens and immune subtypes for the development of mRNA vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Nanotechnology-facilitated vaccine development during the coronavirus disease 2019 (COVID-19) pandemic., References: ['']\n",
      "DEBUG - Citing Paper: Combination of chemically modified SDF-1Î± mRNA and small skin improves wound healing in diabetic rats with full-thickness skin defects., References: ['']\n",
      "DEBUG - Citing Paper: Recent Advances in the Molecular Design and Delivery Technology of mRNA for Vaccination Against Infectious Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Vaccines against SARS-CoV-2 variants and future pandemics., References: ['']\n",
      "DEBUG - Citing Paper: The Pivotal Role of Chemical Modifications in mRNA Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Clinical Development of mRNA Vaccines: Challenges and Opportunities., References: ['']\n",
      "DEBUG - Citing Paper: N<sup>1</sup>-methyl-pseudouridine is incorporated with higher fidelity than pseudouridine in synthetic RNAs., References: ['']\n",
      "DEBUG - Citing Paper: Efficient Induction of Antigen-Specific CD8<sup>+</sup> T-Cell Responses by Cationic Peptide-Based mRNA Nanoparticles., References: ['']\n",
      "DEBUG - Citing Paper: Human RNase 4 improves mRNA sequence characterization by LC-MS/MS., References: ['']\n",
      "DEBUG - Citing Paper: RNA-based therapeutics: an overview and prospectus., References: ['']\n",
      "DEBUG - Citing Paper: The legacy of mRNA engineering: A lineup of pioneers for the Nobel Prize., References: ['']\n",
      "DEBUG - Citing Paper: Therapeutic inÂ vivo delivery of gene editing agents., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticles in the development of mRNA vaccines for COVID-19., References: ['']\n",
      "DEBUG - Citing Paper: Structure Characterization of <i>Escherichia coli</i> Pseudouridine Kinase PsuK., References: ['']\n",
      "DEBUG - Citing Paper: Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial., References: ['']\n",
      "DEBUG - Citing Paper: Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials., References: ['']\n",
      "DEBUG - Citing Paper: The Past, Present, and Future of Non-Viral CAR T Cells., References: ['']\n",
      "DEBUG - Citing Paper: Prediction of lipid nanoparticles for mRNA vaccines by the machine learning algorithm., References: ['']\n",
      "DEBUG - Citing Paper: Photocaged 5' cap analogues for optical control of mRNA translation in cells., References: ['']\n",
      "DEBUG - Citing Paper: Transcription of the Envelope Protein by 1-L Protein-RNA Recognition Code Leads to Genes/Proteins That Are Relevant to the SARS-CoV-2 Life Cycle and Pathogenesis., References: ['']\n",
      "DEBUG - Citing Paper: R848 Adjuvant Laden With Self-Assembled Nanoparticle-Based mRNA Vaccine Elicits Protective Immunity Against H5N1 in Mice., References: ['']\n",
      "DEBUG - Citing Paper: Emerging Role of Epitranscriptomics in Diabetes Mellitus and Its Complications., References: ['']\n",
      "DEBUG - Citing Paper: RNase H-based analysis of synthetic mRNA 5' cap incorporation., References: ['']\n",
      "DEBUG - Citing Paper: Stronger together for in-cell translation: natural and unnatural base modified mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Circular RNA: An emerging frontier in RNA therapeutic targets, RNA therapeutics, and mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Recent Update of COVID-19 Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Biological and Immune Responses to Current Anti-SARS-CoV-2 mRNA Vaccines beyond Anti-Spike Antibody Production., References: ['']\n",
      "DEBUG - Citing Paper: Precision medicine: InÂ vivo CAR therapy as a showcase for receptor-targeted vector platforms., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-based therapeutics: powerful and versatile tools to combat diseases., References: ['']\n",
      "DEBUG - Citing Paper: Lipid-Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Components., References: ['']\n",
      "DEBUG - Citing Paper: RNA in Cancer Immunotherapy: Unlocking the Potential of the Immune System., References: ['']\n",
      "DEBUG - Citing Paper: An imidazole modified lipid confers enhanced mRNA-LNP stability and strong immunization properties in mice and non-human primates., References: ['']\n",
      "DEBUG - Citing Paper: The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: The clinical progress of mRNA vaccines and immunotherapies., References: ['']\n",
      "DEBUG - Citing Paper: New Generation Vaccines for COVID-19 Based on Peptide, Viral Vector, Artificial Antigen Presenting Cell, DNA or mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Role of main RNA modifications in cancer: N<sup>6</sup>-methyladenosine, 5-methylcytosine, and pseudouridine., References: ['']\n",
      "DEBUG - Citing Paper: mRNA- and Adenovirus-Based Vaccines against SARS-CoV-2 in HIV-Positive People., References: ['']\n",
      "DEBUG - Citing Paper: TRMT6/61A-dependent base methylation of tRNA-derived fragments regulates gene-silencing activity and the unfolded protein response in bladder cancer., References: ['']\n",
      "DEBUG - Citing Paper: Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines: the most recent clinical applications of synthetic mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases., References: ['']\n",
      "DEBUG - Citing Paper: mRNA cancer vaccines: Advances, trends and challenges., References: ['']\n",
      "DEBUG - Citing Paper: The repeated setbacks of HIV vaccine development laid the groundwork for SARS-CoV-2 vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Nonviral Delivery Systems of mRNA Vaccines for Cancer Gene Therapy., References: ['']\n",
      "DEBUG - Citing Paper: Vaccines Against COVID-19: A Review., References: ['']\n",
      "DEBUG - Citing Paper: Nucleic Acid-Based COVID-19 Therapy Targeting Cytokine Storms: Strategies to Quell the Storm., References: ['']\n",
      "DEBUG - Citing Paper: Advances in COVID-19 mRNA vaccine development., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic., References: ['']\n",
      "DEBUG - Citing Paper: Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Chemical modifications to mRNA nucleobases impact translation elongation and termination., References: ['']\n",
      "DEBUG - Citing Paper: Immunological barriers to haematopoietic stem cell gene therapy., References: ['']\n",
      "DEBUG - Citing Paper: RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants., References: ['']\n",
      "DEBUG - Citing Paper: Messenger RNA vaccines for cancer immunotherapy: progress promotes promise., References: ['']\n",
      "DEBUG - Citing Paper: Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Towards SINEUP-based therapeutics: Design of an <i>inÂ vitro</i> synthesized SINEUP RNA., References: ['']\n",
      "DEBUG - Citing Paper: The Potential of Nanomedicine to Unlock the Limitless Applications of mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Stability Modelling of mRNA Vaccine Quality Based on Temperature Monitoring throughout the Distribution Chain., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Ribozyme Assays to Quantify the Capping Efficiency of In Vitro-Transcribed mRNA., References: ['']\n",
      "DEBUG - Citing Paper: RNA-Based Strategies for Cell Reprogramming toward Pluripotency., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 mRNA vaccines: Platforms and current developments., References: ['']\n",
      "DEBUG - Citing Paper: Cytidine acetylation yields a hypoinflammatory synthetic messenger RNA., References: ['']\n",
      "DEBUG - Citing Paper: The N6-Methyladenosine Modification and Its Role in mRNA Metabolism and Gastrointestinal Tract Disease., References: ['']\n",
      "DEBUG - Citing Paper: Regulation of antiviral innate immunity by chemical modification of viral RNA., References: ['']\n",
      "DEBUG - Citing Paper: Chemical modification of uridine modulates mRNA-mediated proinflammatory and antiviral response in primary human macrophages., References: ['']\n",
      "DEBUG - Citing Paper: CIMT 2021: report on the 18th Annual Meeting of the Association for Cancer Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Systemically Administered TLR7/8 Agonist and Antigen-Conjugated Nanogels Govern Immune Responses against Tumors., References: ['']\n",
      "DEBUG - Citing Paper: Langerhans cells and cDC1s play redundant roles in mRNA-LNP induced protective anti-influenza and anti-SARS-CoV-2 immune responses., References: ['']\n",
      "DEBUG - Citing Paper: Nanotechnologies in Delivery of DNA and mRNA Vaccines to the Nasal and Pulmonary Mucosa., References: ['']\n",
      "DEBUG - Citing Paper: Recent Advances in RNA Therapy and Its Carriers to Treat the Single-Gene Neurological Disorders., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Therapeutic Modalities Design, Formulation and Manufacturing under Pharma 4.0 Principles., References: ['']\n",
      "DEBUG - Citing Paper: Single-dose SARS-CoV-2 vaccinations with either BNT162b2 or AZD1222 induce disparate Th1 responses and IgA production., References: ['']\n",
      "DEBUG - Citing Paper: Microneedle systems for delivering nucleic acid drugs., References: ['']\n",
      "DEBUG - Citing Paper: CAR T cells produced in vivo to treat cardiac injury., References: ['']\n",
      "DEBUG - Citing Paper: High-throughput and high-content bioassay enables tuning of polyester nanoparticles for cellular uptake, endosomal escape, and systemic in vivo delivery of mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Engineering synthetic RNA devices for cell control., References: ['']\n",
      "DEBUG - Citing Paper: Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities., References: ['']\n",
      "DEBUG - Citing Paper: A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues., References: ['']\n",
      "DEBUG - Citing Paper: mRNA, a Revolution in Biomedicine., References: ['']\n",
      "DEBUG - Citing Paper: The Nanoparticle-Enabled Success of COVID-19 mRNA Vaccines and the Promise of Microneedle Platforms for Pandemic Vaccine Response., References: ['']\n",
      "DEBUG - Citing Paper: Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 - a review., References: ['']\n",
      "DEBUG - Citing Paper: An mRNA vaccine to prevent genital herpes., References: ['']\n",
      "DEBUG - Citing Paper: BiTE secretion from in situ-programmed myeloid cells results in tumor-retained pharmacology., References: ['']\n",
      "DEBUG - Citing Paper: Microorganisms as Shapers of Human Civilization, from Pandemics to Even Our Genomes: Villains or Friends? A Historical Approach., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 infection: efficacy of extensive vaccination of the healthcare workforce in a large Italian hospital., References: ['']\n",
      "DEBUG - Citing Paper: Membrane-dependent relief of translation elongationÂ arrest on pseudouridine- and N1-methyl-pseudouridine-modified mRNAs., References: ['']\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DEBUG - Citing Paper: Building a community to engineer synthetic cells and organelles from the bottom-up., References: ['']\n",
      "DEBUG - Citing Paper: Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza., References: ['']\n",
      "DEBUG - Citing Paper: Guide RNA acrobatics: positioning consecutive uridines for pseudouridylation by H/ACA pseudouridylation loops with dual guide capacity., References: ['']\n",
      "DEBUG - Citing Paper: Chemically modified mRNA beyond COVID-19: Potential preventive and therapeutic applications for targeting chronic diseases., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccines to Protect Against Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Advances in the design and development of SARS-CoV-2 vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Antigenic characterization of influenza and SARS-CoV-2 viruses., References: ['']\n",
      "DEBUG - Citing Paper: QnAs with Katalin KarikÃ³., References: ['']\n",
      "DEBUG - Citing Paper: Current view on novel vaccine technologies to combat human infectious diseases., References: ['']\n",
      "DEBUG - Citing Paper: Interferon inducible pseudouridine modification in human mRNA by quantitative nanopore profiling., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses., References: ['']\n",
      "DEBUG - Citing Paper: The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory., References: ['']\n",
      "DEBUG - Citing Paper: The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview., References: ['']\n",
      "DEBUG - Citing Paper: RNA Vaccines against Infectious Diseases: Vital Progress with Room for Improvement., References: ['']\n",
      "DEBUG - Citing Paper: Co-Delivery of mRNA and pDNA Using Thermally Stabilized Coacervate-Based Core-Shell Nanosystems., References: ['']\n",
      "DEBUG - Citing Paper: Hydrophobic Optimization of Functional Poly(TPAE-co-suberoyl chloride) for Extrahepatic mRNA Delivery following Intravenous Administration., References: ['']\n",
      "DEBUG - Citing Paper: Protein-Based Systems for Translational Regulation of Synthetic mRNAs in Mammalian Cells., References: ['']\n",
      "DEBUG - Citing Paper: The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Current and future nanoparticle vaccines for COVID-19., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticle chemistry determines how nucleoside base modifications alter mRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticle-mRNA Formulations for Therapeutic Applications., References: ['']\n",
      "DEBUG - Citing Paper: Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs., References: ['']\n",
      "DEBUG - Citing Paper: A New Generation of Vaccines in the Age of Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Principles for designing an optimal mRNA lipid nanoparticle vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Vaccine development and technology for SARS-CoV-2: Current insight., References: ['']\n",
      "DEBUG - Citing Paper: The Current Status of COVID-19 Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Engineered mRNA and the Rise of Next-Generation Antibodies., References: ['']\n",
      "DEBUG - Citing Paper: Exploration of Pattern Recognition Receptor Agonists as Candidate Adjuvants., References: ['']\n",
      "DEBUG - Citing Paper: Muscle Regeneration and RNA: New Perspectives for Ancient Molecules., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticles for Organ-Specific mRNA Therapeutic Delivery., References: ['']\n",
      "DEBUG - Citing Paper: Nanoparticle-Mediated <i>In Situ</i> Molecular Reprogramming of Immune Checkpoint Interactions for Cancer Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Immunogenicity of <i>In Vitro</i>-Transcribed RNA., References: ['']\n",
      "DEBUG - Citing Paper: Review: Development of SARS-CoV-2 immuno-enhanced COVID-19 vaccines with nano-platform., References: ['']\n",
      "DEBUG - Citing Paper: Immunology of SARS-CoV-2 infections and vaccines., References: ['']\n",
      "DEBUG - Citing Paper: mRNA - A game changer in regenerative medicine, cell-based therapy and reprogramming strategies., References: ['']\n",
      "DEBUG - Citing Paper: Heterogeneous Longitudinal Antibody Responses to Covid-19 mRNA Vaccination., References: ['']\n",
      "DEBUG - Citing Paper: RNA Modifications and Epigenetics in Modulation of Lung Cancer and Pulmonary Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Nucleic Acid Drugs-Current Status, Issues, and Expectations for Exosomes., References: ['']\n",
      "DEBUG - Citing Paper: CRISPR-derived genome editing therapies: Progress from bench to bedside., References: ['']\n",
      "DEBUG - Citing Paper: Concentration of Na<sup>+</sup>-taurocholate-cotransporting polypeptide expressed after in vitro-transcribed mRNA transfection determines susceptibility of hepatoma cells for hepatitis B virus., References: ['']\n",
      "DEBUG - Citing Paper: Cardiovascular consequences of viral infections: from COVID to other viral diseases., References: ['']\n",
      "DEBUG - Citing Paper: To Be or Not To Be Vaccinated: That Is a Question in Myasthenia Gravis., References: ['']\n",
      "DEBUG - Citing Paper: An Update on mRNA-Based Viral Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Pharma 4.0 Continuous mRNA Drug Products Manufacturing., References: ['']\n",
      "DEBUG - Citing Paper: Cationic Liposomes as Vectors for Nucleic Acid and Hydrophobic Drug Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Challenges and Scientific Prospects of the Newest Generation of mRNA-Based Vaccines against SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: The mRNA vaccine revolution is the dividend from decades of basic science research., References: ['']\n",
      "DEBUG - Citing Paper: Literature Mining and Mechanistic Graphical Modelling to Improve mRNA Vaccine Platforms., References: ['']\n",
      "DEBUG - Citing Paper: The future in an RNA molecule: from mRNA vaccines to therapeutics - An interview with Drew Weissman., References: ['']\n",
      "DEBUG - Citing Paper: Nucleic acid delivery and nanoparticle design for COVID vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Influenza Viruses: Innate Immunity and mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months., References: ['']\n",
      "DEBUG - Citing Paper: Investigating the consequences of mRNA modifications on protein synthesis using in vitro translation assays., References: ['']\n",
      "DEBUG - Citing Paper: Nanotechnology-Assisted RNA Delivery: From Nucleic Acid Therapeutics to COVID-19 Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Pseudouridines in RNAs: switching atoms means shifting paradigms., References: ['']\n",
      "DEBUG - Citing Paper: The infinite possibilities of RNA therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 Pathogenesis: From Molecular Pathway to Vaccine Administration., References: ['']\n",
      "DEBUG - Citing Paper: Genetic in situ engineering of myeloid regulatory cells controls inflammation in autoimmunity., References: ['']\n",
      "DEBUG - Citing Paper: Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticles for mRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: Mapping of pseudouridine residues on cellular and viral transcripts using a novel antibody-based technique., References: ['']\n",
      "DEBUG - Citing Paper: Langerhans cells and cDC1s play redundant roles in mRNA-LNP induced protective anti-influenza and anti-SARS-CoV-2 responses., References: ['']\n",
      "DEBUG - Citing Paper: Detailed Dissection and Critical Evaluation of the Pfizer/BioNTech and Moderna mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across., References: ['']\n",
      "DEBUG - Citing Paper: RNA modifications act as regulators of cell death., References: ['']\n",
      "DEBUG - Citing Paper: From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape., References: ['']\n",
      "DEBUG - Citing Paper: Early approval of COVID-19 vaccines: Pros and cons., References: ['']\n",
      "DEBUG - Citing Paper: [Subjective well-being and ability to work of hospital staff after SARS-CoV2 immunization with the mRNA vaccine BNT162b2]., References: ['']\n",
      "DEBUG - Citing Paper: Serological response to a single dose of a SARS-CoV-2 mRNA vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Immunological mechanisms of vaccine-induced protection against COVID-19 in humans., References: ['']\n",
      "DEBUG - Citing Paper: Lipofection with Synthetic mRNA as a Simple Method for T-Cell Immunomonitoring., References: ['']\n",
      "DEBUG - Citing Paper: Long Non-Coding RNA Epigenetics., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses., References: ['']\n",
      "DEBUG - Citing Paper: An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages., References: ['']\n",
      "DEBUG - Citing Paper: Trigeminal and cervical radiculitis after tozinameran vaccination against COVID-19., References: ['']\n",
      "DEBUG - Citing Paper: Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice., References: ['']\n",
      "DEBUG - Citing Paper: Synthetic modified messenger RNA for therapeutic applications., References: ['']\n",
      "DEBUG - Citing Paper: A Guide to Nucleic Acid Vaccines in the Prevention and Treatment of Infectious Diseases and Cancers: From Basic Principles to Current Applications., References: ['']\n",
      "DEBUG - Citing Paper: Opportunities for innovation: Building on the success of lipid nanoparticle vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Highly efficient CD4+ TÂ cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs., References: ['']\n",
      "DEBUG - Citing Paper: Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: From Antisense RNA to RNA Modification: Therapeutic Potential of RNA-Based Technologies., References: ['']\n",
      "DEBUG - Citing Paper: Non-Immunotherapy Application of LNP-mRNA: Maximizing Efficacy and Safety., References: ['']\n",
      "DEBUG - Citing Paper: Construction and Immunogenicity of Modified mRNA-Vaccine Variants Encoding Influenza Virus Antigens., References: ['']\n",
      "DEBUG - Citing Paper: A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development., References: ['']\n",
      "DEBUG - Citing Paper: BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans., References: ['']\n",
      "DEBUG - Citing Paper: Dual Inhibition of DKC1 and MEK1/2 Synergistically Restrains the Growth of Colorectal Cancer Cells., References: ['']\n",
      "DEBUG - Citing Paper: Lipid-nanoparticle-encapsulated mRNA vaccines induce protective memory CD8 TÂ cells against a lethal viral infection., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines for COVID-19: what, why and how., References: ['']\n",
      "DEBUG - Citing Paper: Future considerations for the mRNA-lipid nanoparticle vaccine platform., References: ['']\n",
      "DEBUG - Citing Paper: Perspectives on RNA Vaccine Candidates for COVID-19., References: ['']\n",
      "DEBUG - Citing Paper: In Situ Programming of CAR T Cells., References: ['']\n",
      "DEBUG - Citing Paper: mRNA therapeutics in cancer immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: CAR T-Cell Production Using Nonviral Approaches., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates., References: ['']\n",
      "DEBUG - Citing Paper: The Limitless Future of RNA Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Role of nanotechnology behind the success of mRNA vaccines for COVID-19., References: ['']\n",
      "DEBUG - Citing Paper: In the Era of mRNA Vaccines, Is There Any Hope for HIV Functional Cure?, References: ['']\n",
      "DEBUG - Citing Paper: An Overview on the Development of mRNA-Based Vaccines and Their Formulation Strategies for Improved Antigen Expression In Vivo., References: ['']\n",
      "DEBUG - Citing Paper: Nano-Enabled COVID-19 Vaccines: Meeting the Challenges of Durable Antibody Plus Cellular Immunity and Immune Escape., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines take on immune tolerance., References: ['']\n",
      "DEBUG - Citing Paper: H/ACA Small Ribonucleoproteins: Structural and Functional Comparison Between Archaea and Eukaryotes., References: ['']\n",
      "DEBUG - Citing Paper: On the Shoulders of Giants - From Jenner's Cowpox to mRNA Covid Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: A Dengue Virus Serotype 1 mRNA-LNP Vaccine Elicits Protective Immune Responses., References: ['']\n",
      "DEBUG - Citing Paper: RNA-based therapies: A cog in the wheel of lung cancer defense., References: ['']\n",
      "DEBUG - Citing Paper: Clinical and immunological effects of mRNA vaccines in malignant diseases., References: ['']\n",
      "DEBUG - Citing Paper: The conundrum of current anti-SARS-CoV-2 vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Exosomes for mRNA delivery: a novel biotherapeutic strategy with hurdles and hope., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 vaccines in patients with SLE., References: ['']\n",
      "DEBUG - Citing Paper: Nucleic Acid Immunotherapeutics for Cancer., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccines against Flaviviruses., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond., References: ['']\n",
      "DEBUG - Citing Paper: Therapeutic RNA Delivery for COVID and Other Diseases., References: ['']\n",
      "DEBUG - Citing Paper: mRNA in cancer immunotherapy: beyond a source of antigen., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccine for cancer immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Characterizing RNA Pseudouridylation by Convolutional Neural Networks., References: ['']\n",
      "DEBUG - Citing Paper: Tricks and threats of RNA viruses - towards understanding the fate of viral RNA., References: ['']\n",
      "DEBUG - Citing Paper: Chemically Modified SDF-1Î± mRNA Promotes Random Flap Survival by Activating the SDF-1Î±/CXCR4 Axis in Rats., References: ['']\n",
      "DEBUG - Citing Paper: A double-edged sword of immuno-microenvironment in cardiac homeostasis and injury repair., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-Based Vaccines and Mode of Action., References: ['']\n",
      "DEBUG - Citing Paper: Advancements in mRNA Encoded Antibodies for Passive Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Synthetic biology in the clinic: engineering vaccines, diagnostics, and therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: The Key Role of Nucleic Acid Vaccines for One Health., References: ['']\n",
      "DEBUG - Citing Paper: HIV mRNA Vaccines-Progress and Future Paths., References: ['']\n",
      "DEBUG - Citing Paper: What We Do Know and Do Not Yet Know about COVID-19 Vaccines as of the Beginning of the Year 2021., References: ['']\n",
      "DEBUG - Citing Paper: Self-assembled miRNA-switch nanoparticles target denuded regions and prevent restenosis., References: ['']\n",
      "DEBUG - Citing Paper: BNT162b vaccines protect rhesus macaques from SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis., References: ['']\n",
      "DEBUG - Citing Paper: Murine liver repair via transient activation of regenerative pathways in hepatocytes using lipid nanoparticle-complexed nucleoside-modified mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Development of mRNA Vaccines: Scientific and Regulatory Issues., References: ['']\n",
      "DEBUG - Citing Paper: Nanomaterial Delivery Systems for mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-Enhanced Cell Therapy and Cardiovascular Regeneration., References: ['']\n",
      "DEBUG - Citing Paper: Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans., References: ['']\n",
      "DEBUG - Citing Paper: The role of m<sup>6</sup>A, m<sup>5</sup>C and Î¨ RNA modifications in cancer: Novel therapeutic opportunities., References: ['']\n",
      "DEBUG - Citing Paper: Next-Generation Vaccines: Nanoparticle-Mediated DNA and mRNA Delivery., References: ['']\n",
      "DEBUG - Citing Paper: RNA Vaccines: A Suitable Platform for Tackling Emerging Pandemics?, References: ['']\n",
      "DEBUG - Citing Paper: Self-assembled mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Nanoparticles as Adjuvants and Nanodelivery Systems for mRNA-Based Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: A mark of disease: how mRNA modifications shape genetic and acquired pathologies., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 vaccines: The status and perspectives in delivery points of view., References: ['']\n",
      "DEBUG - Citing Paper: Neo-Antigen mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection., References: ['']\n",
      "DEBUG - Citing Paper: Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Reverse C-glycosidase reaction provides C-nucleotide building blocks of xenobiotic nucleic acids., References: ['']\n",
      "DEBUG - Citing Paper: Infectious RNA vaccine protects mice against chikungunya virus infection., References: ['']\n",
      "DEBUG - Citing Paper: In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo., References: ['']\n",
      "DEBUG - Citing Paper: The epitranscriptome beyond m<sup>6</sup>A., References: ['']\n",
      "DEBUG - Citing Paper: New Technologies for Influenza Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Plant-Derived Natural Compounds in Genetic Vaccination and Therapy for HPV-Associated Cancers., References: ['']\n",
      "DEBUG - Citing Paper: Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in mice., References: ['']\n",
      "DEBUG - Citing Paper: Self-amplifying RNA vaccines for infectious diseases., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 Vaccine Development: An Overview and Perspectives., References: ['']\n",
      "DEBUG - Citing Paper: Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates., References: ['']\n",
      "DEBUG - Citing Paper: Loss of Pseudouridine Synthases in the RluA Family Causes Hypersensitive Nociception in <i>Drosophila</i>., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19: Current Developments and Further Opportunities in Drug Delivery and Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Engineering Antiviral Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Alkylative damage of mRNA leads to ribosome stalling and rescue by <i>trans</i> translation in bacteria., References: ['']\n",
      "DEBUG - Citing Paper: Single-dose mRNA therapy via biomaterial-mediated sequestration of overexpressed proteins., References: ['']\n",
      "DEBUG - Citing Paper: Vaccines for COVID-19., References: ['']\n",
      "DEBUG - Citing Paper: RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccine Era-Mechanisms, Drug Platform and Clinical Prospection., References: ['']\n",
      "DEBUG - Citing Paper: Regulation and Function of RNA Pseudouridylation in Human Cells., References: ['']\n",
      "DEBUG - Citing Paper: Modified mRNA as a Therapeutic Tool for the Heart., References: ['']\n",
      "DEBUG - Citing Paper: Phosphodiester modifications in mRNA poly(A) tail prevent deadenylation without compromising protein expression., References: ['']\n",
      "DEBUG - Citing Paper: Treating Cystic Fibrosis with mRNA and CRISPR., References: ['']\n",
      "DEBUG - Citing Paper: A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice., References: ['']\n",
      "DEBUG - Citing Paper: Delivery of hepatocyte growth factor mRNA from nanofibrillar scaffolds in a pig model of peripheral arterial disease., References: ['']\n",
      "DEBUG - Citing Paper: Synthetic mRNA Encoding VEGF-A in Patients Undergoing Coronary Artery Bypass Grafting: Design of a Phase 2a Clinical Trial., References: ['']\n",
      "DEBUG - Citing Paper: Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates., References: ['']\n",
      "DEBUG - Citing Paper: Enzymatic covalent labeling of RNA with RNA transglycosylation at guanosine (RNA-TAG)., References: ['']\n",
      "DEBUG - Citing Paper: Pseudouridine as a novel biomarker in prostate cancer., References: ['']\n",
      "DEBUG - Citing Paper: Intramuscular Delivery of Replicon RNA Encoding ZIKV-117 Human Monoclonal Antibody Protects against Zika Virus Infection., References: ['']\n",
      "DEBUG - Citing Paper: Advances in Development of mRNA-Based Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Regulatory Considerations on the Development of mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Impact of mRNA chemistry and manufacturing process on innate immune activation., References: ['']\n",
      "DEBUG - Citing Paper: Designing a novel mRNA vaccine against SARS-CoV-2: An immunoinformatics approach., References: ['']\n",
      "DEBUG - Citing Paper: Controlling timing and location in vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Preparing for Pandemics: RNA Vaccines at the Forefront., References: ['']\n",
      "DEBUG - Citing Paper: Therapeutic siRNA: state of the art., References: ['']\n",
      "DEBUG - Citing Paper: Current Status of Zika Virus Vaccines: Successes and Challenges., References: ['']\n",
      "DEBUG - Citing Paper: Formulation and Delivery Technologies for mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Treatment of Hemophilia A Using Factor VIII Messenger RNA Lipid Nanoparticles., References: ['']\n",
      "DEBUG - Citing Paper: Novel insight into the regulatory roles of diverse RNA modifications: Re-defining the bridge between transcription and translation., References: ['']\n",
      "DEBUG - Citing Paper: Messenger RNA-Based Vaccines Against Infectious Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Vaccines to prevent genital herpes., References: ['']\n",
      "DEBUG - Citing Paper: Big Is Beautiful: Enhanced saRNA Delivery and Immunogenicity by a Higher Molecular Weight, Bioreducible, Cationic Polymer., References: ['']\n",
      "DEBUG - Citing Paper: Posttranscriptional modification of messenger RNAs in eukaryotes., References: ['']\n",
      "DEBUG - Citing Paper: The emerging role of RNA modifications in the regulation of mRNA stability., References: ['']\n",
      "DEBUG - Citing Paper: T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment., References: ['']\n",
      "DEBUG - Citing Paper: In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies., References: ['']\n",
      "DEBUG - Citing Paper: Caliciviral protein-based artificial translational activator for mammalian gene circuits with RNA-only delivery., References: ['']\n",
      "DEBUG - Citing Paper: Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives., References: ['']\n",
      "DEBUG - Citing Paper: Strong Immune Responses Induced by Direct Local Injections of Modified mRNA-Lipid Nanocomplexes., References: ['']\n",
      "DEBUG - Citing Paper: Opportunities and Challenges in the Delivery of mRNA-based Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: The identity and methylation status of the first transcribed nucleotide in eukaryotic mRNA 5' cap modulates protein expression in living cells., References: ['']\n",
      "DEBUG - Citing Paper: A molecular-level perspective on the frequency, distribution, and consequences of messenger RNA modifications., References: ['']\n",
      "DEBUG - Citing Paper: Synthesis of low immunogenicity RNA with high-temperature in vitro transcription., References: ['']\n",
      "DEBUG - Citing Paper: Delivery strategies of cancer immunotherapy: recent advances and future perspectives., References: ['']\n",
      "DEBUG - Citing Paper: mRNA structure regulates protein expression through changes in functional half-life., References: ['']\n",
      "DEBUG - Citing Paper: Epitranscriptomic marks: Emerging modulators of RNA virus gene expression., References: ['']\n",
      "DEBUG - Citing Paper: Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening., References: ['']\n",
      "DEBUG - Citing Paper: Emerging modes-of-action in drug discovery., References: ['']\n",
      "DEBUG - Citing Paper: Pseudouridinylation of mRNA coding sequences alters translation., References: ['']\n",
      "DEBUG - Citing Paper: Mineral-Coated Microparticles Enhance mRNA-Based Transfection of Human Bone Marrow Cells., References: ['']\n",
      "DEBUG - Citing Paper: In search of the mRNA modification landscape in plants., References: ['']\n",
      "DEBUG - Citing Paper: MiR-499 Responsive Lethal Construct for Removal of Human Embryonic Stem Cells after Cardiac Differentiation., References: ['']\n",
      "DEBUG - Citing Paper: Immunological Analysis of a CCHFV mRNA Vaccine Candidate in Mouse Models., References: ['']\n",
      "DEBUG - Citing Paper: Immunogenicity of RNA Replicons Encoding HIV Env Immunogens Designed for Self-Assembly into Nanoparticles., References: ['']\n",
      "DEBUG - Citing Paper: Optimizing Modified mRNA <i>InÂ Vitro</i> Synthesis Protocol for Heart Gene Therapy., References: ['']\n",
      "DEBUG - Citing Paper: Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers., References: ['']\n",
      "DEBUG - Citing Paper: Reprogramming of Urine-Derived Renal Epithelial Cells into iPSCs Using srRNA and Consecutive Differentiation into Beating Cardiomyocytes., References: ['']\n",
      "DEBUG - Citing Paper: Combinatorial targeting of cancer bone metastasis using mRNA engineered stem cells., References: ['']\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DEBUG - Citing Paper: Human 5' UTR design and variant effect prediction from a massively parallel translation assay., References: ['']\n",
      "DEBUG - Citing Paper: Efficient reduction of synthetic mRNA induced immune activation by simultaneous delivery of B18R encoding mRNA., References: ['']\n",
      "DEBUG - Citing Paper: A User's Guide to Cell-Free Protein Synthesis., References: ['']\n",
      "DEBUG - Citing Paper: Discovering and Mapping the Modified Nucleotides That Comprise the Epitranscriptome of mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing., References: ['']\n",
      "DEBUG - Citing Paper: In vitro evolution of enhanced RNA replicons for immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: The Skin You Are In: Design-of-Experiments Optimization of Lipid Nanoparticle Self-Amplifying RNA Formulations in Human Skin Explants., References: ['']\n",
      "DEBUG - Citing Paper: A Comparison of Plasmid DNA and mRNA as Vaccine Technologies., References: ['']\n",
      "DEBUG - Citing Paper: Biomedical applications of mRNA nanomedicine., References: ['']\n",
      "DEBUG - Citing Paper: Advances in mRNA Vaccines for Infectious Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Non-viral Delivery of Zinc Finger Nuclease mRNA Enables Highly Efficient InÂ Vivo Genome Editing of Multiple Therapeutic Gene Targets., References: ['']\n",
      "DEBUG - Citing Paper: RNA Circularization Diminishes Immunogenicity and Can Extend Translation Duration InÂ Vivo., References: ['']\n",
      "DEBUG - Citing Paper: mRNA: A Novel Avenue to Antibody Therapy?, References: ['']\n",
      "DEBUG - Citing Paper: mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases., References: ['']\n",
      "DEBUG - Citing Paper: How mRNA therapeutics are entering the monoclonal antibody field., References: ['']\n",
      "DEBUG - Citing Paper: Turning the corner on therapeutic cancer vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Multiple covalent fluorescence labeling of eukaryotic mRNA at the poly(A) tail enhances translation and can be performed in living cells., References: ['']\n",
      "DEBUG - Citing Paper: Eukaryotic Translation Elongation is Modulated by Single Natural Nucleotide Derivatives in the Coding Sequences of mRNAs., References: ['']\n",
      "DEBUG - Citing Paper: Nucleotide Modification Alters MicroRNA-Dependent Silencing of MicroRNA Switches., References: ['']\n",
      "DEBUG - Citing Paper: Delivery of mRNA Therapeutics for the Treatment of Hepatic Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Segmented poly(A) tails significantly reduce recombination of plasmid DNA without affecting mRNA translation efficiency or half-life., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-Based Protein Replacement Therapy for the Heart., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-Based Genetic Reprogramming., References: ['']\n",
      "DEBUG - Citing Paper: Proximity Ligation Assays for In Situ Detection of Innate Immune Activation: Focus on InÂ Vitro-Transcribed mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Efficient Induction of T Cells against Conserved HIV-1 Regions by Mosaic Vaccines Delivered as Self-Amplifying mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Exploitation of Synthetic mRNA To Drive Immune Effector Cell Recruitment and Functional Reprogramming In Vivo., References: ['']\n",
      "DEBUG - Citing Paper: Conversion of adult human fibroblasts into neural precursor cells using chemically modified mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Chemically modified hCFTR mRNAs recuperate lung function in a mouse model of cystic fibrosis., References: ['']\n",
      "DEBUG - Citing Paper: Post-transcriptional pseudouridylation in mRNA as well as in some major types of noncoding RNAs., References: ['']\n",
      "DEBUG - Citing Paper: m<sup>6</sup>A-mediated translation regulation., References: ['']\n",
      "DEBUG - Citing Paper: PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake., References: ['']\n",
      "DEBUG - Citing Paper: mRNA as novel technology for passive immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Biomaterials for vaccine-based cancer immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: New Vaccine Technologies to Combat Outbreak Situations., References: ['']\n",
      "DEBUG - Citing Paper: Uridine Depletion and Chemical Modification Increase Cas9 mRNA Activity and Reduce Immunogenicity without HPLC Purification., References: ['']\n",
      "DEBUG - Citing Paper: An RNA toolbox for cancer immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Metabolically stabilized double-stranded mRNA polyplexes., References: ['']\n",
      "DEBUG - Citing Paper: Evaluation of modified Interferon alpha mRNA constructs for the treatment of non-melanoma skin cancer., References: ['']\n",
      "DEBUG - Citing Paper: Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies., References: ['']\n",
      "DEBUG - Citing Paper: Double methylation of tRNA-U54 to 2'-O-methylthymidine (Tm) synergistically decreases immune response by Toll-like receptor 7., References: ['']\n",
      "DEBUG - Citing Paper: M<sup>3</sup>RNA Drives Targeted Gene Delivery in Acute Myocardial Infarction., References: ['']\n",
      "DEBUG - Citing Paper: Biocompatible, Purified <i>VEGF-A</i> mRNA Improves Cardiac Function after Intracardiac Injection 1 Week Post-myocardial Infarction in Swine., References: ['']\n",
      "DEBUG - Citing Paper: The Epitranscriptome in Translation Regulation., References: ['']\n",
      "DEBUG - Citing Paper: Purification of mRNA Encoding Chimeric Antigen Receptor Is Critical for Generation of a Robust T-Cell Response., References: ['']\n",
      "DEBUG - Citing Paper: Latest development on RNA-based drugs and vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Vegf-A mRNA transfection as a novel approach to improve mouse and human islet graft revascularisation., References: ['']\n",
      "DEBUG - Citing Paper: Base modifications affecting RNA polymerase and reverse transcriptase fidelity., References: ['']\n",
      "DEBUG - Citing Paper: Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses., References: ['']\n",
      "DEBUG - Citing Paper: Oxidative damage of SP-D abolishes control of eosinophil extracellular DNA trap formation., References: ['']\n",
      "DEBUG - Citing Paper: Aligned Nanofibrillar Scaffolds for Controlled Delivery of Modified mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Combinatorial programming of human neuronal progenitors using magnetically-guided stoichiometric mRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: Exploring Cytotoxic mRNAs as a Novel Class of Anti-cancer Biotherapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Tapping the RNA world for therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Messenger RNA Delivery for Tissue Engineering and Regenerative Medicine Applications., References: ['']\n",
      "DEBUG - Citing Paper: Modulation of mRNA Translation and Cell Viability by Influenza A Virus Derived Nonstructural Protein 1., References: ['']\n",
      "DEBUG - Citing Paper: Design and assessment of engineered CRISPR-Cpf1 and its use for genome editing., References: ['']\n",
      "DEBUG - Citing Paper: New Kids on the Block: RNA-Based Influenza Virus Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Efforts to Improve the Seasonal Influenza Vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Rapid, Single-Cell Analysis and Discovery of Vectored mRNA Transfection InÂ Vivo with a loxP-Flanked tdTomato Reporter Mouse., References: ['']\n",
      "DEBUG - Citing Paper: Light-Activated Control of Translation by Enzymatic Covalent mRNA Labeling., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines - a new era in vaccinology., References: ['']\n",
      "DEBUG - Citing Paper: RNA Pseudouridylation in Physiology and Medicine: For Better and for Worse., References: ['']\n",
      "DEBUG - Citing Paper: Design, Assembly, Production, and Transfection of Synthetic Modified mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Translation of Angiotensin-Converting Enzyme 2 upon Liver- and Lung-Targeted Delivery of Optimized Chemically Modified mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Elimination of large tumors in mice by mRNA-encoded bispecific antibodies., References: ['']\n",
      "DEBUG - Citing Paper: Modified mRNAs in the Cardiovascular System: A New Platform for Gene Therapy., References: ['']\n",
      "DEBUG - Citing Paper: Optimizing Cardiac Delivery of Modified mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Efficient Presentation of Multiple Endogenous Epitopes to Both CD4<sup>+</sup> and CD8<sup>+</sup> Diabetogenic T Cells for Tolerance., References: ['']\n",
      "DEBUG - Citing Paper: Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge., References: ['']\n",
      "DEBUG - Citing Paper: Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Chemical and structural effects of base modifications in messenger RNA., References: ['']\n",
      "DEBUG - Citing Paper: Modified mRNA as a therapeutic tool to induce cardiac regeneration in ischemic heart disease., References: ['']\n",
      "DEBUG - Citing Paper: Cap analogs modified with 1,2-dithiodiphosphate moiety protect mRNA from decapping and enhance its translational potential., References: ['']\n",
      "DEBUG - Citing Paper: Efficacy and immunogenicity of unmodified and pseudouridine-modified mRNA delivered systemically with lipid nanoparticles inÂ vivo., References: ['']\n",
      "DEBUG - Citing Paper: Differential effects of toll-like receptor stimulation on mRNA-driven myogenic conversion of human and mouse fibroblasts., References: ['']\n",
      "DEBUG - Citing Paper: The notorious R.N.A. in the spotlight - drug or target for the treatment of disease., References: ['']\n",
      "DEBUG - Citing Paper: Viral and Synthetic RNA Vector Technologies and Applications., References: ['']\n",
      "DEBUG - Citing Paper: mRNA modifications: Dynamic regulators of gene expression?, References: ['']\n",
      "DEBUG - Citing Paper: Translating the epitranscriptome., References: ['']\n",
      "DEBUG - Citing Paper: Particle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I Interferon., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-Mediated Gene Supplementation of Toll-Like Receptors as Treatment Strategy for Asthma In Vivo., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccine delivery using lipid nanoparticles., References: ['']\n",
      "DEBUG - Citing Paper: The oral and craniofacial relevance of chemically modified RNA therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Poly(glycoamidoamine) Brushes Formulated Nanomaterials for Systemic siRNA and mRNA Delivery in Vivo., References: ['']\n",
      "DEBUG - Citing Paper: Human iPSC for Therapeutic Approaches to the Nervous System: Present and Future Applications., References: ['']\n",
      "DEBUG - Citing Paper: RNA-Based Vaccines in Cancer Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: The Epitranscriptome and Innate Immunity., References: ['']\n",
      "DEBUG - Citing Paper: Modified mRNA as a new therapeutic option for pediatric respiratory diseases and hemoglobinopathies., References: ['']\n",
      "DEBUG - Citing Paper: Mesenchymal stem cells engineered to express selectin ligands and IL-10 exert enhanced therapeutic efficacy in murine experimental autoimmune encephalomyelitis., References: ['']\n",
      "DEBUG - Citing Paper: Nucleotide modifications within bacterial messenger RNAs regulate their translation and are able to rewire the genetic code., References: ['']\n",
      "DEBUG - Citing Paper: Aerosolized Non-viral Nucleic Acid Delivery in the Vaginal Tract of Pigs., References: ['']\n",
      "DEBUG - Citing Paper: Messenger RNA-based therapeutics for the treatment of apoptosis-associated diseases., References: ['']\n",
      "DEBUG - Citing Paper: Nebulisation of IVT mRNA Complexes for Intrapulmonary Administration., References: ['']\n",
      "DEBUG - Citing Paper: mRNA: Fulfilling the Promise of Gene Therapy., References: ['']\n",
      "DEBUG - Citing Paper: Transcriptome-wide dynamics of RNA pseudouridylation., References: ['']\n",
      "DEBUG - Citing Paper: Variable presence of 5-methylcytosine in commercial RNA and DNA., References: ['']\n",
      "DEBUG - Citing Paper: Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes., References: ['']\n",
      "DEBUG - Citing Paper: Self-assembled Messenger RNA Nanoparticles (mRNA-NPs) for Efficient Gene Expression., References: ['']\n",
      "DEBUG - Citing Paper: Efficient expression of stabilized mRNA PEG-peptide polyplexes in liver., References: ['']\n",
      "DEBUG - Citing Paper: Identification of Cyclobutane Pyrimidine Dimer-Responsive Genes Using UVB-Irradiated Human Keratinocytes Transfected with In Vitro-Synthesized Photolyase mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals., References: ['']\n",
      "DEBUG - Citing Paper: Business: The billion-dollar biotech., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-transfected Dendritic Cells Expressing Polypeptides That Link MHC-I Presentation to Constitutive TLR4 Activation Confer Tumor Immunity., References: ['']\n",
      "DEBUG - Citing Paper: In vivo genome editing using nuclease-encoding mRNA corrects SP-B deficiency., References: ['']\n",
      "DEBUG - Citing Paper: A Recombinant Collagen-mRNA Platform for Controllable Protein Synthesis., References: ['']\n",
      "DEBUG - Citing Paper: Pseudouridine: still mysterious, but never a fake (uridine)!, References: ['']\n",
      "DEBUG - Citing Paper: Efficient delivery and functional expression of transfected modified mRNA in human embryonic stem cell-derived retinal pigmented epithelial cells., References: ['']\n",
      "DEBUG - Citing Paper: In vitro synthesis of modified mRNA for induction of protein expression in human cells., References: ['']\n",
      "DEBUG - Citing Paper: An expanding universe of mRNA modifications., References: ['']\n",
      "DEBUG - Citing Paper: Transcriptome-wide mapping of pseudouridines: pseudouridine synthases modify specific mRNAs in S. cerevisiae., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-based therapeutics--developing a new class of drugs., References: ['']\n",
      "DEBUG - Citing Paper: Organ-targeted high-throughput in vivo biologics screen identifies materials for RNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma., References: ['']\n",
      "DEBUG - Citing Paper: Messenger RNA (mRNA) nanoparticle tumour vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies., References: ['']\n",
      "DEBUG - Citing Paper: A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs., References: ['']\n",
      "DEBUG - Citing Paper: The dynamic epitranscriptome: N6-methyladenosine and gene expression control., References: ['']\n",
      "DEBUG - Citing Paper: Optimized conditions for successful transfection of human endothelial cells with in vitro synthesized and modified mRNA for induction of protein expression., References: ['']\n",
      "DEBUG - Citing Paper: Transfection of pseudouridine-modified mRNA encoding CPD-photolyase leads to repair of DNA damage in human keratinocytes: a new approach with future therapeutic potential., References: ['']\n",
      "DEBUG - Citing Paper: Engine out of the chassis: cell-free protein synthesis and its uses., References: ['']\n",
      "DEBUG - Citing Paper: Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-engineered mesenchymal stem cells for targeted delivery of interleukin-10 to sites of inflammation., References: ['']\n",
      "DEBUG - Citing Paper: RNA-based tools for nuclear reprogramming and lineage-conversion: towards clinical applications., References: ['']\n",
      "DEBUG - Citing Paper: RNA-based vaccination: sending a strong message., References: ['']\n",
      "DEBUG - Citing Paper: Reprogramming human fibroblasts to pluripotency using modified mRNA., References: ['']\n",
      "DEBUG - Citing Paper: In vivo messenger RNA introduction into the central nervous system using polyplex nanomicelle., References: ['']\n",
      "DEBUG - Citing Paper: RNA pseudouridylation: new insights into an old modification., References: ['']\n",
      "DEBUG - Citing Paper: Combinatorial anti-HIV gene therapy: using a multipronged approach to reach beyond HAART., References: ['']\n",
      "DEBUG - Citing Paper: N6-methyl-adenosine modification in messenger and long non-coding RNA., References: ['']\n",
      "DEBUG - Citing Paper: Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format., References: ['']\n",
      "DEBUG - Citing Paper: Developing mRNA-vaccine technologies., References: ['']\n",
      "DEBUG - Citing Paper: mRNA leapfrogs DNA to show promise for therapeutic gene transfer., References: ['']\n",
      "DEBUG - Citing Paper: Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin., References: ['']\n",
      "DEBUG - Citing Paper: Nucleofection induces transient eIF2Î± phosphorylation by GCN2 and PERK., References: ['']\n",
      "DEBUG - Citing Paper: Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase resistance to cleavage by RNase L., References: ['']\n",
      "DEBUG - Citing Paper: Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Towards mRNA with superior translational activity: synthesis and properties of ARCA tetraphosphates with single phosphorothioate modifications., References: ['']\n",
      "DEBUG - Citing Paper: Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation., References: ['']\n",
      "DEBUG - focal: Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability., NF: 0, NB: 0, NR: 0, D: 0\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DEBUG - Focal Paper: Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin., References: \n",
      "David R, \n",
      "Burgess AL, \n",
      "Parker BJ, \n",
      "Pulsford KE, \n",
      "Sibbritt T, \n",
      "Preiss T, \n",
      "Searle IR (\n",
      "2016) \n",
      "Transcriptomeâwide mapping of RNA 5âmethylcytosine in Arabidopsis mRNAs and ncRNAs. \n",
      "Genome Res\n",
      "dx.doi.org/10.6084/m9.figshare.3408193.v2\n",
      "\n",
      "DEBUG - Citing Paper: Potential Application of Modified mRNA in Cardiac Regeneration., References: ['']\n",
      "DEBUG - Citing Paper: State-of-the-Art Review on Inhalable Lipid and Polymer Nanocarriers: Design and Development Perspectives., References: ['']\n",
      "DEBUG - Citing Paper: A tale of Science - The Nobel Prize in Physiology or Medicine 2023., References: ['']\n",
      "DEBUG - Citing Paper: Profile of Katalin KarikÃ³ and Drew Weissman: 2023 Nobel laureates in Physiology or Medicine., References: ['']\n",
      "DEBUG - Citing Paper: Strategies to reduce the risks of mRNA drug and vaccine toxicity., References: ['']\n",
      "DEBUG - Citing Paper: Delivery of gene editing therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications., References: ['']\n",
      "DEBUG - Citing Paper: Improved tropoelastin synthesis in the skin by codon optimization and nucleotide modification of tropoelastin-encoding synthetic mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Harnessing cell reprogramming for cardiac biological pacing., References: ['']\n",
      "DEBUG - Citing Paper: Development of an Alcohol Dilution-Lyophilization Method for the Preparation of mRNA-LNPs with Improved Storage Stability., References: ['']\n",
      "DEBUG - Citing Paper: Regulation and functions of non-m<sup>6</sup>A mRNA modifications., References: ['']\n",
      "DEBUG - Citing Paper: The impact of nucleoside base modification in mRNA vaccine is influenced by the chemistry of its lipid nanoparticle delivery system., References: ['']\n",
      "DEBUG - Citing Paper: Decoding the 'Fifth' Nucleotide: Impact of RNA Pseudouridylation on Gene Expression and Human Disease., References: ['']\n",
      "DEBUG - Citing Paper: Advances in Genetic Reprogramming: Prospects from Developmental Biology to Regenerative Medicine., References: ['']\n",
      "DEBUG - Citing Paper: Promoter-independent synthesis of chemically modified RNA by human DNA polymerase Î¸ variants., References: ['']\n",
      "DEBUG - Citing Paper: Broadly neutralizing antibodies against Omicron variants of SARS-CoV-2 derived from mRNA-lipid nanoparticle-immunized mice., References: ['']\n",
      "DEBUG - Citing Paper: A selective and atom-economic rearrangement of uridine by cascade biocatalysis for production of pseudouridine., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-From COVID-19 Treatment to Cancer Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Development of mRNA Vaccines/Therapeutics and Their Delivery System., References: ['']\n",
      "DEBUG - Citing Paper: mRNA in the Context of Protein Replacement Therapy., References: ['']\n",
      "DEBUG - Citing Paper: Race with virus evolution: The development and application of mRNA vaccines against SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: Nanoformulations targeting immune cells for cancer therapy: mRNA therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticle Delivery System for mRNA Encoding B7H3-redirected Bispecific Antibody Displays Potent Antitumor Effects on Malignant Tumors., References: ['']\n",
      "DEBUG - Citing Paper: The landscape of mRNA nanomedicine., References: ['']\n",
      "DEBUG - Citing Paper: Exploring the epitranscriptome by native RNA sequencing., References: ['']\n",
      "DEBUG - Citing Paper: Chemically modified <i>in-vitro</i>-transcribed mRNA encoding thrombopoietin stimulates thrombopoiesis in mice., References: ['']\n",
      "DEBUG - Citing Paper: Engineering Lipid Nanoparticles for Enhanced Intracellular Delivery of mRNA through Inhalation., References: ['']\n",
      "DEBUG - Citing Paper: Non-Viral Delivery of Gene Therapy to the Tendon., References: ['']\n",
      "DEBUG - Citing Paper: Structure-Uptake Relationship Study of DABCYL Derivatives Linked to Cyclic Cell-Penetrating Peptides for Live-Cell Delivery of Synthetic Proteins., References: ['']\n",
      "DEBUG - Citing Paper: STABILON, a Novel Sequence Motif That Enhances the Expression and Accumulation of Intracellular and Secreted Proteins., References: ['']\n",
      "DEBUG - Citing Paper: Sequence-Specific Features of Short Double-Strand, Blunt-End RNAs Have RIG-I- and Type 1 Interferon-Dependent or -Independent Anti-Viral Effects., References: ['']\n",
      "DEBUG - Citing Paper: Immune Response to SARS-CoV-2 Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Human RNase 4 improves mRNA sequence characterization by LC-MS/MS., References: ['']\n",
      "DEBUG - Citing Paper: The legacy of mRNA engineering: A lineup of pioneers for the Nobel Prize., References: ['']\n",
      "DEBUG - Citing Paper: Engineering circular RNA for enhanced protein production., References: ['']\n",
      "DEBUG - Citing Paper: RNase H-based analysis of synthetic mRNA 5' cap incorporation., References: ['']\n",
      "DEBUG - Citing Paper: An imidazole modified lipid confers enhanced mRNA-LNP stability and strong immunization properties in mice and non-human primates., References: ['']\n",
      "DEBUG - Citing Paper: Role of main RNA modifications in cancer: N<sup>6</sup>-methyladenosine, 5-methylcytosine, and pseudouridine., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines: the most recent clinical applications of synthetic mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases., References: ['']\n",
      "DEBUG - Citing Paper: Advances in COVID-19 mRNA vaccine development., References: ['']\n",
      "DEBUG - Citing Paper: Stability Modelling of mRNA Vaccine Quality Based on Temperature Monitoring throughout the Distribution Chain., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 mRNA vaccines: Platforms and current developments., References: ['']\n",
      "DEBUG - Citing Paper: Frequency and Associations of Adverse Reactions of COVID-19 Vaccines Reported to Pharmacovigilance Systems in the European Union and the United States., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Therapeutic Modalities Design, Formulation and Manufacturing under Pharma 4.0 Principles., References: ['']\n",
      "DEBUG - Citing Paper: Intracranial delivery of synthetic mRNA to suppress glioblastoma., References: ['']\n",
      "DEBUG - Citing Paper: Added to pre-existing inflammation, mRNA-lipid nanoparticles induce inflammation exacerbation (IE)., References: ['']\n",
      "DEBUG - Citing Paper: Hydrophobic Optimization of Functional Poly(TPAE-co-suberoyl chloride) for Extrahepatic mRNA Delivery following Intravenous Administration., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticle chemistry determines how nucleoside base modifications alter mRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticle-mRNA Formulations for Therapeutic Applications., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients., References: ['']\n",
      "DEBUG - Citing Paper: Immunogenicity of <i>In Vitro</i>-Transcribed RNA., References: ['']\n",
      "DEBUG - Citing Paper: mRNA - A game changer in regenerative medicine, cell-based therapy and reprogramming strategies., References: ['']\n",
      "DEBUG - Citing Paper: RNA-based therapeutics to treat human fungal infections., References: ['']\n",
      "DEBUG - Citing Paper: Concentration of Na<sup>+</sup>-taurocholate-cotransporting polypeptide expressed after in vitro-transcribed mRNA transfection determines susceptibility of hepatoma cells for hepatitis B virus., References: ['']\n",
      "DEBUG - Citing Paper: An Update on mRNA-Based Viral Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency., References: ['']\n",
      "DEBUG - Citing Paper: Detailed Dissection and Critical Evaluation of the Pfizer/BioNTech and Moderna mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across., References: ['']\n",
      "DEBUG - Citing Paper: From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases., References: ['']\n",
      "DEBUG - Citing Paper: mRNA therapeutics in cancer immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Deciphering Epitranscriptome: Modification of mRNA Bases Provides a New Perspective for Post-transcriptional Regulation of Gene Expression., References: ['']\n",
      "DEBUG - Citing Paper: An Overview on the Development of mRNA-Based Vaccines and Their Formulation Strategies for Improved Antigen Expression In Vivo., References: ['']\n",
      "DEBUG - Citing Paper: mRNA in cancer immunotherapy: beyond a source of antigen., References: ['']\n",
      "DEBUG - Citing Paper: A double-edged sword of immuno-microenvironment in cardiac homeostasis and injury repair., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-Based Vaccines and Mode of Action., References: ['']\n",
      "DEBUG - Citing Paper: HIV mRNA Vaccines-Progress and Future Paths., References: ['']\n",
      "DEBUG - Citing Paper: BMP-2 and VEGF-A modRNAs in collagen scaffold synergistically drive bone repair through osteogenic and angiogenic pathways., References: ['']\n",
      "DEBUG - Citing Paper: Reverse C-glycosidase reaction provides C-nucleotide building blocks of xenobiotic nucleic acids., References: ['']\n",
      "DEBUG - Citing Paper: NADPH oxidase correction by mRNA transfection of apheresis granulocytes in chronic granulomatous disease., References: ['']\n",
      "DEBUG - Citing Paper: Phosphodiester modifications in mRNA poly(A) tail prevent deadenylation without compromising protein expression., References: ['']\n",
      "DEBUG - Citing Paper: Delivery of hepatocyte growth factor mRNA from nanofibrillar scaffolds in a pig model of peripheral arterial disease., References: ['']\n",
      "DEBUG - Citing Paper: Synthetic mRNA Encoding VEGF-A in Patients Undergoing Coronary Artery Bypass Grafting: Design of a Phase 2a Clinical Trial., References: ['']\n",
      "DEBUG - Citing Paper: Intramuscular Delivery of Replicon RNA Encoding ZIKV-117 Human Monoclonal Antibody Protects against Zika Virus Infection., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Transfection-Induced Activation of Primary Human Monocytes and Macrophages: Dependence on Carrier System and Nucleotide Modification., References: ['']\n",
      "DEBUG - Citing Paper: Correction of bleeding in experimental severe hemophilia A by systemic delivery of factor VIII-encoding mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Efficient reduction of synthetic mRNA induced immune activation by simultaneous delivery of B18R encoding mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Advances in mRNA Vaccines for Infectious Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Chitosan in Non-Viral Gene Delivery: Role of Structure, Characterization Methods, and Insights in Cancer and Rare Diseases Therapies., References: ['']\n",
      "DEBUG - Citing Paper: A Facile Method for the Removal of dsRNA Contaminant from InÂ Vitro-Transcribed mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Recent Developments in mRNA-Based Protein Supplementation Therapy to Target Lung Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Concise Review: Application of Chemically Modified mRNA in Cell Fate Conversion and Tissue Engineering., References: ['']\n",
      "DEBUG - Citing Paper: mRNA: A Novel Avenue to Antibody Therapy?, References: ['']\n",
      "DEBUG - Citing Paper: Improved Efficacy in a Fabry Disease Model Using a Systemic mRNA Liver Depot System as Compared to Enzyme Replacement Therapy., References: ['']\n",
      "DEBUG - Citing Paper: mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Genome Editing with mRNA Encoding ZFN, TALEN, and Cas9., References: ['']\n",
      "DEBUG - Citing Paper: How mRNA therapeutics are entering the monoclonal antibody field., References: ['']\n",
      "DEBUG - Citing Paper: mRNA as novel technology for passive immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: New Vaccine Technologies to Combat Outbreak Situations., References: ['']\n",
      "DEBUG - Citing Paper: Uridine Depletion and Chemical Modification Increase Cas9 mRNA Activity and Reduce Immunogenicity without HPLC Purification., References: ['']\n",
      "DEBUG - Citing Paper: Biocompatible, Purified <i>VEGF-A</i> mRNA Improves Cardiac Function after Intracardiac Injection 1 Week Post-myocardial Infarction in Swine., References: ['']\n",
      "DEBUG - Citing Paper: A \"top-down\" approach to actuate poly(amine-co-ester) terpolymers for potent and safe mRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: Advances in Biomaterials for Drug Delivery., References: ['']\n",
      "DEBUG - Citing Paper: Aligned Nanofibrillar Scaffolds for Controlled Delivery of Modified mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Combinatorial programming of human neuronal progenitors using magnetically-guided stoichiometric mRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: Messenger RNA Delivery for Tissue Engineering and Regenerative Medicine Applications., References: ['']\n",
      "DEBUG - Citing Paper: Design, Assembly, Production, and Transfection of Synthetic Modified mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Engineering CRISPR-Cpf1 crRNAs and mRNAs to maximize genome editing efficiency., References: ['']\n",
      "DEBUG - Citing Paper: mRNA mediates passive vaccination against infectious agents, toxins, and tumors., References: ['']\n",
      "DEBUG - Citing Paper: Biodegradable Amino-Ester Nanomaterials for Cas9 mRNA Delivery in Vitro and in Vivo., References: ['']\n",
      "DEBUG - Citing Paper: Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge., References: ['']\n",
      "DEBUG - Citing Paper: Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems., References: ['']\n",
      "DEBUG - Citing Paper: Efficacy and immunogenicity of unmodified and pseudouridine-modified mRNA delivered systemically with lipid nanoparticles inÂ vivo., References: ['']\n",
      "DEBUG - Citing Paper: Cognitive neuroepigenetics: the next evolution in our understanding of the molecular mechanisms underlying learning and memory?, References: ['']\n",
      "DEBUG - Citing Paper: The notorious R.N.A. in the spotlight - drug or target for the treatment of disease., References: ['']\n",
      "DEBUG - Citing Paper: Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose., References: ['']\n",
      "DEBUG - Citing Paper: Viral and Synthetic RNA Vector Technologies and Applications., References: ['']\n",
      "DEBUG - Citing Paper: Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system., References: ['']\n",
      "DEBUG - Citing Paper: mRNA modifications: Dynamic regulators of gene expression?, References: ['']\n",
      "DEBUG - Citing Paper: Translating the epitranscriptome., References: ['']\n",
      "DEBUG - Citing Paper: mRNA capping: biological functions and applications., References: ['']\n",
      "DEBUG - Citing Paper: Deciphering the epitranscriptome: A green perspective., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-Mediated Gene Supplementation of Toll-Like Receptors as Treatment Strategy for Asthma In Vivo., References: ['']\n",
      "DEBUG - Citing Paper: Effects of local structural transformation of lipid-like compounds on delivery of messenger RNA., References: ['']\n",
      "DEBUG - Citing Paper: Bioinspired Alkenyl Amino Alcohol Ionizable Lipid Materials for Highly Potent In Vivo mRNA Delivery., References: ['']\n",
      "DEBUG - Citing Paper: Poly(glycoamidoamine) Brushes Formulated Nanomaterials for Systemic siRNA and mRNA Delivery in Vivo., References: ['']\n",
      "DEBUG - Citing Paper: RNA epigenetics--chemical messages for posttranscriptional gene regulation., References: ['']\n",
      "DEBUG - Citing Paper: Mesenchymal stem cells engineered to express selectin ligands and IL-10 exert enhanced therapeutic efficacy in murine experimental autoimmune encephalomyelitis., References: ['']\n",
      "DEBUG - Citing Paper: Nucleotide modifications within bacterial messenger RNAs regulate their translation and are able to rewire the genetic code., References: ['']\n",
      "DEBUG - Citing Paper: mRNA: Fulfilling the Promise of Gene Therapy., References: ['']\n",
      "DEBUG - Citing Paper: Self-assembled Messenger RNA Nanoparticles (mRNA-NPs) for Efficient Gene Expression., References: ['']\n",
      "DEBUG - Citing Paper: Efficient expression of stabilized mRNA PEG-peptide polyplexes in liver., References: ['']\n",
      "DEBUG - Citing Paper: Identification of Cyclobutane Pyrimidine Dimer-Responsive Genes Using UVB-Irradiated Human Keratinocytes Transfected with In Vitro-Synthesized Photolyase mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals., References: ['']\n",
      "DEBUG - Citing Paper: Business: The billion-dollar biotech., References: ['']\n",
      "DEBUG - Citing Paper: In vivo genome editing using nuclease-encoding mRNA corrects SP-B deficiency., References: ['']\n",
      "DEBUG - Citing Paper: Pseudouridine: still mysterious, but never a fake (uridine)!, References: ['']\n",
      "DEBUG - Citing Paper: Transient delivery of modified mRNA encoding TERT rapidly extends telomeres in human cells., References: ['']\n",
      "DEBUG - Citing Paper: Pseudouridine in a new era of RNA modifications., References: ['']\n",
      "DEBUG - Citing Paper: Synthetic chemically modified mRNA (modRNA): toward a new technology platform for cardiovascular biology and medicine., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-based therapeutics--developing a new class of drugs., References: ['']\n",
      "DEBUG - Citing Paper: Non-viral vectors for gene-based therapy., References: ['']\n",
      "DEBUG - Citing Paper: Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity., References: ['']\n",
      "DEBUG - Citing Paper: A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs., References: ['']\n",
      "DEBUG - Citing Paper: Whole blood cells loaded with messenger RNA as an anti-tumor vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Transfection of pseudouridine-modified mRNA encoding CPD-photolyase leads to repair of DNA damage in human keratinocytes: a new approach with future therapeutic potential., References: ['']\n",
      "DEBUG - Citing Paper: Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction., References: ['']\n",
      "DEBUG - Citing Paper: Augmentation of epithelial resistance to invading bacteria by using mRNA transfections., References: ['']\n",
      "DEBUG - Citing Paper: RNA-based tools for nuclear reprogramming and lineage-conversion: towards clinical applications., References: ['']\n",
      "DEBUG - Citing Paper: Evaluation of RNA Amplification Methods to Improve DC Immunotherapy Antigen Presentation and Immune Response., References: ['']\n",
      "DEBUG - Citing Paper: Reprogramming human fibroblasts to pluripotency using modified mRNA., References: ['']\n",
      "DEBUG - Citing Paper: In vivo messenger RNA introduction into the central nervous system using polyplex nanomicelle., References: ['']\n",
      "DEBUG - Citing Paper: RNA pseudouridylation: new insights into an old modification., References: ['']\n",
      "DEBUG - Citing Paper: Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format., References: ['']\n",
      "DEBUG - Citing Paper: Developing mRNA-vaccine technologies., References: ['']\n",
      "DEBUG - Citing Paper: mRNA leapfrogs DNA to show promise for therapeutic gene transfer., References: ['']\n",
      "DEBUG - focal: Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin., NF: 0, NB: 0, NR: 0, D: 0\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DEBUG - Focal Paper: Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses., References: \n",
      "\n",
      "Walker, J. A.\n",
      ", & \n",
      "McKenzie, A. N.\n",
      " (2018). \n",
      "<math xmlns=\"http://www.w3.org/1998/Math/MathML\"><mrow><msup><msub><mi mathvariant=\"normal\">T</mi><mi mathvariant=\"normal\">H</mi></msub><mn>2</mn></msup></mrow></math> cell development and function. Nature Reviews Immunology, 18(2), 121â133.\n",
      "DEBUG - Citing Paper: Innate and Adaptive Immune Parameters following mRNA Vaccination in Mice., References: ['']\n",
      "DEBUG - Citing Paper: Diagnosis of Angioimmunoblastic T Cell Lymphoma After Receiving First Dose of Pfizer/BioNTech (BNT162b2) Vaccine: A Case Report., References: ['']\n",
      "DEBUG - Citing Paper: Tumor microenvironment reprogramming by nanomedicine to enhance the effect of tumor immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Potent cancer therapy by liposome microstructure tailoring with active-to-passive targeting and shell-to-core thermosensitive features., References: ['']\n",
      "DEBUG - Citing Paper: Triple tandem trimer immunogens for HIV-1 and influenza nucleic acid-based vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Carrier-free mRNA vaccine induces robust immunity against SARS-CoV-2 in mice and non-human primates without systemic reactogenicity., References: ['']\n",
      "DEBUG - Citing Paper: Influenza a Neuraminidase-Based Bivalent mRNA Vaccine Induces Th1-Type Immune Response and Provides Protective Effects in Mice., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccine designs for optimal adjuvanticity and delivery., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity., References: ['']\n",
      "DEBUG - Citing Paper: Profile of Katalin KarikÃ³ and Drew Weissman: 2023 Nobel laureates in Physiology or Medicine., References: ['']\n",
      "DEBUG - Citing Paper: Takotsubo syndrome and vaccines: a systematic review., References: ['']\n",
      "DEBUG - Citing Paper: Strategies to reduce the risks of mRNA drug and vaccine toxicity., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccine Nanoplatforms and Innate Immunity., References: ['']\n",
      "DEBUG - Citing Paper: Editorial: Post COVID-19: the nucleoside-modified messenger RNA (modRNA) platform., References: ['']\n",
      "DEBUG - Citing Paper: Ipsilateral immunization after a prior SARS-CoV-2 mRNA vaccination elicits superior B cell responses compared to contralateral immunization., References: ['']\n",
      "DEBUG - Citing Paper: Intradermal Delivery of Naked mRNA Vaccines via Iontophoresis., References: ['']\n",
      "DEBUG - Citing Paper: A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax., References: ['']\n",
      "DEBUG - Citing Paper: Straight to the point: targeted mRNA-delivery to immune cells for improved vaccine design., References: ['']\n",
      "DEBUG - Citing Paper: Influence of N1-Methylpseudouridine in Guide RNAs on CRISPR/Cas9 Activity., References: ['']\n",
      "DEBUG - Citing Paper: Delineation of DNA and mRNA COVID-19 vaccine-induced immune responses in preclinical animal models., References: ['']\n",
      "DEBUG - Citing Paper: Liposomes: from August Wassermann to vaccines against COVID-19., References: ['']\n",
      "DEBUG - Citing Paper: Clinical Analysis and Applications of mRNA Vaccines in Infectious Diseases and Cancer Treatment., References: ['']\n",
      "DEBUG - Citing Paper: The Expression Kinetics and Immunogenicity of Lipid Nanoparticles Delivering Plasmid DNA and mRNA in Mice., References: ['']\n",
      "DEBUG - Citing Paper: The advances of adjuvants in mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Reducing cell intrinsic immunity to mRNA vaccine alters adaptive immune responses in mice., References: ['']\n",
      "DEBUG - Citing Paper: New-Onset Acute Interstitial Nephritis Post-SARS-CoV-2 Infection and COVID-19 Vaccination: A Panoramic Review., References: ['']\n",
      "DEBUG - Citing Paper: The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: Lipid carriers for mRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Cytotoxic CD4 development requires CD4 effectors to concurrently recognize local antigen and encounter type I IFN-induced IL-15., References: ['']\n",
      "DEBUG - Citing Paper: Guiding HIV-1 vaccine development with preclinical nonhuman primate research., References: ['']\n",
      "DEBUG - Citing Paper: An mRNA-based broad-spectrum vaccine candidate confers cross-protection against heterosubtypic influenza A viruses., References: ['']\n",
      "DEBUG - Citing Paper: Adjuvanted-SARS-CoV-2 Spike Protein-Based Microparticulate Vaccine Delivered by Dissolving Microneedles Induces Humoral, Mucosal, and Cellular Immune Responses in Mice., References: ['']\n",
      "DEBUG - Citing Paper: From Bench to Bedside: Implications of Lipid Nanoparticle Carrier Reactogenicity for Advancing Nucleic Acid Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Multi-phasic gene profiling using candidate gene approach predict the capacity of specific antibody production and maintenance following COVID-19 vaccination in Japanese population., References: ['']\n",
      "DEBUG - Citing Paper: Recent Advances in Messenger Ribonucleic Acid (mRNA) Vaccines and Their Delivery Systems: A Review., References: ['']\n",
      "DEBUG - Citing Paper: Impact of stabilizing mutations on the antigenic profile and glycosylation of membrane-expressed HIV-1 envelope glycoprotein., References: ['']\n",
      "DEBUG - Citing Paper: Development of an mRNA-lipid nanoparticle vaccine against Lyme disease., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 mRNA vaccination is associated with IgA nephropathy: an analysis of the Japanese adverse drug event report database., References: ['']\n",
      "DEBUG - Citing Paper: Knife's edge: Balancing immunogenicity and reactogenicity in mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Emerging Progress of RNA-Based Antitumor Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Comparison of Immune Responses between Inactivated and mRNA SARS-CoV-2 Vaccines Used for a Booster Dose in Mice., References: ['']\n",
      "DEBUG - Citing Paper: An Overview of the Use of Nanoparticles in Vaccine Development., References: ['']\n",
      "DEBUG - Citing Paper: Unmodified rabies mRNA vaccine elicits high cross-neutralizing antibody titers and diverse B cell memory responses., References: ['']\n",
      "DEBUG - Citing Paper: Strong immune responses and protection of PcrV and OprF-I mRNA vaccine candidates against Pseudomonas aeruginosa., References: ['']\n",
      "DEBUG - Citing Paper: saRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concern., References: ['']\n",
      "DEBUG - Citing Paper: Targeting the hallmarks of aging to improve influenza vaccine responses in older adults., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Immune-mediated liver injury following COVID-19 vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Biomimetic Nanotechnology for SARS-CoV-2 Treatment., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19-Induced Myocarditis: Pathophysiological Roles of ACE2 and Toll-like Receptors., References: ['']\n",
      "DEBUG - Citing Paper: Editorial: Adaptive immunity to respiratory pathogens., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 and earlier pandemics, sepsis, and vaccines: A historical perspective., References: ['']\n",
      "DEBUG - Citing Paper: Hepatitis C virus E1 and modified E2 delivered from an mRNA vaccine induces protective immunity., References: ['']\n",
      "DEBUG - Citing Paper: An Insight into Current Treatment Strategies, Their Limitations, and Ongoing Developments in Vaccine Technologies against Herpes Simplex Infections., References: ['']\n",
      "DEBUG - Citing Paper: T-follicular helper cells in malaria infection and roles in antibody induction., References: ['']\n",
      "DEBUG - Citing Paper: Humoral immune response to SARS-CoV-2 mRNA vaccines is associated with choice of vaccine and systemic adverse reactions., References: ['']\n",
      "DEBUG - Citing Paper: Optimization of 5'UTR to evade SARS-CoV-2 Nonstructural protein 1-directed inhibition of protein synthesis in cells., References: ['']\n",
      "DEBUG - Citing Paper: A Comprehensive Review of mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 vaccines and a perspective on Africa., References: ['']\n",
      "DEBUG - Citing Paper: Licensed liposomal vaccines and adjuvants in the antigen delivery system., References: ['']\n",
      "DEBUG - Citing Paper: Mutant and non-mutant neoantigen-based cancer vaccines: recent advances and future promises., References: ['']\n",
      "DEBUG - Citing Paper: The mRNA Vaccine Technology Era and the Future Control of Parasitic Infections., References: ['']\n",
      "DEBUG - Citing Paper: An extended SARS-CoV-2 mRNA vaccine prime-boost interval enhances B cell immunity with limited impact on T cells., References: ['']\n",
      "DEBUG - Citing Paper: Exploring <i>in vitro</i> expression and immune potency in mice using mRNA encoding the <i>Plasmodium falciparum</i> malaria antigen, CelTOS., References: ['']\n",
      "DEBUG - Citing Paper: Vaccination against Borna Disease: Overview, Vaccine Virus Characterization and Investigation of Live and Inactivated Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Recent Advances in Lipid Nanoparticles for Delivery of mRNA., References: ['']\n",
      "DEBUG - Citing Paper: Nucleoside-Modified mRNA-Based Influenza Vaccines Circumvent Problems Associated with H3N2 Vaccine Strain Egg Adaptation., References: ['']\n",
      "DEBUG - Citing Paper: Lipid-Based Delivery Systems in Development of Genetic and Subunit Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-LNP expressing PfCSP and Pfs25 vaccine candidates targeting infection and transmission of Plasmodium falciparum., References: ['']\n",
      "DEBUG - Citing Paper: A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes., References: ['']\n",
      "DEBUG - Citing Paper: cGAMP-adjuvanted multivalent influenza mRNA vaccines induce broadly protective immunity through cutaneous vaccination in mice., References: ['']\n",
      "DEBUG - Citing Paper: Tissue-Targeted Drug Delivery Strategies to Promote Antigen-Specific Immune Tolerance., References: ['']\n",
      "DEBUG - Citing Paper: Immune Senescence Markers Predict the Cellular Immune Response to BNT162b2 Vaccination in Hemodialysis Patients., References: ['']\n",
      "DEBUG - Citing Paper: The landscape of mRNA nanomedicine., References: ['']\n",
      "DEBUG - Citing Paper: Innate immune mechanisms of mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: A systematic and thematic analysis of the top 100 cited articles on mRNA vaccine indexed in Scopus database., References: ['']\n",
      "DEBUG - Citing Paper: Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses., References: ['']\n",
      "DEBUG - Citing Paper: Do we miss rare adverse events induced by COVID-19 vaccination?, References: ['']\n",
      "DEBUG - Citing Paper: Polymeric Nanoparticles for Inhaled Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Predictors of impaired antibody response after SARS-CoV-2 mRNA vaccination in hematopoietic cell transplant recipients: A Japanese multicenter observational study., References: ['']\n",
      "DEBUG - Citing Paper: Antibody and T-Cell Subsets Analysis Unveils an Immune Profile Heterogeneity Mediating Long-term Responses in Individuals Vaccinated Against SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 Vaccines: Types, Working Principle, and Its Impact on Thrombosis and Gastrointestinal Disorders., References: ['']\n",
      "DEBUG - Citing Paper: Comparison of renal histopathology in three patients with gross hematuria after SARS-CoV-2 vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus., References: ['']\n",
      "DEBUG - Citing Paper: Design and lyophilization of lipid nanoparticles for mRNA vaccine and its robust immune response in mice and nonhuman primates., References: ['']\n",
      "DEBUG - Citing Paper: Potential of mRNA vaccines to become versatile cancer vaccines., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 and children., References: ['']\n",
      "DEBUG - Citing Paper: Pemphigus foliaceous after mRNA COVID-19 vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Pre-exposure to mRNA-LNP inhibits adaptive immune responses and alters innate immune fitness in an inheritable fashion., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines in the prevention and treatment of diseases., References: ['']\n",
      "DEBUG - Citing Paper: Risk Assessment of COVID-19 Vaccination Among Childbearing Women., References: ['']\n",
      "DEBUG - Citing Paper: Current Vaccine Platforms in Enhancing T-Cell Response., References: ['']\n",
      "DEBUG - Citing Paper: Application of mRNA Technology in Cancer Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Immunogenicity, effectiveness, safety and psychological impact of COVID-19 mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies., References: ['']\n",
      "DEBUG - Citing Paper: Nanoparticles in clinical trials of COVID-19: An update., References: ['']\n",
      "DEBUG - Citing Paper: Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses., References: ['']\n",
      "DEBUG - Citing Paper: Nanotechnology-facilitated vaccine development during the coronavirus disease 2019 (COVID-19) pandemic., References: ['']\n",
      "DEBUG - Citing Paper: Clinical Development of mRNA Vaccines: Challenges and Opportunities., References: ['']\n",
      "DEBUG - Citing Paper: A Single Dose of Anti-HBsAg Antibody-Encoding mRNA-LNPs Suppressed HBsAg Expression: a Potential Cure of Chronic Hepatitis B Virus Infection., References: ['']\n",
      "DEBUG - Citing Paper: Immunogenicity of SARS-CoV-2 Trimeric Spike Protein Associated to Poly(I:C) Plus Alum., References: ['']\n",
      "DEBUG - Citing Paper: Single-cell profiling of immune cells after neoadjuvant pembrolizumab and chemotherapy in IIIA non-small cell lung cancer (NSCLC)., References: ['']\n",
      "DEBUG - Citing Paper: Prediction of lipid nanoparticles for mRNA vaccines by the machine learning algorithm., References: ['']\n",
      "DEBUG - Citing Paper: Sibling cases of gross hematuria and newly diagnosed IgA nephropathy following SARS-CoV-2 vaccination., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Materials-based vaccines for infectious diseases., References: ['']\n",
      "DEBUG - Citing Paper: Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects., References: ['']\n",
      "DEBUG - Citing Paper: Messenger ribonucleic acid vaccines against infectious diseases: current concepts and future prospects., References: ['']\n",
      "DEBUG - Citing Paper: Correlates of protection against SARS-CoV-2 infection and COVID-19 disease., References: ['']\n",
      "DEBUG - Citing Paper: Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and Its Variants., References: ['']\n",
      "DEBUG - Citing Paper: Synthesis and Characterization of Dihydrouracil Analogs Utilizing Biginelli Hybrids., References: ['']\n",
      "DEBUG - Citing Paper: Pro-inflammatory concerns with lipid nanoparticles., References: ['']\n",
      "DEBUG - Citing Paper: Modified mRNA-Based Vaccines Against Coronavirus Disease 2019., References: ['']\n",
      "DEBUG - Citing Paper: Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates., References: ['']\n",
      "DEBUG - Citing Paper: IgA nephropathy relapse following COVID-19 vaccination treated with corticosteroid therapy: case report., References: ['']\n",
      "DEBUG - Citing Paper: Post-Immune Antibodies in HIV-1 Infection in the Context of Vaccine Development: A Variety of Biological Functions and Catalytic Activities., References: ['']\n",
      "DEBUG - Citing Paper: Advances in COVID-19 mRNA vaccine development., References: ['']\n",
      "DEBUG - Citing Paper: Insights From Early Clinical Trials Assessing Response to mRNA SARS-CoV-2 Vaccination in Immunocompromised Patients., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice., References: ['']\n",
      "DEBUG - Citing Paper: Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine., References: ['']\n",
      "DEBUG - Citing Paper: The Safety of Anti-SARS-CoV-2 Vaccines: Vigilance Is Still Required., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccine Development for Emerging Animal and Zoonotic Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Glomerular endothelial injury following vaccination for SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 mRNA vaccines: Platforms and current developments., References: ['']\n",
      "DEBUG - Citing Paper: Strong influenza-induced T<sub>FH</sub> generation requires CD4 effectors to recognize antigen locally and receive signals from continuing infection., References: ['']\n",
      "DEBUG - Citing Paper: Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination., References: ['']\n",
      "DEBUG - Citing Paper: A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: IgA Nephropathy with Gross Hematuria Following COVID-19 mRNA Vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Langerhans cells and cDC1s play redundant roles in mRNA-LNP induced protective anti-influenza and anti-SARS-CoV-2 immune responses., References: ['']\n",
      "DEBUG - Citing Paper: Adverse Effects and Antibody Titers in Response to the BNT162b2 mRNA COVID-19 Vaccine in a Prospective Study of Healthcare Workers., References: ['']\n",
      "DEBUG - Citing Paper: Drug delivery systems for RNA therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccine Protects against Zika Virus., References: ['']\n",
      "DEBUG - Citing Paper: An mRNA vaccine to prevent genital herpes., References: ['']\n",
      "DEBUG - Citing Paper: Developments in Vaccination for Herpes Simplex Virus., References: ['']\n",
      "DEBUG - Citing Paper: Protein-Based Nanoparticle Vaccines for SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: Single-cell profiling of T and B cell repertoires following SARS-CoV-2 mRNA vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung., References: ['']\n",
      "DEBUG - Citing Paper: The Development of mRNA Vaccines for Infectious Diseases: Recent Updates., References: ['']\n",
      "DEBUG - Citing Paper: Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report., References: ['']\n",
      "DEBUG - Citing Paper: A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques., References: ['']\n",
      "DEBUG - Citing Paper: Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses., References: ['']\n",
      "DEBUG - Citing Paper: The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory., References: ['']\n",
      "DEBUG - Citing Paper: Nucleoside-Modified mRNA Vaccines Protect IFNAR<sup>-/-</sup> Mice against Crimean-Congo Hemorrhagic Fever Virus Infection., References: ['']\n",
      "DEBUG - Citing Paper: Strategies for induction of HIV-1 envelope-reactive broadly neutralizing antibodies., References: ['']\n",
      "DEBUG - Citing Paper: Current approaches to HIV vaccine development: a narrative review., References: ['']\n",
      "DEBUG - Citing Paper: The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Nano-therapeutic strategies to target coronavirus., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccines Induce Rapid Antibody Responses in Mice., References: ['']\n",
      "DEBUG - Citing Paper: Specific Protein Antigen Delivery to Human Langerhans Cells in Intact Skin., References: ['']\n",
      "DEBUG - Citing Paper: Strategies for eliciting multiple lineages of broadly neutralizing antibodies to HIV by vaccination., References: ['']\n",
      "DEBUG - Citing Paper: T Cell/B Cell Interactions in the Establishment of Protective Immunity., References: ['']\n",
      "DEBUG - Citing Paper: Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticles for Organ-Specific mRNA Therapeutic Delivery., References: ['']\n",
      "DEBUG - Citing Paper: The Importance of Cellular Immune Response to HIV: Implications for Antibody Production and Vaccine Design., References: ['']\n",
      "DEBUG - Citing Paper: Heterogeneous Longitudinal Antibody Responses to Covid-19 mRNA Vaccination., References: ['']\n",
      "DEBUG - Citing Paper: An Update on mRNA-Based Viral Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Literature Mining and Mechanistic Graphical Modelling to Improve mRNA Vaccine Platforms., References: ['']\n",
      "DEBUG - Citing Paper: Nucleic acid delivery and nanoparticle design for COVID vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines for infectious diseases: principles, delivery and clinical translation., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 (Covid-19) vaccines structure, mechanisms and effectiveness: A review., References: ['']\n",
      "DEBUG - Citing Paper: Ability of nucleoside-modified mRNA to encode HIV-1 envelope trimer nanoparticles., References: ['']\n",
      "DEBUG - Citing Paper: Immunogenicity after the first dose of the BNT162b2 mRNA Covid-19 vaccine: real-world evidence from Greek healthcare workers., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticles for mRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: Development and Delivery Systems of mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration., References: ['']\n",
      "DEBUG - Citing Paper: Langerhans cells and cDC1s play redundant roles in mRNA-LNP induced protective anti-influenza and anti-SARS-CoV-2 responses., References: ['']\n",
      "DEBUG - Citing Paper: HIV and Messenger RNA (mRNA) Vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: Prioritizing the First Doses of SARS-CoV-2 Vaccine to Save the Elderly: The Case Study of Italy., References: ['']\n",
      "DEBUG - Citing Paper: Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Trigeminal and cervical radiculitis after tozinameran vaccination against COVID-19., References: ['']\n",
      "DEBUG - Citing Paper: Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice., References: ['']\n",
      "DEBUG - Citing Paper: Cyclic Helix B Peptide Prolongs Skin Allograft Survival <i>via</i> Inhibition of B Cell Immune Responses in a Murine Model., References: ['']\n",
      "DEBUG - Citing Paper: BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Nanomaterial-based delivery vehicles for therapeutic cancer vaccine development., References: ['']\n",
      "DEBUG - Citing Paper: Future considerations for the mRNA-lipid nanoparticle vaccine platform., References: ['']\n",
      "DEBUG - Citing Paper: mRNA therapeutics in cancer immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccination compared to infection elicits an IgG-predominant response with greater SARS-CoV-2 specificity and similar decrease in variant spike recognition., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19: Insights into Potential Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: In the Era of mRNA Vaccines, Is There Any Hope for HIV Functional Cure?, References: ['']\n",
      "DEBUG - Citing Paper: An Overview on the Development of mRNA-Based Vaccines and Their Formulation Strategies for Improved Antigen Expression In Vivo., References: ['']\n",
      "DEBUG - Citing Paper: The dawn of mRNA vaccines: The COVID-19 case., References: ['']\n",
      "DEBUG - Citing Paper: Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Nano-Enabled COVID-19 Vaccines: Meeting the Challenges of Durable Antibody Plus Cellular Immunity and Immune Escape., References: ['']\n",
      "DEBUG - Citing Paper: Protein/AS01<sub>B</sub> vaccination elicits stronger, more Th2-skewed antigen-specific human T follicular helper cell responses than heterologous viral vectors., References: ['']\n",
      "DEBUG - Citing Paper: A Dengue Virus Serotype 1 mRNA-LNP Vaccine Elicits Protective Immune Responses., References: ['']\n",
      "DEBUG - Citing Paper: Clinical and immunological effects of mRNA vaccines in malignant diseases., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 vaccines in patients with SLE., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccines against Flaviviruses., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond., References: ['']\n",
      "DEBUG - Citing Paper: Development of Spike Receptor-Binding Domain Nanoparticles as a Vaccine Candidate against SARS-CoV-2 Infection in Ferrets., References: ['']\n",
      "DEBUG - Citing Paper: Adenoviral Vectors as Vaccines for Emerging Avian Influenza Viruses., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-Based Vaccines and Mode of Action., References: ['']\n",
      "DEBUG - Citing Paper: HIV mRNA Vaccines-Progress and Future Paths., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Development of spike receptor-binding domain nanoparticle as a vaccine candidate against SARS-CoV-2 infection in ferrets., References: ['']\n",
      "DEBUG - Citing Paper: Nanomaterial Delivery Systems for mRNA Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans., References: ['']\n",
      "DEBUG - Citing Paper: [STIKO vaccination recommendations : Vaccination of immunodeficient patients and vaccination against COVID-19]., References: ['']\n",
      "DEBUG - Citing Paper: Promising Adjuvants and Platforms for Influenza Vaccine Development., References: ['']\n",
      "DEBUG - Citing Paper: Self-assembled mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19: A review of therapeutic strategies and vaccine candidates., References: ['']\n",
      "DEBUG - Citing Paper: Self-amplifying RNA vaccines for infectious diseases., References: ['']\n",
      "DEBUG - Citing Paper: Challenges for the Newborn Following Influenza Virus Infection and Prospects for an Effective Vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Protection against herpes simplex virus type 2 infection in a neonatal murine model using a trivalent nucleoside-modified mRNA in lipid nanoparticle vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Are long-term influenza vaccines possible and how do we discover them?, References: ['']\n",
      "DEBUG - Citing Paper: COVID-19: Current Developments and Further Opportunities in Drug Delivery and Therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Mixed Amphiphilic Polymeric Nanoparticles of Chitosan, Poly(vinyl alcohol) and Poly(methyl methacrylate) for Intranasal Drug Delivery: A Preliminary In Vivo Study., References: ['']\n",
      "DEBUG - Citing Paper: A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice., References: ['']\n",
      "DEBUG - Citing Paper: Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates., References: ['']\n",
      "DEBUG - Citing Paper: An HSV-2 nucleoside-modified mRNA genital herpes vaccine containing glycoproteins gC, gD, and gE protects mice against HSV-1 genital lesions and latent infection., References: ['']\n",
      "DEBUG - Citing Paper: An mRNA Vaccine against SARS-CoV-2 - Preliminary Report., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticle technology for therapeutic gene regulation in the liver., References: ['']\n",
      "DEBUG - Citing Paper: Gene delivery for immunoengineering., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccines: Possible Tools to Combat SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: Vaccine Advances against Venezuelan, Eastern, and Western Equine Encephalitis Viruses., References: ['']\n",
      "DEBUG - Citing Paper: Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer., References: ['']\n",
      "DEBUG - Citing Paper: Self-assembling influenza nanoparticle vaccines drive extended germinal center activity and memory B cell maturation., References: ['']\n",
      "DEBUG - Citing Paper: Anti-PfGARP activates programmed cell death of parasites and reduces severe malaria., References: ['']\n",
      "DEBUG - Citing Paper: A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice., References: ['']\n",
      "DEBUG - Citing Paper: Messenger RNA-Based Vaccines Against Infectious Diseases., References: ['']\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DEBUG - Citing Paper: Vaccines to prevent genital herpes., References: ['']\n",
      "DEBUG - Citing Paper: Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization., References: ['']\n",
      "DEBUG - Citing Paper: The promise of mRNA vaccines: a biotech and industrial perspective., References: ['']\n",
      "DEBUG - Citing Paper: Innovations in HIV-1 Vaccine Design., References: ['']\n",
      "DEBUG - Citing Paper: Nucleoside-modified mRNA vaccination partially overcomes maternal antibody inhibition of de novo immune responses in mice., References: ['']\n",
      "DEBUG - Citing Paper: Comparison of DNA and mRNA vaccines against cancer., References: ['']\n",
      "DEBUG - Citing Paper: Strategies for inducing effective neutralizing antibody responses against HIV-1., References: ['']\n",
      "DEBUG - Citing Paper: Evaluation of a Single-Dose Nucleoside-Modified Messenger RNA Vaccine Encoding Hendra Virus-Soluble Glycoprotein Against Lethal Nipah virus Challenge in Syrian Hamsters., References: ['']\n",
      "DEBUG - Citing Paper: Enlisting the mRNA Vaccine Platform to Combat Parasitic Infections., References: ['']\n",
      "DEBUG - Citing Paper: Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes., References: ['']\n",
      "DEBUG - Citing Paper: Immunogenicity of RNA Replicons Encoding HIV Env Immunogens Designed for Self-Assembly into Nanoparticles., References: ['']\n",
      "DEBUG - Citing Paper: Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers., References: ['']\n",
      "DEBUG - Citing Paper: Cricket paralysis virus internal ribosome entry site-derived RNA promotes conventional vaccine efficacy by enhancing a balanced Th1/Th2 response., References: ['']\n",
      "DEBUG - Citing Paper: Antibody responses to crucial functional epitopes as a novel approach to assess immunogenicity of vaccine adjuvants., References: ['']\n",
      "DEBUG - Citing Paper: Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques., References: ['']\n",
      "DEBUG - Citing Paper: Advances in mRNA Vaccines for Infectious Diseases., References: ['']\n",
      "DEBUG - Citing Paper: mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Assessing the Protective Potential of H1N1 Influenza Virus Hemagglutinin Head and Stalk Antibodies in Humans., References: ['']\n",
      "DEBUG - Citing Paper: CD4+ T cells promote humoral immunity and viral control during Zika virus infection., References: ['']\n",
      "DEBUG - Citing Paper: An mRNA Vaccine Protects Mice against Multiple Tick-Transmitted Flavivirus Infections., References: ['']\n",
      "DEBUG - Citing Paper: Bispecific antibodies: Potential immunotherapies for HIV treatment., References: ['']\n",
      "DEBUG - Citing Paper: mRNA as novel technology for passive immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: Immunizing the Immune: Can We Overcome Influenza's Most Formidable Challenge?, References: ['']\n",
      "DEBUG - Citing Paper: Immune Correlate-Guided HIV Vaccine Design., References: ['']\n",
      "DEBUG - Citing Paper: Harnessing T Follicular Helper Cell Responses for HIV Vaccine Development., References: ['']\n",
      "DEBUG - focal: Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses., NF: 0, NB: 0, NR: 0, D: 0\n",
      "DEBUG - Focal Paper: A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis., References: \n",
      "\n",
      " https://clinicaltrials.gov/ct2/show/NCT04880577\n",
      "DEBUG - Citing Paper: Optimized lipid nanoparticles (LNPs) for organ-selective nucleic acids delivery <i>inÂ vivo</i>., References: ['']\n",
      "DEBUG - Citing Paper: CNS Resident Innate Immune Cells: Guardians of CNS Homeostasis., References: ['']\n",
      "DEBUG - Citing Paper: Potential Application of Modified mRNA in Cardiac Regeneration., References: ['']\n",
      "DEBUG - Citing Paper: Nucleic Acid Vaccines Encoding Proteins and Virus-like Particles for HIV Prevention., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccine designs for optimal adjuvanticity and delivery., References: ['']\n",
      "DEBUG - Citing Paper: Current status of immunological therapies for rheumatoid arthritis with a focus on antigen-specific therapeutic vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Recent advances in nanoparticulate RNA delivery systems., References: ['']\n",
      "DEBUG - Citing Paper: Cell-Specific mRNA Therapeutics for Cardiovascular Diseases and Regeneration., References: ['']\n",
      "DEBUG - Citing Paper: The therapeutic potential of immunoengineering for systemic autoimmunity., References: ['']\n",
      "DEBUG - Citing Paper: Nanotechnology's frontier in combatting infectious and inflammatory diseases: prevention and treatment., References: ['']\n",
      "DEBUG - Citing Paper: Emerging strategies for nanomedicine in autoimmunity., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccine boosters and impaired immune system response in immune compromised individuals: a narrative review., References: ['']\n",
      "DEBUG - Citing Paper: Harnessing the Stem Cell Niche in Regenerative Medicine: Innovative Avenue to Combat Neurodegenerative Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Future Prospects, Approaches, and the Government's Role in the Development of a Hepatitis C Virus Vaccine., References: ['']\n",
      "DEBUG - Citing Paper: Liver-Targeting Nanoplatforms for the Induction of Immune Tolerance., References: ['']\n",
      "DEBUG - Citing Paper: Therapeutic induction of antigen-specific immune tolerance., References: ['']\n",
      "DEBUG - Citing Paper: An engineered Fc fusion protein that targets antigen-specific T cells and autoantibodies mitigates autoimmune disease., References: ['']\n",
      "DEBUG - Citing Paper: Cell and biomaterial delivery strategies to induce immune tolerance., References: ['']\n",
      "DEBUG - Citing Paper: Vaccines for immune tolerance against autoimmune disease., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-based Vaccines Targeting the T-cell Epitope-rich Domain of Epstein Barr Virus Latent Proteins Elicit Robust Anti-Tumor Immunity in Mice., References: ['']\n",
      "DEBUG - Citing Paper: The advances of adjuvants in mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Advances in dendritic cell targeting nano-delivery systems for induction of immune tolerance., References: ['']\n",
      "DEBUG - Citing Paper: Reducing cell intrinsic immunity to mRNA vaccine alters adaptive immune responses in mice., References: ['']\n",
      "DEBUG - Citing Paper: Sweeten the deal: Glycopolymer-based engineering to modulate autoreactive TÂ cell responses., References: ['']\n",
      "DEBUG - Citing Paper: Lipid carriers for mRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: RNA Nanomedicine: Delivery Strategies and Applications., References: ['']\n",
      "DEBUG - Citing Paper: Understanding How Cationic Polymers' Properties Inform Toxic or Immunogenic Responses via Parametric Analysis., References: ['']\n",
      "DEBUG - Citing Paper: Recent Advances and Innovations in the Preparation and Purification of In Vitro-Transcribed-mRNA-Based Molecules., References: ['']\n",
      "DEBUG - Citing Paper: Tolerogenic Lipid Nanoparticles for Delivering Self-Antigen mRNA for the Treatment of Experimental Autoimmune Encephalomyelitis., References: ['']\n",
      "DEBUG - Citing Paper: Killing tumor-associated bacteria with a liposomal antibiotic generates neoantigens that induce anti-tumor immune responses., References: ['']\n",
      "DEBUG - Citing Paper: mRNA nanodelivery systems: targeting strategies and administration routes., References: ['']\n",
      "DEBUG - Citing Paper: RNA-based medicine: from molecular mechanisms to therapy., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines in disease prevention and treatment., References: ['']\n",
      "DEBUG - Citing Paper: mRNA lipid nanoparticles induce immune tolerance to treat human diseases., References: ['']\n",
      "DEBUG - Citing Paper: Progress in nanoparticle-based regulation of immune cells., References: ['']\n",
      "DEBUG - Citing Paper: Incorporation of noncanonical base Z yields modified mRNA with minimal immunogenicity and improved translational capacity in mammalian cells., References: ['']\n",
      "DEBUG - Citing Paper: Circular RNA vaccine in disease prevention and treatment., References: ['']\n",
      "DEBUG - Citing Paper: Synthetically glycosylated antigens for the antigen-specific suppression of established immune responses., References: ['']\n",
      "DEBUG - Citing Paper: Targeting materials and strategies for RNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: RNA Vaccines: Yeast as a Novel Antigen Vehicle., References: ['']\n",
      "DEBUG - Citing Paper: Smouldering Lesion in MS: Microglia, Lymphocytes and Pathobiochemical Mechanisms., References: ['']\n",
      "DEBUG - Citing Paper: Nanoadjuvants: Promising Bioinspired and Biomimetic Approaches in Vaccine Innovation., References: ['']\n",
      "DEBUG - Citing Paper: Lactate limits CNS autoimmunity by stabilizing HIF-1Î± in dendritic cells., References: ['']\n",
      "DEBUG - Citing Paper: Recent Advances in Messenger Ribonucleic Acid (mRNA) Vaccines and Their Delivery Systems: A Review., References: ['']\n",
      "DEBUG - Citing Paper: New consensus guidelines on vaccination in multiple sclerosis., References: ['']\n",
      "DEBUG - Citing Paper: Messenger RNA-Based Therapeutics and Vaccines: What's beyond COVID-19?, References: ['']\n",
      "DEBUG - Citing Paper: Treg-based immunotherapy for antigen-specific immune suppression and stable tolerance induction: a perspective., References: ['']\n",
      "DEBUG - Citing Paper: Protective RNA nanovaccines against <i>Mycobacterium avium</i> subspecies <i>hominissuis</i>., References: ['']\n",
      "DEBUG - Citing Paper: Carrier strategies boost the application of CRISPR/Cas system in gene therapy., References: ['']\n",
      "DEBUG - Citing Paper: RNA Therapeutics: A Healthcare Paradigm Shift., References: ['']\n",
      "DEBUG - Citing Paper: Cap analogs with a hydrophobic photocleavable tag enable facile purification of fully capped mRNA with various cap structures., References: ['']\n",
      "DEBUG - Citing Paper: Revolutionizing viral disease vaccination: the promising clinical advancements of non-replicating mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Multiple sclerosis: Neuroimmune crosstalk and therapeutic targeting., References: ['']\n",
      "DEBUG - Citing Paper: An mRNA vaccine elicits STING-dependent antitumor immune responses., References: ['']\n",
      "DEBUG - Citing Paper: Delivery route considerations for designing antigen-specific biomaterial strategies to combat autoimmunity., References: ['']\n",
      "DEBUG - Citing Paper: Pathophysiology of myelin oligodendrocyte glycoprotein antibody disease., References: ['']\n",
      "DEBUG - Citing Paper: Single-Cell Genomics for Investigating Pathogenesis of Inflammatory Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Use of a Liver-Targeting Immune-Tolerogenic mRNA Lipid Nanoparticle Platform to Treat Peanut-Induced Anaphylaxis by Single- and Multiple-Epitope Nucleotide Sequence Delivery., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-Based Therapeutics in Cancer Treatment., References: ['']\n",
      "DEBUG - Citing Paper: Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases, in Patients with Cardiac Issues, and in the Healthy Population., References: ['']\n",
      "DEBUG - Citing Paper: Opposite Effects of mRNA-Based and Adenovirus-Vectored SARS-CoV-2 Vaccines on Regulatory T Cells: A Pilot Study., References: ['']\n",
      "DEBUG - Citing Paper: Roadmap for understanding mechanisms on how Epstein-Barr virus triggers multiple sclerosis and for translating these discoveries in clinical trials., References: ['']\n",
      "DEBUG - Citing Paper: RNA modification in mRNA cancer vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Nanomaterials-Based Novel Immune Strategies in Clinical Translation for Cancer Therapy., References: ['']\n",
      "DEBUG - Citing Paper: Epitope-based precision immunotherapy of Type 1 diabetes., References: ['']\n",
      "DEBUG - Citing Paper: Experimental encephalomyelitis at age 90, still relevant and elucidating how viruses trigger disease., References: ['']\n",
      "DEBUG - Citing Paper: Biomaterial Strategies for Selective Immune Tolerance: Advances and Gaps., References: ['']\n",
      "DEBUG - Citing Paper: Excipient-Free Ionizable Polyester Nanoparticles for Lung-Selective and Innate Immune Cell Plasmid DNA and mRNA Transfection., References: ['']\n",
      "DEBUG - Citing Paper: Impact of disease-modifying therapy on dendritic cells and exploring their immunotherapeutic potential in multiple sclerosis., References: ['']\n",
      "DEBUG - Citing Paper: mRNA therapy for myocardial infarction: A review of targets and delivery vehicles., References: ['']\n",
      "DEBUG - Citing Paper: Immunomodulatory nano-preparations for rheumatoid arthritis., References: ['']\n",
      "DEBUG - Citing Paper: Tissue-Targeted Drug Delivery Strategies to Promote Antigen-Specific Immune Tolerance., References: ['']\n",
      "DEBUG - Citing Paper: Lipid-mRNA nanoparticles landscape for cancer therapy., References: ['']\n",
      "DEBUG - Citing Paper: The landscape of mRNA nanomedicine., References: ['']\n",
      "DEBUG - Citing Paper: Advancing mRNA technologies for therapies and vaccines: An African context., References: ['']\n",
      "DEBUG - Citing Paper: Innate immune mechanisms of mRNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Understanding Pathogenesis Intersects With Effective Treatment for Thyroid Eye Disease., References: ['']\n",
      "DEBUG - Citing Paper: Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination., References: ['']\n",
      "DEBUG - Citing Paper: Unlocking the promise of mRNA therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: A systematic and thematic analysis of the top 100 cited articles on mRNA vaccine indexed in Scopus database., References: ['']\n",
      "DEBUG - Citing Paper: Nanomaterial-assisted CRISPR gene-engineering - A hallmark for triple-negative breast cancer therapeutics advancement., References: ['']\n",
      "DEBUG - Citing Paper: Treatment with an antigen-specific dual microparticle system reverses advanced multiple sclerosis in mice., References: ['']\n",
      "DEBUG - Citing Paper: Peptide Microarrays for Studying Autoantibodies in Neurological Disease., References: ['']\n",
      "DEBUG - Citing Paper: Cutting-Edge Delivery Systems and Adjuvants in Tolerogenic Vaccines: A Review., References: ['']\n",
      "DEBUG - Citing Paper: RNA modifications: importance in immune cell biology and related diseases., References: ['']\n",
      "DEBUG - Citing Paper: IL-10-Functionalized Hydrogels Support Immunosuppressive Dendritic Cell Phenotype and Function., References: ['']\n",
      "DEBUG - Citing Paper: Nanomaterials for antigen-specific immune tolerance therapy., References: ['']\n",
      "DEBUG - Citing Paper: Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities., References: ['']\n",
      "DEBUG - Citing Paper: Neuroinflammation: Extinguishing a blaze of T cells., References: ['']\n",
      "DEBUG - Citing Paper: iCodon customizes gene expression based on the codon composition., References: ['']\n",
      "DEBUG - Citing Paper: Protective Immune Responses Induced by an mRNA-LNP Vaccine Encoding prM-E Proteins against Japanese Encephalitis Virus Infection., References: ['']\n",
      "DEBUG - Citing Paper: Thinking outside the box: non-canonical targets in multiple sclerosis., References: ['']\n",
      "DEBUG - Citing Paper: Adverse effects of COVID-19 vaccines and measures to prevent them., References: ['']\n",
      "DEBUG - Citing Paper: Editorial: Nanoparticle-Mediated Signaling Rewiring and Reprogramming of Immune Responses., References: ['']\n",
      "DEBUG - Citing Paper: Antigen targeting to dendritic cells: Still a place in future immunotherapy?, References: ['']\n",
      "DEBUG - Citing Paper: Robust tolerogenic dendritic cells via push/pull pairing of toll-like-receptor agonists and immunomodulators reduces EAE., References: ['']\n",
      "DEBUG - Citing Paper: Engineered RBCs Encapsulating Antigen Induce Multi-Modal Antigen-Specific Tolerance and Protect Against Type 1 Diabetes., References: ['']\n",
      "DEBUG - Citing Paper: Nanoparticles for Inducing Antigen-Specific T Cell Tolerance in Autoimmune Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases., References: ['']\n",
      "DEBUG - Citing Paper: Delivery of mRNA for regulating functions of immune cells., References: ['']\n",
      "DEBUG - Citing Paper: IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Targeted Immunotherapy for Autoimmune Disease., References: ['']\n",
      "DEBUG - Citing Paper: Microfluidic fabrication of lipid nanoparticles for the delivery of nucleic acids., References: ['']\n",
      "DEBUG - Citing Paper: The Potential of Nanomedicine to Unlock the Limitless Applications of mRNA., References: ['']\n",
      "DEBUG - Citing Paper: TSAFinder: exhaustive tumor-specific antigen detection with RNAseq., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 mRNA vaccines: Platforms and current developments., References: ['']\n",
      "DEBUG - Citing Paper: Systemic lupus erythematosus as a genetic disease., References: ['']\n",
      "DEBUG - Citing Paper: CIMT 2021: report on the 18th Annual Meeting of the Association for Cancer Immunotherapy., References: ['']\n",
      "DEBUG - Citing Paper: mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2., References: ['']\n",
      "DEBUG - Citing Paper: Immunotherapeutic Strategies in Cancer and Atherosclerosis-Two Sides of the Same Coin., References: ['']\n",
      "DEBUG - Citing Paper: Novel artful applications of vaccines at the horizon., References: ['']\n",
      "DEBUG - Citing Paper: Mechanistic and Biomarker Studies to Demonstrate Immune Tolerance in Multiple Sclerosis., References: ['']\n",
      "DEBUG - Citing Paper: Fewer LAG-3<sup>+</sup> T Cells in Relapsing-Remitting Multiple Sclerosis and Type 1 Diabetes., References: ['']\n",
      "DEBUG - Citing Paper: 100 Years of Insulin: Lifesaver, immune target, and potential remedy for prevention., References: ['']\n",
      "DEBUG - Citing Paper: CAR T cells produced in vivo to treat cardiac injury., References: ['']\n",
      "DEBUG - Citing Paper: COVID-19 and Traumatic Brain Injury (TBI); What We Can Learn From the Viral Pandemic to Better Understand the Biology of TBI, Improve Diagnostics and Develop Evidence-Based Treatments., References: ['']\n",
      "DEBUG - Citing Paper: Drug delivery systems for RNA therapeutics., References: ['']\n",
      "DEBUG - Citing Paper: Modulating Autoimmunity against LDL: Development of a Vaccine against Atherosclerosis., References: ['']\n",
      "DEBUG - Citing Paper: MODOMICS: a database of RNA modification pathways. 2021 update., References: ['']\n",
      "DEBUG - Citing Paper: New Perspectives on the Immunopathogenesis and Treatment of Uveitis Associated With Vogt-Koyanagi-Harada Disease., References: ['']\n",
      "DEBUG - Citing Paper: The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview., References: ['']\n",
      "DEBUG - Citing Paper: Retinoic Acid-Containing Liposomes for the Induction of Antigen-Specific Regulatory T Cells as a Treatment for Autoimmune Diseases., References: ['']\n",
      "DEBUG - Citing Paper: Advances in mRNA and other vaccines against MERS-CoV., References: ['']\n",
      "DEBUG - Citing Paper: Pathophysiology of Antiphospholipid Syndrome., References: ['']\n",
      "DEBUG - Citing Paper: Cumulative Roles for Epstein-Barr Virus, Human Endogenous Retroviruses, and Human Herpes Virus-6 in Driving an Inflammatory Cascade Underlying MS Pathogenesis., References: ['']\n",
      "DEBUG - Citing Paper: Immune Checkpoint Ligand Bioengineered Schwann Cells as Antigen-Specific Therapy for Experimental Autoimmune Encephalomyelitis., References: ['']\n",
      "DEBUG - Citing Paper: The role of dendritic cells and their interactions in the pathogenesis of antibody-associated autoimmune encephalitis., References: ['']\n",
      "DEBUG - Citing Paper: Lipid Nanoparticles for Organ-Specific mRNA Therapeutic Delivery., References: ['']\n",
      "DEBUG - Citing Paper: T regulatory cells as a potential therapeutic target in psychosis? Current challenges and future perspectives., References: ['']\n",
      "DEBUG - Citing Paper: Immunology of SARS-CoV-2 infections and vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Multiple Sclerosis and SARS-CoV-2: Has the Interplay Started?, References: ['']\n",
      "DEBUG - Citing Paper: Induction of Tolerance to Therapeutic Proteins With Antigen-Processing Independent T Cell Epitopes: Controlling Immune Responses to Biologics., References: ['']\n",
      "DEBUG - Citing Paper: Silybin Alleviates Experimental Autoimmune Encephalomyelitis by Suppressing Dendritic Cell Activation and Th17 Cell Differentiation., References: ['']\n",
      "DEBUG - Citing Paper: Nanotechnology-Assisted RNA Delivery: From Nucleic Acid Therapeutics to COVID-19 Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Therapeutic cancer vaccines revamping: technology advancements and pitfalls., References: ['']\n",
      "DEBUG - Citing Paper: Pseudouridines in RNAs: switching atoms means shifting paradigms., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines for infectious diseases: principles, delivery and clinical translation., References: ['']\n",
      "DEBUG - Citing Paper: Immune cell compartmentalization for brain surveillance and protection., References: ['']\n",
      "DEBUG - Citing Paper: Prevention of EAE by tolerogenic vaccination with PEGylated antigenic peptides., References: ['']\n",
      "DEBUG - Citing Paper: Lipid nanoparticles for mRNA delivery., References: ['']\n",
      "DEBUG - Citing Paper: Pathogenesis of autoimmune demyelination: from multiple sclerosis to neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease., References: ['']\n",
      "DEBUG - Citing Paper: Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across., References: ['']\n",
      "DEBUG - Citing Paper: Lipids and Lipid Derivatives for RNA Delivery., References: ['']\n",
      "DEBUG - Citing Paper: B cell depletion impairs vaccination-induced CD8<sup>+</sup> T cell responses in a type I interferon-dependent manner., References: ['']\n",
      "DEBUG - Citing Paper: Autoimmune diseases - New insights into a troublesome field., References: ['']\n",
      "DEBUG - Citing Paper: Targeted Expression of Myelin Autoantigen in the Periphery Induces Antigen-Specific T and B Cell Tolerance and Ameliorates Autoimmune Disease., References: ['']\n",
      "DEBUG - Citing Paper: Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Multifunctional Immunoadjuvants for Use in Minimalist Nucleic Acid Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Therapeutic Liposomal Vaccines for Dendritic Cell Activation or Tolerance., References: ['']\n",
      "DEBUG - Citing Paper: Antigen-Specific Regulatory T Cell Therapy in Autoimmune Diseases and Transplantation., References: ['']\n",
      "DEBUG - Citing Paper: Editorial: Epidemiology of Atypical Demyelinating Diseases., References: ['']\n",
      "DEBUG - Citing Paper: The Mechanism of Action of Antigen Processing Independent T Cell Epitopes Designed for Immunotherapy of Autoimmune Diseases., References: ['']\n",
      "DEBUG - Citing Paper: mRNA-Based Vaccines., References: ['']\n",
      "DEBUG - Citing Paper: Manipulating antigen presentation for antigen-specific immunotherapy of autoimmune diseases., References: ['']\n",
      "DEBUG - Citing Paper: Emerging Therapeutics for Immune Tolerance: Tolerogenic Vaccines, T cell Therapy, and IL-2 Therapy., References: ['']\n",
      "DEBUG - Citing Paper: Capturing pathogenic immune cells before they home to brain., References: ['']\n",
      "DEBUG - Citing Paper: mRNA vaccines take on immune tolerance., References: ['']\n",
      "DEBUG - Citing Paper: <i>In vitro</i> and <i>ex vivo</i> functional characterization of human HLA-DRB1â04 restricted T cell receptors., References: ['']\n",
      "DEBUG - Citing Paper: Human Vaccines & Immunotherapeutics: news., References: ['']\n",
      "DEBUG - Citing Paper: SARS-CoV-2 vaccines in patients with SLE., References: ['']\n",
      "DEBUG - Citing Paper: Non-Genetically Encoded Epitopes Are Relevant Targets in Autoimmune Diabetes., References: ['']\n",
      "DEBUG - Citing Paper: Suppressing autoimmunity with mRNA vaccines., References: ['']\n",
      "DEBUG - focal: A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis., NF: 0, NB: 0, NR: 0, D: 0\n"
     ]
    }
   ],
   "source": [
    "# Prepare the data\n",
    "results = []\n",
    "\n",
    "for focal_paper in kariko_papers[focal_column].unique():\n",
    "    citing_papers = kariko_papers[kariko_papers[focal_column] == focal_paper][citing_column].unique()\n",
    "    references = kariko_papers[kariko_papers[focal_column] == focal_paper][references_column]#.unique()\n",
    "    \n",
    "    references = np.unique(sum(references,[]))\n",
    "    references = references[0] if len(references) > 0 and isinstance(references[0], str) else []\n",
    "    \n",
    "#     references = references[0].split(';') if len(references) > 0 and isinstance(references[0], str) else []\n",
    "\n",
    "    # Debugging information for focal paper and its references\n",
    "    print(f\"DEBUG - Focal Paper: {focal_paper}, References: {references}\")\n",
    "\n",
    "    # Calculate the disruption index\n",
    "    di = calculate_disruption_index(focal_paper, citing_papers, references, data)\n",
    "    results.append({'Focal_Paper': focal_paper, 'Disruption_Index': di})\n",
    "\n",
    "# Convert results to a DataFrame\n",
    "results_df = pd.DataFrame(results)\n",
    "\n",
    "# Save results to a CSV file\n",
    "results_df.to_csv('disruption_index_results1.csv', index=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "a510a19d",
   "metadata": {},
   "outputs": [],
   "source": [
    "kariko_papers"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "befee26c",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python (myNEWenv)",
   "language": "python",
   "name": "mynewenv"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.12"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
